TPI-1700CXC2 PCT) by Tawa et al.; U. S. Provisional Application Serial Nos.

60/437,516 (filed December 30,2002) ; 60/441,335 (filed January 21,2003) ; 60/456,608 (filed March 21,2003) ; 60/459,501 (filed April 1,2003) ; 60/486,713 (filed July 11, 2003); 60/437,516, filed December 30,2002 ; and 60/441,335, filed January 21,2003, are incorporated herein by reference in its entirety.

FIELD OF THE INVENTION The present invention relates to drug-containing compositions, pharmaceutical compositions comprising such drugs, and methods for preparing same.

BACKGROUND OF THE INVENTION Drugs in pharmaceutical compositions can be prepared in a variety of different forms.

Such drugs can be prepared so as to have a variety of different chemical forms including chemical derivatives or salts. Such drugs can also be prepared to have different physical forms. For example, the drugs may be amorphous or may have different crystalline polymorphs, perhaps existing in different solvation or hydration states. By varying the form of a drug, it is possible to vary the physical properties thereof. For example, crystalline polymorphs typically have different solubilities from one another, such that a more thermodynamically stable polymorph is less soluble than a less thermodynamically stable polymorph. Pharmaceutical polymorphs can also differ in properties such as shelf-life, bioavailability, morphology, vapor pressure, density, color, and compressibility. Accordingly, variation of the solvation state of a drug is one of many ways in which to modulate the physical properties thereof.

A solvate may be defined as a compound formed by solvation, for example as a combination of solvent molecules with molecules or ions of a solute. Well known solvent molecules include water, alcohols and other polar organic solvents. Alcohols include methanol, ethanol, n-propanol, isopropanol, n-butanol, isobutanol, and t- butanol. Alcohols also include polymerized alcohols such as polyalkylene glycols (e. g. , polyethylene glycol, polypropylene glycol). The best-known and preferred solvent is typically water, and solvate compounds formed by solvation with water are termed hydrates.

Propylene glycol (1,2-propanediol) is a known substance which is a liquid at ambient temperature. As far as the applicants are aware, propylene glycol is not generally well-known for use in the formation of solvates. US Pat. No. 3,970, 651 does disclose the use of propylene glycol in the formation of a crystalline cephalosporin derivative.

According to this disclosure a propylene glycolate derivative of a specific cephalosporin zwitterion may be formed in the presence of propylene glycol at acidic pH. This disclosure indicates that the propylene glycol derivative is more stable in solid form than the corresponding ethanolate, especially having excellent colour stability and thermal stability. No other solvates are disclosed in this US patent other than the specific solvate of cephalosporin.

In pharmaceutical formulations certain chemical classes of drugs pose particular problems in preparing pharmaceutical formulations for medical use. One such problem arises in the case of hygroscopic drugs, which tend to absorb water from the air. This is disadvantageous because it makes storage of the drug difficult and can cause degradation of the drug in some cases. Such compounds must be handled in controlled humidity environments during manufacture in order to prevent potency errors due to the changing weight of the drug. The final product must be packaged in individual moisture resistant blisters in order to prevent changes in or degradation of the product. Another problem arises from variable hydration states: molecules may change to a more or less stable form as water, a volatile liquid, is lost. Such changes have been known to cause some hydrates to become amorphous. Likewise, absorption of water by a hygroscopic molecule can plasticise the system and lead to recrystallization as a less stable polymorph.

SUMMARY OF THE INVENTION Solvates are rarely used in pharmaceuticals because the solvents are usually volatile thus making it difficult to maintain the solvent in the crystal. If one were to desolvate a pharmaceutical solvate or if it desolvated due to storage conditions or otherwise, it could lead to the formation of multiple polymorphs or complete collapse of the crystal structure, forming an amorphous compound with different physical properties.

Obviously, this batch-to-batch variability and questionable shelf life is undesired.

Typically people find solvates of common solvents, such as propanol and ethanol.

Propylene glycol is similar in structure to propanol, but is not thought of as a solvent.

Propylene glycol solvates of the present invention desolvate only at considerably higher temperatures and harsher conditions than traditional solvates. Propylene glycol solvates are also pharmaceutically acceptable in much larger amounts thanone would expose people to with a traditional solvate. Thus, the propylene glycol solvates of the present invention have characteristics that are vastly superior to traditional solvates.

It has now been found that amorphous, crystalline, hygroscopic, or poorly soluble drugs can be made more soluble, more stable, and less hygroscopic and can be prepared simply, reliably and inexpensively.

In a first aspect, the present invention provides a pharmaceutical composition comprising a propylene glycol solvate of a drug which is hygroscopic or has low aqueous solubility.

It has surprisingly been found that by using propylene glycol to form a solvate of a hygroscopic drug, the hygroscopicity of the drug is decreased and/or the stability and aqueous solubility is increased. The drug is therefore much easier to formulate and store than its counterpart untreated or hydrated form.

A number of advantages have been found from the use of propylene glycol in this way. First of all, a higher temperature is required to remove propylene glycol as compared with water or ethanol. This therefore results in an increased thermal stability. Thus the invention further relates to methods of making a pharmaceutical solvate more stable at high temperatures by making a PG solvate of the drug.

Secondly, propylene glycol solvates are generally more pharmaceutically acceptable than other common solvates, including those formed from alcohols other than ethanol.

It has further been found that the PG solvates of the present invention have fewer solvation states than hydration states. This is beneficial because production and quality of a drug can be more predictable and consistent. Thus an aspect of the present invention relates to methods of reducing the number of hydration states by making a PG solvate of a drug. PG solvates are also beneficial in addressing the problem of polymorphism. Thus an aspect of the present invention relates to methods of reducing the rate and extent a drug changes form and methods of reducing the chance of making an unwanted form because the PG solvates drive production of a single form. Another aspect of the present invention relates to changing the crystal habit of the drug crystal and preventing a drug crystalline habit from changing to a different habit.

The invention relates to making a pharmaceutical that can be made as a hydrate, more soluble or stable by forming a PG solvate of the drug.

The invention further relates to making a pharmaceutical more stable in a humid environment by making a PG solvate of the drug.

The invention further relates to making a crystalline compound from a pharmaceutical that does not readily crystallize by making a crystalline PG solvate of the drug.

The invention further relates to increasing the solubility of a crystalline pharmaceutical by making a PG solvate of the drug.

The invention further relates to methods of lowering the amount of drug solvation during wet granulation by making a PG solvate of the drug.

A particularly important aspect of the present invention is the realization that formation of propylene glycol solvates is applicable in a general way to drugs whereby the above advantages may be conferred. For example, the invention further relates to reducing the level of hygroscopicity of a pharmaceutical metal salt (crystalline, amorphous, solvate (e. g., hydrate) ) by forming a PG solvate of the salt.

Surprisingly, it has been found that the invention is particularly applicable to those drugs that are in the form of metal salts, such as alkali metal or alkaline earth metal salts. This is especially the case where the metal is selected from sodium, potassium, lithium, calcium and magnesium. Such salts can be hygroscopic and it has hitherto been difficult to find a suitable general means of formulation for these drugs.

Generally, the molar ratio of propylene glycol to drug in the solvate is in the range 0.5 to 2, (e. g. , 0.5, 1.0, 1.5, 2.0). Depending on the nature of the drug, the ratio of propylene glycol to drug in the solvate may be approximately 0.25, 0.33, 0.5, 0.67, 0.75, 1.0, 1.5, 2.0 or 3.0.

The composition may further comprise a pharmaceutically-acceptable diluent, excipient or carrier and details of pharmaceutical compositions are also set out in further detail below. The solvate of the pharmaceutical composition according to the present invention is preferably in a crystalline form.

Advantageously, the powder X-ray diffraction spectrum of the composition according to the invention differs from the corresponding powder X-ray diffraction spectrum of unsolvated drug by at least one property selected from: (i) a loss of at least one peak; (ii) shifting of more than half the peaks at the 2-theta angle by at least 0.2, 0.3, 0.4, or 0.5 degrees; or (iii) formation of at least one new peak.

It is preferred that the solvate is stable to temperatures of up to 50 degrees C under a stream of nitrogen gas in a thermogravimetric analysis apparatus.

The PXRD could be the same if their were a host-guest relationship and the PG was not completely frozen out. This would be an inclusion compound rather than a true solvate, but it may still be less hygroscopic than a hydrate, less prone to solvent loss than an inclusion with ethanol, less prone to being filled by some toxic co-solvent if PG fits well, and less prone to polymorphism to a less soluble form due to instability caused by a vacated void in the structure. The DSC transitions are likely to occur at different temperatures and have different intensities than for the parent molecule and it's other hydrates/solvates. In one aspect of the invention, the drug is a hygroscopic drug, including hygroscopic metal salts. A non-exhaustive list of hygroscopic drugs is set out in Table 1, along with their suppliers and routes of administration.

Table 1-Hygroscopic Drugs Product (company) Active ingredient Hygroscopic Route (s) of Administration Solu-Medrol (P&U) Methyl prednisolone X Intravenous succinate ester Primaxin IV and IM Imipenem/cilastatin X (cilastatin) Intravenous/ (Merck) Intramuscular Vitravene Injection (CIBA) Fomivirsen sodium X Intravenous Baycol (Bayer) Cerivastatin sodium X Oral Synercid IV (Aventis) Dalfopristin/Quinoprist X Intravenous in Factrel (Wyeth) Gonadorelin HC1 X Intravenous/ (decapeptide) Subcutaneous Clindets Pledgets (Stiefel) Clindamycin phosphate X Topical (ester prodrug) Famvir (SKB) Famciclovir X Oral Nascobal Gel (Schwarz) Cyanocobalamin X Intranasal Tasmar (Roche) Tolcapone X Oral Ellence Injection (P&U) Epirubicin HC1 X Intravenous Colestid (P&U) Colestipol HCl (anion X Oral excluded) Pfizerpen Injection (Pfizer) Penicillin G potassium X Intravenous Bacitracin Injection Bacitracin (peptide) X Intravenous (Paddock) Lescol (Novartis) Fluvastatin sodium X Oral Voltaren XR (Novartis) Diclofenac sodium X Oral Salagen (MGI) Pilocarpine HC1 X Oral Urecholine injection Bethanechol chloride X Intravenous (Merck) Syprine (Merck) Trientine 2 (HCl) X Oral Singular chewable (Merck) Montelukast sodium X Oral Mustargen injection Mechlorethamine HC1 X Intravenous (Merck) Hydrocortone phosphate Hydrocortisone X Intravenous injection Merck) phosphate ester Decadron phosphate Dexamethasone X Intravenous injection (Merck) phosphate ester Gastrocrom (Medeva) Chromolyn sodium X Oral Mestinon (ICN) Pyridostigmine X Oral bromide Adipex-P (Gate) Phentermine HC1 X Oral Micardis (Boehringer-Telmisartan X Oral Ingelh.) Cerubidine injection Daunorubicin HC1 X Intravenous (Bedford) Biltricide (Bayer) Praziquantel X Oral Elmiron (Alza) Pentosan polysulfate X Oral sodium In one embodiment, the formulation comprises celecoxib. Although the invention is not limited to this particular drug, celecoxib provides a suitable example of the efficacy of the invention. Further details of celecoxib are set out below. In a further embodiment, the drug comprises naproxen, further details of which are also set out below.

In another aspect of the invention, the drug has low aqueous solubility. Typically, low aqueous solubility in the present application refers to a compound having a solubility in water which is less than or equal to lO0mg/ml, when measured at 37 degrees C, and preferably less than or equal to 5mg/ml or lmg/ml."Low aqueous solubility"can further be defined as less than or equal to 900,800, 700,600, 500,400, 300,200 150 100,90, 80,70, 60,50, 40,30, 20 micrograms/ml, or further 10,5 or 1 micrograms/ml, or further 900,800, 700,600, 500,400, 300,200 150,100 90,80, 70, 60, 50, 40, 30, 20, or 10 ng/ml, or less than 10 ng/ml when measured at 37 degrees C.

Aqueous solubility can also be specified as less than 500,400, 300,200, 150,100, 75, 50 or 25 mg/ml. As embodiments of the present invention, solubility can be increased 2,3, 4,5, 7,10, 15,20, 25,50, 75,100, 200,300, 500,750, 1000,5000, or 10,000 times by making a PG solvate of the neutral (crystalline or amorphous), salt, or solvate form (e. g. , hydrate, ethanolate, methanolate, isopropanolate, etc. ). Further aqueous solubility can be measured in simulated gastric fluid (SGF) rather than water.

SGF (non-diluted) of the present invention is made by combining 1 g/L Triton X-100 and 2 g/L NaCl in water and adjusting the pH with 200mM HCI to obtain a solution with a final pH=1. 7.

PG solvates of steroids are also included as embodiments of the present invention.

Steroids are an important class of drugs which have low aqueous solubility.

Particularly important steroids include acetoxypregnenolone, alclometasone dipropionate, aldosterone, anagestone, norethynodrel. , androsterone, betamethasone, budesonide, chlormadinone, chloroprednisone, corticosterone, cortisone, cyclosporine, desogestrel, desoximethasone, desoxycorticosterone, dexamethasone, dichlorisone, dimethisterone, equilenin, equilin, estradiol, estriol, estrogens, estrone, ethisterone, ethynodiol di, ethynyl estradiol, fludrocortisone, fludrocortisone, flunsolide, fluocinolone acetonide, fluorohydrocortisone, fluorometholone, fluoxymesterone, fluprednisolone, flurandrenolide, flurandrenolone, flurogestone, fluticasone propionate, hydrocortisone, hydroxydion, hydroxymethylprogesterone, hydroxyprogesterone, leuprolide, levonorgestrel, loteprednol etabonate, medroxyprogesterone, melengestrol, mesalamine, mestranol, methandrostenolone, methazolamide, methyl testosterone, methylandrostenediol, methylprednisolone, mometasone furoate, norelgestromin, norethandrolone, norethindrone, norethindrone, norethisterone, norgestimate, norgestrel, normethisterone, ondansetron hydrochloride, oxandrolone, oxymetholone, paramethasone, paramethasone, prednisolone, prednisolone, prednisone, pregnenolone, progesterone, prometholone, spironolactone, testosterone, testosterone enanthate, triamcinolone, triamcinolone acetonide, triamcinolone acetonide, vetamethasone disodium phosphate (for some steroids alternative names are included). Formulating steroid drugs presents a problem because of their low aqueous solubility. Embodiments of the present invention are methods of increasing the solubility of steroids by making a PG solvate. Solubility can be specified as discussed above. It is difficult to make crystals of steroids because of their planar structure. Crystallization can be facilitated by making PG solvates.

Thus, crystalline PG solvates of steroids and methods of making the same are included in embodiments of the present invention. Steroids generally tend to form non-stoichiometric channel hydrates in which water molecules are trapped in channels between planar steroid regions. Thus, embodiments of the present invention include inhibiting channel formation in steroids by making a PG solvate. Metal salts of steroid drugs can be made and are another example of hygroscopic drugs. Thus, steroid PG solvates are in accordance with one aspect of the present invention.

Steroid drugs, whether hygroscopic or not, surprisingly and advantageously form stoichiometric solvates with propylene glycol. Further, the dissolution rate and solubility can be increased with propylene glycol solvates. Thus, the steroid solvates have surprisingly new properties that make them more favourable for pharmaceutical use and are easier to handle than other forms such as hydrates.

In a further aspect, the present invention provides a method for preparing a propylene glycol solvate of a drug, which method comprises: (a) contacting propylene glycol with a drug in solution; (b) crystallizing a propylene glycol solvate of the drug from the solution; and (c) isolating the solvate. (the drug may be, for example, a hygroscopic drug or a drug of low aqueous solubility).

In a further aspect, the present invention provides a method for decreasing the hygroscopicity of a drug, which method comprises (a) contacting the drug with propylene glycol in solution; (b) crystallizing a propylene glycol solvate of the drug from the solution; and (c) isolating the solvate, wherein the solvate has decreased hygroscopicity as compared to the drug.

In a further aspect, the present invention provides a method for increasing the aqueous solubility of a drug, which method comprises (a) contacting the drug with propylene glycol in solution; (b) crystallizing a propylene glycol solvate of the drug from the solution; and (c) isolating the solvate, wherein the solvate has increased aqueous solubility as compared to the drug.

Typically, conditions for making a solvate are the same as for preparing the corresponding non-solvated form of the drug: the solvate of neutral compound would not be pH controlled; the solvate of an acid addition salt would be prepared by including PG with the drug and the acid; and the solvate of a base addition salt would involve adding the drug, the desired base, and the PG. Different co-solvent systems, anti-solvents, or temperature conditions may be used to encourage PG solvate formation. Seed crystals may be added if they have previously been prepared and isolated.

The step of isolating the solvate may include separating the solution phase from the solvate. Any common method of separation may be employed, including filtration and decanting. The crystalline solvate may be rinsed one or more times with an appropriate solvent following filtration or decanting. The crystalline solvate is preferably dried to remove excess solution phase. Drying may be carried out by thermal processing, vacuum, blowing a stream of gas such as air, nitrogen, argon or another inert gas, or a combination of any or all of these methods. The intention of the rinsing and drying steps is to remove impurities including residual co-solvents and excess PG, acid, or base if used.

The invention will now be described in further detail, by way of example only, with reference to the accompanying drawings.

BRIEF DESCRIPTION OF THE DRAWINGS Fig. 1 shows a thermogravimetric analysis of a propylene glycol solvate of a celecoxib sodium salt.

Fig. 2A-D shows the PXRD pattern of a propylene glycol solvate of a celecoxib sodium salt.

Fig. 3 shows a thermogravimetric analysis of a propylene glycol solvate of a celecoxib potassium salt.

Fig. 4 shows the PXRD pattern of a propylene glycol solvate of a celecoxib potassium salt.

Fig. 5 shows a thermogravimetric analysis of a propylene glycol solvate of a celecoxib lithium salt.

Fig. 6 shows the PXRD pattern of a propylene glycol solvate of a celecoxib lithium salt.

Fig. 7 shows the thermogravimetric analysis of a propylene glycol solvate of naproxen sodium salt.

Fig. 8 shows a PXRD pattern of a propylene glycol solvate of naproxen sodium salt.

Fig. 9 shows the thermogravimetric analysis of a propylene glycol solvate of olanzapine form I.

Fig. 10 shows the differential scanning calorimetry thermogram ofapropylene glycol solvate of olanzapine form I.

Fig. 1 lA-B shows PXRD patterns of a propylene glycol solvate of olanzapine form I.

Fig. 12 shows a packing diagram of olanzapine form I PG solvate.

Fig. 13 shows the thermogravimetric analysis of a propylene glycol solvate of cortisone acetate.

Fig. 14 shows the differential scanning calorimetry thermogram of a propylene glycol solvate of cortisone acetate.

Fig. 15A-B shows PXRD patterns of a propylene glycol solvate of cortisone acetate.

Fig. 16 shows a PXRD pattern of cortisone acetate.

Fig. 17 shows a packing diagram of cortisone acetate PG solvate.

Fig. 18 shows the thermogravimetric analysis of a trihydrate of celecoxib sodium PG solvate.

Fig. 19 shows the PXRD pattern of a trihydrate of celecoxib sodium PG solvate.

Fig. 20 shows the thermogravimetric analysis of a trihydrate of celecoxib sodium PG solvate.

Fig. 21 shows the PXRD pattern of a trihydrate of celecoxib sodium PG solvate.

Fig. 22 shows the PXRD pattern of celecoxib sodium salt.

Fig. 23 shows the PXRD pattern of celecoxib lithium salt.

Fig. 24 shows the PXRD pattern of celecoxib potassium salt.

DETAILED DESCRIPTION OF THE INVENTION The present invention relates to propylene glycol solvate forms, preferably stoichiometric, of certain drugs, including those which are hygroscopic or have low aqueous solubility. Whilst the invention is applicable to any such drugs in general, metal salts of the non-steroidal anti-inflammatory drug celecoxib serve to illustrate the present invention by way of example. Unlike traditional non-steroidal anti- inflammatory drugs (NSAIDs), celecoxib is a selective inhibitor of cyclooxygenase II (COX-2) which causes fewer side effects when administered to a subject. The present applicants have identified new forms of celecoxib that have improved properties, particularly as oral formulations. The applicants have found that a stable, crystalline sodium salt of celecoxib can be synthesised which is significantly more soluble in water than the neutral celecoxib on the market. This sodium salt, or other metal salts can subsequently be improved according to the present invention by the production of a propylene glycol solvate thereof.

Salts of celecoxib are formed by reaction of celecoxib with an acceptable base.

Acceptable bases include, but are not limited to, metal hydroxides and alkoxides with sufficiently high pKa's (e. g., pKa's greater than about 11 to about 12).

Naproxen is a further API which may be used to illustrate the present invention.

Naproxen is a member of the ibufenac group of NSAIDs. This API is practically insoluble in water. Other examples of illustrations of the present invention include olanzapine and cortisone acetate.

An aspect of the present invention provides a pharmaceutical composition comprising a propylene glycol solvate of a drug that is less hygroscopic than the amorphorous, neutral crystalline, or salt crystalline form, and/or has greater aqueous solubility.

Hygroscopicity should be assessed by dynamic vapor sorption analysis, in which 5-50 mg of the compound is suspended from a Cahn microbalance. The compound being analyzed should be placed in a non-hygroscopic pan and its weight should be measured relative to an empty pan composed of identical material and having nearly identical size, shape, and weight. Ideally, platinum pans should be used. The pans should be suspended in a chamber through which a gas, such as air or nitrogen, having a controlled and known percent relative humidity (% RH) is flowed until eqilibrium criteria are met. Typical equilibrium criteria include weight changes of less than 0. 01 % change over 3 minutes at constant humidity and temperature. The relative humidity should be measured for samples dried under dry nitrogen to constant weight (<0.01 % change in 3 minutes) at 40 degrees C unless doing so would de- solvate or otherwise convert the material to an amorphous compound. In one aspect, the hygroscopicity of a dried compound can be assessed by increasing the RH from 5 to 95 % in increments of 5 % RH and then decreasing the RH from 95 to 5 % in 5 % increments to generate a moisture sorption isotherm. The sample weight should be allowed to equilibrate between each change in % RH. If the compound deliquesces or becomes amorphous between above 75 % RH, but below 95 % RH, the experiment should be repeated with a fresh sample and the relative humidity range for the cycling should be narrowed to 5-75 % RH or 10-75 % RH instead of 5-95 % RH. If the sample cannot be dried prior to testing due to lack of form stability, than the sample should be studied using two complete humidity cycles of either 10-75 % RH or 5-95 % RH, and the results of the second cycle should be used if there is significant weight loss at the end of the first cycle.

Hygroscopicity can be defined using various parameters. For purposes of the present invention, a non-hygroscopic molecule should not gain or lose more than 1.0%, or more preferably, 0.5 % weight at 25 degrees C when cycled between 10 and 75 % RH (relative humidity at 25 degrees C). The non-hygroscopic molecule more preferably should not gain or lose more than 1.0%, or more preferably, 0.5 % weight when cycled between 5 and 95 % RH at 25 degrees C, or more than 0.25 % of its weight between 10 and 75 % RH. Most preferably, a non-hygroscopic molecule will not gain or lose more than 0.25 % of its weight when cycled between 5 and 95 % RH.

Alternatively, for purposes of the present invention, hygroscopicity can be defined using the parameters of Callaghan et al., Equilibrium moisture content Of pharmaceutical excipierats, in Drug Dev. Ind. Pharm., Vol. 8, pp. 335-369 (1982).

Callaghan et al. classified the degree of hygroscopicity into four classes.

Class 1: Non-hygroscopic Essentially no moisture increases occur at relative humidities below 90%.

Class 2: Slightly hygroscopic Essentially no moisture increases occur at relative humidities below 80%.

Class 3: Moderately hygroscopic Moisture content does not increase more than 5% after storage for 1 week at relative humidities below 60%.

Class 4: Very hygroscopic Moisture content increase may occur at relative humidities as low as 40 to 50%.

Alternatively, for purposes of the present invention, hygroscopicity can be defined using the parameters of the European Pharmacopoeia Technical Guide (1999, p. 86) which has defined hygrospocity, based on the static method, after storage at 25 degrees C for 24 h at 80 % RH: Slightly hygroscopic: Increase in mass is less than 2 percent m/m and equal to or greater than 0.2 percent m/m.

Hygroscopic: Increase in mass is less than 15 percent m/m and equal to or greater than 0.2 percent m/m.

Very hygroscopic: Increase in mass is equal to or greater than 15 percent m/m.

Deliquescent: Sufficient water is absorbed to form a liquid.

PG solvates of the present invention can be set forth as being in Class 1, Class 2, or Class 3, or as being Slightly hygroscopic, Hygroscopic, or Very hygroscopic. PG solvates of the present invention can also be set forth based on their ability to reduce hygroscopicity. Thus, preferred PG solvates of the present invention are less hygroscopic than the non-PG solvated reference compound, e. g. , the reference compound of a celecoxib sodium salt PG solvate is celecoxib sodium salt. Further included in the present invention are PG solvates that do not gain or lose more than 1.0% weight at 25 degrees C when cycled between 10 and 75 % RH, wherein the reference compound gains or loses more than 1.0% weight under the same conditions.

Further included in the present invention are PG solvates that do not gain or lose more than 0.5% weight at 25 degrees C when cycled between 10 and 75 % RH, wherein the reference compound gains or loses more than 0.5% or more than 1.0% weight under the same conditions. Further included in the present invention are PG solvates that do not gain or lose more than 1.0% weight at 25 degrees C when cycled between 5 and 95 % RH, wherein the reference compound gains or loses more than 1.0% weight under the same conditions. Further included in the present invention are PG solvates that do not gain or lose more than 0.5% weight at 25 degrees C when cycled between 5 and 95 % RH, wherein the reference compound gains or loses more than 0.5% or more than 1.0% weight under the same conditions. Further included in the present invention are PG solvates that do not gain or lose more than 0.25% weight at 25 degrees C when cycled between 5 and 95 % RH, wherein the reference compound gains or loses more than 0.5% or more than 1.0% weight under the same conditions.

Further included in the present invention are PG solvates that have a hygroscopicity (according to Callaghan et al. ) that is at least one class lower than the reference compound or at least two classes lower than the reference compound. Non-limiting examples include; a Class 1 PG solvate of a Class 2 reference compound, a Class 2 PG solvate of a Class 3 reference compound, a Class 3 PG solvate of a Class 4 reference compound, a Class 1 PG solvate of a Class 3 reference compound, a Class 1 PG solvate of a Class 4 reference compound, or a Class 2 PG solvate of a Class 4 reference compound.

Further included in the present invention are PG solvates that have a hygroscopicity (according to the European Pharmacopoeia Technical Guide) that is at least one class lower than the reference compound or at least two classes lower than the reference compound. Non-limiting examples include; a Slightly hygroscopic PG solvate of a Hygroscopic reference compound, a Hygroscopic PG solvate of a Very Hygroscopic reference compound, a Very Hygroscopic PG solvate of a Deliquescent reference compound, a Slightly hygroscopic PG solvate of a Very Hygroscopic reference compound, a Slightly hygroscopic PG solvate of a Deliquescent reference compound, a Hygroscopic PG solvate of a Deliquescent reference compound.

In another aspect of the present invention, the dissolution profile of the API (active pharmaceutical ingredient) (e. g. celecoxib) is modulated whereby the aqueous dissolution rate or the dissolution rate in simulated gastric fluid (SGF) or in simulated intestinal fluid (SIF), or in a solvent or plurality of solvents is increased. Dissolution rate is the rate at which API solids dissolve in a dissolution medium. For APIs whose absorption rates are faster than the dissolution rates (e. g. , steroids), the rate-limiting step in the absorption process is often the dissolution rate. Because of a limited residence time at the absorption site, APIs that are not dissolved before they are removed from the intestinal absorption site are considered useless. Therefore, the rate of dissolution has a major impact on the performance of APIs that are poorly soluble.

Because of this factor, the dissolution rate of APIs in solid dosage forms is an important, routine, quality control parameter used in the API manufacturing process.

Dissolution rate = K S (Cs-C) (1) where K is dissolution rate constant, S is the surface area, Cs is the apparent solubility, and C is the concentration of API in the dissolution media. For rapid API absorption, Cs-C is approximately equal to Cs. The dissolution rate of APIs may be measured by conventional means known in the art.

The increase in the dissolution rate of a composition of the present invention, as compared to the unsolvated form, may be specified, such as by 10,20, 30,40, 50,60, 70,80, 90, or 100 %, or by 2,3, 4, 5, 6,7, 8,9, 10,15, 20,25, 30,40, 50,75, 100, 125,150, 175,200, 250,300, 350,400, 500,1000, 10,000, or 100,000 fold greater than the unsolvated form in the same solution. Conditions under which the dissolution rate is measured are discussed above. The increase in dissolution may be further specified by the time the composition remains supersaturated. Examples of above embodiments include: compositions with a dissolution rate, at 37 degrees C and a pH of 7.0, that is increased at least 5 fold over the unsolvated form, compositions with a dissolution rate in SGF that is increased at least 5 fold over the unsolvated form, compositions with a dissolution rate in SIF that is increased at least 5 fold over the unsolvated form.

The present invention demonstrates that the length of time in which celecoxib or other APIs remains in solution can be increased to a surprising high degree by using a PG solvate form as discussed herein. The presence of propylene glycol allows the formation of a supersaturated solution of the API and a high concentration of API will remain in solution for an extended period of time. Celecoxib, for example, has a solubility in water of less than 1 microgram/mL and cannot be maintained as a supersaturated solution for any appreciable time. The present invention has drawn compositions that can be maintained for a period of time (e. g. , 15,30, 45,60, minutes and longer) as supersaturated solutions at concentrations 2,3, 5,7, 10,20, 30,40, 50, 60,70, 80,90, or 100%, or by 3,4, 5,6, 7,8, 9,10, 15,20, 25, 30, 40,50, 75,100, 125,150, 175,200, 250,300, 350,400, 500,1000, 10,000, or 100,000 fold greater than the solubility of the unsolvated form in the same solution (e. g. , water or SGF).

The methods of the present invention can be used to make a pharmaceutical API formulation with greater solubility, dissolution, bioavailability, AUC, reduced time to Tmax. the average time from administration to reach peak blood serum levels, higher Cmax,, the average maximum blood serum concentration of API following administration, and longer Tl/2, the average terminal half-life of API blood serum concentration following Tmax, when compared to the unsolvated form.

AUC is the area under the plot of plasma concentration of API (not logarithm of the concentration) against time after API administration. The area is conveniently determined by the"trapezoidal rule" : the data points are connected by straight line segments, perpendiculars are erected from the abscissa to each data point, and the sum of the areas of the triangles and trapezoids so constructed is computed. When the last measured concentration (Cn, at time tn) is not zero, the AUC from tn to infinite time is estimated by Cn/ke ;.

The AUC is of particular use in estimating bioavailability of drugs, and in estimating total clearance of drugs (C1T). Following single intravenous doses, AUC = D/C1T, where D is the dose, for single compartment systems obeying first-order elimination kinetics ; alternatively, AUC = Co/kel, where kl is the drug elimination rate constant.

With routes other than the intravenous AUC = F D/C1T, where F is the bioavailability of the drug.

Thus, in a further aspect, the present invention provides a process for modulating the bioavailability of an API when administered in its normal and effective dose range, whereby the AUC is increased, the time to TmaX is reduced, or Cmax is increased, which process comprises the preparation of a PG solvate.

Examples of the above embodiments include: compositions with a time to Tmax that is reduced by at least 10% as compared to the neutral free form, compositions with a time to Tmax that is reduced by at least 20% over the free form, compositions with a time to Tmax that is reduced by at least 40% over the free form, compositions with a time to Tmax that is reduced by at least 50% over the free form, compositions with a TmaX that is reduced by at least 60% over the free form, compositions with a Tmax that is reduced by at least 70% over the free form, compositions with a Tmax that is reduced by at least 80% over the free form, compositions with a Cmax that is increased by at least 20% over the free form, compositions with a Cmax that is increased by at least 30% over the free form, compositions with a Cmax that is increased by at least 40% over the free form, compositions with a Cmax that is increased by at least 50% over the free form, compositions with a Cmax that is increased by at least 60% over the free form, compositions with a Cmax that is increased by at least 70% over the free form, compositions with a Cmax that is increased by at least 80% over the free form, compositions with a Cmax that is increased by at least 2 times the free form, compositions with a Cmax that is increased by at least 3 times the free form, compositions with a Cmax that is increased by at least 4 times the free form, compositions with a Cmax that is increased by at least 5 times the free form, compositions with a Cmax that is increased by at least 6 times the free form, compositions with a Cmax that is increased by at least 7 times the free form, compositions with a Cmax that is increased by at least 8 times the free form, compositions with a Cmax that is increased by at least 9 times the free form, compositions with a Cmax that is increased by at least 10 times the free form, compositions with an AUC that is increased by at least 10% over the free form, compositions with an AUC that is increased by at least 20% over the free form, compositions with an AUC that is increased by at least 30% over the free form, compositions with an AUC that is increased by at least 40% over the free form, compositions with an AUC that is increased by at least 50% over the free form, compositions with an AUC that is increased by at least 60% over the free form, compositions with an AUC that is increased by at least 70% over the free form, compositions with an AUC that is increased by at least 80% over the free form, compositions with an AUC that is increased by at least 1 times the free form, compositions with an AUC that is increased by at least 2 times the free form, compositions with an AUC that is increased by at least 3 times the free form, or compositions with an AUC that is increased by at least 4 times the free form.

The uptake of a drug by a subject can also be assessed in terms of maximum blood serum concentration and time to reach maximum blood serum concentration.

Pharmaceutical compositions with a more rapid onset to therapeutic effect typically reach a higher maximum blood serum concentration (Cmax) a shorter time after oral administration (Tmax). Preferably, compositions of the present invention have a higher Cmax and/or a shorter Tmzx than in the unsolvated form. The Tmax for the compositions of the present invention occurs within about 60 minutes, 55 minutes, 50 minutes, 45 minutes, 40 minutes, 35 minutes, 30 minutes, 25 minutes, 20 minutes, 15 minutes, 10 minutes, or within about 5 minutes of administration (e. g. , oral administration). Even more preferably, the therapeutic effects of compositions of the present invention begin to occur within about 60 minutes, 55 minutes, 50 minutes, 45 minutes, 40 minutes, 35 minutes, 30 minutes, within about 25 minutes, within about 20 minutes, within about 15 minutes, within about 10 minutes, or within about 5 minutes of administration (e. g. , oral administration).

Compositions of the present invention have a bioavailability greater than their respective unsolvated forms. In other embodiments, the compositions of the present invention have a bioavailability of at least 50%, 60%, 65%, 70%, 75%, 80%, 85%, 87%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99%.

In a particular embodiment of the present invention, administration of celecoxib PG solvate to a subject may result in effective pain relief. Pain relief can be attained by inter alia reaching an appropriate blood serum concentration of a suitable analgesic.

In the case of the selective COX-2 inhibitor celecoxib, about 250 ng/mL is an appropriate concentration for the relief of pain of various causes. Any standard pharmacokinetic protocol can be used to determine blood serum concentration profile in humans following oral administration of a celecoxib formulation, and thereby establish whether that formulation meets the-pharmacokinetic criteria set out herein.

The prior art includes many examples of pharmacokinetic studies and as such US Pat.

No. 6,579, 895 and WO 01/91750 are hereby included as references in their entirety.

In a further aspect the present invention provides a process for improving the dose response of an API by making a composition of the present invention. Dose response is the quantitative relationship between the magnitude of response and the dose inducing the response and may be measured by conventional means known in the art.

The curve relating therapeutic effect (as the dependent variable) to dose (as the independent variable) for an API-cell system is the"dose-response curve". Typically, the dose-response curve is the measured response to an API plotted against the dose of the API (mg/kg) given. The dose response curve can also be a curve of AUC against the dose of the API given.

The dose-response curve for many APIs (e. g. presently-marketed celecoxib (CELEBREX)) is nonlinear. Preferably, the dose-response curves for the PG solvate compositions of the present invention are linear or contain a larger linear region than presently-marketed celecoxib. A preferred embodiment of the present invention may incorporate a dose-response curve with a linear slope that is steeper than that of celecoxib. This would allow a faster-onset of therapeutic relief from a smaller dosage of API. An initially steep dose-response curve which gradually levels out could be employed to generate a controlled-release formulation. Also, the absorption or uptake of many APIs (e. g. presently-marketed celecoxib) depends in part on food effects, such that uptake of the API increases when taken with food, especially fatty food. Preferably, uptake of the PG solvates of the present invention exhibit a decreased dependence on food, such that the difference in uptake of the PG solvates when taken with food and when not taken with food is less than the difference in uptake of the unsolvated form.

The compositions of the present invention, including the active pharmaceutical ingredient (API) and formulations comprising the API, are suitably stable for pharmaceutical use. Preferably, the API or formulations thereof of the present invention are stable such that when stored at 30 degrees C for 2 years, less than 0.2% of any one degradant is formed. The term degradant refers herein to product (s) of a single type of chemical reaction. For example, if a hydrolysis event occurs that cleaves a molecule into two products, for the purpose of the present invention, it would be considered a single degradant. More preferably, when stored at 40 degrees C for 2 years, less than 0.2% of any one degradant is formed. Alternatively, when stored at 30 degrees C for 3 months, less than 0.2% or 0.15%, or 0.1% of any one degradant is formed, or when stored at 40 degrees C for 3 months, less than 0.2% or 0. 15%, or 0. 1% of any one degradant is formed. Further alternatively, when stored at 60 degrees C for 4 weeks, less than 0.2% or 0.15%, or 0. 1 % of any one degradant is formed. The relative humidity (RH) may be specified as ambient (RH), 75% (RH), or as any single integer between 1 to 99%.

APIs prepared in the form of propylene glycol solvates have several important advantages over other solvates and their free form counterparts. In general, solvates are more commonly formed with water, methanol, ethanol, or other alcohols than with propylene glycol. These more common solvates are more easily removed from the crystal matrix by elevated temperatures than propylene glycol. PG solvates have an increased thermal stability over those of more traditional solvates. Also, PG solvates are generally more pharmaceutically acceptable than other common solvates, including those formed from alcohols other than ethanol. Investigations of the PG solvates of the present invention have shown fewer solvation states than hydration states. Reference compounds for PG solvates can be unsolvated free acid, unsolvated free base, zwitter ions, hydrates, or other solvates (e. g. methanol, ethanol, etc. ). This decrease in form diversity associated with PG solvates can lead to more predictability and more consistent results during production and quality control. Stabilization of a desired solvate or polymorph can be achieved by causing the less desirable forms (e. g. solvates, polymorphs, hydrates) to be energetically less favorable than the desired form. In this way, PG solvates can aid in the production of pharmaceutical formulations with increased form stability.

The present invention further relates to methods of making a pharmaceutical solvate more stable at elevated temperatures (e. g. 30,40, 50 degrees C) by producing a PG solvate of the drug. The present invention further relates to methods of making a more pharmaceutically acceptable solvate of many APIs by employing propylene glycol rather than more biologically harmful solvents (e. g. methanol). The present invention further relates to methods of reducing the number of forms (e. g. hydration states, solvation states, polymorphs, etc. ) possible for a pharmaceutical solvate.

Pharmaceutically acceptable PG solvates can be administered by controlled-or delayed-release means. Controlled-release pharmaceutical products have a common goal of improving drug therapy over that achieved by their non-controlled release counterparts. Ideally, the use of an optimally designed'controlled-release preparation in medical treatment is characterized by a minimum of drug substance being employed to cure or control the condition in a minimum amount of time. Advantages of controlled-release formulations include: 1) extended activity of the drug; 2) reduced dosage frequency; 3) increased patient compliance; 4) usage of less total drug; 5) reduction in local or systemic side effects; 6) minimization of drug accumulation; 7) reduction in blood level fluctuations; 8) improvement in efficacy of treatment ; 9) reduction of potentiation or loss of drug activity ; and 10) improvement in speed of control of diseases or conditions. (Kim, Chemg-ju, Controlled Release Dosage Form Design, Technomic Publishing, Lancaster, Pa.: 2000).

Conventional dosage forms generally provide rapid or immediate drug release from the formulation. Depending on the pharmacology and pharmacokinetics of the drug, use of conventional dosage forms can lead to wide fluctuations in the concentrations of the drug in a patient's blood and other tissues. These fluctuations can impact a number of parameters, such as dose frequency, onset of action, duration of efficacy, maintenance of therapeutic blood levels, toxicity, side effects, and the like.

Advantageously, controlled-release formulations can be used to control a drug's onset of action, duration of action, plasma levels within the therapeutic window, and peak blood levels. In particular, controlled-or extended-release dosage forms or formulations can be used to ensure that the maximum effectiveness of a drug is achieved while minimizing potential adverse effects and safety concerns, which can occur both from under dosing a drug (i. e. , going below the minimum therapeutic levels) as well as exceeding the toxicity level for the drug.

Most controlled-release formulations are designed to initially release an amount of drug (active ingredient) that promptly produces the desired therapeutic effect, and gradually and continually release other amounts of drug to maintain this level of therapeutic or prophylactic effect over an extended period of time. In order to maintain this constant level of drug in the body, the drug must be released from the dosage form at a rate that will replace the amount of drug being metabolized and excreted from the body. Controlled-release of an active ingredient can be stimulated by various conditions including, but not limited to, pH, ionic strength, osmotic pressure, temperature, enzymes, water, and other physiological conditions or compounds.

A variety of known controlled-or extended-release dosage forms, formulations, and devices can be adapted for use with the PG solvates of the present invention.

Examples include, but are not limited to, those described in U. S. Pat. Nos.: 3,845, 770; 3, 916, 899; 3,536, 809; 3,598, 123; 4,008, 719; 5,674, 533; 5,059, 595; 5,591, 767; 5, 120,548 ; 5,073, 543; 5,639, 476 ; 5,354, 556; 5,733, 566; and 6,365, 185 Bl ; each of which is incorporated herein by reference. These dosage forms can be used to provide slow or controlled-release of one or more active ingredients using, for example, hydroxypropylmethyl cellulose, other polymer matrices, gels, permeable membranes, osmotic systems (such as OROS@ (Alza Corporation, Mountain View, Calif. USA)), multilayer coatings, microparticles, liposomes, or microspheres or a combination thereof to provide the desired release profile in varying proportions. Additionally, ion exchange materials can be used to prepare immobilized, adsorbed salt forms and thus effect controlled delivery of the drug. Examples of specific anion exchangers include, but are not limited to, Duolite (3) A568 and Duolite (E) AP143 (Rohm & Haas, Spring House, PA. USA).

One embodiment of the invention encompasses a unit dosage form which comprises a pharmaceutically acceptable PG solvate, or a polymorph, solvate, hydrate, dehydrate, co-crystal, anhydrous, or amorphous form thereof, and one or more pharmaceutically acceptable excipients or diluents, wherein the pharmaceutical composition or dosage form is formulated for controlled-release. Specific dosage forms utilize an osmotic drug delivery system.

A particular and well-known osmotic drug delivery system is referred to as OROS@ (Alza Corporation, Mountain View, Calif. USA). This technology can readily be adapted for the delivery of compounds and compositions of the invention. Various aspects of the technology are disclosed in U. S. Pat. Nos. 6,375, 978 B1 ; 6,368, 626 B1 ; 6,342, 249 Bl ; 6,333, 050 B2; 6,287, 295 Bl ; 6,283, 953 B1 ; 6,270, 787 Bl ; 6,245, 357 B 1 ; and 6, 132, 420; each of which is incorporated herein by reference. Specific adaptations of OROS@ that can be used to administer compounds and compositions of the invention include, but are not limited to, the OROS@ Push-PullTM, Delayed Push-Pull, Multi-Layer Push-PulITM, and Push-Stick Systems, all of which are well known. See, e. g. , http://www. alza. com. Additional OROS@ systems that can be used for the controlled oral delivery of compounds and compositions of the invention include OROS@-CT and L-OROS@. Id.; see also, Delivery Times, vol. II, issue II (Alza Corporation).

Conventional OROS@ oral dosage forms are made by compressing a drug powder (e. g. , celecoxib sodium PG solvate) into a hard tablet, coating the tablet with cellulose derivatives to form a semi-permeable membrane, and then drilling an orifice in the coating (e. g. , with a laser). (Kim, Cherng-ju, Controlled Release Dosage Form Design, Technomic Publishing, Lancaster, Pa.: 2000). The advantage of such dosage forms is that the delivery rate of the drug is not influenced by physiological or experimental conditions. Even a drug with a pH-dependent solubility can be delivered at a constant rate regardless of the pH of the delivery medium. But because these advantages are provided by a build-up of osmotic pressure within the dosage form after administration, conventional OROS@ drug delivery systems cannot be used to effectively deliver drugs with low water solubility. Because PG solvates and complexes of this invention (e. g. , celecoxib sodium PG solvate) are far more soluble in water than unsolvated forms, they are well suited for osmotic-based delivery to patients.

A specific dosage form of the invention comprises: a wall defining a cavity, the wall having an exit orifice formed or formable therein and at least a portion of the wall being semipermeable; an expandable layer located within the cavity remote from the exit orifice and in fluid communication with the semipermeable portion of the wall; a dry or substantially dry state drug layer located within the cavity adjacent to the exit orifice and in direct or indirect contacting relationship with the expandable layer; and a flow-promoting layer interposed between the inner surface of the wall and at least the external surface of the drug layer located within the cavity, wherein the drug layer comprises a PG solvate, or a polymorph, solvate, hydrate, dehydrate, co-crystal, anhydrous, or amorphous form thereof. See U. S. Pat. No. 6,368, 626, the entirety of which is incorporated herein by reference.

Another specific dosage form of the invention comprises: a wall defining a cavity, the wall having an exit orifice formed or formable therein and at least a portion of the wall being semipermeable; an expandable layer located within the cavity remote from the exit orifice and in fluid communication with the semipermeable portion of the wall; a drug layer located within the cavity adjacent the exit orifice and in direct or indirect contacting relationship with the expandable layer; the drug layer comprising a liquid, active agent formulation absorbed in porous particles, the porous particles being adapted to resist compaction forces sufficient to form a compacted drug layer without significant exudation of the liquid, active agent formulation, the dosage form optionally having a placebo layer between the exit orifice and the drug layer, wherein the active agent formulation comprises a PG solvate, or a polymorph, solvate, hydrate, dehydrate, co-crystal, anhydrous, or amorphous form thereof. See U. S. Pat. No.

6,342, 249, the entirety of which is incorporated herein by reference.

Excipients employed in pharmaceutical compositions of the present invention can be solids, semi-solids, liquids or combinations thereof. Compositions of the invention containing excipients can be prepared by any known technique of pharmacy that comprises admixing an excipient with a drug or therapeutic agent. A pharmaceutical composition of the invention contains a desired amount of API per dose unit and, if intended for oral administration, can be in the form, for example, of a tablet, a caplet, a pill, a hard or soft capsule, a lozenge, a cachet, a dispensable powder, granules, a suspension, an elixir, a dispersion, a liquid, or any other form reasonably adapted for such administration. Presently preferred are oral dosage forms that are discrete dose units each containing a predetermined amount of the drug, such as tablets or capsules.

Non-limiting examples follow of excipients that can be used to prepare pharmaceutical compositions of the invention.

Pharmaceutical compositions of the invention optionally comprise one or more pharmaceutically acceptable carriers or diluents as excipients. Suitable carriers or diluents illustratively include, but are not limited to, either individually or in combination, lactose, including anhydrous lactose and lactose monohydrate; starches, including directly compressible starch and hydrolyzed starches (e. g., CelutabTM and EmdexTM) ; mannitol; sorbitol; xylitol; dextrose (e. g., Cerelose 2000) and dextrose monohydrate; dibasic calcium phosphate dihydrate; sucrose-based diluents; confectioner's sugar; monobasic calcium sulfate monohydrate; calcium sulfate dihydrate; granular calcium lactate trihydrate ; dextrates; inositol; hydrolyzed cereal solids; amylose; celluloses including microcrystalline cellulose, food grade sources of alpha-and amorphous cellulose (e. g. , RexcelJ), powdered cellulose, hydroxypropylcellulose (HPC) and hydroxypropylmethylcellulose (HPMC); calcium carbonate; glycine; bentonite; block co-polymers; polyvinylpyrrolidone; and the like.

Such carriers or diluents, if present, constitute in total about 5% to about 99%, preferably about 10% to about 85%, and more preferably about 20% to about 80%, of the total weight of the composition. The carrier, carriers, diluent, or diluents selected preferably exhibit suitable flow properties and, where tablets are desired, compressibility.

Lactose, mannitol, dibasic sodium phosphate, and microcrystalline cellulose (particularly Avicel PH microcrystalline cellulose such as Avicel PH 101), either individually or in combination, are preferred diluents. These diluents are chemically compatible with celecoxib. The use of extragranular microcrystalline cellulose (that is, microcrystalline cellulose added to a granulated composition) can be used to improve hardness (for tablets) and/or disintegration time. Lactose, especially lactose monohydrate, is particularly preferred. Lactose typically provides compositions having suitable release rates of celecoxib, stability, pre-compression flowability, and/or drying properties at a relatively low diluent cost. It provides a high density substrate that aids densification during granulation (where wet granulation is employed) and therefore improves blend flow properties and tablet properties.

Pharmaceutical compositions of the invention optionally comprise one or more pharmaceutically acceptable disintegrants as excipients, particularly for tablet formulations. Suitable disintegrants include, but are not limited to, either individually or in combination, starches, including sodium starch glycolate (e. g., Explotab of PenWest) and pregelatinized corn starches (e. g., National 1551 of National Starch and Chemical Company, National 1550, and Colorcon 1500), clays (e. g., VeegUMTm HV of R. T. Vanderbilt), celluloses such as purified cellulose, microcrystalline cellulose, methylcellulose, carboxymethylcellulose and sodium carboxymethylcellulose, croscarmellose sodium (e. g., Ac-Di-SolTM of FMC), alginates, crospovidone, and gums such as agar, guar, locust bean, karaya, pectin and tragacanth gums.

Disintegrants may be added at any suitable step during the preparation of the composition, particularly prior to granulation or during a lubrication step prior to compression. Such disintegrants, if present, constitute in total about 0.2 % to about 30 %, preferably about 0.2 % to about 10 %, and more preferably about 0.2 % to about 5 %, of the total weight of the composition.

Croscarmellose sodium is a preferred disintegrant for tablet or capsule disintegration, and, if present, preferably constitutes about 0.2 % to about 10 %, more preferably about 0.2 % to about 7 %, and still more preferably about 0.2 % to about 5 %, of the total weight of the composition. Croscarmellose sodium confers superior intragranular disintegration capabilities to granulated pharmaceutical compositions of the present invention.

Pharmaceutical compositions of the invention optionally comprise one or more pharmaceutically acceptable binding agents or adhesives as excipients, particularly for tablet formulations. Such binding agents and adhesives preferably impart sufficient cohesion to the powder being tableted to allow for normal processing operations such as sizing, lubrication, compression and packaging, but still allow the tablet to disintegrate and the composition to be absorbed upon ingestion. Such binding agents may also prevent or inhibit crystallization or recrystallization of a celecoxib salt of the present invention once the salt has been dissolved in a solution. Suitable binding agents and adhesives include, but are not limited to, either individually or in combination, acacia; tragacanth ; sucrose; gelatin; glucose; starches such as, but not limited to, pregelatinized starches (e. g., National 1511 and National 1500); celluloses such as, but not limited to, methylcellulose and carmellose sodium (e. g., Lose) ; alginic acid and salts of alginic acid; magnesium aluminum silicate; PEG; guar gum; polysaccharide acids; bentonites; povidone, for example povidone K-15, K-30 and K-29/32; polymethacrylates; HPMC; hydroxypropylcellulose (e. g., Klucel of Aqualon) ; and ethylcellulose (e. g., Ethocel of the Dow Chemical Company). Such binding agents and/or adhesives, if present, constitute in total about 0.5 % to about 25 %, preferably about 0.75 % to about 15 %, and more preferably about 1 % to about 10 %, of the total weight of the pharmaceutical composition.

Many of the binding agents are polymers comprising amide, ester, ether, alcohol or ketone groups and, as such, are preferably included in pharmaceutical compositions of the present invention. Polyvinylpyrrolidones such as povidone K-30 are especially preferred. Polymeric binding agents can have varying molecular weight, degrees of crosslinking, and grades of polymer. Polymeric binding agents can also be copolymers, such as block co-polymers that contain mixtures of ethylene oxide and propylene oxide units. Variation in these units'ratios in a given polymer affects properties and performance. Examples of block co-polymers with varying compositions of block units are Poloxamer 188 and Poloxamer 237 (BASF Corporation).

Pharmaceutical compositions of the invention optionally comprise one or more pharmaceutically acceptable wetting agents as excipients. Non-limiting examples of surfactants that can be used as wetting agents in pharmaceutical compositions of the invention include quaternary ammonium compounds, for example benzalkonium chloride, benzethonium chloride and cetylpyridinium chloride, dioctyl sodium sulfosuccinate, polyoxyethylene alkylphenyl ethers, for example nonoxynol 9, nonoxynol 10, and octoxynol 9, poloxamers (polyoxyethylene and polyoxypropylene block copolymers), polyoxyethylene fatty acid glycerides and oils, for example polyoxyethylene (8) caprylic/capric mono-and diglycerides (e. g., LabrasolTM of Gattefosse), polyoxyethylene (35) castor oil and polyoxyethylene (40) hydrogenated castor oil; polyoxyethylene alkyl ethers, for example polyoxyethylene (20) cetostearyl ether, polyoxyethylene fatty acid esters, for example polyoxyethylene (40) stearate, polyoxyethylene sorbitan esters, for example polysorbate 20 and polysorbate 80 (e. g., Tween 80 of ICI), propylene glycol fatty acid esters, for example propylene glycol laurate (e. g., LauroglycolTM of Gattefosse), sodium lauryl sulfate, fatty acids and salts thereof, for example oleic acid, sodium oleate and triethanolamine oleate, glyceryl fatty acid esters, for example glyceryl monostearate, sorbitan esters, for example sorbitan monolaurate, sorbitan monooleate, sorbitan monopalmitate and sorbitan monostearate, tyloxapol, and mixtures thereof. Such wetting agents, if present, constitute in total about 0.25 % to about 15 %, preferably about 0.4 % to about 10 %, and more preferably about 0.5 % to about 5 %, of the total weight of the pharmaceutical composition.

Wetting agents that are anionic surfactants are preferred. Sodium lauryl sulfate is a particularly preferred wetting agent. Sodium lauryl sulfate, if present, constitutes about 0.25 % to about 7 %, more preferably about 0.4 % to about 4 %, and still more preferably about 0.5 % to about 2 %, of the total weight of the pharmaceutical composition.

Pharmaceutical compositions of the invention optionally comprise one or more pharmaceutically acceptable lubricants (including anti-adherents and/or glidants) as excipients. Suitable lubricants include, but are not limited to, either individually or in combination, glyceryl behapate (e. g., Compritol 888 of Gattefossé), stearic acid and salts thereof, including magnesium, calcium and sodium stearates; hydrogenated vegetable oils (e. g., Sterotex of Abitec) ; colloidal silica; talc ; waxes; boric acid; sodium benzoate; sodium acetate; sodium fumarate; sodium chloride; DL-leucine; PEG (e. g., Carbowax 4000 and CarbowaXTm 6000 of the Dow Chemical Company); sodium oleate; sodium lauryl sulfate; and magnesium lauryl sulfate. Such lubricants, if present, constitute in total about 0.1 % to about 10 %, preferably about 0.2 % to about 8 %, and more preferably about 0.25 % to about 5 %, of the total weight of the pharmaceutical composition.

Magnesium stearate is a preferred lubricant used, for example, to reduce friction between the equipment and granulated mixture during compression of tablet formulations.

Suitable anti-adherents include, but are not limited to, talc, cornstarch, DL-leucine, sodium lauryl sulfate and metallic stearate. Talc is a preferred anti-adherent or glidant used, for example, to reduce formulation sticking to equipment surfaces and also to reduce static in the blend. Talc, if present, constitutes about 0.1 % to about 10 %, more preferably about 0.25 % to about 5 %, and still more preferably about 0.5 % to about 2 %, of the total weight of the pharmaceutical composition.

Glidants can be used to promote powder flow of a solid formulation. Suitable glidants include, but are not limited to, colloidal silicon dioxide, starch, talc, tribasic calcium phosphate, powdered cellulose and magnesium trisilicate. Colloidal silicon dioxide is particularly preferred.

Other excipients such as colorants, flavors and sweeteners are known in the pharmaceutical art and can be used in pharmaceutical compositions of the present invention. Tablets can be coated, for example with an enteric coating, or uncoated.

Compositions of the invention can further comprise, for example, buffering agents.

Optionally, one or more effervescent agents can be used as disintegrants and/or to enhance organoleptic properties of pharmaceutical compositions of the invention.

When present in pharmaceutical compositions of the invention to promote dosage form disintegration, one or more effervescent agents are preferably present in a total amount of about 30 % to about 75 %, and preferably about 45 % to about 70 %, for example about 60 %, by weight of the pharmaceutical composition.

According to a particularly preferred embodiment of the invention, an effervescent agent, present in a solid dosage form in an amount less than that effective to promote disintegration of the dosage form, provides improved dispersion of the celecoxib in an aqueous medium. Without being bound by theory, it is believed that the effervescent agent is effective to accelerate dispersion of the drug, such as celecoxib, from the dosage form in the gastrointestinal tract, thereby further enhancing absorption and rapid onset of therapeutic effect. When present in a pharmaceutical composition of the invention to promote intragastrointestinal dispersion but not to enhance disintegration, an effervescent agent is preferably present in an amount of about 1 % to about 20 %, more preferably about 2.5 % to about 15 %, and still more preferably about 5 % to about 10 %, by weight of the pharmaceutical composition.

An"effervescent agent"herein is an agent comprising one or more compounds which, acting together or individually, evolve a gas on contact with water. The gas evolved is generally oxygen or, most commonly, carbon dioxide. Preferred effervescent agents comprise an acid and a base that react in the presence of water to generate carbon dioxide gas. Preferably, the base comprises an alkali metal or alkaline earth metal carbonate or bicarbonate and the acid comprises an aliphatic carboxylic acid.

Non-limiting examples of suitable bases as components of effervescent agents useful in the invention include carbonate salts (e. g. , calcium carbonate), bicarbonate salts (e. g. , sodium bicarbonate), sesquicarbonate salts, and mixtures thereof. Calcium carbonate is a preferred base.

Non-limiting examples of suitable acids as components of effervescent agents and/or solid organic acids useful in the invention include citric acid, tartaric acid (as D-, L-, or D/L-tartaric acid), malic acid, maleic acid, fumaric acid, adipic acid, succinic acid, acid anhydrides of such acids, acid salts of such acids, and mixtures thereof. Citric acid is a preferred acid.

In a preferred embodiment of the invention, where the effervescent agent comprises an acid and a base, the weight ratio of the acid to the base is about 1: 100 to about 100: 1, more preferably about 1: 50 to about 50: 1, ~and-still more preferably about 1: 10 to about 10: 1. In a further preferred embodiment of the invention, where the effervescent agent comprises an acid and a base, the ratio of the acid to the base is approximately stoichiometric.

Excipients which solubilize metal salts of drugs like celecoxib typically have both hydrophilic and hydrophobic regions, or are preferably amphiphilic or have amphiphilic regions. One type of amphiphilic or partially-amphiphilic excipient comprises an amphiphilic polymer or is an amphiphilic polymer. A specific amphiphilic polymer is a polyalkylene glycol, which is commonly comprised of ethylene glycol and/or propylene glycol subunits. Such polyalkylene glycols can be esterified at their termini by a carboxylic acid, ester, acid anhyride or other suitable moiety. Examples of such excipients include poloxamers (symmetric block copolymers of ethylene glycol and propylene glycol; e. g. , poloxamer 237), polyalkyene glycolated esters of tocopherol (including esters formed from a di-or multi-functional carboxylic acid; e. g. , d-alpha-tocopherol polyethylene glycol-1000 succinate), and macrogolglycerides (formed by alcoholysis of an oil and esterification of a polyalkylene glycol to produce a mixture of mono-, di-and tri-glycerides and mono-and di-esters; e. g. , stearoyl macrogol-32 glycerides). Such pharmaceutical compositions are advantageously administered orally.

Solid dosage forms of the invention can be prepared by any suitable process, not limited to processes described herein.

An illustrative process comprises (a) a step of blending a celecoxib salt of the invention with one or more excipients to form a blend, and (b) a step of tableting or encapsulating the blend to form tablets or capsules, respectively.

In a preferred process, solid dosage forms are prepared by a process comprising (a) a step of blending a drug salt such as a celecoxib salt of the invention with one or more excipients to form a blend, (b) a step of granulating the blend to form a granulate, and (c) a step of tableting or encapsulating the blend to form tablets or capsules respectively. Step (b) can be accomplished by any dry or wet granulation technique known in the art, but is preferably a dry granulation step. A salt of the present invention is advantageously granulated to form particles of about 1 micrometer to about 100 micrometer, about 5 micrometer to about 50 micrometer, or about 10 micrometer to about 25 micrometer. One or more diluents, one or more disintegrants and one or more binding agents are preferably added, for example in the blending step, a wetting agent can optionally be added, for example in the granulating step, and one or more disintegrants are preferably added after granulating but before tableting or encapsulating. A lubricant is preferably added before tableting. Blending and granulating can be performed independently under low or high shear. A process is preferably selected that forms a granulate that is uniform in drug content, that readily disintegrates, that flows with sufficient ease so that weight variation can be reliably controlled during capsule filling or tableting, and that is dense enough in bulk so that a batch can be processed in the selected equipment and individual doses fit into the specified capsules or tablet dies.

In an alternative embodiment, solid dosage forms are prepared by a process that includes a spray drying step, wherein a celecoxib salt is suspended with one or more excipients in one or more sprayable liquids, preferably a non-protic (e. g. , non-aqueous or non-alcoholic) sprayable liquid, and then is rapidly spray dried over a current of warm air.

A granulate or spray dried powder resulting from any of the above illustrative processes can be compressed or molded to prepare tablets or encapsulated to prepare capsules. Conventional tableting and encapsulation techniques known in the art can be employed. Where coated tablets are desired, conventional coating techniques are suitable.

Excipients for tablet compositions of the invention are preferably selected to provide a disintegration time of less than about 30 minutes, preferably about 25 minutes or less, more preferably about 20 minutes or less, and still more preferably about 15 minutes or less, in a standard disintegration assay.

Celecoxib dosage forms of the invention preferably comprise celecoxib in a daily dosage amount of about 10 mg to about 1000 ring, more preferably about 25 mg to about 400 mg, and most preferably about 50 mg to about 200 mg.

In a further embodiment the PG solvate comprises an API from Table 3. For APIs in Table 3 listed as salts, solvates, hydrates, and the like, the PG solvate can either be of the form listed in Table 3 or a PG solvate of the free form, or a PG solvate of another form that is not listed. Table 3 includes the CAS number, chemical name or a PCT or patent reference (each incorporated herein in their entireties). In another embodiment, any one or more of the APIs of Table 3 may be specifically excluded from the present invention. Any APIs currently known in the art may also be specifically excluded from the present invention. For example, azithromycin and cephalosporin may be specifically excluded from the present invention.

EXEMPLIFICATION Procedure for Raman Acquisition Acquisition The sample was either left in the glass vial in which it was processed or an aliquot of the sample was transferred to a glass slide. The glass vial or slide was positioned in the sample chamber. The measurement was made using an Almega Dispersive Raman (Almega Dispersive Raman, Thermo-Nicolet, 5225 Verona Road, Madison, WI 53711-4495) system fitted with a 785 nm laser source. The sample was manually brought into focus using the microscope portion of the apparatus with a lOx power objective (unless otherwise noted), thus directing the laser onto the surface of the sample. The spectrum was acquired using the parameters outlined in Table 1.

(Exposure times and number of exposures may vary; changes to parameters will be indicated for each acquisition.) Table 2. Raman Spectral acquisition parameters Parameter Setting Used Exposure time (s) 2.0 Number of exposures 10 Laser source wavelength 785 ( Laser power (%) 100 Aperture shape pin hole Aperture size (um) 100 Spectral range 104-3428 Grating position Single Temperature at acquisition 24.0 (degrees C) Procedure for Powder X-Ray Diffraction (PXRD) All powder x-ray diffraction patterns were obtained using the D/Max Rapid X-ray Diffractometer (D/Max Rapid, Contact Rigaku/MSC, 9009 New Trails Drive, The Woodlands, Texas, USA 77381-5209) equipped with a copper source (Cu/K 1. 5406A), manual x-y stage, and 0.3 mm collimator, unless otherwise indicated. The sample was loaded into a 0.3 mm boron rich glass capillary tube (e. g. , Charles Supper Company, 15 Tech Circle, Natick Massachusetts 01760-1024) by sectioning off one end of the tube and tapping the open, sectioned end into a bed of the powdered sample or into the sediment of a slurried precipitate. Note, precipitate can be amorphous or crystalline. The loaded capillary was mounted in a holder that was secured into the x- y stage. A diffractogram was acquired (e. g. , Control software: RINT Rapid Control Software, Rigaku Rapid/XRD, version 1.0. 0, C) 1999 Rigaku Co. ) under ambient conditions at a power setting of 46 kV at 40 mA in reflection mode, while oscillating about the omega-axis from 0-5 degrees at 1 degree/s and spinning about the phi-axis at 2 degrees/s. The exposure time was 15 minutes unless otherwise specified. The diffractogram obtained was integrated over 2-theta from 2-60 degrees and chi (1 segment) from 0-360 degrees at a step size of 0.02 degrees using the cyllnt utility in the RINT Rapid display software (Analysis software: RINT Rapid display software, version 1.18, Rigaku/MSC. ) provided by Rigaku with the instrument. The dark counts value was set to 8 as per the system calibration (System set-up and calibration by Rigaku); normalization was set to average; the omega offset was set to 180° ; and no chi or phi offsets were used for the integration. The analysis software JADE XRD Pattern Processing, versions 5.0 and 6.0 ((81995-2002, Materials Data, Inc. was also used.

The relative intensity of peaks in a diffractogram is not necessarily a limitation of the PXRD pattern because peak intensity can vary from sample to sample, e. g. , due to crystalline impurities. Further, the angles of each peak can vary by about +/-0.1 degrees, preferably +/-0. 05. The entire pattern or most of the pattern peaks may also shift by about +/-0.1 degree due to differences in calibration, settings, and other variations from instrument to instrument and from operator to operator. The above limitations result in a PXRD error of +/-0. 1 degrees 2-theta for each diffraction peak.

Procedure for Differential Scanning Calorimetry (DSC) An aliquot of the sample was weighed into an aluminum sample pan. (e. g., Pan part # 900786.091 ; lid part # 900779.901 ; TA Instruments, 109 Lukens Drive, New Castle, Delaware 19720) The sample pan was sealed either by crimping for dry samples or press fitting for wet samples (e. g. , hydrated or solvated samples). The sample pan was loaded in to the apparatus (DSC: Q1000 Differential Scanning Calorimeter, TA Instruments, 109 Lukens Drive, New Castle, Delaware 19720), which is equipped with an autosampler, and a thermogram was obtained by individually heating the sample (e. g., Control software: Advantage for QW-Series, version 1.0. 0.78, Thermal Advantage Release 2.0, O 2001 TA instruments-Water LLC) at a rate of 10 degrees C/min from Tmin (typically 20 degrees C) to Tmax (typically 300 degrees C) (Heating rate and temperature range may vary, changes to these parameters will be indicated for each sample) using an empty aluminum pan as a reference. Dry nitrogen (e. g., Compressed nitrogen, grade 4.8, BOC Gases, 575 Mountain Avenue, Murray Hill, New Jersey 07974-2082) was used as a sample purge gas and was set at a flow rate of 50 mL/min. Thermal transitions were viewed and analyzed using the analysis software (Analysis Software: Universal Analysis 2000 for Windows 95/95/2000/NT, version 3. 1E ; Build 3.1. 0.40, (O 1991-2001TA instruments-Water LLC) provided with the instrument.

Procedure for Thermogravimetric Analysis (TGA) An aliquot of the sample was transferred into a platinum sample pan. (Pan part # 952019.906 ; TA Instruments, 109 Lukens Drive, New Castle, Delaware 19720) The pan was placed on the loading platform and was then automatically loaded in to the apparatus (TGA: Q500 Thermogravimetric Analyzer, TA Instruments, 109 Lukens Drive, New Castle, Delaware 19720) using the control software (Control software: Advantage for QW-Series, version 1.0. 0.78, Thermal Advantage Release 2.0, (C) 2001 TA instruments-Water LLC). Thermograms were obtained by individually heating the sample at 10 degrees C/min from 25 degrees C to 300 degrees C (Heating rate and temperature range may vary, changes in parameters will be indicated for each sample) under flowing dry nitrogen (e. g., Compressed nitrogen, grade 4.8, BOC Gases, 575 Mountain Avenue, Murray Hill, New Jersey 07974-2082), with a sample purge flow rate of 60 mL/min and a balance purge flow rate of 40 mL/min. Thermal transitions (e. g. weight changes) were viewed and analyzed using the analysis software (Analysis Software: Universal Analysis 2000 for Windows 95/95/2000/NT, version 3. 1E ; Build 3.1. 0.40, (C) 1991-2001TA instruments-WaterLLC) provided with the instrument.

Example 1 Celecoxib Sodium Salt PG solvate A propylene glycol solvate of the sodium salt of celecoxib was prepared. To a solution of celecoxib (312 mg; 0.818 mmol) in diethyl ether (6 mL) was added propylene glycol (0.127 mL, 1.73 mmol). To the clear solution was added sodium ethoxide in ethanol (21%, 0.275 mL, 0.817 mmol). After 1 minute, crystals began to form. After 5 minutes, the solid had completely crystallized. The solid was collected by filtration and was washed with additional diethyl ether (10 rnL). The off-white solid was then air-dried and collected. The crystalline salt form was identified as a 1: 1 solvate of propylene glycol. The solid was characterized by TGA and PXRD.

The results are depicted in Figs. 1 and 2A.

Fig. 1 shows the results of TGA. A weight loss of about 15.6 % was observed between about 65 and 200 degrees C which represents 1 molar equivalent of propylene glycol to celecoxib Na salt. Fig. 2A shows the results of PXRD. Peaks, in 2-theta angles, that can be used to characterize the solvate include any 1, 2,3, 4,5, 6, 7,8, 9, or 10 of the following: 3.77, 7.57, 8.21, 11.33, 14.23, 16.13, 18.69, 20.65, 22.69 and 24.77 degrees or any one or any combination of 1,2, 3,4, 5,6, 7,8, 9,10, or more peaks of Fig. 2A. The TGA thermogram or PXRD diffractogram data may be used alone or in any combination to characterize the solvate. A 0.8 mm collimator was used during acquisition of the diffractogram.

Several closely related, yet distinguishable, PXRD diffractograms have been obtained by performing the above synthesis several times. Figs. 2B, 2C, and 2D are additional diffractograms of the propylene glycol solvate of celecoxib sodium salt. A comparison of these diffractograms yields a number of noticeable differences. For example, the peak at 8.21 degrees 2-theta in Fig. 2A is not present in Figs. 2B or 2C.

Another peak at 8.79 degrees 2-theta, present in Figs. 2B and 2D, is not found in Figs.

2A or 2C. Other distinctions can also be found between the four diffractograms.

Such distinctions in otherwise similar diffractograms suggest the existence of polymorphism or perhaps a variable hydrate.

In another embodiment of the present invention, a PG solvate of an API can give rise to distinct PXRD diffractograms. This can be caused by polymorphism, a variable hydrate, a different environmental condition, etc. In one embodiment, the propylene glycol solvate of celecoxib sodium salt can yield a PXRD pattern with the absence or presence of a peak at 8.21 degrees 2-theta. In another embodiment, the propylene glycol solvate of celecoxib sodium salt can yield a PXRD pattern with the absence or presence of a peak at 8.79 degrees 2-theta.

Example 2 Celecoxib Potassium Salt PG Solvate A propylene glycol solvate of the potassium salt of celecoxib was prepared.

To a solution of celecoxib (253 mg, 0.664 mmol) in diethyl ether (6 mL) was added propylene glycol (0.075 mL, 1.02 mmol). To the clear solution was added potassium t-butoxide in tetrahydrofuran (THF) (1 M, 0.66 mL, 0.66 mmol). Crystals immediately began to form. After 5 minutes, the solid had completely crystallized.

The solid was collected by filtration and was washed with additional diethyl ether (10 mL). The white solid was then air-dried and collected. The crystalline salt form was found to be a 1: 1 propylene glycol solvate of celecoxib K salt. The solid was characterized by TGA and PXRD. The results are depicted in Figs. 3 and 4.

Fig. 3 shows the results of TGA. A weight loss of about 14.94 % was observed between about 65 and about 250 degrees C which is consistent with 1 molar equivalent of propylene glycol to celecoxib K. Fig. 4 shows the results of PXRD.

Peaks, in 2-theta angles, that can be used to characterize the solvate include any 1,2, 3,4, 5,6, 7,8, 9, or 10 of the following : 3.75, 7.47, 11.33, 14.89, 15.65, 18.31, 20.49, 21.73, 22. 51, and 24.97 degrees or any one or any combination of 1, 2,3, 4,5, 6,7, 8,9, 10, or more peaks of Fig. 4.

Example 3 Celecoxib Lithium Salt PG Solvate A propylene glycol solvate of the lithium salt of celecoxib was prepared. To a solution of celecoxib (264 mg, 0.693 mmol) in diethyl ether (8 mL) was added propylene glycol (0.075 mL, 1.02 mmol). To the clear solution was added t-butyl lithium in pentane (1.7 M, 0.40 mL, 0.68 mmol). A brown solid formed immediately but dissolved within one minute which subsequently yielded a white fluffy solid. The white solid crystallized completely after 10 minutes. The solid was collected by filtration and was washed with additional diethyl ether (10 mL). The white solid was then air-dried and collected. The crystalline salt form was found to be a 1: 1 propylene glycol solvate of celecoxib Li. The solid was characterized by TGA and PXRD.

The results of TGA are depicted in Fig. 5 and show a weight loss of about 16.3 % between 50 degrees C and 210 degrees C which is consistent with 1 molar equivalent of propylene glycol to celecoxib Li. The results of PXRD are shown in Fig. 6.

Characteristic peaks of 2-theta angles that can be used to characterize the salt include any one, or combination of any 2,3, 4,5, 6,7, 8,9, 10,11, or 12 of 3.79, 7.51, 8.19, 9.83, 11.41, 15.93, 18.29, 19.19, 19. 87, 20.63, 22.01, or 25. 09 degrees or any one or any combination of peaks of Fig. 6.

Example 4 Naproxen Sodium Salt PG Solvate A propylene glycol solvate of a sodium salt of naproxen was prepared. To a solution of naproxen (348 mg, 1.51 mmol) in diethyl ether (10 mL) was added propylene glycol (0.200 ml, 2.72 mmol). To the clear solution was added sodium ethoxide in ethanol (21 %, 0.750 mL, 2.01 mmol). The solution became slightly yellow due to the sodium ethoxide. After 1 minute, crystals began to form. After 5 minutes, the solid had completely crystallized. The solid was collected by filtration and was washed with diethyl ether (10 mL). The product was then air-dried and collected. The solvate was 2: 1 naproxen Na: propylene glycol. The solid was characterized by TGA and PXRD The TGA thermogram of naproxen sodium salt PG solvate is shown in Fig. 7, and indicates a 13.5 percent weight loss between about 75 and 150 degrees C. This weight loss is consistent with a 2: 1 naproxen Na: propylene glycol solvate. The PXRD diffractogram of naproxen sodium salt PG solvate is shown in Fig. 8, and shows peaks at 2-theta angles, including but not limited to, 6.67, 9.65, 13.41, 15.77, 18.55, 20.83, 22.79, and 27.17 degrees. Any one, any two, any three, any four, any five, any six, any seven, or all eight of the above peaks or any one or any combination of peaks in Fig. 8 can be used to characterize naproxen sodium salt PG solvate.

Example 5 Preparation of Olanzapine PG solvate Olanzapine PG solvate was prepared by dissolving 1.05 g of olanzapine fonn I in 8 mL of isopropylacetate and 2.0 mL of propylene glycol with heating. The hot liquid was filtered through a 0.2 micrometer nylon syringe filter. Crystallization occurred after cooling to room temperature. The addition of a small amount of seed crystals from a previous reaction followed by sonication for 10 seconds also facilitated crystallization. Olanzapine PG solvate was isolated by suction filtration, rinsed with isopropylacetate and allowed to air dry. The product was a fine yellow powder. The crystals grew in three dimensions, yielding chunks.

A second preparation of olanzapine form I PG solvate was completed by dissolving 16.2 mg of olanzapine form I in 0.05 ml of propylene glycol and 0.05 ml of isopropylacetate with heating. The sample was cooled to room temperature and a single crystal from a previous preparation was added. The sample was allowed to sit undisturbed for 2 days during which an aggregate clump of several large crystals grew. The crystals were transferred to filter paper, rinsed with a single drop of isopropylacetate, and dried by dabbing with the filter paper. The rinse procedure was repeated a total of four times with fresh filter paper. Characterization of the product has been achieved via TGA, DSC, PXRD, and Raman spectroscopy.

Results from TGA analysis show an 18.05 % weight loss representing loss of about 1 equivalent of propylene glycol (Fig. 9). Results from DSC show a peak endothermic transition at 92.63 degrees C (Fig. 10).

The PXRD pattern has characteristic peaks as shown for two sample preparations in Fig. 11A and 1 in. Peaks can be seen at 2-theta angles including but not limited to 8.33, 8.95, 11.75, 14.47, 15.61, 17.95, 19.21, 19.57, 20.65, 21.41, 22.03, and 23.29 in Fig. 1 lA. The crystal can be characterized by any one, any two, any three, any four, any 5, any 6, any 7, any 8, any 9, any 10, any 11, or all 12 of the peaks above or one or a combination of peaks in Fig. 11A. In the second representative sample, peaks can be seen at 2-theta angles including, but not limited to, 8.39, 8.89, 13.95, 14.45, 15.55, 17.91, 19.13, 19.55, 20.61, 21.47, 22.07, and 23.31 in Fig. 11B. The crystal can be characterized by any one, any two, any three, any four, any 5, any 6, any 7, any 8, any 9, any 10, any 11, or all 12 of the peaks above or one or a combination of peaks in Fig. 1 in.

Single-crystal x-ray studies of olanzapine form I PG solvate were also completed. Fig. 12 shows a packing diagram of the single-crystal structure of olanzapine form I PG solvate. The unit cell data are as follows: space group P2 (1)/c, A=10.4264 (9), B=13.3916 (11), C=14.4424 (12), Alpha=90, Beta=95. 503 (2), Gamma=90, Volume=2007.2 (3).

Example 6 Preparation of Cortisone Acetate PG Solvate Cortisone acetate PG solvate was prepared by dissolving 9.7 mg cortisone acetate in 0.6 mL propylene glycol with heating. Needle-like crystals formed upon cooling, followed by the conversion to large, very thin, rectangular plates over a couple hours.

A second preparation of cortisone acetate PG solvate was completed by dissolving 11.9 mg cortisone acetate in 0.7 mL isopropylacetate with heating to reflux. Upon crystal formation, 0.05 mL propylene glycol was added, heated to reflux to dissolve, and crystals again formed. The resultant crystals were collected and analyzed by PXRD, TGA, and DSC.

A third preparation of cortisone acetate PG solvate was completed by dissolving 65.8 mg cortisone acetate in 7.0 mL isopropylacetate and 0.05 mL propylene glycol with heating. The mixture was cooled slightly and seed crystals from a previous reaction (second preparation above) were added. The resultant crystals form rods, or long rectangular plates that are birefringent when viewed by plane polarized microscopy. Crystals were harvested after 30 minutes and analyzed by single crystal x-ray. Prior to PXRD measurement, the sample was ground, transferred to a vial, and left open to the atmosphere for 4 days.

) Results from TGA analysis show a 15.9 % weight loss at temperatures up to 150 degrees C (Fig. 13). 14.9 % weight loss occured between 70 and 150 degrees C while up to 1.2 % weight loss occurred at lower temperatures. This weight loss is representative of a cortisone acetate PG solvate with 1.0 equivalents of propylene glycol. DSC was completed in a closed, not sealed aluminium pan from room temperature to 300 degrees C at 10 degrees/minute (Fig. 14). The compound was discovered to have two endothermic transitions, one at 148 degrees C with an intensity of 146 J/g, and the second at 237 degrees C with an intensity of 77 J/g.

The PXRD of cortisone acetate PG solvate crystallized from isopropylacetate/propylene glycol solution is shown in two diffractograms in Fig. 15A and Fig. 15B. Peaks can be seen at 2-theta angles including, but not limited to, 5. 31, 10.71, 14.54, 15.66, 18.49, 21.33, and 23. 49 degrees. The crystal can be characterized by any one, any two, any three, any four, any five, any six, or any seven, or any combination of the peaks listed above or one or a combination of peaks listed in Fig. 15A. In the second representative sample, peaks can be seen at 2-theta angles including, but not limited to, 5.29, 10.73, 14.57, 15.69, 18.51, 21.39, 23. 51, and 27.49 in Fig. 15B. The crystal can be characterized by any one, any two, any three, any four, any 5, any 6, any 7, or all 8 of the peaks above or one or a combination of peaks in Fig. 15B. Fig. 16 shows a PXRD diffractogram of material crystallized from isopropylacetate alone. This is provided only to differentiate the PG solvate from the unsolvated form of the API.

Single-crystal x-ray studies of cortisone acetate PG solvate were also completed. Fig. 17 shows a packing diagram of the single-crystal structure of cortisone acetate PG solvate. The unit cell data are as follows: space group P2 (1), A=9.728 (2), B=7.6306 (15), C=16. 454 (3), Alpha=90, Beta=92. 568 (4), Gamma=90, Volume=1220. 2 (4).

Example 7 Celecoxib Sodium PG Solvate Trihydrat Preparation: Celecoxib Na propylene glycol trihydrate was formed by allowing the celecoxib sodium salt propylene glycol solvate to sit at 60 % RH and 20 degrees C for 3 days. (Note: Formation of the trihydrate at 75 % and 40 degrees C occurs as well).

The trihydrate begins to form somewhere between 31 and 40 % RH at room temperature.

The solid was characterized by TGA and PXRD, which are shown in Fig. 18 and 19, respectively. Fig. 18 shows the results of the TGA where 9.64 % weight loss was observed between room temperature and 60 degrees C and 13.6 % weight loss was observed between 60 degrees C and 175 degrees C. The PXRD pattern has characteristic peaks at 2-theta angles shown in Fig. 19. Any 1, 2,3, 4,5, 6,7, 8,9, 10, or more peaks can be used to characterize the trihydrate, including for example, peaks at 3.47, 6.97, 10.37, 13.97, 16.41, 19.45, 21.29, 22.69, 23.87, and 25.75 degrees. A 0.8 mm collimator was used during acquisition of the diffractogram.

The trihydrate can also be formed by crystallization of celecoxib Na propylene glycol solvate in the presence of H20. To a solution of celecoxib (136.2 mg; 0.357 mmol) in diethyl ether (6.0 mL), water (0.025 mL; 1.39 mmol), and propylene glycol (0.030 mL; 0.408 mmol) was added sodium ethoxide in ethanol (21 wt. %; 0.135 mL; 0.362 mmol). A solid formed within one minute and was isolated via filtration. The solid was then washed with additional diethyl ether (2.0 mL) and allowed to air dry.

This procedure gives essentially the same PXRD pattern but there is a slight excess of water, which is probably surface water.

The solid was characterized by TGA and PXRD, which are shown in Fig. 20 and 21, respectively. Fig. 20 shows the results of TGA where 10.92% weight loss was observed between room temperature and 50 degrees C and 12.95% weight loss was observed between 50 degrees C and 195 degrees C. The PXRD pattern has characteristic peaks at 2-theta angles shown in Fig. 21. Any 1,2, 3,4, 5,6, 7,8, 9,10, 11,12, or more peaks can be used to characterize the trihydrate, including for example, peaks at 3.43, 6.95, 10.25, 13.95, 16.39, 17.39, 17.75, 18.21, 19.43, 21.21, 22.61, and 25.71 degrees. A 0.8 mm collimator was used during acquisition of the diffractogram.

Figs. 22-24 have been included as reference PXRD diffractograms. Fig. 22 shows the PXRD diffractogram of celecoxib sodium salt. Fig. 23 shows the PXRD diffractogram of celecoxib lithium salt. Fig. 24 shows the PXRD diffractogram of celecoxib potassium salt. Dynamic moisture sorption studies of several embodiments of the present invention have been discussed in PCT/US03/XXXXX filed on December 24,2003, entitled"Pharmaceutical Compositions With Improved Dissolution" (Attorney Docket No. TPI-1700CXC2 PCT) by Tawa et al, which is hereby incorporated by reference, in its entirety. Dynamic moisture sorption studies can be used to illustrate important characteristics of the solvates of the present invention, such as decreased hygroscopicity or increased form stability.

While this invention has been particularly shown and described with references to preferred embodiments thereof, it will be understood by those skilled in the art that various changes in form and details may be made therein without departing from the scope of the invention encompassed by the appended claims. Table 3 I Patent API Generic Name API Chemical Name CAS No. Reference Example of Therapeutic Use Example of Indication 3, 5-Pyridinedicarboxylic acid, 2- ( (2- aminoethoxy) methyl)-4- (2-chlorophenyl)-1, 4 dihydro-6-methyl-, 3-ethyl-5-methyl ester, (-)-amlodipine (S)- [CAS] 103129-82-4 WO 9310779 Antihypertensive, other Hypertension, general (-)-Benzeneacetic acid, 4-chloro-Alpha-13- (trifluoromethyl)-phenoxy]-, 2- (acetylamino) ethyl ester (-)-halofenate US 6262118 Antidiabetic Diabetes, Type lí 1, 3-Benzenedimethanol, Alpha1-(((1, 1- dimithylethyl) amino) methyl)-4-hydroxy- (R)-salbutamol [CAS] Formulation, modified-release, <=24hr Asthma 1, 3-Benzenedimethanol, Alpha1-(((1, 1- dimethylethyl) amino) methyl)-4-hydroxy- (R)-salbutamol [CAS] 34391-04-3 US 5547994 Antiasthma Asthma Formamide, N- (2-hydroxy-5- (1-hydroxy-2- ((2-(4-methoxyphenyl)-1- methylethyl) amino) ethyl) phenyl)- (R- (R, R)-formoterol (R*, R*))- [CAS] 67346-49-0 US 5795564 Antiasthma Asthma (S)-1- (4-amino-6, 7-dimethoxy-2- quinazolinyl)-4- (1, 4-benzodioxan-2-yl (S)-doxazosin carbonyl) piperazine 70918-18-2 WO 9409785 Prostate disorders Benign prostatic hyperplasia Benzenepropanamide, N-methyl-Gamma- (4 (trifluoromethyl) phenoxy)- (S) (S)-fluoxetine Antimigraine Migraine Benzeneacetic acid, Alpha-cyclohexyl- Alpha-hydroxy-, 4- (diethylamino)-2-butynyl (S)-oxybutynin ester, (S)- [CAS] 119618-22-3 Urological Incontinence 1, 2-Naphthoquinone 524-42-5 17a-Hydroxyprogesterone 68-96-2 17-Methyltestosterone 58-18-4 Platinum-195m, diamminedichloro, (SP-4-2) 195mPt-cisplatin US 6074626 Anticancer, alkylating Cancer, liver 1 a-Hydroxycholecalciferol 41294-56-8 1-Naphthyl Salicylate 550-97-0 Patent API Generic Name API Chemical Name CAS No. Reference Example of Therapeutic Use Example of Indication 1-Naphthylamine-4-sulfonic Acid 84-86-6 1-Theobromineacetic Acid 5614-56-2 2, 4, 6-Tribromo-m-cresol 4619-74-3 2, 6-Diamino-2¢-butyloxy-3, 5¢-617-19-6 azopyridine 21-Acetoxypregnenolone 566-78-9 2-Amino-4-picoline 695-34-1 2-Aminothiazole 96-50-4 2-Ethoxybenzoic acid 2-ethoxybenzoic acid DE 5134001 Analgesic, NSAID Pain, general 2-Naphthol 135-19-3 2-Naphthyl Benzoate 93-44-7 2-Naphthyl Lactate 93-43-6 2-Naphthyl Salicylate 613-78-5 2-p-Sulfanilylanilinoethanol 80-02-4 2-Thiouracil 141-90-2 3¢, 3¢¢, 5¢, 5¢¢ 76-62-0 Tetrabromophenolphthalein 3-Amino-4-hydroxybutyric Acid 589-44-6 3-Bromo-d-camphor 76-29-9 3-Hydroxycamphor 10373-81-6 3-O-Lauroylpyridoxol Diacetate 1562-13-6 3-Pentadecylcatechol 492-89-7 3-Quinuclidinol 1619-34-7 4, 4¢-Oxydi-2-butanol 821-33-0 4, 4¢-Sulfinyldianiline 119-59-5 4-Amino-3-hydroxybutyric Acid 352-21-6 4-Amino-3-phenylbutyric Acid 1078-21-3 4-aminosalicylic add Benzoic acid, 4-amino-2-hydroxy- [CAS] 65-49-6 Gl inflammatory/bowel disorders Inflammatory bowel disease 4-Chloro-m-cresol 59-50-7 4-Hexylresorcinol 136-77-6 Patent API Generic Name API Chemical Name CAS No. Reference Example of Therapeutic Use Example of Indication 4-Salicyloylmorpholine 3202-84-4 5¢-Nitro-2¢-propoxyacetanilide 553-20-8 5-aminolevulinic acid, Pentanoic acid, 5-amino-4-oxo- [CAS] 106-60-5 Dermatological Keratosis 1, 3, 5-Triazin-2 (1 H)-one, 4-amino-1-ß-D-_ 5-azacitidine ribofuranosyl- [CAS] 320-67-2 _ Anticancer, antimetabolite MyelodysplasUc syndrome 5-Bromosalicylhydroxamic Acid 5798-94-7 2- (4-Amino-3-methylphenyl)-6- hydroxybenzothiazole 5F-DF-203 Anticancer, other Cancer, breast 5-FU 2, 4 (1H, 3H)-Pyrimidinedione, 5-fluoro [CAS] 51-21-8 Formulation, parenteral, targeted Cancer, general 5-HT3 antagonists US 6037360 Male sexual dysfunction Premature ejaculation 6-Azauridine 54-25-1 6-Mercaptopurine 50-44-2 8-Hydroxyquinoline 148-24-3 9-Aminocamptothecin 91421-43-1 f N- [2- (2, 2, 2-Trifluoro-1-hydroxy-1- trifluoromethyl-ethyl)-naphthalen-1-yi] amide A-151892 Urological Overactive bladder a1-Anttrypsin 9041-92-3 6H-Purin-6-one, 2-amino-9- ( ( (1S, 2R)-1, 2- bis (hydroxymethyl) cyclopropyl) methyl)-1, 9- A-5021 dihydro- [CAS] 145512-85-2 Antiviral, other Infection, varicella zoster virus 2-Cyclopentene-1-methanol, 4-(2-amino-6- (cyclopropylamino)-9H-purin-9-yl)-, (1S-cis)-136470-78-5 abacavir [CAS] 188062-50-2 EP 434450 Antiviral, anti-HIV Infection, HIVIAIDS 7- [3- [4- (6-Fluoro-1, 2-benzisoxazol-3- yl) piperidin-1-yl] propoxy]-3- (hydroxymethyl) chromen-4-one abaperidone 183849-43-6 WO 9632389 Neuroleptic Schizophrenia Patent API Generic Name API Chemical Name CAS No. Reference Example of Therapeutic Use Example of Indication D-Alaninamide, N-acetyl-3- (2-naphthalenyl)- D-alanyl-4-chloro-D-phenylalanyl-3- (3- pyridinyl)-D-alanyl-L-seryl-N-methyl-L- tyrosyl-D-asparaginyl-L-leucyl-N6- (1- abarelix methylethyl)-L-lysyl-L-prolyl-[CAS] 183552-38-7 US 5843902 Anticancer, hormonal Cancer, prostate Abciximab 143653-53-6 Abecarnil 111841-85-1 abetimus 169147-32-4 US 5552391 Immunosuppressant Lupus erythematosus, systemic Androsta-5, 16-dien-3-ol, 17- (3-pyridinyl)-, abiraterone acetate (ester), (3ß)- [CAS] 154229-18-2 GB 2265624 Anticancer, hormonal Cancer, prostate a-Bisabolol 515-69-5 1397-89-3 ABLC Amphotericin B [CAS] 30652-87-0 Formulation, conjugate, carbohydrate Infection, Candida, general Benzenesulfonamide, N- [2- [ (4- hydroxyphenyl) amino]-3-pyridinyl]-4- ABT-751 methoxy- [CAS] 141430-65-1 EP 472053 Anticancer, other Cancer, general N-benzyl-N-ethyl-2- (7, 8-dihydro-7-methyl-8- oxo-2-phenyl-9H-purin-9-yl) acetamide AC-5216 Anxiolytic Anxiety, general Acadesine 2627-69-2 1-Propanesulfonic acid, 3- (acetylamino)- acamprosate [CAS] 77337-76-9 GB 2051789 Dependence treatment Addiction, alcohol Acamprosate 77337-73-6 Acarbose 56180-94-0 7H-Purine-7-acetic acid, 1, 2, 3, 6-tetrahydro- 1, 3-dimethyl-2, 6-dioxo-, compd. with trans-4- [ [ (2-amino-3, 5- dibromophenyl) methyl] amino] cyclohexanol acebrophylline (1 : 1) [CAS] 96989-76-3 DE 3425007 Antiasthma Asthma Butanamide, N- [3-acetyl-4- [2-hydroxy-3- [ (1- methylethyl) amino] propoxy] phenyl]-, (+/-)-34381-68-5 acebutolol [CAS] 37517-30-9 US 3726919 Antihypertensive, adrenergic Acecainide 32795-44-1 Acecarbromal 77-66-7 = Patent API Generic Name API Chemical Name CAS No. Reference Example of Therapeutic Use Example of Indication Benzeneacetic acid, 2- [ (2, 6- dichlorophenyl) amino]-, carboxymethyl ester aceclofenac [CAS] 89796-99-6 EP 119932 Anti-inflammatory Pain, musculoskeletal Acedapsone 77-46-3 Acediasulfone 80-03-5 Acefylline 652-37-9 Aceglutamide 2490-97-3 Aluminum, pentakis (N2-acetyl-L- aceglutamide glutaminato) tetrahydroxytri- [CAS] 12607-92-0 DE 2127176 Antiulcer Ulcer, Gl, general 1 H-lndole-3-acetic acid, 1- (4-chlorobenzoyl) 5-methoxy-2-methyl-, carboxymethyl ester acemetacin [CAS] 53164-05-9 US 3910952 Anti-inflammatory Acenocoumarol 152-72-7 Acetal 105-57-7 Acetamidoeugenol 305-13-5 Acetaminophen 103-90-2 Acetaminosalol 118-57-0 Acetanilide 103-84-4 Acetarsone 97-44-9 Acetazolamide 59-66-5 Acetiamine 299-89-8 Acetohexamide 968-81-0 Acetohydroxamic Acid 546-88-3 Acetophenazine 2751-68-0 Acetophenone 98-86-2 Acetosulfone 128-12-1 _ Olean-12-en-30-oic acid, 3R.-hydroxy-11-29728-34-5 acetoxolone oxo-acetate, aluminium salt [CAS] 6277-14-1 US 3764618 Antiulcer Acetrizoate 129-63-5 Acetyl Sulfamethoxypyrazine 3590-05-4 Acetylcarnitine 14992-62-2 Acetylcholine 66-23-9 Acetylcholine 60-31-1 Acetylcysteine 616-- Patent API Generic Name API Chemical Name CAS No. Reference Example of Therapeutic Use Example of Indication Acetylleucine Monoethanolamine 149-90-6 Acetylpheneturide 13402-08-9 50-78-2 530-Formulation, optimized, acetylsalicylic acid Benzoic _ ~_ 75-6 microencapsulate Pain, general a-Chloralose 15879-93-3 6H-Purin-6-one, 2-amino-1, 9-dihydro-9- [ (2- acidovir hydroxyethoxy) methyl- [CAS] 59277-89-3 Acifran 72420-38-3 'yrazinecarboxylic acid, 5-methyl-, 4-oxide acipimox acid, 51037-30-0 GB 1361967 Hypolipaemic (Antatherosclerosis Hyperlipidaemia, general Acetic acid, oxo [p- (l H-tetrazol-5- acitazanolast yl) phenyl] amino]- [CAS] 114607-46-4 EP 256507 Ophthalmological Conjunctivitis 2, 4, 6, 8-Nonatetraenoic acid, 9- (4-methoxy- 2, 3, 6-trimethylphenyl)-3, 7-dimethyl-, (all-E) acitretin AS] 55079-83-9 GB 1468401 Antipsoriasis Psoriasis 57576-44-0 aclarubicin 75443-99-1 US 3988315 Anticancer, antibiotic Aclatonium Napadisilate 55077-30-0 Aconitine 302-27-2. Acranilf) _ 1684-42-0 Acriflavine 8048-52-0 Acrisorcin 7527-91-5 2-Propenoic acid, 3- [6- [1- (4-methylphenyl)- 3- (1-pyrrolidinyl)-1-propenyl]-2-pyridinyl]-, acrivastine (E, E)- [CAS] 87848-99-5 EP 85959 Antipruritic/inflamm, allergic Rhinitis, allergic, general Benzenemethanol, Alpha- [1- methylamino) ethyl]-, hydrochloride, [S- (R*, R*)]-, mixtwith 2-Propenoic acid, 3- [6- [1- (4-methylphenyl)-3- (1-pyrrolidinyl)-1- acrivastine + pseudoephedrine propenyl]-2-pyridinyl]-, (E, E)- Antiallergic, non-asthma Rhinitis, allergic, seasonal 3-dimethyl-1-propylamide HCI actagardine derivative onocarboxamide actagardine Peptide antibiotic Infection, general Actarit 3699-02-D ACTH 9002-60-2 Acyclovir 59277-89-3 Patent API Generic Name API Chemical Name CAS No. Reference Example of Therapeutic Use Example of Indication 2-Naphthalenecarboxylic acid, 6- (4-methoxy adapalene 3-tricyclo [3. 3. 1. 13, 7] dec-1-ylphenyl)- [CAS] 106685-40-9 EP 199636 Antiacne Acne ADCON-L GL 402 [CAS] 137802-74-5 Formulation, other Fibrosis, epidural Adefovir 106941-25-7 Propanoic acid, 2, 2-dimethyl-, ( ( (2- (-6- amino-gH-purin-9- yl) ethoxy) methyl) phosphinylidene) bis (oxym adefovir dipivoxil ethylene) ester- [CAS] 142340-99-6 EP 205826 Antiviral, other Infection, hepatitis-B virus 6-Amino-9-ß-D-ribofuranosyl-9H-purine Adenoscan [CAS] 58-61-7 Imaging agent Diagnosis, coronary Adenosine Triphosphate 56-65-5 ADEPT 156079-88-8 Immunoconjugate, other Cancer, colorectal Adinazolam 37115-32-5 Adiphenine 64-95-9 ADL-10-0101 WO 9732857 Analgesic, other Pain, general Adrafinil 63547-13-7 Adrenalone 99-45-6 Adrenochrome 54-06-8 Benzo (f) thieno (2, 3-c) quinoline-9, 10-diol, 4, 5, 5a, 6, 7, 11 b-hexahydro-2-propyl-, diacetate (ester), hydrochloride (5aR-trans)-166591-11-3 adrogolide [CAS] 171752-56-0 US 5597832 Dependence treatment Addiction, cocaine AEOL-10150 US 6103714 Neuroprotective Unspecified AET 56-10-0 a-Ethylbenzyl Alcohol 93-54-9 Benzeneacetic acid, Alpha-methyl-4- (2- methylpropyl)-, 2-methoxyphenyl ester AF-2259 [CAS] 66332-77-2 DE 2726435 Anti-inflammatory Inflammation, general Afloqualone 56287-74-2 1 H-Indole-3-acetamide, 1- (2, 2- diethoxyethyl)-2, 3-dihydro-N- (4- methylphenyl)-3- ( ( ( (4- methylphenyl) amino) carbonyl) amino)-2-oxo- , (3R)- AG-041R [CAS] 199800-49-2 WO 9419322 Alimentary/Metabolic, other Unspecified Patent API Generic Name API Chemical Name CAS No. Reference Example of Therapeutic Use Example of Indication N- (5- [2- (2-amino-4 (3H)-oxo-5, 6, 7, 8- tetrahydropyrido [2, 3-d] pyrimidin-6-yl) ethy]-4- methylthieno-2-yl) glutamic acid AG-2037 Anticancer, antimetabolite Cancer, general a-Glucose-1-phosphate 59-56-3 Benzoic acid, 4- ( (4- (4-ethylphenyl)-2, 2- dimethyi-2H-1-benzothiopyran-6-yl) ethynyl)- AGN-194310 [CAS] 229961-45-9 WO 9709297 Dermatological Psoriasis Acetamide, N- (2- (7-methoxy-1- agomelatine naphthalenyl) ethyl)- [CAS] 138112-76-2 EP 447285 Antidepressant Sleep disorder, general Ahistan 518-61-6 AHL-157 US 5411972 Hypolipaemic/Antiatherosclerosis Atherosclerosis 9H-Purine-9-propanamide, 1, 6-dihydro-6- oxo-N- (3- (2-oxo-1-pyrrolidinyl) propyl)- AIT-034 [CAS] 138117-48-3 US 5447939 Cognition enhancer Dementia, senile, general N- [2- (5-Hydroxy-1 H-indol-3-yl) ethyl]-3- (6- oxo-6, 9-dihydro-1 H-purin-9-yl) propionamide AIT-202 WO 9957120 Antidepressant Unspecified Acetic acid, ( (3- ( (2R)-2- ( ( (2R)-2- (3- chlorophenyl)-2-hydroxyethyl) amino) propyl)- AJ-9677 1H-indol-7-yl) oxy)- [CAS] 244081-42-3 Antidiabetic Diabetes, Type II AJG-049 WO 9733885 Gastroprokinetic Motility dysfunction, Gi, general Ajmaline 12/07/4360 Alacepril 74258-86-9 4 (3H)-Quinazolinone, 7-chloro-3- [ (1 R, 2R)-2 (2, 4-difluorophenyl)-2-hydroxy-1-methyl-3- albaconazole (1 H-1, 2, 4-triazol-1-yl) propyl]- [CAS] 187949-02-6 WO 9705131 Antifungal Infection, Candida, general Carbamic acid, [5-(propylthio)-1 H-54029-12-8 albendazole benzimidazol-2-yl]-, methyl ester [CAS] 54965-21-8 GB 1464326 Anthelmintic Infection, helminth, general Albuterol 18559-94-9 Albutoin 830-89-7 Patent API Generic Name API Chemical Name CAS No. Reference Example of Therapeutic Use Example of Indication Benzeneacetic acid, 3-chloro-4- (2- alclofenac propenyloxy)- [CAS] 22131-79-9 GB 1174535 Anti-inflammatory Pregna-1, 4-diene-3, 20-dione, 7-chloro-11- hydroxy-16-methyl-17, 21-bis (1-oxopropoxy 66734-13-2 alclometasone, (7Alpha, 11f3, 16Alpha)- [CAS] 67452-97-5 US 4124707 Antipruritic/inflamm, allergic Inflammation, dermal Alcuronium 23214-96-2 Aldioxa 5579-81-7 Aldol 107-89-1 Aldosterone 52-39-1 Phosphonic acid, (4-amino-1-121268-17-5 alendronate hydroxybutylidene) bis- [CAS] 129318-43-0 GB 2118042 Osteoporosis treatment Osteoporosis Alendronic Acid 66376-36-1 Alexidine 22573-93-9 9, 10-Secocholesta-5, 7, 10 (19)-triene-1, 3- alfacalcidol diol, (1Alpha, 3, 5Z, 7E)- [CAS] 41294-56-8 Osteoporosis treatment Osteodystrophy Alfadolone 23930-37-2 Alfaxalone 23930-19-0 Alfentanil 71195-58-9 alfimeprase 259074-76-5 Fibrinolytic Peripheral vascular disease 2-Furancarboxamide, N- [3- [ (4-amino-6, 7- dimethoxy-2- quinazolinyl) methylamino] propyl] tetrahydro- 81403-68-1 alfuzosin [CAS] 81403-80-7 GB 2013679 Prostate disorders Benign prostatic hyperplasia 2-Furancarboxamide, N- [3- [ (4-amino-6, 7- dimethoxy-2- quinazolinyl) methylamino] propyl] tetrahydro- 81403-68-1 alfuzosin [CAS] 81403-80-7 Formulation, modified-release, other Benign prostatic hyperplasia Algestone 595-77-7 Algestone Acetophenide 24356-94-3 Algin 9005-38-3 Alglucerase 143003-46-7 Alibendol 26750-81-2 Patent API Generic Name API Chemical Name CAS No. Reference Example of Therapeutic Use Example of Indication (2S, 4S, 5S, 7S)-5-Amino-N- (2-carbamoyl-2- methylpropyl)-4-hydroxy-2-isopropyl-7- [4- methoxy-3- (3-methoxypropoxy) benzyl]-8- methyinonanamide aliskiren 173334-57-1 Antihypertensive, renin system Hypertension, general 9-cis retinoic acid alitretinoin 03/08/5300 Antipruriticlinflamm, allergic Eczema, general 1H-Benzotriazole-5-carboxamide, 6- methoxy-N-[[1-(2-propenyl)-2- alizapride pyrrolidinyl] methyl]- [CAS] 59338-93-1 GB 1475234 Antiemetic Nausea and vomiting, general Alkannin 517-88-4 Alkofanone 7527-94-8 Allantoin 97-59-6 Allobarbital 52-43-7 Allopurinol 315-30-0 Allyl Isothiocyanate 57-06-7 Allylestrenol 432-60-0 Magnesium, [carbonato (2- )] heptahydroxy (aluminum) tri-, dihydrate 66827-12-1 almagate [CAS] 72526-11-5 US 4447417 Antacid/Antiflatulent Benzeneacetic acid, Alpha-methyl-4-[(2- alminoprofen methyl-2-propenyl) amino]- [CAS] 39718-89-3 US 3957850 Analgesic, NSAID 1, 3, 5-Triazine-2, 4-diamine, 6- [4- [bis (4- fluorophenyl) methyl]-1-piperazinyl]-N, N'-di-2 27469-53-0 almitrine propenyl-, dimethanesulfonate [CAS] 29608-49-9 GB 1256513 Respiratory Bronchitis, chronic Pyrrolidine, 1- ( ( (3- (2- (dimethylamino) ethyl)- almotriptan 1 H-indol-5-yl) methyl) sulfonyl)- [CAS] 154323-57-6 WO 9402460 Antimigraine Migraine Aloe-Emodin 481-72-1 Aloin 5133-19-7 2, 3, 4, 5-Tetrahydro-5-methyl-2- [ (5-methyl- 122852-42-0 1 H-imidazol-4-yl) methyl]-1 H-pyrido [4, 3- 122852-69-1 alosetron b] indol-1-one [CAS] 132414-02-9 EP 306323 G inflammatory/bowel disorders Irritable bowel syndrome alto Thymidine, 3'-deoxy-3'-fluoro- [CAS] 25526-93-6 EP 470355 Antiviral, anti-HIV Infection, HIV/AIDS Aioxiprin 9014-67-9 Patent API Generic Name API Chemical Name CAS No. Reference Example of Therapeutic Use Example of Indication Emphysema, alpha-1 antitrypsin Alpha-1 protease inhibitor US 5780014 Formulation, inhalable, topical deficiency Ergocryptine, 9, 10-dihydro- Alpha-dihydroergocryptine methanesulfonate (salt)- [CAS] 29261-93-6 Formulation, other Parkinson's disease Alphaprodine 77-20-3 Alpidem 82626-01-5 Alpiropride 81982-32-3 4H- [1, 2, 4] Triazol [4, 3- a] [1, 4] benzodiazepine, 8-chloro-1-methyi-6- alprazolam phenyl- [CAS] 28981-97-7 US 3987052 Anxiolytic Anxiety, general Alprenolol 13655-52-2 Alpha1-17-Corticotropin, 1-ikalanine-17-[N- alsactide (4-aminobutyl)-L-lysinamide]- [CAS] 34765-96-3 US 3749704 ACTH Arthritis, rheumatoid Thiazolium, 4, 5-dimethyl-3- (2-oxo-2- ALT-711 phenylethyl)-, bromide [CAS] 181069-80-7 WO 9622095 Symptomatic antidiabetic Hypertension, general Althiazide 5588-16-9 Pyridine, 3-ethynyl-5-((2S)-1-methyl-2- altinicline pyrrolidinyl)- [CAS] 179120-92-4 US 5594011 Antiparkinsonian Parkinson's disease 1, 3, 5-Triazine-2, 4, 6-triamine, altretamine N, N, N', N', N", N"-hexamethyl- [CAS] 645-05-6 US 3424752 Anticancer, alkylating Cancer, ovarian 7446-70-0 aluminium chloride hexahydrate Aluminium chloride, hexahydrate 7784-13-6 Dermatological Hyperhidrosis Aiuminon 569-58-4 Aluminum Acetate Solution 8006-13-1 Aluminum Chlorate 15477-33-5 Aluminum Hydroxychloride 1327-41-9 Aluminum Potassium Sulfate. 10043-67-1 Aluminum Sodium Sulfate 10102-71-3 Aluminum hydroxide sulfate alusulf (Ai7 (OH) 17 (S04) 2), dodecahydrate [CAS] 61115-28-4 DE 2510663 Urological Hyperphosphataemia Alverine 150-59-4 Glycine, N- [ (2S)-2- [ [ (3R, 4R)-4- (3- hydroxyphenyl)-3, 4-dimethyl-1- piperidinyl] methyl]-1-oxo-3-phenylpropyl]- alvimopan [CAS] 156053-89-3 EP 657428 Gl inflammatorylbowel disorders lleus Patent API Generic Name API Chemical Name CAS No. Reference Example of Therapeutic Use Example of Indication 4H-1-Benzopyran-4-one, 2- (2-chlorophenyl) 5, 7-dihydroxy-8- (3-hydroxy-1-methyl-4-131740-09-5 alvocidib piperidinyl)-, cis-(-)- [CAS] 146426-40-6 Anticancer, other Cancer, renal ALX-0646 WO 9506638 Antimigraine Migraine 2, 4, 6-Triiodophenol AM-24 609-23-4 G inflammatory/bowel disorders Crohn's disease 1-Piperazineethanol, 4- [ [3, 5-bis (1, 1- dimethylethyl)-4-hydroxyphenyl] methyl]- AM-36 Alpha- (4-chlorophenyl)- [CAS] 199467-52-2 Neuroprotective Unspecified 2-Methoxyoestradiol AM-477 Antiasthma Asthma Amantadine 768-94-5 1-Decanaminium, N, N-dimethyl-N- [2- [(tricyclo [3. 3. 1. 13, 7] dec-1- amantanium ylcarbonyl) oxy] ethyl]-, bromide [CAS] 58158-77-3 US 4288609 Antifungal Infection, general Ambazone 539-21-9 Ambenonium 115-79-7 (+)- (2S)-2- [ (4, 6-dimethylpyrimidin-2-yl) oxy]- 3-methoxy-3, 3-diphenylpropanoic acid ambrisentan 177036-94-1 Vasodilator, peripheral Heart failure Cydohexanol, 4-ft (2-amino-3, 5- 18683-91-5 ambroxol dibromophenyl) methyl] amino]-, trans- [CAS] 23828-92-4 GB 1178034 COPD treatment Bronchitis, chronic Ambucaine 119-29-9 Ambuphylline 5634-34-4 Ambuside 3754-19-6 Ambutonium Bromide 115-51-5 Pregna-1, 4-diene-3, 20-dione, 21- (acetyloxy)-16, 17-[cyclopentylidenebis (oxy)] amcinonide 9-fluoro-11-hydroxy-, (11 iN, 16Aipha)- [CAS] 51022-69-6 DE 2437847 Antipsoriasis 1, 4, 8, 11-Tetraazacydotetradecane, 1, 11- Chemotherapy-induced injury, (1, 4-phenylenebis (methylene)) bis-, Chemotherapy-induced injury, AMD-3100 octahydrochloride [CAS] 155148-31-5 US 5612478 Haematological bone marrow, leucopenia Amdinocillin 32887-01-7 Patent API Generic Name API Chemical Name CAS No. Reference Example of Therapeutic Use Example of Indication Amdinocillin Pivoxil 32886-97-8 1, 3-Dioxclane-2-methanol, 4-(2, 6-diamino- amdoxovir 9H-purin-9-yl)- (2R-cis)- [CAS] 145514-04-1 EP 656778 Antiviral, anti-HIV Infection, HIV/AIDS Carbamic acid, ( (4- ( (3- ( (4- (1- (4- hydroxyphenyl)-1- methylethyl) phenoxy) methyl) phenyl) methox Chronic obstructive pulmonary amelubant y) phenyl) iminomethyl)- ethyl ester [CAS] 346735-24-8 DE 10000907 COPD treatment disease Benzenemethanaminium, N, N-dimethyl-N- [2- [2- [4- (1, 1, 3, 3- tetramethylbutyl) phenoxy] ethoxy] ethyl]-, chloride, mixt. with ethyl 4-aminobenzoate Americaine [CAS] 129128-13-8 Formulation, inhalable, other Pain, general Amezinium 30578-37-1 Amfenac 51579-82-9 Amidephrine 3354-67-4 Amidinomycin 3572-60-9 Ethanethiol, 2- [ (3-aminopropyl) amino]-, 20537-88-6 Chemotherapy-induced injury, amifostine hydrogen phosphate (ester)- [CAS] 63717-27-1 EP 131500 Radio/chemoprotective renal Pentanoic acid, 5-(dipentylamino)-4-((2- naphthalenylcarbonyl) amino)-5-oxo- (R)- amiglumide [CAS] 119363-62-1 WO 8805774 GI inflammatorylbowel disorders Pancreatitis 37517-28-5 Formulation, optimized, amikacin 39831-55-5 microencapsulate Infection, general Amiloride 2609-46-3 Aminacrine 90-45-9 Heptanoicacid, 7- [ (10, 11-dihydro-5H- 30272-08-3 amineptine dibenzo [a, d] cyclohepten-5-yl) amino]- [CAS] 57574-09-1 US 3758528 Antidepressant Aminitrozole 140-40-9 Amino Acid Preparations Aminocaproic Acid 2, 6-Piperidinedione, 3- (4-aminophenyl)-3- aminoglutethimide ethyl- [CAS] 125-84-8 US 3944671 Anticancer, hormonal Cancer, breast Aminoguanidine 79-17-4 Aminohippurate Aminometradine 642-44-4 Patent API Generic Name API Chemical Name CAS No. Reference Example of Therapeutic Use Example of Indication Aminopentamide 60-46-8 1 H-Purine-2, 6-dione, 3, 7-dihydro-1, 3- dimethyl-, compd. with 1, 2-ethanediamine aminophylline (2 : 1) [CAS] 317-34-0 Formulation, modified-release, other Asthma Aminopromazine 58-37-7 Aminopyrine 58-15-1 Aminoquinuride 3811-56-1 Aminorex 2207-50-3 Methanone, (2-butyl-3-benzofuranyl) [4- [2- (diethylamino) ethoxy]-3, 5-diiodophenyl]- 1951-25-3 amiodarone [CAS] 19774-82-4 US 3248401 Antiarrhythmic Arrhythmia, general Amiphenazole 490-55-1 Amiprilose 56824-20-5 Benzamide, 4-amino-N- [ (1-ethyl-2- pyrrolidinyl) methyl]-5- (ethylsulfonyl)-2- amisulpride methoxy- [CAS] 71675-85-9 US 4401822 Neuroleptic Schizophrenia Amitriptyline 50-48-6 1-Propanamine, 3- (10, 11-dihydro-5H- dibenzo [a, d] cyclohepten-5-ylidene)-N, N- dimethyl + cyclohexanone, 2- (2- chlorophenyl)-2- (methylamino) amitriptyline+ketamine Formulation, fixed-dose combinations Pain, neuropathic Amitriptylinoxide 4317-14-0 5H- [1] Benzopyrano [2, 3-b] pyridine-3- carboxylic acid, 2-amino-7- (1-methylethyl)-5 amlexanox oxo- [CAS] 68302-57-8 US 4299963 Antiasthma Asthma 3, 5-Pyridinedicarboxylic acid, 2- [ (2- aminoethoxy) methyl]-4- (2-chlorophenyl)-1, 4 111470-99-6 dihydro-6-methyl-, 3-ethyl 5-methyl ester 88150-42-9 amlodipine [CAS] 88150-47-4 EP 89167 Antianginal Hypertension, general Ammonium 03/07/9000 Ammonium Benzoate 1863-63-4 Ammonium Mandelate 530-31-4 Ammonium Salicylate 528-94-9 Ammonium Valerat 42739-38-8 Amobarbital 57-43-2 Patent API Generic Name API Chemical Name CAS No. Reference Example of Therapeutic Use Example of Indication Amocarzine 36590-19-9 Amodiaquin 86-42-0 Morpholine, 4- [3- [4- (1, 1- dimethylpropyl) phenyl]-2-methylpropyl]-2, 6- 78613-35-1 amorolfine dimethyl-, cis- [CAS] 78613-38-4 EP 24334 Antifungal Infection, fungal, general Amoscanate 26328-53-0 Benzenesulfonamide, 5- [I-hydroxy-2- [ [2- (2- methoxyphenoxy) ethyl] amino] ethyi]-2-70958-86-0 amosulalol methyl-, (+/-)- [CAS] 85320-68-9 EP 136103 Antihypertensive, adrenergic Hypertension, general Amotriphene 5585-64-8 Dibenz [b, f] [1, 4] oxazepine, 2-chloro-11- (1- amoxapine piperazinyl)- [CAS] 14028-44-5 GB 1192812 Antidepressant Depression, general 4-Thia-1-azobicyclo [3, 2, 0] heptane-2- carboxylic acid, 6- [ [amino (4- hydroxyphenyl) acetyl] amino]-3, 3-dimethyl-7- 26787-78-0 amoxicillin oxo-, [2S-[2Alpha, 5Aipha, 6ß (S*)]] [CAS] 61336-70-7 Formulation, modified-release, other Infection, general Infection, respiratory tract, amoxicillin+potassium clavulan 74469-00-4 GB 1508977 Formulation, fixed-dose combinations general Piperidine, 1-(6-quinoxalinylcarbonyl)- MPAlex [CAS] 154235-83-3 US 5650409 Psychostimulant Attention deficit disorder Amphetamine 300-62-9 Amphetaminil 17590-01-1 Amphotericin B compd. with (3ß)-cholest-5-120895-52-5 amphotericin B en-3-yl hydrogen sulfate (1 : 1) [CAS] 1397-89-3 US 4822777 Formulation, optimized, liposomes Infection, general 4-Thia-1-azabicyclo [3. 2. 0] heptane-2- carboxylic acid, 6- [(aminophenylacetyl) amino]-3, 3-dimethyl-7-69-53-4 ampicillin oxo-, [2S- [2Alpha, 5Alpha, 6fl (S*)]] 7177-48-2 Formulation, fixed-dose combinations Infection, general Ampiroxicam 99464-64-9 Ampligen 38640-92-5 Patent API Generic Name API Chemical Name CAS No. Reference Example of Therapeutic Use Example of Indication Carbamic acid, (3- ( ( (4- aminophenyl) sulfonyl) (2- methylpropyl) amino)-2-hydroxy-1- (phenylmethyl) propyl)-, tetrahydro-3-furanyl amprenavir ester, (3S- (3R* (1R*, 2S*)))- [CAS] 161814-49-9 US 5783701 Antiviral, anti-HIV Infection, HIV/AIDS 60719-84-8 amrinone [3, 4'-Bipyridin]-6 (1 H)-one, 5-amino- [CAS] 75898-90-7 US 4004012 Cardiostimulant 5, 12-Naphthacenedione, 9-acetyl-9-amino- 7- [ (2-deoxy-B-D-erythro- pentopyranosyi) oxy]-7, 8, 9, 10-tetrahydro- 6, 11-dihydroxy-, hydrochloride, (7S-cis)- amrubicin [CAS] 92395-36-3 EP 107486 Anticancer, antibiotic Cancer, lung, non-small cell Methanesulfonamide, N- [4- (9- Cancer, leukaemia, acute amsacrine acridinylamino)-3-methoxyphenyl]- [CAS] 51264-14-3 Anticancer, other lymphocytic Glycine, N-[[1-methyl-5-(4-methylbenzoyi)- 1. H-pyrrol-2-yl] acetyl]-, 2-methoxyphenyl amtolmetin guacil ester [CAS] 87344-06-7 GB 2115417 Analgesic, NSAID Arthritis, rheumatoid Amylocaine 532-59-2 AN-152 WO 9719954 Anticancer, antibiotic Cancer, prostate anabolic steroids WO 9848812 Cardiovascular Heart failure Anagestone 2740-52-5 Imidazo [2, 1-b] quinazolin-2 (3H)-one, 6, 7- dichloro-1, 5-dihydro-, monohydrochloride 58579-51-4 anagrelide [CAS] 68475-42-3 GB 1418822 Haematological Thrombocytosis 1, 3-Benzenediacetonitrile, Alpha, Alpha, Alpha, Alpha'-tetramethyl-5- (1 H anastrozole 1 2, 4-triazol-1-ylmethyl)- [CAS] 120511-73-1 EP 296749 Anticancer, hormonal Cancer, breast Anazolene 3861-73-2 Ancitabine 31698-14-3 Ancrod 9046-56-4 N-4'- [5-Tetrazolyl]-phenyl-4- (5-tetrazolyl)- benzamide andolast 132640-22-3 EP 460083 Antiasthma Asthma Androisoxazole 360-66-7 Androstenediol 521-17-5 Patent API Generic Name API Chemical Name CAS No. Reference Example of Therapeutic Use Example of Indication 21-(Acetyloxy)-17-hydroxypregna-4, 9 (11)- diene-3, 20-dione anecortave 7753-60-8 Ophthalmological Macular degeneration Anethole 4180-23-8 ; 104-46 1 (unspecified) Anethole Trithione 532-11-6 Angiogenix US 6417205 Cardiovascular Cardiomyopathy, ischaemic Angiotensin 1407-47-2 Vincaleukoblastine, 3'. 4'-didehydro-4'-deoxy anhydrovinblastine [CAS] 38390-45-3 US 6011041 Anticancer, other Cancer, general Echinocandin B, 1- ( (4R, 5R)-4, 5-dihydroxy- N 2- ( (4"- (pentyloxy) (1, 1': 4', 1"-terphenyl)-4- anidulafungin yl) carbonyl} L-ornithine)- [CAS] 166663-25-8 US 6384013 Antifungal Infecton, Candida, general Anileridine 144-14-9 Aniracetam 72432-10-1 Anisindione 117-37-3 Anisomycin 22862-76-6 Anisotropine Methylbromide 80-50-2 anistreplase Anistreplase [CAS] 81669-57-0 EP 28489 Fibrinolytic Infarction, myocardial Antazoline 91-75-8 Anthiolimine 305-97-5 Anthralin 1143-38-0 Anthramycin 4803-27-4 Anthrarobin 577-33-3 anthrax inhibitor US 6436933 Anti-infective, other Infection, anthrax antiangiogenic dendrimers US 6426067 Anticancer, other Cancer, general L-Ascorbic acid, mixt with 2- (diethylamino) ethyl 4-aminobenzoate monohydrochloride, disodium hydrogen phosphate, potassium benzoate and zinc Anticort sulfate (1 : 1) [CAS] 186646-39-9 WO 9640038 Anabolic Cachexia antidepressants US 5898036 Antidepressant Depression, general anti-invasins US 6303302 Antifungal Infection, fungal, general Antimony Potassium Tartrate 28300-74-5 Patent API Generic Name API Chemical Name CAS No. Reference Example of Therapeutic Use Example of Indication Antimony Sodium Thioglycollate 539-54-8 Antimony Thioglycollamide 6533-78-4 19-Norpregna-4, 9-dien-3-one, (acetylphenyl) 20, 20, 21, 21, 21-pentafluoro-17-hydroxy- Antiprogestin (11 15, 17Alpha) [CAS] 211254-73-8 DE 19706061 Anticancer, hormonal Cancer, breast Antipyrine 60-80-0 Antipyrine Salicylate 520-07-0 9000-94-6 antithrombin III Antithrombin, III [CAS] 90170-80-2 Blood fraction Antithrombin III deficiency anxiolytics US 5756538 Anxiolytic Anxiety, general N-Piperonyl-2-amino-1, 2, 3, 4- tetrahydrobenzo (b) thieno (2, 3-c) pyridine-3- AP-521 carbamide 151227-08-6 WO 9321189 Anxiolytic Anxiety, general AP-5280 US 5965118 Anticancer, alkylating Cancer, general Apalcillin 63469-19-2 1 H-lndole-4, 7-dione, 5-(1-aåridinyl)-3- (hydroxymethyl)-2- (3-hydroxy-1-propenyl)-1- apaziquone methyl-, (E)- [CAS] 114560-48-4 WO 8706227 Anticancer, alkylating Cancer, breast Apazone 13539-59-8 a-Phenylbutyramide 90-26-6 Apocodeine 641-36-1 Phosphonic acid, (2- (3, 5-bis (1, 1- dimethylethyl)-4- hydroxyphenyl) ethylidene) bis-tetrakis (1- apomine methylethyl) ester [CAS] 126411-13-0 Anticancer, other Cancer, prostate 4H-Dibenzo [de, g] quinoline-10, 11-diol, 5, 6, 6a, 7-tetrahydro-6-methyi-, hydrochloride 314-19-2 58 apomorphine 00-4 Formulation, transmucosal, nasal Impotence 1, 4-Benzenediamine, 2, 6-dichloro-N1- (4, 5- 66711-21-5 apraclonidine dihydro-1 H-imidazol-2-yl)- [CAS] 73218-79-8 US 4517199 Antiglaucoma Glaucoma Patent API Generic Name API Chemical Name CAS No. Reference Example of Therapeutic Use Example of Indication 3H-1, 2, 4-Triazol-3-one, 5-[[(2R, 3S)-2-[(1R)- 1- [3, 5-bis (trifluoromethyl) phenyl] ethoxy]-3- (4-fluorophenyl)-4-morpholinyl] methyl]-1, 2-Chemotherapy-induced nausea aprepitant dihydro- [CAS] 170729-80-3 US 5719147 Antiemetic and vomiting 1, 3-Propanediamine, N- (2, 3-dihydro-1H- 33237-74-0 aprindine inden-2-yl)-N', N'-diethyl-N-phenyl- [CAS] 37640-71-4 GB 1321424 Antiarrhythmic Aprobarbital 77-02-1 Apronalide 528-92-7 Aprotinin 9087-70-1 Aptiganel 137159-92-3 9, 10-Anthracenedione, 1, 4-bis ( (2- (dimethyloxidoamino) ethyl) amino)-5, 8- AQ4N dihydroxy- [CAS] 136470-65-0 US 5132327 Anticancer, other Cancer, general Aquavan US 6204257 Anaesthetic, injectable Anaesthesia AR-116081 US 6107324 Neuroleptic Unspecified (R)-N- [5-methyl-8- (4-methylpiperazin-1-yl)- 1, 2, 3, 4-tetrahydro-2-naphthyl]-4- morpholinobenzamide AR-A2 Anxiolytic Anxiety, general Arachidonic Acid 506-32-1 3, 5-Pyridinedicarboxylic acid, 1, 4-dihydro- 2, 6-dimethyl-4- (2-nitrophenyl)-, methyl 2- aranidipine oxopropyl ester- [CAS] 86780-90-7 GB 2111978 Antihypertensive, other Hypertension, general D-Streptamine, 0-3-amino-3-deoxy-Alpha-D glucopyranosyl- (1-6)-O- [2, 6-diamino-2, 3, 4, 6 tetradeoxy-Alpha-D-erythro-hexopyranosyl- (1-4)]-N (4-amino-2-hydroxy-1-oxobutyl)-2- 51025-85-5 arbekacin deoxy-, (S)- [CAS] 75282-65-4 US 4001208 Aminoglycoside antibiotic Infection, general 1 H-indole-3-carboxylic acid, 6-bromo-4- ((dimethylamino) methyl)-5-hydroxy-1-methyl 2- ( (phenylthio) methyl)-, ethylester, Arbidol monohydrochloride [CAS] 131707-23-8 WO 9008135 Immunostimulant, other Infection, influenza virus 1, 2-Benzenediol, 4- [1-hydroxy-2- [ [4- (4- hydroxyphenyl) butyl] amino] ethyl]-, (R)- arbutamine [CAS] 128470-16-6 WO 9220324 Diagnostic Diagnosis, coronary Patent API Generic Name API Chemical Name CAS No. Reference Example of Therapeutic Use Example of Indication Arcitumomab 154361-48-5 ardeparin Heparin [CAS] 9005-49-6 Anticoagulant Thrombosis, venous 1, 2, 5, 6-Tetrahydro-1-methyl-3-pyridine carboxylic acid methyl ester arecoline Formulation, transdermal, patch Alzheimer's disease 2-Piperidinecarboxylic acid, 1- [5- [(aminoiminomethyl) amino]-1-oxo-2- [ [ (1, 2, 3, 4-tetrahydro-3-methyl-8- quinolinyl) sulfonyl] amino] pentyl]-4-methyl- argatroban [CAS] 74863-84-6 EP 8746 Anticoagulant Thrombosis, arterial Arginin 74-79-3 Arif) 153259-65-5 2 (1 H)-Quinolinone, 7- [4- [4- (2, 3- dichlorophenyl)-1-piperazinyl] butoxy]-3, 4- aripiprazole dihydro- [CAS] 129722-12-9 EP 367141 Neuroleptic Schizophrenia 1 H-Purine-2, 6-dione, 3- (4-chlorophenyl)-3, 7 Chronic obstructive pulmonary arofylline dihydro-1-propyl- [CAS] 136145-07-8 EP 435811 COPD treatment disease 2-Thiophenecarboxamide, 5- [2- [ [3- [ (1, 1- dimethylethyl) amino]-2-hydroxypropyl] thio]-4 104766-23-6 arotinolol thiazolyl]-, ()- [CAS] 68377-92-4 US 3932400 Antihypertensive, adrenergic Hypertension, general Arsacetin 618-22-4 Cancer, leukaemia, acute arsenic trioxide Arsenic oxide (As203) [CAS] 1327-53-3 Anticancer, other myelogenous Arsphenamine 139-93-5 Arsthinol 119-96-0 Arteether 75887-54-6 Arteflene 123407-36-3 (Z- form) Artemether 71963-77-4 Artemisinin 63968-64-9 3, 12-Epoxy-12H-pyrano [4, 3-j]-1, 2- benzodioxepin, 10-ethoxydecahydro-3, 6, 9- trimethyl-, [3R- (3Alpha, 5aß, 6ß, 8aß, 9aAlpha, 1 OAlpha, 12ß, artemotil 12aR*)]- [CAS] 75887-54-6 Antimalarial Infection, malaria Patent API Generic Name API Chemical Name CAS No. Reference Example of Therapeutic Use Example of Indication Butanedioic acid mono- [ (3R, 5aS, 6R, 8aS, 9R, 10R, 12R, 12aR)- decahydro-3, 6, 9-trimethyl-3, 12-epcxy-12H- pyrano [4, 3 j]-1, 2-benzodioxepin-10-yl] ester artesunate 88495-63-0 Formulation, transmucosal, systemic Infection, malaria Benzo (b) thiophene-6-ol, 2- (4- methoxyphenyl)-3- (4- (2- (1- arzoxifene piperidinyl) ethoxy) phenoxy)- [CAS] 182133-27-3 WO 9609041 Anticancer, hormonal Cancer, breast Spiro (pyrroildine-3, 4' (I'H)-pyrrolo (1, 2- a) pyrazine)-1', 2, 3', 5 (2'H)-tetrone, 2'- ( (4- bromo-2-fluorophenyl) methyl)-, (3'R)- AS-3201 [CAS] 147254-64-6 EP 520320 Syrnptomatic antidiabetic Diabetic complication, general 50-78-2 ASA Benzoic acid, 2- (acetyloxy)- [CAS] 56449-07-1 Formulation, modified-release, other Pain, general a-Santonin 481-06-1 Ascaridole 512-85-6 Ascorbic Acid 50-81-7 1 H-Dibenz [2, 3 : 6, 7] oxepino [4, 5-c] pyrrole, 5- chloro-2, 3, 3a, 12b-tetrahydro-2-methyi-, asenapine trans-, (Z)-2-butenedioate (1 : 1) [CAS] 85650-56-2 WO 9523600 Neuroleptic Psychosis, general Benzeneacetamide, N- [2- (3-hydroxy-1- pyrrolidinyl)-1-phenylethyl]-N-methyl-Alpha- asimadoline phenyl-, [S- (R*, R*)]- [CAS] 153205-46-0 DE 4215213 GI inflammatory/bowel disorders Irritable bowel syndrome 11 fl- [4- (Hydroxyiminomethyi) phenyl]-l 7f&- methoxy-17AI (methoxymethyl) estra-4, 9 asoprisnil dien-3-one 199396-76-4 EP 0648778 Menstruation disorders Endometriosis Asoxime 34433-31-3 Aspartic Acid 56-84-8 Aspidin 584-28-1 Aspidinol 519-40-4 Aspirin 50-78-2 Aspirin, Dipyridamole Patent API Generic Name API Chemical Name CAS No. Reference Example of Therapeutic Use Example of Indication Glycinamide, N-methyl-D-asparaginyl-N- (2- carboxy-3, 3-dimethyl-7-oxo-4-thia-1- azabicyclo [3. 2. 0] hept-6-yi)-D-2- (4- hydroxyphenyl)-, [2S- (2Alpha, 5Alpha, 6f5)]- Infection, respiratorytract, aspoxicillin [CAS] 63358-49-6 GB 1533413 Penicillin, injectable general AST-120 AST 120 [CAS] 90597-58-3 Urological Renal failure Astemizole 68844-77-9 4-Acridinecarboxamide, 9- [ [2-methoxy-4- [(methylsulfonyl) amino] phenyl] amino]-N, 5- 80841-47-0 asulacrine dimethyl- [CAS] 80841-48-1 EP 39224 Anticancer, other Cancer, general (N- [2- [4- (5H-Dibenzo [a, d] cyclohepten-5- ylidene)-piperdino] ethyl]-1-formyl-4- piperidinecarboxamide monohydrochloride monohydrate AT-1015 Antithrombotic Thrombosis, general Androsta-1, 4-diene-3, 17-dione, 1-methyl- atamestane [CAS] 96301-34-7 DE 3338212 Anticancer, hormonal Cancer, breast 2, 5, 6, 10, 13-Pentaazatetradecanedioic acid, 3, 12-bis (1, 1-dimethylethyl)-8-hydroxy-4, 11- dioxo-9- (phenylmethyl)-6- ( (4- (2- pyridinyl) phenyl) methyl)-dimethyl ester, atazanavir (3S, 8S, 9S, 12S)-, sulfate (1 : 1) (salt) [CAS] 229975-97-7 Antiviral, anti-HIV Infection, HIVIAIDS Benzeneacetamide, 4- [2-hydroxy-3- [ (1- 29122-68-7 atenofo) methylethyl) amino] propoxy]- [CAS] 73677-19-7 GB 1285038 Antihypertensive, adrenergic Hypertension, general Benzeneacetamide, 4- [2-hydroxy-3- [ (1- methylethyl) amino] propoxy]-, mixt. with 2- chloro-5-(2, 3-dihydro-1-hydroxy-3-oxo-1 H- atenolol + chlorthalidone isoindol-1-yl) benzenesulfonamide [CAS] 73677-19-7 US 3836671 Formulation, fixed-dose combinations Hypertension, general Benzeneacetamide, 4- [2-hydroxy-3- [ (1- methylethyl) amino] propoxy]- + 4- (2'- nitrophenyl)-2, 6-dimethyl-3, 5- dicarbomethoxy-1, 4-dihydropyridine atenolol + nifedipine Formulation, fixed-dose combinations Hypertension, general a-Terpineol 98-55-5 Atevirdine 1136816-76-6 ! i Patent API Generic Name API Chemical Name CAS No. Reference Example of Therapeutic Use Example of Indication 1 H-Imidazole, 4- (2-ethyl-2, 3-dihydro-1 H- atipamezole inden-2-yl)- [CAS] 104054-27-5 EP 183492 Reproductivetgonadal, general Sexual dysfunction, female 2-Azaspivo [4. 5] decane-2-propanamine, N, N diethyl-8, 8-dipropyl, dimaleate atiprimod dimaleate 130065-61-1 US 5744495 Antiarthritic, immunological Arthritis, rheumatoid ATL-146e us 6232297 Imaging agent Unspecified a-Tocopherol 59-02-9 Benzenepropanamine, N-methyl-Gamma-(2 82248-59-7 atomoxetine methylphenoxy)-, (R)- [CAS] 83015-26-3 EP 52492 Neurological Attention deficit disorder 1 H-Pyrrole-1-heptanoic acid, 2- (4- flucrophenyl)-B, delta-dihydroxy-5- (1- methylethyl)-3-phenyl-4-134523-03-8 atorvastatin [(phenyiamino) carbonyl]- [CAS] 134523-00-5 EP 409281 Hypolipaemic/Antiatherosclerosis Hypercholesterolaemia Oxytocin, 1- (3-mercaptopropanoic acid)-2- (0-ethyl-D-tyrosine)-4-L-threonine-8-L- atosiban omithine- [CAS] 90779-69-4 EP 112809 Labour inhibitor Labour, preterm 1, 4-Naphthalenedione, 2- [4- (4- chlorophenyl) cyclohexyl]-3-hydroxy-, trans- atovaquone [CAS] 95233-18-4 EP 123238 Antifungal Infection, Pneumocystisjiroveci 1, 4-Naphthalenedione, 2- [4- (4- chlorophenyl) cyclohexyl]-3-hydroxy-, trans + -(4-chloro-phenyl)-N-(1- methylethyl) imidiodicarbonimidic diamide atovaquone + proguanil Antimalarial Infection, malaria Isoquinolinium, 2, 2'- [1, 5- pentanediylbis [oxy (3-oxo-3, 1- propanediyl)]] bis [1- [ (3, 4- dimethoxyphenyl) methyl]-1, 2, 3, 4-tetrahydro- atracurium 6, 7-dimethoxy-2-methyl- [CAS] 64228-81-5 US 4179557 Muscle relaxant Surgery adjunct 3-Pyrrolidinecarboxylic acid, 4- (1, 3- enzodioxol-5-yl)-1-[2-(d ibutyiamino)-2- oxoethyl]-2- (4-methoxyphenyl)-, (2R, 3R, 4S)- atrasentan [CAS] 173937-91-2 WO 9730045 Anticancer, other Cancer, prostate Atrial Natriuretic Peptide 85637-73-6 Atrolactamide 2019-68-3 Atropine 51-55-8 Patent API Generic Name API Chemical Name CAS No. Reference Example of Therapeutic Use Example of Indication Infection, respiratory tract, Augmentin 74469-00-4 Formulation, modified-release, other general Gold, (1-thio-ß-Dglucopyranose 2, 3, 4, 6- auranofin tetraacetato-S) (triethylphosphine)- [CAS] 34031-32-8 US 3708579 Antiarthritic, other Arthritis, rheumatoid Aurothioglucose 12192-57-3 Sulfamic acid, [ [2, 4, 6-tris (1- methylethyl) phenyl] acetyl]-, 2, 6-bis (1- avasimibe methylethyl) phenyl ester [CAS] 166518-60-1 US 5491172 Hypolipaemic/Antiatherosclerosis Atherosclerosis Avobenzone 70356-09-1 AWD-12-281 AWD 12-281 [CAS] 257892-33-4 Antiallergic, non-asthma Rhinitis, allergic, general Azacitidine 320-67-2 Azacyclonol 115-46-8 2-Pyrimidinamine, 4-[2-(1-methyl-5-nitro-1H-_ azanidazole imidazol-2-yl) ethenyl]-, (E)- [CAS] 62973-76-6 US 3882105 Antibacterial, other Infection, trichomoniasis 1 H-Pyrazolo [1, 2-a] [1, 2, 4] benzotriazine- 1, 3 (2H)-dione, 5- (dimethylamino)-9-methyl- azapropazone 2-propyl- [CAS] 13539-59-8 FR 1440629 Anti-inflammatory AZ2serine 115-02-6 2H-1, 4-Benzoxazine-8-carboxamide, N-1-123040-16-4 azabicyclo [2. 2. 2] oct-3-yl-6-chloro-3, 4- 123040-94-8 dihydro-4-methyl-3-oxo-, 123040-96-0 azasetron monohydrochloride- [CAS] 123040-69-7 EP 313393 Antiemetic Nausea and vomiting, general Azatadine 3964-81-6 6- [ (1-Methyl-4-nitro-1 H-imidazol-5-yl) thio]- 1H-purine Transplant rejection, bone azathioprine 446-86-6 Formulation, oral, other marrow glycine AZD-4282 Analgesic, other Pain, neuropathic 3, 4 ! cyctopropytamine AZD-6140 Antithrombotic Thrombosis, arterial azelaic acid Nonanedioic acid [CAS] 123-99-9 Antiacne Acne 1 (2H)-Phthalazinone, 4- [ (4- chlorophenyl) methyl]-2-(hexahydro-1-methyl 58581-89-8 azelastine 1H-azepin-4-yl)-, monohydrochloride [CAS] 79307-93-0 GB 1377231 Antiasthma Asthma Patent API Generic Name API Chemical Name CAS No. Reference Example of Therapeutic Use Example of Indication 3, 5-Pyridinedicarboxylic acid, 2-amino-1, 4- dihydro-6-methyl-4- (3-nitrophenyl)-, 3- [l- (diphenylmethyl)-3-azetidinyl] 5- (1- azelnidipine methylethyl) ester, (+/-)- [CAS] 123524-52-7 EP 266922 Antihypertensive, other Hypertension, general Azidamfenicol 13838-08-9 Azidocillin 17243-38-8 Azimilide 149908-53-2 Azintamide 1830-32-6 76801-85-9 9-deoxo-9a-aza-9a-methyl-9a-83905-01-5 azithromycin homoerythromycin-A 92395-24-9 US 4328334 Macro ! ide antibiotic infection, respiratory tract, lower 4-Thia-1-azabicyclo [3. 2. 0] heptane-2- carboxylic acid, 3, 3-dimethyl-7-oxo-6-[[[[(2- oxo-1- imidazolidinyl) carbonyl] amino] phenylacetyl] amino]-, [2S- [2. aipha., 5Aipha. 6H (S')]]- 37091-65-9 aziocillin [CAS] 37091-66-0 GB 1392849 Penicillin, injectable Infection, general Azosemide 27589-33-9 Propanoic acid, 2- [ ( [l- (2-aminc-4-thiazolyl)- 2-[(2-methyl-4-oxo-1-sulfo-3- azetidinyl) amino-2- oxoethylidenelamino] oxy]-2-methyl-, [2S-104184-69-2 aztreonam [2Alpha, 3f5 (Z)]]- [CAS] 78110-38-0 GB 2071650 Beta-lactam antibiotic Infection, general Sodium 5-isopropyl-3, 8-dimethyl-1-azulene azulene sulfonate 6223-35-4 EP 88958 Formulation, modified-release, other Inflammation, general 4-Thia-1-azabicyclo [3. 2. 0] heptane-2- carboxylic acid, 6- [ (aminophenylacetyl) amino]-3, 3-dimethyl-7- oxo-, 1-[(ethoxywarbonyl) oxylethyi ester, [2S 37661-08-8 bacampicillin [2Alpha, 5Alpha, 6f5 (S*)]]- [CAS] 50972-17-3 GB 1363506 Penicillin, oral Infection, general Bacitracin 1405-87-4 ß-(Aminomethyl)-4- baclofen chlorobenzenepropanoic add [CAS] 1134-47-0 Formulation, implant Spastic paralysis Baicalein 491-67-8 Patent API Generic Name API Chemical Name CAS No. Reference Example of Therapeutic Use Example of Indication 3-Quinolinecarboxylic acid, 1-cyclopropyl-6- fluoro-1, 4-dihydro-8-methoxy-7- [3- balofloxacin (methylamino)-1-piperidinyl]-4-oxo- [CAS] 127294-70-6 EP 342675 Quinolone antibacterial Infection, urinary tract Benzoic acid, 5- [ [4- [ [ (2- carboxyethyl) amino] carbonyl] phenyl] azo]-2- balsalazide hydroxy-, (E)- [CAS] 80573-04-2 US 4412992 GI inflammatory/bowel disorders Colitis, ulcerative Carbamic acid, dimethyl-, 5- [2- [ (1, 1- dimethylethyl) amino]-1-hydroxyethyl]-1, 3- 81732-46-9 bambuterol phenylen ester, monohydrochloride [CAS] 81732-65-2 EP 43807 Antiasthma Asthma Bamethan 3703-79-5 Bamifylline 2016-63-9 Bamipine 4945-47-5 Barbital 57-44-3 3, 5-Pyridinedicarboxylic acid, 1, 4-dihydro- 2, 6-dimethyl-4- (3-nitrophenyl)-, methyl-1- (phenylmethyl)-3-pyrrolidinyl ester, [S-104713-75-9 (R*, R*)]- 104757-53-1 barnidipine 71863-56-4 US 4220649 Antihypertensive, other Hypertension, general N-Methyl-3- [2- (2- napthyl) acetylamino] benzamide BAS-118 Antibacterial, other Infection, Helicobacter pylori Basic Aluminum Carbonate Gel 1339-92-0 Basiliximab 179045-86-4 Batimastat 130370-60-4 Batroxobin 9039-61-6 5-cyclopropyl-2- [1 (2-fluoro-benzyl)-1 H- pyrazol [3, 4-b] pyridine-3-yi] pyrimidin- 4ylamine Sexual dysfunction, male, Bay-41-2272 Male sexual dysfunction general 2- [1- (2-Fluorobenzyl)1 H-pyrazolo [3, 4- b] pyridin-3-yl]-5- (4-mopholinyl) pyrimidine- 4, 6-diamine Bay-41-8543 Cardiovascular Unspecified Patent API Generic Name API Chemical Name CAS No. Reference Example of Therapeutic Use Example of Indication N- (4-chloro-3- (trifluoromethyl) phenyl)-N'- (4- (2-(N-methylcarbamoyl)-4- pyridyloxy) phenyl) urea BAY-43-9006 Anticancer, other Cancer, liver N- [5 (aminosulfonyl)-4-methyl-1, 3-thiazol-2- yl]-N-methyl-2- [4- (2- pyridinyl) phenyl] acetamide BAY-57-1293 Antiviral, other Infection, herpes simplex virus bazedoxifen TSE 424 [CAS] 198481-33-3 EP 802183 Osteoporosis treatment Osteoporosis b-Benzalbutyramide 7236-47-7 Platinum (4+), hexaaminedichlorobis (N- (1, 6- hexanediamine-N : N')) tri-stereoisomer, BBR-3464 tetranitrate [CAS] 172903-00-3 US 5744497 Anticancer, alkylating Cancer, lung, non-small cell BBR-3576 US 5519029 Anticancer, antibiotic Cancer, prostate BBR-3610 US 6060616 Anticancer, alkylating Cancer, general b-Carotene 7235-40-7 (-)-2-R-dihydroxyphosphinyol-5- (S)- (guanin- 9'-yl-methyl) tetrahydrofuran BCH-1868 Anticancer, antimetabolite Cancer, general Bebeerine 477-60-1 Beciamide 501-68-8 Pregna-1, 4-diene-3, 20-dione, 9-chloro-5534-09-8 beclometasone 11f3, 17, 21-trihydroxy-16 (3-methyl, [CAS] 4419-39-0 WO 0006132 Formulation, inhalable, solution Asthma Befloxatone 134564-82-2 Ethanone, 1- [7- [2-hydroxy-3- [ (1- methylethyl) amino] propoxy]-2-benzofuranyl] 39543-79-8 befunolol [CAS] 39552-01-7 Antiglaucoma Bemegride 64-65-3 Benactyzine 302-40-9 1H-1-Benzazepine-1-aceticacid, 3- [ [1- 86541-74-4 (ethoxycarbonyl)-3-phenylpropyl] amino]- 86541-75-5 benazepril 2, 3, 4, 5-tetrahydro-2-oxo-, [S- (R*, R*)]- [CAS] 86541-78-8 EP 72352 Antihypertensive, renin system Hypertension, general 1-Propanamine, N, N-dimethyl-3-[[1- (phenylmethyl) cycloheptyl] oxy]-, (E)-2-14286-84-1 bencyclane butenedioate (1 : 1) [CAS] 2179-37-5 WO 9829409 Vasodilator, peripheral Patent API Generic Name API Chemical Name CAS No. Reference Example of Therapeutic Use Example of Indication L-Lysine, mono [[[1-(phenylmethyl)-1 H-81919-14-4 bendazac indazol-3-yl] oxy] acetate] [CAS] 20187-55-7 GB 2081708 Ophthalmological Bendroflumethiazide 73-48-3 Benexate 78718-25-9 Ethanol, 2- [ [1-methyl-2- [3- (trifluoromethyl) phenyl] ethyl] amino]-, 23602-78-D benfluorex benzoate (ester) [CAS] 23642-66-2 GB 1175516 Hypolipaemic/Antiatherosclerosis Benfotiamine 22457-89-2 Benfurodil 3447-95-8 3, 5-Pyridinedicarboxylicacid, 1, 4-dihydro- 2, 6-dimethyl-4- (3-nitrophenyl)-, methyl 1- (phenylmethyl)-3-piperidinyl ester, 105979-17-7 benidipine monohydrochloride (R*, R*)- (+/-)- [CAS] 91599-74-5 EP 63365 Antihypertensive, other Hypertension, general Benorylate 5003-48-5 Benoxaprofen 67434-14-4 Benoxinate 99-43-4 Benperidol 2062-84-2 Benproperine 2156-27-6 Benserazide 322-35-0 2H- [1] Benzothieno [2, 3-e]-1, 4-diazepin-2- bentazepam one, 1, 3, 6, 7, 8, 9-hexahydro-5-phenyl [CAS] 29462-18-8 DE 2005276 Anxiolytic Bentiromide 37106-97-1 Bentoquatam 1340-69-8 Benzalkonium 8001-54-5 Benzarone 1477-19-6 Methanone, (3, 5-dibromo-4- hydroxyphenyl) (2-ethyl-3-benzofuranyl)- benzbromarone [CAS] 3562-84-3 US 3012042 Antigout Benzethonium 121-54-0 Benzetimide 14051-33-3 Benzilonium 1050-48-2 Benziodarone 68-90-6 benznidazole N-benzyl-2-nitroimidazole-1-acetamide 22994-85-0 GB 1138529 Protozoacide Patent API Generic Name API Chemical Name CAS No. Reference Example of Therapeutic Use Example of Indication benzocaine Benzoic acid, 4-amino-, ethyl ester 94-09-7 Formulation, fixed-dose combinations Pain, musculoskeletal Benzoctamine 17243-39-9 Benzonatate 104-31-4 Benzoxonium Chloride 19379-90-9 benzoyl peroxide Peroxide, dibenzoyl [CAS] 94-36-0 Formulation, other Acne Benzoylpas 13898-58-3 Benzphetamine 156-08-1 Benzpiperylon 53-89-4 Benzquinamide 63-12-7 Benzthiazide 91-33-8 Benztropine 132-17-2 1-Propanamine, N, N-dimethyl-3-[[1-132-69-4 Stomatological, reproductive/gonadal, benzydamine (phenylmethyl)-1 H-indazol-3-yl] oxy]- [CAS] 642-72-8 anti-inflammatory Benzyl Benzoate 120-51-4 Benzylhydrochlorothiazide 1824-50-6 Benzylmorphine 14297-87-1 Bephenium Hydroxynaphthoate 3818-50-6 1-Piperidinebutanoic acid, 4-((4- chlorophenyl)-2-pyridinylmethoxy)-, (S)-, 190786-44-8 bepotastine monobenzenesulfonate [CAS] 190786-43-7 WO 9829409 Antiallergic, non-asthma Ailergy, general 1-Pyrrolidineethanamine, ß-[(2-64706-54-3 methylpropoxy) methyl]-N-phenyl-N- 74764-40-2 bepridil (phenylmethyl)- [CAS] 74764-75-3 EP 146155 Antianginal Angina, general 1 H-Cyclopenta [b] benzofuran-5-butanoic acid, 2, 3, 3a, 8b-tetrahydro-2-hydroxy-1- (3- 88475-69-8 beraprost hydroxy-4-methyl-1-octen-6-ynyl)- [CAS] 88430-50-6 US 4474802 Prostaglandin Peripheral vascular disease Berberine 2086-83-1 Bergapten 484-20-8 Bermoprofen 78499-27-1 Besipirdine 119257-34-0 Patent API Generic Name API Chemical Name CAS No. Reference Example of Therapeutic Use Example of Indication 2-Pyridineethanamine, N-methyl-, dihydrochloride 5579-84-0 betahistine 5638-76-6 Formulation, modified-release, <=24hr Meniere's disease betaine Betaine- [CAS] 107-43-7 Metabolic and enzyme disorders Homocystinuria Pregna-1, 4-diene-3, 20-dione, 9-fluor- 11, 17, 21-trihydroxy-1 6-methyl-, (11 ß, 1613)- betamethasone [CAS] 378-44-9 Formulation, dermal, topical Psoriasis Betamipron 3440-28-6 Betasine 3734-24-5 2-Propanol, 1- [4- [2- (cyclopropylmethoxy) ethyl] phenoxy]-3- [ (1- 63659-18-7 Hypertension, general, betaxolol methylethyl) amino]- [CAS] 63659-19-8 US 4252984 Antihypertensive, adrenergic glaucoma Betazole 105-20-4 Bethanechol 590-63-6 Bethanidine 55-73-2 Betoxycaine 3818-62-0 b-Eucaine 500-34-5 2-Propanol, 1- [ [2- (3, 4- dimethoxyphenyl) ethyl] amino]-3- (3- 42864-78-8 bevantolol methylphenoxy)- [CAS] 59170-23-9 US 3857891 Antihypertensive, adrenergic Hypertension, general Bevonium 5205-82-3 Benzoic acid, 4- (1- (5, 6, 7, 8-tetrahydro- 3, 5, 5, 8, 8-pentamethyl-2- bexarotene naphthalenyl) ethenyl)- [CAS] 153559-49-0 WO 9321146 Anticancer, other Cancer, lymphoma, T-cell Propanoic acid, 2- [4- [2- [ (4- chlorobenzoyl) amino] ethyl] phenoxy]-2- bezafibrate methyl- [CAS] 41859-67-0 GB 1359264 HypolipaemiclAntiatherosclerosis Bezitramide 15301-48-1 BG-9928 166374-48-7 Cardiostimulant Heart failure 10, 11-dihydro-10-hydroxyimino-5H- dibenztb, f/azepine-5-carboxamide BIA-2-024 199997-15-4 WO 9745416 Antiepileptic Epilepsy, general (S)- (-)-10-acetoxy-10, 11-dihydro-5H- BIA-2-093 dibenzo/b, f/azepine-5-carboxamide- [CAS] 236395-14-5 Antiepileptic Epilepsy, general Patent API Generic Name API Chemical Name CAS No. Reference Example of Therapeutic Use Example of Indication 1- (3, 4-dihydroxy-5-nitrophenyl)-2-phenyl- ethanone BIA-3-202 274925-86-9 EP 1010688 Antiparkinsonian Parkinson's disease Bialamicol 493-75-4 5H-Pyrazolo [1, 2-a] [1, 2, 4] triazol-4-ium, 6-[[2- carboxy-6- (I-hydroxyethyl)-4-methyl-7-oxo- 1-azabicyclo [3. 2. 0] hept-2-en-3-yl] thio]-6, 7- dihydro-, hydroxide, inner salt, [4R-Infection, beta-lactamase biapenem [4Alpha, 5ß, 6ß (R*)]]- [CAS] 120410-24-4 EP 289801 Beta-lactam antibiotic resistant Bibenzonium 15585-70-3 Bibrocathol 6915-57-7 Propanamide, N- [4-cyano-3- (trifluoromethyl) phenyl]-3- [ (4- fluorophenyl) sulfonyl]-2-hydroxy-2-methyl-, bicalutamide (+/-)- [CAS] 90357-06-5 EP 100172 Anticancer, hormonal Cancer, prostate 3-Azabicyclo [3. 1. 0] hexane, 1- (4- 66504-75-4 bicifadine methylphenyl)-, (+/-)- [CAS] 71195-57-8 DE 2740562 Analgesic, other Pain, general bicyclic monoterpene diols US 6294585 Dermatological Unspecified Bidisomide 116078-65-0 Bietamiverine 479-81-2 Bietanautine 6888-11-5 Bietaserpine 53-18-9 1-Butanamine, N-methyl-4- [2- (phenylmethyl) phenoxy]-, hydrochloride 62232-46-6 bifemelane [CAS] 90293-01-9 GB 1512880 Cognition enhancer Attention deficit disorder Bifluranol 34633-34-6 60628-96-8 1H-Imidazole, 1- ( [1, 1'-biphenyl]-4- 60629-08-5 bifonazole ylphenylmethyl)- [CAS] 60629-09-6 US 4118487 Antifungal Infection, fungal, general 5-Heptenamide, 7- (3, 5-dihydroxy-2- (3- hydroxy-5-phenyl-1-pentenyl) cyclopentyl)-N- ethyl (1 R- bimatoprost (1Alpha (Z) 2ß (1E, 3S, 3AIpha, 5Alpha)) [CAS] 155206-00-1 US 5688819 Prostaglandin Glaucoma Patent API Generic Name API Chemical Name CAS No. Reference Example of Therapeutic Use Example of Indication N- [2-hydroxy-3- (1-piperidinyl) propoxy]-3- pyridinecarboximidoyl chloride, (Z)-2- bimoclomol butanedioate (1 : 1) 130493-04-8 US 5147874 Symptomatic antidiabetic Neuropathy, diabetic (1, 1'-Biphenyl)-3-acetic acid, 3', 3"'- (1, 6- hexanediyl) bis (6'-Alpha-D- bimosiamose mannopyranosyloxy)-, [CAS] 187269-40-5 US 5444050 Antiasthma Asthma Binifibrate 69047-39-8 Adenosine, 2- binodenoson ((cyclohexylmethylene) hydrazino)- [CAS] 144348-08-3 Vasodilator, coronary Diagnosis, coronary Biomed-101 US 6423744 Anticancer, other Cancer, renal Biotin 58-85-5 Biperiden 514-65-8 2-Piperidinecarboxylic acid, 1- (oxo (3, 4, 5- trimethoxyphenyl) acetyl)-, 4- (3-pyridinyl)-1- (3 (3-pyridinyl) propyl) butyl ester, (S)-, 2- hydroxy-1, 2, 3-propanetricarboxylate (1 : 2) 174254-13-8 biricodar [CAS] 159997-94-1 Radio/chemosensitizer Cancer, breast 1-Butanone, 1- (4-fluorophenyl)-4- (3, 4, 6, 7, 12, 12a- hexahydropyrazino [1', 2' : 1, 6] pyrido [3, 4- biriperone b] indol-2 (1H)-yl)- [CAS] 42021-34-1 DE 2333922 Neuroleptic Bisacodyl 603-50-9 Bisantrene 78186-34-2 Bisbentiamine 2667-89-2 Bisdequalinium 52951-36-7 Bismuth Aluminate 12284-76-3 Bismuth Butylthiolaurate 53897-25-9 Bismuth Ethyl Camphorate 52951-37-8 Bismuth lodosubgallate 138-58-9 Bismuth Sodium lodide 53778-50-0 Bismuth Sodium Triglycollamate 5798-43-6 Bismuth Subcarbonate 5892-10-4 Bismuth Subgallate 22650-86-8 Patent API Generic Name API Chemical Name CAS No. Reference Example of Therapeutic Use Example of Indication Bismuth Subnitrate 1304-85-4 Bismuth Subsalicylate 14882-18-9 Bismuth Tribromophenate 5175-83-7 2-Propanol, 1- [4- [ [2- (1- methylethoxy) ethoxy] methyl] phenoxy]-3- [ (1- 104344-23-2 bisoprolol methylethyl) amino]- [CAS] 66722-44-9 GB 1532380 Antihypertensive, adrenergic Heart failure 2-Propanol, 1- [4- [ [2- (1- methylethoxy) ethoxy] methyl] phenoxy]-3- [ (1- methylethyl) amino] mixt. with 6-chloro-3, 4- dihydro-2H-1, 2, 4-benzothiadiazine-7- bisoprolol + HCTZ sulfonamide 1, 1-dioxide Formulation, fixed-dose combinations Hypertension, general 2-Propano (, 1- [4- [ [2- (1- methylethoxy) ethoxy] methyl] phenoxy]-3- [ (1- methylethyl) amino] mixt. with 6-chloro-3- (dichloromethyl)-3, 4-dihydro-2H-1, 2, 4- benzothiadiazine-7-sulfonamide 1, 1-dioxide bisoprolol+trichloromethiazide Formulation, fixed-dose combinations Hypertension, general Bisoxatin 14008-48-1 Bithionol 97-18-7 l eitofterol 30392-40-6 Bitoscanate 4044-65-9 BL-3875 WO 0218378 Anti-inflammatory Unspecified 11056-06-7 bleomycin Bleomycin [CAS] 9041-93-4 Formulation, transdermal, enhanced Cancer, head and neck Cycloocta [b] pyridine, 2- (4-ethyl-1- piperazinyl)-4- (4-fluorophenyl)-5, 6, 7, 8, 9, 10- blonanserin hexahydro- [CAS] 132810-10-7 EP 385237 Neuroleptic Schizophrenia a BMS-184476 EP 639577 Anticancer, other Cancer, breast cis- (+/-)-2- (Ethylthio)-5, 7-dihydroxy-8- (3- hydroxy-1-methyl-4-piperidinyl)-4H-1- BMS-387032 benzopyran-4-one WO 9742949 Anticancer, other Cancer, general 4- [2- (aminomethyl)-1, 3-thiazol-4-yl]-2, 6-di- tert-butylphenol, dihydrochloride BN-82451 Neuroprotective Unspecified Patent API Generic Name API Chemical Name CAS No. Reference Example of Therapeutic Use Example of Indication Ethanesulfonic acid, 2, 2'-dithiobis-, disodium salt Chemotherapy-induced nausea BNP-7787 [CAS] 16208-51-8 Radio/chemoprotective and vomiting 5-Benzofuranol, 4, 6-bis (1, 1-dimethylethyl)- BO-653 2, 3-dihydro-2, 2-dipentyl- [CAS] 157360-23-1 WO 9408930 Hypolipaemic/Antiatherosclerosis Atherosclerosis Bolandiol 19793-20-5 Bolasterone 1605-89-6 Boldenone 846-48-0 2-Propanol, 1- [ (1, 1-dimethylethyl) amino]-3- [(2-methyl-1 H-indol-4-yl) oxy]-, benzoate 62658-63-3 bopindolol (ester), (+/-)- [CAS] 82857-38-3 US 4340541 Antihypertensive, adrenergic Hypertension, general Bornyl Chloride 464-41-5 Bornyl Salicylate 560-88-3 Boronic acid, [(1 R)-3-methyl-1-[[(2S)-1-oxo- 3-phenyl-2- [(pyrazinylcarbonyl) amino] propyl] amino] buty bortezomib I]- [CAS] 179324-69-7 US 6271199 Anticancer, other Cancer, myeloma Benzenesulfonamide, 4- (1, 1-dimethylethyl)- N- [6- (2-hydroxyethoxy)-5- (2- methoxyphenoxy) [2, 2'-bipyrimidin]-4-yi]- bosentan [CAS] 147536-97-8 EP 633259 Vasodilator, peripheral Hypertension, pulmonary Phenol, 2- [ [ [ (1 R)-2- (1 H-imidazol-4-yl)-1- BP2. 94 methylethyl] imino] phenylmethyq- [CAS] 139191-80-3 WO 9117146 Respiratory Rhinitis, general N- [4- [4- (2-methoxyphenyl)-1- piperazinyl] butyl] naphthalene-2- carboxamide BP4. 897 EP 779284 Dependence treatment Addiction, cocaine b-Propiolactone 57-57-8 Bradycor 140661-97-8 Brain Natriuretic Peptide 114471-18-0 Brallobarbital 561-86-4 8-Azabicyclo (3. 2. 1) octane-2- carboxaldehyde, 3-(3, 4-dichlorophenylf8- methyl-, O-methyloxime, (1R- brasofensine (1 Alpha, 2ß (E), 3Alpha, 5Alpha))- [CAS] 171655-91-7 WO 9528401 Antiparkinsonian Parkinson's disease Brequinar 96187-53-0 Patent API Generic Name API Chemical Name CAS No. Reference Example of Therapeutic Use Example of Indication Bretylium 61-75-6 Brilliant Green 633-03-4 6-Quinoxalinamine, 5-bromo-N- (4, 5-dihydro brimonidine 1 H-imidazol-2-yl)- [CAS] 59803-98-4 DE 2538620 Antiglaucoma Glaucoma 2H-Thieno (3, 2-e)-1, 2-thiazine-6- sulfonamide, 4-(ethylamino)-3, 4-dihydro-2- brinzolamide (3-methoxypropyl)-, 1, 1-dioxide, (R)- [CAS] 138890-62-7 US 5378703 Antiglaucoma Glaucoma Uridine, 5-(2-bromoethenyl)-2'-deoxy, (E)- brivudin [CAS] 69304-47-8 Antiviral, other Infection, varicella zostervirus Brodimoprim 56518-41-3 Bromazepam 1812-30-2 Benzeneacetic acid, 2-amino-3- (4- 91714-93-1 bromfenac bromobenzoyl)- [CAS] 91714-94-2 Formulation, mucosal, topical Inflammation, ocular Bromhexine 3572-43-8 Bromindione 1146-98-1 Bromisovalum 496-67-3 Bromocriptine 25614-03-3 Bromodiphenhydramine 118-23-0 Bromoform 75-25-2 Bromopride 4093-35-0 Bromosalicylchloranilide 3679-64-9 1-Butanone, 4- [4- (4-bromophenyl)-4- hydroxy-1-piperidinyl]-1- (4-fluorophenyl)- bromperidol [CAS] 10457-90-6 US 3438991 Neuroleptic Psychosis, general Brompheniramine 86-22-6 Broparoestrol 479-68-5 Bropirimine 56741-95-8 4- (2-Bromoacryiamido)-N"'- (2- guanidinoethyl)-1, 1', 1", 1"'-tetramethyl- N, 4' : N', 4" : N", 4"'-quater- [pyrrole-2- brostallicin carboxamide] [CAS] Anticancer, other Cancer, general . 6H-Thieno [3, 2-f j [1, 2, 4] triazolo [4, 3- a] [1, 4] diazepine, 2-bromo-4- (2- brotizolam chlorophenyl)-9-methyl- [CAS] 57801-81-7 US 4094984 Hypnotic/Sedative Brovincamine 57475-17-9 Patent API Generic Name API Chemical Name CAS No. Reference Example of Therapeutic Use Example of Indication Broxuridine 59-14-3 Broxyquinoline 521-74-4 Brucine 357-57-3 b-Sitosterol 83-46-5 Bucetin 1083-57-4 Bucillamine 65002-17-7 Bucindolol 71119-11-4 Adenosine, N- (1-oxobutyl)-, cyclic 3', 5'- bucladesine (hydrogen phosphate) 2'-butanoate [CAS] 362-74-3 JP 51113896 Cardiostimulant Wound healing Buclizine 82-95-1 Buclosamide 575-74-6 Bucolome 841-73-6 9-Acridinamine, N-butyl-1, 2, 3, 4-tetrahydro-, bucricaine monohydrochloride [CAS] 82636-28-0 Anaesthetic, local Bucumolol 58409-59-9 Pregna-1, 4-diene-3, 20-dione, 16, 17- [butylidenebis (oxy)]-11, 21-dihydroxy-, budesonide (11 16A 16Alpha)- [CAS] 51333-22-3 GB 1429922 Antiasthma Asthma Pregna-1, 4-diene-3, 20-dione, 16, 17- [butylidenebis (oxy)]-11, 21-dihydroxy- , (11f3, 1bAlpha) +formamide, N- [2-hydroxy- 5- [I-hydroxy-2- [ [2- (4-methoxyphenol)-i- methylethyl] amino] ethyl] phenyl]- (R*, R*)- () budesonide + formoterol Formulation, fixed-dose combinations Asthma Piperidine, 1- (1, 1-dimethylethyl)-4, 4- 57982-78-2 budipine diphenyl- [CAS] 63661-61-0 DE 2825322 Antiparkinsonian Parkinson's disease Budraiazine 36798-79-5 Bufeniode 22103-14-6 Bufetolol 53684-49-4 bufexamac p-butoxyacetohydroxamic acid 2438-72-4 US 3479396 Anti-inflammatory 1-Butanone, 4- (1-pyrrolidinyl)-1- (2, 4, 6- 35543-24-9 buflomedil trimethoxyphenyl)- [CAS] 55837-25-7 GB 1325192 Vasodilator, peripheral Buformin692-13-7 Patent API Generic Name API Chemical Name CAS No. Reference Example of Therapeutic Use Example of Indication Bufuralol 54340-62-4 Bumadizon 3583-64-0 Benzoic acid, 3- (aminosulfonyl)-5- bumetanide (butyiamino)-4-phenoxy- [CAS] 28395-03-1 US 3806534 Antihypertensive, diuretic Hypertension, general 1-Naphthalenecarboxamide, N-butyl-N- [2- bunaftine (diethylamino) ethyl]- [CAS] 32421-46-8 DE 2009894 Antiarrhythmic Bunamiodyl Sodium 1923-76-8 1H-1, 4-Diazepine, 1- (4-amino-6, 7- dimethoxy-2-quinazolinyl) hexahydro-4- (1- 52712-76-2 bunazosin oxobutyl)- [CAS] 80755-51-7 GB 1398455 Antihypertensive, adrenergic Hypertension, general Benzonitrile, 2- [3- [ (1, 1-dimethylethyl) amino]- unitrolol 2-hydroxypropoxy]- [CAS] 34915-68-9 US 3940489 Antihypertensive, adrenergic 2-Piperidinecarboxamide, 1-butyl-N- (2, 6- 38396-39-3 bupivacaine dimethylphenyl)- [CAS] 2180-92-9 Formulation, modified-release, >24hr Anaesthesia Bupranolol 14556-46-8 6, 14-Ethenomorphinan-7-methanol, 17- (cyclopropylmethyl)-Alpha- (1, 1- dimethylethyl)-4, 5-epoxy-18, 19-dihydro-3- hydroxy-6-methoxy-Alpha-methyl-, 52485-79-7 buprenorphine [5Alpha, 7Alpha (S)]- [CAS] 53152-21-9 US 3433791 Analgesic, other 1-Propanone, 1- (3-chlorophenyl)-2- [ (1, 1- 31677-93-7 bupropion dimethylethyl) amino]-, (+/-)- [CAS] 34911-55-2 US 4425363 Antidepressant Depression, general Buramate 4663-83-6 Luteinizing hormone-releasing factor (pig), 6- [O- (1, 1-dimethylethyl)-D-serine]-9- (N-ethyl 57982-77-1 userelin L-prolinamide)-10-deglycinamide- [CAS] 68630-75-1 GB 1523623 Releasing hormones Cancer, prostate 8-Azaspiro [4. 5] decane-7, 9-dione, 8- [4- [4- (2- buspirone pyrimidinyl)-1-piperazinyl] butyl]-[CAS] 36505-84-7 EP 276536 Anxiolytic Anxiety, general busulfan 1, 4-Butanediol, dimethanesulfonate [CAS] 55-98-1 Formulation, optimized, microparticles Cancer, general Cancer, leukaemia, acute busulfan 1, 4-Butanediol, dimethanesulfonate- [CAS] 55-98-1 Formulation, parenteral, other myelogenous l Butabarbital 143-81-7 Butacaine 149-16-6 Butacetin 2109-73-1 Patent API Generic Name API Chemical Name CAS No. Reference Example of Therapeutic Use Example of Indication Butalamine 22131-35-7 Butalbital 77-26-9 Butallylonal 1142-70-7 butamben 4-Aminobenzoic acid butyl ester [CAS] 94-25-7 Formulation, modified-release, other Pain, cancer Benzeneacetic acid, Alpha-ethyl-, 2- [2- (diethylamino) ethoxy] ethylester, 2-hydroxy-18109-80-3 butamirate 1, 2, 3-propanetricarboxylate (1 : 1) [CAS] 18109-81-4 Antitussive Cough Butanilicaine 3785-21-5 Butaperazine 653-03-2 Butaverine 55837-14-4 Butazolamide 16790-49-1 Butedronic Acid 51395-42-7 1-Naphthalenemethanamine, N- ( (4- (1, 1- dimethylethyl) phenyl) methyl)-N-methyl- 101827-46-7 butenafine [CAS] 101828-21-1 EP 164697 Antifungal Infection, dermatological Butethal 77-28-1 Butethamate 14007-64-8 Butethamine 2090-89-3 Buthalital 510-90-7 Buthiazide 2043-38-1 Butibufen 55837-18-8 Butidrine 1506-12-3 benzoic acid, 3, 4, 5-trimethoxy-, 1, 2- ethanediylbis [(methylimino) (2-ethyl-2, 1-55769-64-7 butobendineethanediyf)] ester, [S- (R*, R*)]- [CASI 55769-65-8 US 4021473 Antiarrhythmic Arrhythmia, general 1H-Imidazole, 1- [4- (4-chlorophenyl)-2- [ (2, 6- 64872-76-0 butoconazole dichlorophenyl) thio] butyl]-, (+/-)-[CAS] 64872-77-1 GB 1567431 Antifungal Infection, Candida, general Butoctamide 32838-26-9 Butofilolol 64552-17-6 Morphinan-3, 14-diol, 17- (cyclobutylmethyl)-, [S- (R*, R*)]-2, 3-dihydroxybutanedioate (1 : 1) 42408-82-2 butorphanol (salt) [CAS] 58786-99-5 GB 1412129 Analgesic, other Butoxycaine 3772-43-8 Patent API Generic Name API Chemical Name CAS No. Reference Example of Therapeutic Use Example of Indication Butriptyline 35941-65-2 Butropium 29025-14-7 _ Buzepide 3691-21-2 BVT-5182 WO 0208178 Anorectic/Antiobesity Obesity 2H-1, 2-Benzoselenazine, 3, 4-dihydro-4, 4- BXT-51072 dimethyl- [CAS] 173026-17-0 GI inflammatory/bowel disorders Colitis, ulcerative 6H-imidazo [4, 5, 1-de] acridin-6-one, 5-[[2- (diethylamino) ethyl] amino]-8-hydroxy-, 2HCI, 2H20 C-1311 Anticancer, other Cancer, general Ergoline-8-carboxamide, N- [3- (dimethylamino) propyl]-N- [(ethylamino) carbonyl]-6-(2-propenyl)-, (8ß)-81409-90-7 abergoline [CAS] 85329-89-1 GB 2103603 Antiprolactin Galactorrhoea Cabergoline 81409-90-7 Cacodylic Acid 75-60-5 Cactinomycin 8052-16-2 cadexomer iodine Cadexomer iodine [CAS] 94820-09-4 Anti-infective, other Ulcer, venostasis Cadmium Salicylate 19010-79-8 Cadralazine 64241-34-5 Cafaminol 30924-31-3 1, 2, 3,-Propanetricarboxylic acid, 2-hydroxy- mixt. with 3, 7-dihydro-1, 3, 7-trimethyl-1 H-69-22-7 58 caffeine purine-2, 6-dione [CAS] 08-2 Respiratory Apnoea Calcifediol 19356-17-3 Calcipotriene 112965-21-6 9, 10-Secochola-5, 7, 10 (19), 22-tetraene- 1, 3, 24-triol, 24-cyclopropyl- calcipotriol, (1 Alpha, 3ß, SZ, 7E, 22E)- [CAS] 112965-21-6 WO 8700834 Antipsoriasis Psoriasis 9, 10-Secochola-5, 7, 10 (19), 22-tetraene- 1, 3, 24-triol, 24-cyclopropyl- , (1Alpha, 3R, 5Z, 7E, 22E) + Pregna-1, 4-diene 3, 20-dione, 9-chloro-1113, 17, 21-trihydroxy- 16ß-methyl, 17, 21-dipropionate calcipotriol+beclometasone Formulation, fixed-dose combinations Psoriasis Patent API Generic Name API Chemical Name CAS No. Reference Example of Therapeutic Use Example of Indication 9, 10-Secocholesta-5, 7, 10 (19)-triene-1. 3, 25- calcitriol triol, (1 Alpha, 3ß, 5Z, 7E)- [CAS] 32222-06-3 Antipsoriasis Psoriasis Calcium 3-Aurothio-2-propanol-1-5743-29-3 sulfonate Calcium Acetylsalicylate 69-46-5 Calcium Bromolactobionate 33659-28-8 Calcium Carbonate 471-34-1 Calcium Gluconate 299-28-5 Calcium Glycerophosphate 27214-00-2 Calcium D- (+)-4- (2, 4-dihydroxy-3, 3- dimethylbutyramido) butyrate (hemihydrate) calcium hopantothenate [CAS] 17097-76-6 EP 117260 Neurological Attention deficit disorder Calcium lodobehenate 1319-91-1 Calcium lodostearate 1301-16-2 Calcium Lactate 814-80-2 Calcium Levulinate 591-64-0 Calcium Mesoxalate 21085-60-9 Calcium N-Carbamoylaspartate 16649-79-9 126040-58-2 calcium polycarbophil Polycarbophil, calcium salt- [CAS] 9003-97-8 GI inflammatory/bowel disorders Irritable bowel syndrome Calcium Propionate 4075-81-4 Calcium Succinate 140-99-8 5-methyl-2- (1-piperazinyl)-benzenesulfonic acid monohydrate caldaret 133804-44-1 Cardiostimulant Heart failure Calusterone 17021-26-0 Camazepam 36104-80-0 Benzeneacetic acid, 4- [ [4- [(aminoiminomethyl) amino] benzoylloxyl-, 2-59721-28-7 (dimethylamino)-2-oxoethyl ester, 59721-29-8 camostat monomethanesulfonate [CAS] 71079-09-9 US 4021472 Gi inflammatorylbowel disorders Pancreatitis Camphor 76-22-2 Camphotamide 4876-45-3 Patent API Generic Name API Chemical Name CAS No. Reference Example of Therapeutic Use Example of Indication 4-Ethyl-4-hydroxy-1 H-pyrano- [13'4' : 6, 7] indolizinol [1, 2-b ;] quinoline- 3, 14 (4H, 12H)-dione camptothecin Formulation, optimized, microemulsion Cancer, general Candesartan 139481-59-7 1 H-Benzimidazole-7-carboxylic acid, 2- ethoxy-1-[[2'-(1 H-tetrazol-5-yl) [1, 1'-biphenyl]. 4-yl] methyl]-, 1- [[(cyclohexyloxy) carbonyl] oxy] ethyl ester, (+/ candesartan cilexetil [CAS] 145040-37-5 EP 520423 Antihypertensive, renin system Hypertension, general Candoxatril 123122-55-4 N- [4- (3- (Chloro-4-fluoro-phenylamino)-7- (3- morpholin-4-yl-propoxy)-quinazolin-6-yl]- acrylamide canertinib 289499-45-2 Anticancer, other Cancer, lung, non-small cell Canrenone 976-71-6 Cantharidin 56-25-7 Maytansine, N2-deacetyl-N2- (3-mercapto-l- oxopropyl)-, conjugated humanized C242 monoclonal antibody cantuzumab mertansine 139504-50-0 Immunotoxin Cancer, colorectal Cytidine, 5-deoxy-5-fluoro-N- capecitabine [(pentyloxy) carbonyl]- [CAS] 154361-50-9 EP 602454 Anticancer, antimetabolite Cancer, breast Capobenic Acid 21434-91-3 1H-imidazole-2-methanol, 5- (3, 5- dichlorophenyl) thio-4- (1-methylethyl)-1- (4- capravirine pyridinyl) methyl carbamate (ester) [CAS] 178979-85-6 Antiviral, anti-HIV Infection HIV/AIDS Capromab 151763-64-3 N- [ (4-hydroxy-3-methoxyphenyl) methyl]-8- capsaicin cream methyl-, (E)- [CAS] 404-86-4 Formulation, dermal, topical Pain, post-herpetic Captodiamine 486-17-9 L-Proline, 1-(3-mercapto-2-methyl-1- captopril oxopropyl)-, (S)- [CAS] 62571-86-2 US 4105776 Antihypertensive, renin system Hypertension, general Patent API Generic Name API Chemical Name CAS No. Reference Example of Therapeutic Use Example of Indication L-Proline, 1- (3-mercapto-2-methyl-1- oxopropyl)-, (S)-, mixt. with 6-chloro-3, 4- dihydro-2H-1, 2, 4-benzothiadiazine-7- captopril + HCTZ sulfonamide 1, 1-dioxide [CAS] 110075-07-5 US 4217347 Antihypertensive, renin system Capuride 5579-13-5 Benzamide, N- (6-acetyl-3, 4-dihydro-3- hydroxy-2, 2-dimethyl-2H-1-benzopyran-4-yl) carabersat 4-fluor, (3R-trans)- [CAS] 184653-84-7 WO 9811890 Antiepileptic Epilepsy, general Caramiphen 77-22-5 2-Propanol, 1- (9H-carbazol-4-yloxy)-3- [ (i- carazolol methylethyl) amino]- [CAS] 57775-29-8 DE 2240599 Antihypertensive, adrenergic Carbachol 51-83-2 5H-Dibenz [b, t] azepine-5-carboxamide carbamazepine [CAS] 298-46-4 Formulation, modified-release, other Epilepsy, general Carbamide Peroxide 124-43-6 Carbarsone 121-59-5 Carbaryl 63-25-2 Carbazochrome 13051-01-9 51460-26-5 Methyl-2-benzimidazolecarbamate carbendazim Anticancer, other Cancer, general Carbenicillin 4697-36-3 Carbenoxolone 5697-56-3 Carbetapentane 77-23-6 Carbonic acid disodium salt, mixt. with Carbicarb monosodium salt- [CAS] 72227-05-5 Alimentary/Metabolic, other Acidosis Carbidopa 28860-95-9 S-Alpha Hydrazino-3, 4-dihydroxy-Alpha methyl benzene propanoic acid monohydrate +3-hydroxy-L-tyrosine carbidopa+levodopa-1 Formulation, fixed-dose combinations Parkinson's disease Carbimazole 22232-54-8 Carbinoxamine 486-16-8 Carbocloral 541-79-7 151756-26-2 carbocysteine 638-23-3 EP 546272 Cystic fibrosis treatment Cystic fibrosis Carbon Tetrachloride 56-23-5 Patent API Generic Name API Chemical Name CAS No. Reference Example of Therapeutic Use Example of Indication Platinum, diammine [1, 1- cyclobutanedicarboxylato (2-)]-, (SP-4-2)- carboplatin [CAS] 41575-94-4 Anticancer, alkylating Cancer, ovarian Carboprost 35700-23-3 Prosta-5, 13-dien-1-oic acid, 9, 11, 15- trihydroxy-15-methyl-, (5Z, 9. alpha., 11Alpha, 13E, 15S)-, compd. with 2-amino-2- (hydroxymethyl)-1, 3- 58551-69-2 carboprost trometamol propanediol (1 : 1) [CAS] 74849-93-7 US 3728382 Prostaglandin Abortion 2, 5-Cyclohexadiene-1, 4-dione, 2- [2- [(aminocarbonyl) oxy]-1-methoxyethyl]-3, 6- Carboquone bis (1-aziridinyl)-5-methyl- [CAS] 24279-91-2 DE 1905224 Anticancer, antibiotic Carbromal 77-65-6 Carbubarb 960-05-4 Carbutamide 339-43-5 Carbuterol 34866-47-2 Carfimate 3567-38-2 N-Carbamoyl-L-glutamic acid carglumic acid 1188-38-1 Metabolic and enzyme disorders Hyperammonaemia Cargutocin 33605-67-3 Carindacillin 35531-88-5 Benzamide, N- (aminoiminomethyl)-4- (1- 159138-80-4 cariporide methylethyl)-3-(methylsulfonyl)- [CAS] 159138-81-5 EP 589336 Antianginal Angina, general Cariporide 159138-80-4 Carisoprodol 78-44-4 1 (2H)-Pyrimidinecarboxamide, 5-fluoro-N- carmofur hexyl-3, 4-dihydro-2, 4-dioxo- [CAS] 61422-45-5 US 4071519 Anticancer, antimetabolite Carmoxirole 98323-83-2 Urea, N, N'-bis (2-chloroethyl)-N-nitroso- carmustine [CAS] 154-93-8 Formulation, implant Cancer, brain Carnitine 461-06-3 Caroverine 23465-76-1 Caroxazone 18464-39-6 Carphenazine 2622-30-2 Carpipramine 5942-95-0 Patent API Generic Name API Chemical Name CAS No. Reference Example of Therapeutic Use Example of Indication 9H-Carbazole-2-acetic acid, 6-chloro-Alpha- carprofen methyl-, (+I-)- [CAS] 53716-49-7 US 3896145 Anti-inflammatory Carsalam 2037-95-8 2 (1H)-Quinolinone, 5- [3- [ (1, 1- dimethylethyl) amino]-2-hydroxypropoxy]-3, 4- 51781-06-7 carteolol dihydro-, monohydrochloride [CAS] 51781-21-6 US 3910924 Antihypertensive, adrenergic Glaucoma Carticaine 23964-58-1 Carubicin 50935-04-1 Carumonam 87638-04-8 Carvacrol 499-75-2 2-Propanol, 1-(9H-carbazol-4-yloxy)-3-[[2-(2 carvedilol methoxyphenoxy) ethyl] amino]-[CAS] 72956-09-3 EP 4920 Antihypertensive, adrenergic Hypertension, general Carvone 99-49-0 Cascarillin 10118-56-6 Pneumocandin B0, 1-((4R, 5S)-5-((2- aminoethyl) amino)-N2- (10, 12-dimethyl-1- oxotetradecyl)-4-hydroxy-L-ornithine)-5- (threo-3-hydroxy-L-omithine)-, diacetate 162808-62-0 caspofungin (salt) [CAS] 179463-17-3 WO 9421677 Antifungal Infection, Aspergillus Catechin 154-23-4 N- (1-benzothien-2-ylcarbonyl)-N- [2- (2- fluorophenyl)-4-oxo-1, 2, 3, 4- cathepsin K inhibitors tetrahydropyrimidin-5-yl]-L-leucinamide WO 9613523 Osteoporosis treatment Osteoporosis N- (1-benzothien-2-ylcarbonyl)-N- [2- (2- fluorophenyl)-4-oxo-1, 2, 3, 4- tetrahydropyrimidin-5-yi]-L-leucinamide cathepsin S inhibitors Antiasthma Asthma CC-401 US 6342595 Immunosuppressant Arthritis, rheumatoid Rapamycin 42- (3-hydroxy-2- CCI-779 (hydroxymethyl)-2-methylpropanoate) [CAS] 162635-04-3 Anticancer, antibiotic Cancer, renal CCR5 antagonists WO 9732019 Antiviral, anti-HIV Infection, HIV/AIDS CDC-394 US 634061 Anticancer, other Cancer, myeloma CDC-801 US 5605914 GI inflammatory/bowel disorders Crohn's disease Patent API Generic Name API Chemical Name CAS No. Reference Example of Therapeutic Use Example of Indication 1H-3-Benzazepin-7-ol, 5-(2, 3-dihydro-7- benzofuranyl)-2, 3, 4, 5,-tetrahydro-3-methyl- CEE-03-310 8-nitro, (5S)- [CAS] 128022-68-4 EP 347672 Dependence treatment Addiction, alcohol 5-Thia-1-azabicyclo [4. 2. 0] oct-2-ene-2- carboxylic acid, 7- [(aminophenylacetyl) amino]-3-chloro-8-oxo-53994-73-3 Infection, Haemophilus cefaclor, [6R-[6Alpha, 7ß (R*)]]- [CAS] 70356-03-5 GB 1461323 Cephalosporin, oral influenzae prophylaxis 5-Thia-1-azabicyclo [4. 2. 0] oct-2-ene-2- carboxylic acid, 7-1 [amino (4- hydroxyphenyl) acetyllamino]-3-methyl-8-oxo 50370-12-2 cefadroxil, [6R- [6A ! pha, 7H (R*)]]- [CAS] 66592-87-8 GB 1240687 Cephalosporin, oral Infection, general 5-Thia-1-azabicyclo [4. 2. 0] oct-2-ene-2- carboxylic acid, 7- [(aminophenylacetyl) amino]-3-methyl-8-oxo-105879-42-3 Infection, respiratory tract, cefalexin, [CAS] 15686-71-2 US 4775751 Cephalosporin, oral upper 5-Thia-1-azabicyclo [4. 2. 0] oct-2-ene-2- carboxylic acid, 7- [(aminophenylacetyl) amino]-3-methyl-8-oxo- , (2, 2-dimethyl-1-oxopropoxy) methyl ester, monohydrochloride, [6R-[6Alpha. 7ß (R*) g- cefalexin pivoxil [CAS] 27726-31-4 Cephalosporin oral Infection general l 7-D-mandelamido-3 [[(1-methyl-1 H-tetrazol- cefamandole 5-yl) thio] methyl]-3-cephem-4-carboxylic acid 34444-01-4 US 3641021 Cephalosporin, injectable Infection, general l 5-Thia-1-azabicyclo [4. 2. 0] oct-2-ene-2- carboxylic acid, 7-[[amino (4- hydroxyphenyl) acetyl] 2minol-B-oxo-3- [ (l H- 1, 2, 3-triazol-4-ylthio) methyl]-, [6R- cefatrizine [6Alpha, 75 (R*)]]- [CAS] 51627-14-6 GB 1460914 Cephalosporin, oral Infection, general Cefazedone 56187-47-4 Cefazolin 25953-19-9 Cefbuperazone 76610-84-9 7B- [ (Z)-2- (2-amino-4-thiazolyl)-2- pentenoylamino]-3-carbamoyloxymethyl-3- cephem-4-carboxylic acid, 105889-45-0 Infection, respiratory tract, cefcapene pivoxil pivaloyloxymethyl ester HCI- [CAS] 105889-46-1 GB 2173194 Cephalosporin, oral general Cefclidin 105239-91-6 = Patent API Generic Name API Chemical Name CAS No. Reference Example of Therapeutic Use Example of Indication 5-Thia-1-azabicyclo [4. 2. 0] oct-2-ene-2- carboxylic acid, 7-[[(2-amino-4- thiazolyl) (hydroxyimino) acetyl] amino]-3- cefdinir ethenyl-8-oxo-, [6R- [6Alpha, 7a (Z)]]- [CAS] 91832-40-5 EP 105459 Cephalosporin, oral Infection, dermatological 5-Thia-1-azabicyclo [4. 2. 0] oct-2-ene-2- carboxylic acid, 7- [ [ (2-amino-4- thiazolyl) (methoxyimino) acetyl] amino]-3-[2- (4-methyl-5-thiazolyl) ethenyl]-8-oxo-, (2, 2- 104145-95-1 dimethyl-1-oxopropoxy) methyl ester, [6R-104146-53-4 cefditoren pivoxil [3 (Z), 6Alpha, 7f5 (Z)]]- [CAS] 117467-28-4 JP 61178991 Cephalosporin, oral Infection, general Pyrrolidinium, 1-[|7-1 (2-amino-4- thiazolyl) (methoxyimino) acetyl] amino]-2- carboxy-8-oxo-5-thia-1-azabicyclo [4. 2. 0] oct- 107648-80-6 2-en-3-yl] methyl]-1-methyl-, hydroxide, inner 123171-59-5 cefepime salt, [6R-[6Alpha, 7ß (Z)]]- [CAS] 88040-23-7 EP 531981 Cephalosporin, injectable Infection, respiratory tract, lower Cefetamet 65052-63-3 5-Thia-1-azabicyclo [4. 2. 0] oct-2-ene-2- carboxylic acid, 7-[[(2-amino-4- thiazolyl) (methoxyimino) acetyl] amino]-3- methyl-8-oxo-, (2, 2-dimethyl-1- oxopropoxy) methyl ester, monohydrochloride, [6R- [6AIpha, 7fl (Z)]]- cefetamet pivoxil [CAS] 111696-23-2 GB 1581854 Cephalosporin, oral Infection, general 5-Thia-1-azabicyclo [4. 2. 0] oct-2-ene-2- carboxylic acid, 7- [ [ (2-amino-4- thiazolyl) [(carboxymethoxy) imino] acetyl] ami no]-3-ethenyl-8-oxo-, [6R-[6Alpha, 7ß (Z)]]- cefixime [CAS] 79350-37-1 EP 30630 Cephalosporin, oral Infection, general 5-Thia-1-azabicyclo [4. 2. 0] oct-2-ene-2- carboxylic acid, 7- [ [ (2-amino-4- thiazolyl) (methoxyimino) acetyl] amino]-3-[[(1- methyl-1 H-tetrazol-5-yl) thio] methyl]-8-oxo-, 65085-01-0 cefmenoxime [6R- [6Alpha, 7S (Z)]]- [CAS] 75738-58-8 GB 1536281 Cephalosporin, injectable Infection, ocular Patent API Generic Name API Chemical Name CAS No. Reference Example of Therapeutic Use Example of Indication 5-Thia-1-azabicyclo [4. 2. 0] oct-2-ene-2- carboxylic acid, 7- [ff (cyanomethyl) thio] acetyl] amino]-7- methoxy-3-[[(1-methyl-1 H-tetrazol-5-56796-20-4 cefmetazole yl) thio] methyl]-8-oxo-, (6R-cis)- [CAS] 56796-39-5 GB 1449420 Cephalosporin, injectable Infection, general 5-Thia-1-azabicyclo [4. 2. 0] oct-2-ene-2- carboxylic acid, 7-[[[(2-amino-2- carboxyethyl) thio] acetyi] amino]-7-methoxy-3 [[(1-methyl-1 H-tetrazol-5-yl) thio] methyl]-8- cefminox oxo-, [6R-[6Alpha, 7Alpha, 7 (S*)]]- [CAS] 84305-41-9 EP 24879 Cephalosporin, injectable Infection urinary tract 5-Thia-1-azabicyclo [4. 2. 0] oct-2-ene-2- carboxylic acid, 7- [ [ (2-amino-4- thiazolyl) (methoxyimino) acetyl] amino]-3- [ [ [5- (carboxymethyl)-4-methyl-2- thiazolyl] thio] methyl]-8-oxo-, [6R-69739-16-8 cefodizime [6Alpha, 73 (Z)]]- [CAS] 86329-79-5 US 4590267 Cephalosporin, injectable Infection, respiratory tract, lower 5-Thia-1-azabicyclo [4. 2. 0] oct-2-ene-2- carboxylic acid, 7- [(hydroxyphenylacetyl) amino]-8-oxo-3-[[[1- (sulfomethyl)-1 H-tetrazol-5-yl] thio] methyl]-, 61270-78-8 cefonicid disodium salt, [6R-[6Alpha, 7ß (R*)]]- [CAS] 61270-58-4 GB 1547473 Cephalosporin, injectable Infection, general 5-Thia-1-azabicyclo [4. 2. 0] oct-2-ene-2- carboxylic acid, 7- [ [ [ [ (4-ethyl-2, 3-dioxo-1- piperazinyl) carbonyl] amino] (4- hydroxyphenyl) acetyl] amino]-3-[[(1-methyl- 1H-tetrazol-5-yl) thio] methyl]-8-oxo-, [6R- cefoperazone [6A ! pha, 7R (R*)]]- [CAS] 62893-19-0 GB 1508071 Cephalosporin, injectable Infection, general cefoperazone + sulbactam 92739-15-6 US 4234579 Antibiotic, other Infection, general Ceforanide 60925-61-3 5-Thia-1-azabicyclo [4. 2. 0] oct-2-ene-2- carboxylic acid, 7- [ [ (2-amino-4- thiazolyi) (methoxyimino) acetyl] amino]-3- [[2, 3-dihydro-2-(2-hydroxyethyl)-3-imino-1 H- pyrazol-1-yl] methyl]-8-oxo-, [6R-122841-12-7 cefoselis 1 [6AIpha, 7f (Z)]] 122841-10-5 EP 307804 Cephalosporin, injectable Infection, general t Patent API Generic Name API Chemical Name CAS No. Reference Example of Therapeutic Use Example of Indication (6R, 7R)-7- [ [ (2-amino-4- thiazolyl) (methoxyimino) acetyqamino] cephal 64485-93-4 cefotaxime sporanic acidsodium salt 63527-52-6 GB 1580621 Cephalosporin, injectable Infection, general Cefotetan 69712-56-7 5-Thia-1-azabicyclo [4. 2. 0] oct-2-ene-2- carboxylic acid. 7-[[(2-amino-4- thiazolyl) acetyl] amino]-3-[[[1-[2- (dimethylamino) ethyl]-1 H-tetrazol-5- 61622-34-2 cefotiam yl] thio] methyl]-8-oxo-, (6R-trans)- [CAS] 66309-69-1 US 4080498 Cephalosporin, injectable Infection, general 1- (cyclohexyloxycarbonyloxy) ethyl 7R- [2- (2- aminothiazol-4-yl) atamido]-3-[[[1-(2- dimethylaminoethyl)-1 H-tetrazol-5- yl] thio] methyl] ceph-3-em-4-carboxylate cefotiam hexetil 2HCI [CAS] 95789-30-3 EP 128029 Cephalosporin, oral Infection, respiratory tract, lower 5-Thia-1-azabicyclo (4. 2. 0) oct-2-ene-2- carboxylic acid, 3- ( ( (aminocarbonyl) oxy) methyl)-7-methoxy-8- oxo-7-((2-thienylacetyl) amino)-, 33564-30-6 cefoxitin monosodium salt, (6R-cis)- [CAS] 35607-66-0 GB 1348984 Cephalosporin, oral Infection, general Imidazo [1, 2-b] pyridazinium, 1- [ [7- [ [ (5-amino 1, 2, 4-thiadiazol-3- yi) (methoxyimino) acetyl] amino]-2-carboxy-8 oxo-5-thia-1-azabicyclo [4. 2. 0] oct-2-en-3- yl] methyl]-, hydroxide, inner salt, [6R- cefozopran [6Alpha, 7ß (Z)]]- [CAS] 113359-04-9 EP 203271 Cephalosporin, injectable Infection, general Pyridinium, 1- [ [2-carboxy-7-Q [ [ (5-carboxy- 1 H-imidazol-4- yl) carbonyl] amino] phenylacetyl] amino]-8- oxo-5-thia-1-azabicyclo [4. 2. 0] oct-2-en-3- yl] methyl]-4- (2-sulfoethyl)-, hydroxide, inner 84880-03-5 Infection, respiratory tract, cefpimizole salt, [6R- [6Alpha, 7R (R*)]]- [CAS] 85287-61-2 EP 60028 Cephalosporin, injectable general i Patent API Generic Name API Chemical Name CAS No. Reference Example of Therapeutic Use Example of Indication 5-Thia-1-azabicyclo [4. 2. 0] oct-2-ene-2- carboxylic acid, 7- [ [ [ [ (4-hydroxy-6-methyl-3- pyridinyl) carbonyi jamino] (4- hydroxyphenyl) acetyl] amino]-3-[[(1-methyl- 1H-tetrazol-5-yl) thio] methyl]-8-oxo-, [6R- cefpiramide [6Alpha, 7ß (R*)]]-[CAS] 70797-11-4 US 4156724 Cephalosporin, injectable Infection, general 5H-1-Pyrindinium, 1- [ [7- [ [ (2-amino-4- thiazolyl) (methoxyimino) acetyl] amino]-2- carboxy-8-oxo-5-thia-1-azabicyclo [4. 2. 0] oct- 2-en-3-yl] methyl]-6, 7-dihydro-, hydroxide, 84957-29-9 cefpirome inner salt, [6R-[6Alpha, 7ß (Z)]]- [CAS] 98753-19-6 EP 64740 Cephalosporin, injectable Infection, respiratory tract, lower Cefpodoxime Proxetil 87239-81-4 5-Thia-1-azabicyclo [4. 2. 0] oct-2-ene-2- carboxylic acid, 7-[[amino (4- hydroxyphenyl) acetyl] amino]-8-oxo-3- (1- 92665-29-7 cefproål propenyl)-, [6R-[6Alpha, 7ß (R*)]]- [CAS] 121123-17-9 GB 2173798 Cephalosporin, oral Infection, dermatological 5-Thia-1-azabicyclo [4. 2. 0] oct-2-ene-2- carboxylic acid, 7-[(amino-1, 4- cyclohexadien-1-ylacetyl) amino]-3-methoxy- cefroxadine 8-oxo-, [6R-[6Alpha, 7ß (R*)]]- [CAS] 51762-05-1 GB 1435111 Cephalosporin, oral Infection, general Pyridinium, 4-(aminocarbonyl)-1-[[2-carboxy 8-oxo-7-[(phenyisulfoacetyl) amino]-5-thia-1- azabicyclo [4. 2. 0] oct-2-en-3-yl] methyl]-, hydroxide, inner salt, [6R-[6Alpha, 713 (R*)]]-52152-93-9 cefsulodin [CAS] 62587-73-9 GB 1387656 Cephalosporin, injectable Infection, pseudomonal Pyridinium, 1- r7-[[(2-amino-4-thiazolyl) [(1- carboxy-1-methylethoxy) imino] acetyl] amino] 2-carboxy-8-oxo-5-thia-1- azabicyclo [4. 2. 0] oct-2-en-3-yl] methyl]-, hydroxide, inner salt, [6R-[6Alpha, 7ß (Z)]]-Infection, respiratory tract, ceftazidime [CAS] 72558-82-8 GB 2025398 Cephalosporin, injectable upper Cefteram 82547-58-8 Ceftezole 26973-24-0 Patent API Generic Name API Chemical Name CAS No. Reference Example of Therapeutic Use Example of Indication 5-Thia-1-azabicyclo [4. 2. 0] oct-2-ene-2- carboxylic acid, 7- [ [2- (2-amino-4-thiazolyl)-4 carboxy-1-oxo-2-butenyl] amino]-8-oxo-, [6R- ceftibuten [6Alpha, 7R (Z)]]- [CAS] 97519-39-6 EP 136721 Cephalosporin, oral Infection, respiratory tract, lower 5-Thia-1-azabicyclo [4. 2. 0] oct-2-ene-2- carboxylic acid, 7-1 (2-amino-4- thiazolyl) (methoxyimino) acetyl] amino]-8-oxo 68401-81-0 ceftizoxime, [6R-[6Aípha, 7ß (Z)]]- [CAS] 68401-82-1 GB 1600735 Cephalosporin, injectable Infection, general 5-Thia-1-azabicyclo [4. 2. 0] oct-2-ene-2- carboxylic acid, 7-1 [[2-[(2-amino-1- oxopropyl) amino]-4- thiazolyl] (methoxyimino) acetyl] amino]-8-oxo , (2, 2-dimethyl-1-oxopropoxy) methyl ester, monohydrochloride, [6R- [6AIpha, 7f& (Z (Si))]] 113812-94-5 ceftizoxime alapivoxil [CAS] 135767-36-1 JP 62209112 Cephalosporin, oral Infection, general 5-Thia-1-azabicyclo [4. 2. 0] oct-2-ene-2- carboxylic acid, 7-2 (2-amino-4- thiazolyl) (methoxyimino) acetyl] amino]-8-oxo 3- [ [ (1, 2, 5, 6-tetrahydro-2-methyl-5, 6-dioxo- 1, 2, 4-triazin-3-yl) thio] methyl]-, [6R-73384-59-5 ceftriaxone [6Alpha, 7ß (Z)]]- [CAS] 74578-69-1 GB 2022090 Cephalosporin, injectable Infection, respiratory tract, lower 5-Thia-1-azabicyclo [4. 2. 0] oct-2-ene-2- carboxylic acid, 3- [ [ (aminocarbonyl) oxy] methyl]-7-[[2- furanyl (methoxyimino) acetyl] amino]-8-oxo-, 1- (acetyloxy) ethyl ester, [6R-[6Alpha, 7ß (Z)]] 15686-71-2 Infection, respiratorytract, cefuroxime axetil [CAS] 64544-07-6 GB 1571683 Cephalosporin, oral upper 5=Thia-1-azabicyclo [4. 2. 0] oct-2-ene-2- carboxylic acid, 3- [[(aminocarbonyl) oxy] methyl]-7-[[2- furanyl (methoxyimino) acetyl] amino]-8-oxo-, 55268-75-2 cefuroxime [6R-[6Alpha, 7ß (Z)]]- [CAS] 56238-63-2 GB 1453049 Cephalosporin, injectable Infection, general Cefuzonam 82219-78-1 Benzenesulfonamide, 4- (5- (4-methylphenyl) celecoxib 3- (trifluoromethyl)-1H-pyrazol-1-yl)- [CAS] 169590-42-5 US 5760068 Antiarthritic, other Arthritis, rheumatoid Patent API Generic Name API Chemical Name CAS No. Reference Example of Therapeutic Use Example of Indication Butanoic acid, octahydro-1, 7, 8-trihydroxy-6- indolizinyl ester, [1S-Infection, hepatitis virus, celgosivir (1Alpha, 6ß, 7Alpha, 8ß, 8aß)]- [CAS] 121104-96-9 US 5017563 Antiviral, other general Urea, N'- [3-acetyl-4- [3- [ (1, 1- dimethylethyl) amino]-2- 56980-93-9 celiprolol hydroxypropoxy] phenyl]-N, N-diethyl- [CAS] 57470-78-7 GB 1441359 Antihypertensive, adrenergic Angina, unstable Cellulose Ethyl Hydroxyethyl 9004-58-4 Ether Centchroman 31477-60-8 9, 12-Epoxy-1 H-diindolo [1, 2, 3-fg : 3', 2', 1'- kl] pyrrolo [3, 4-i] [1, 6] benzodiazocine-10- carboxylic acid, 5, 16-bis ( (ethylthio) methyl)- 2, 3, 9, 10, 11, 12-hexahydro-10-hydroxy-9- methyl-l-oxo-, methyl ester, (9S, 10R. 12R)- CEP-1347 [CAS] 156177-65-0 WO 9731002 Antiparkinsonian Parkinson's disease 9, 12-Epoxy-1 H-diindolo [1, 2, 3-fg : 3', 2', 1'- kl] pyrrolo [3, 4-i] [1, 6] benzodiazocin-1-one, 2, 3, 9, 10, 11, 12-hexahydro-10-hydroxy-10- (hydroxymethyl)-9-methyl-, (9S, 10S, 12R)- CEP-701 [CAS] 111358-88-4 Anticancer, antimetabolite Cancer, prostate Cephacetrile 23239-41-0 Cephaeline 483-17-0 Cephalexin 15686-71-2 Cephaloglycin 3577-1-3 Cephaloridine 50-59-9 Cephalosporin C 61-24-5 Cephalothin 153-61-7 Cephapirin 24356-60-3 Cephradine 38821-53-3 Cerivastatin 145599-86-6 Ceronapril 111223-26-8 certoparin Heparin [CAS] 9005-49-6 Anticoagulant Thrombosis, venous Ceruletide 17650-98-5 Prosta-5, 13-dien-1-oicacid, 11, 15- dihydroxy-9-oxo-, (5Z, 11Alpha, 13E,-15S)- Cerviprost [CAS] 363-24-6 Formulation, dermal, topical Patent API Generic Name API Chemical Name CAS No. Reference Example of Therapeutic Use Example of Indication Cetalkonium 122-18-9 Cetamolol 34919-98-7 Cethexonium 1794-74-7 2H-Oxacyclotetradecino (4, 3-d) oxazol- 2, 6, 8, 14 (1H, 7H, 9H)-tetrone 4- ethyloctahydro-3a, 7, 9, 11, 13, 15-hexamethyl- 11-((3-(3-quinolinyi)-2-propenyl) oxy)-10- ( (3, 4, 6-trideoxy-3-(dimethylamino)-ß-D-xylo- hexapyranosyl) oxy)-, (3a S, 4R, 7R, 9R, 10R, 11R, 13R, 15R, 15aR)-Infection, respiratorytract, cethromycin [CAS] 205110-48-1 EP 929563 Macrolide antibiotic general Cetiedil 14176-10-4 Cetirizine 83881-51-0 Acetic acid, [2- [4- [ (4- chlorophenyl) phenylmethyl]-1-83881-51-0 cetirizine piperazinyl] ethoxy]-, [CAS] 83881-52-1 EP 58146 Antiallergic, non-asthma Allergy, general Acetic acid, [2- [4- [ (4- chlorophenyl) phenylmethyl]-1- piperazinyl] ethoxy]-, dihyrochloride, Benzenemethanol, Alpha- [1- (methylamino) ethyl]-, hydrochloride, [S-83881-52-1 Formulation, optimized, cetirizine+pseudoephedrine (R*R*)]-90-82-4 microencapsulate Allergy, general Cetotiamine 137-76-8 Cetoxime 25394-78-9 Benzenepropanoic acid, 4- [ [ [4- (aminomethyl) cyclohexyi] carbonyl] oxy]-, 27724-96-5 cetraxate trans- [CAS] 34675-84-8 JP 48075547 Antiulcer Cetrimonium 57-09-0 Cetrorelix 120287-85-6 Cetyidimethylethylammonium 124-03-8 Cetylpyridinium 123-03-5 Spiro [i-azabicyclo [2. 2. 2] octane-3, 5'-107220-27-9 cevimeline [1, 3] oxathiolane], 2'-methyl-, cis- [CAS] 107233-08-9 EP 205247 tomatological Sjogren's syndrome 7-phenyl-2, 4, 6-heptatrienoyihydroxamic acid CG-1521 Anticancer, other Cancer, general Patent API Generic Name API Chemical Name CAS No. Reference Example of Therapeutic Use Example of Indication Chaulmoogric Acid 29106-32-9 Chenodiol 474-25-9 CHF-3381 EP 951465 Analgesic, other Pain, neuropathic Chlophedianol 791-35-5 Chloracizine 800-22-6 302-17-0 2218-68-0 chloral 1, 1-Ethanediol, 2, 2, 2-trichloro- [CAS] 515-82-2 Formulation, transmucosal, systemic Insomnia Chlorambucil 305-03-3 Chloramine-B 127-52-6 Chloramine-T 127-65-1 Chloraminophenamide 121-30-2 Chloramphenicol 56-75-7 Chlorazanil 500-42-5 Chlorbenzoxamine 522-18-9 Chlorbetamide 97-27-8 Chlorcyclizine 82-93-9 Chlordantoin 5588-20-5 Chlordiazepoxide 58-25-3 Chlorguanide 500-92-5 Chlorhexadol 3563-58-4 2, 4, 11, 13-Tetraazatetradecanediimidamide, N, N"-bis (4-chlorophenyl)-3, 12-diimino- chlorhexidine [CAS] 55-56-1 Formulation, other Xerostomia, Periodontitis Chlorisondamine 69-27-2 Chlormadinone 302-22-7 Chlormerodrin 62-37-3 Chlormezanone 80-77-3 Chlormidazole 3689-76-7 Chlornaphazine 494-03-1 Chloroazodin 502-98-7 Chlorophyll 1406-65-1 Chloroprednisone 52080-57-6 Chloroprocaine 3858-89-7 Patent API Generic Name API Chemical Name CAS No. Reference Example of Therapeutic Use Example of Indication Chloropyramine 59-32-5 Chloroquine 54-05-7 Chlorothen 148-65-2 Chlorothiazide 58-94-6 Chlorotrianisene 569-57-3 Chloroxine 773-76-2 Chloroxylenol 88-04-0 Chlorozotocin 54749-90-5 2-Pyridinepropanamine, Gamma- (4- chlorphenamine chlorophenyl)-N, N-dimethyl- [CAS] 132-22-9 Formulation, modified-release, other Allergy, general Chlorphenesin 104-29-0 886- 74-8 Chlorpheniramine 132-229 Chlorphenoxamide 3576-64-5 Chlorphenoxamine 77-38-3 Chlorphentermine 461-78-9 Chlorproethazine 84-01-5 Chlorproguanil 537-21-3 4, 4'-Sulfonyidianiline + 1-(3, 4- Dichlorophenyl) 5-isopropylbiguanide 537-21-3 chlorproguanil + dapsone 80-08-0 Antimalarial Infection, malaria Chlorpromazine 50-53-3 Chlorpropamide 94-20-2 Chlorprothixene 113-59-7 Chlorquinaldol 72-80-0 Chlortetracycline 57-62-5 Chlorthalidone 77-36-1 Chlorthenoxazin (e) 132-89-8 Chlorzoxazone 95-25-0 Cholic Acid 81-25-4 Choline 67-48-1 2016- 36-6 28319-77- 9 Patent API Generic Name API Chemical Name CAS No. Reference Example of Therapeutic Use Example of Indication Ethanaminium, 2-hydroxy-N, N, N-trimethyl-, salt with 3, 7-dihydro-1, 3-dimethyl-1 H-purine choline theophyllinate 2, 6-dione (1 : 1) [CAS] 4499-40-5 Formulation, modified-release, other Ethanaminium, 2- [ [ (2, 3- dihydroxypropoxy) hydroxyphosphinylloxyl- N, N, N-trimethyl-, hydroxide, inner salt, (R)- choline-L-alfoscerate [CAS] 28319-77-9 JP 55028955 Cognition enhancer Amnesia Chromocarb 4940-39-0 Chromonar 804-10-4 Chrysoidine 532-82-1 Guanidine, N- [6- (4-chlorophenoxy) hexyl]-N'- CHS-828 cyano-N"-4-pyridinyl- [CAS] 200484-11-3 US 5696140 Anticancer, other Cancer, general Glycine, N- [2- [5- (aminoiminomethyl)-2- hydroxyphenoxy]-6- [3- (4, 5-dihydro-1-methyl 1 H-imidazol-2-yl) phenoxy]-3, 5-difluoro-4- CI-1031 pyridinyl]-N-methyl- [CAS] 183305-24-0 WO 9638421 Antianginal Angina, unstable Benzamide, 2- {(2-chloro-4- iodophenyl) amino]-N- (cyclopropylmethoxy)- CI-1040 3, 4-difluoro- [CAS] 212631-79-3 WO 9837881 Anticancer, other Cancer, general 1H-Imidazole, 2- (2, 2-diphenylcyclopropyl)- cibenzoline 4, 5-dihydro- [CAS] 53267-01-9 GB 1417174 Antiarrhythmic Arrhythmia, general Pregna-1, 4-diene-3, 20-dione 16, 17- ((cyclohexylmethylene) bis (oxy))-11-hydroxy- 21- 21-(2-methyl-1-oxopropoxy) (11 ß, 16Alpha) ciclesonide [CAS] 126544-47-6 DE 4129535 Antiasthma Asthma Furo [3, 4-c] pyridin-7-ol, 3- (4-chlorophenyl)- 82747-56-6 åcletanine 1, 3-dihydro-6-methyl-, (+/-)- [CAS] 89943-82-8 US 4383998 Antihypertensive, other 3-Pyridinecarboxylic acid, 3, 3, 5- ciclonicate trimethylcyclohexyl ester, trans- [CAS] 53449-58-4 DE 1910481 Vasodilator, peripheral Cancer, lung, small cell 2 (1H)-Pyridinone, 6-cyclohexyl-1-hydroxy-4-41621-49-2 ciclopirox methyí-, [CAS] 9342-05-0 US 3883545 Antifungal Infection, fungal, general Ciclosidomine 66564-16-7 Patent API Generic Name API Chemical Name CAS No. Reference Example of Therapeutic Use Example of Indication ciclosporin A Cyclosporin A- [CAS] 59865-13-3 Formulation, optimized, microemulsion Transplant rejection, general Phosphonic acid, [ [2- (4-amino-2-oxo-1 (2H)- pyrimidinyl)-1- cidofovir (hydroxymethyl) ethoxy] methyl]-, (S)- [CAS] 113852-37-2 EP 253412 Antiviral, other Infection, cytomegalovirus Cifenline 53267-01-9 4H-Pyrido [3, 2, 1 jk] carbazol-11 (8H)-one, 5, 6, 9, 10-tetrahydro-10-[(2-methyl-1 H- cilansetron imidazol-1-yl) methyl]-, (R)- [CAS] 120635-74-7 EP 297651 GI inflammatory/bowel disorders Irritable bowel syndrome Cilastatin 82009-34-5 6H-Pyridazino [1, 2-a] [1, 2] diazepine-1- carboxylic acid, 9- [ [1- (ethoxycarbonyl)-3- phenylpropyl] amino] octahydro-10-oxo-, [1 S-88768-40-5 cilazapril [1Alpha, 9Alpha (R*) B- [CAS] 90139-06-3 GB 2128984 Antihypertensive, renin system Hypertension, general Cyclo (L-arginylglycyl-L-Alpha-aspartyl-D- cilengitide phenylalanyl-N-methyl-L-valyl) [CAS] 188968-51-6 EP 770622 Anticancer, other Cancer, lung, non-small cell 3, 5-Pyridinedicarboxylic acid, 1, 4-dihydro- 2, 6-dimethyl-4- (3-nitrophenyl)-, 2- methoxyethyl 3-phenyl-2-propenyl ester-102106-21-8 cilnidipine [CAS] 132203-70-4 EP 161877 Antihypertensive, other Hypertension, general Cis-4-cyano-4- [3- (cyclopentyloxy)-4- methoxyphenyl] cyclohexane-1-carboxylic acid Chronic obstructive pulmonary cilomilast 153259-65-5 US 5602157 COPD treatment disease 2 (1 H)-Quinolinone, 6- [4- (l-cyclohexyl-1 H- cilostazol tetrazol-5-yl) butoxy]-3, 4-dihydro- [CAS] 73963-72-1 tithrombotic Cimetidine 51481-61-9 3-Oxa-9-azoniatricyclo [3. 3. 1. 02, 4] nonane, 9 (cyclopropylmethyl)-7- (3-hydroxy-l-oxo-2- phenylpropoxy)-9-methyl-, [7 (S)- cimetropium (1Alpha, 2f5, 4f5, 5Alpha, 7f3)]- [CAS] 51598-60-8 US 3853886 Antispasmodic Muscle spasm, general 1-napthalenemethanamine, Alpha-methyl-N- [3- [3- (trifluoromethyi) phenyl] propyl]-, cinacalcet (AlphaR)-, 364782-34-3 Hormone Hyperparathyroidism' Patent API Generic Name API Chemical Name CAS No. Reference Example of Therapeutic Use Example of Indication Cinchonidine 485-71-2 Cinchonine 118-10-5 Cinchophen 132-60-5 Cinepazet 23887-41-4 Cinepazide 23887-46-9 Piperazine, 1- [2-oxo-2- (1-pyrrolidinyl) ethyl]- 4- [1-oxo-3- (3, 4, 5-trimethoxyphenyl)-2- cinepazide propenyl]-, (Z)-2-butenedioate (1 : 1) [CAS] 26328-04-1 GB 1218591 Vasodilator, peripheral Peripheral vascular disease Cinitapride 66564-14-5 Cinmetacin 20168-99-4 Cinnamedrine 90-86-8 Cinnarizine 298-57-7 1H-1, 4-Benzodiazepine-1-propanenitrile, 7- chloro-5- (2-fluorophenyl)-2, 3-dihydro-3- cinolazepam hydroxy-2-oxo- [CAS] 75696-02-5 DE 2950235 Hypnotic/Sedative Insomnia [1, 3] Dioxolo [4, 5-g] cinnoline-3-carboxylic cinoxacin acid, 1-ethyl-1, 4-dihydro-4-oxo- [CAS] 28657-80-9 GB 1296753 Quinolone antibacterial Infection, urinarytract Cinoxate 104-28-9 Cinromide 58473-74-8 Cioteronel 89672-11-7 1H-Purine-2, 6-dione, 8-amino-1, 3- cipamfylline bis (cyclopropylmethyl)-3, 7-dihydro- [CAS] 132210-43-6 EP 389282 Antipruritic/inflamm, allergic Eczema, atopic 1 H-Imidazole, 4- [ (1R, 2R)-2- (5, 5-dimethyl-1- cipralisant hexynyl) cyclopropyl]- [CAS] 213027-19-1 US 6008240 Psychostimulant Attention deficit disorder Propanoic acid, 2- [4- (2, 2- dichlorocyclopropyl) phenoxy]-2-methyl- ciprofibrate [CAS] 52214-84-3 GB 1385828 Hypolipaemic/Antiatherosclerosis Hyperlipidaemia, general 3-Quinolinecarboxylic acid, 1-cyclopropyl-6- fluoro-1, 4-dihydro-4-oxo-7- (1-piperazinyl)- ciprofloxadn [CAS] 85721-33-1 US 4670444 Quinolone antibacterial Infection, general Patent API Generic Name API Chemical Name CAS No. Reference Example of Therapeutic Use Example of Indication 3-Quinolinecarboxylic acid, 1-cyclopropyl-6- fluor-1, 4-dihydro-4-oxo-7- (1-piperazinyl)- + (6Alpha, 11ß, 16Alpha)-6, 9-Difluoro-11, 21- dihydroxy-16, 17- [ (1-methylethylidene) bis- (oxy)]-pregna-1, 4-diene-3, 20-dione ciprofloxacin+fluocinolone, SAL Formulation, fixed-dose combinations Otitis Ciramadol 63269-31-8 Benzamide, 4-amino-5-chloro-N- [1- [3- (4- fluorophenoxy) propyl]-3-methoxy-4- cisapride piperidinyl]-2-methoxy-, cis- [CAS] 81098-60-4 EP 76530 Gastroprokinetic Isoquinolinium, 2, 2'- [1, 5- pentanediylbis [oxy (3-oxo-3, 1- propanediyl)]] bis [1- [ (3, 4- dimethoxyphenyl) methyl]]-1, 2, 3, 4-tetrahydro 6, 7-dimethoxy-2-methyl-, [1R- cisatracurium [1Alpha, 2Alpha (1'R*, 2'R*)]]-, [CAS] 96946-42-8 US 5453510 Muscle relaxant Surgery adjunct Platinum, diamminedichloro-, (SP-4-2)- cisplatin [CAS] 15663-27-1 US 4177263 Anticancer, alkylating 5-lsobenzofurancarbonitrile, 1- [3- (dimethylamino) propyl]-1- (4-fluorophenyl)- 59729-32-7 citalopram 1, 3-dihydro-[CAS] 59729-33-8 GB 1526331 Antidepressant Depression, general Cytidine 5'- (trihydrogen diphosphate), P'- [2- (trimethylammonio) ethyl] ester, hydroxide, citicoline inner salt [CAS] 987-78-0 JP 39006541 Cognition enhancer Infarction, cerebral Citiolone 1195-16-0 Citric Acid 77-92-9 Citrulline 372-75-8 Ethanamine, N, N-dimethyl-2- [ (1-methyl-1H- pyrazol-5-yl) phenylmethoxy]-, 2-hydroxy- cizolirtine 1, 2, 3-propanetricarboxylate [CAS] 142155-44-0 Urological Incontinence 4- (3- [4- (2-Methyl-imidazol-1-yi)- phenylsulfanyl]-phenyl)-tetrahydro-pyran-4- carboxylic acid amide Chronic obstructive pulmonary CJ-13610 COPD treatment disease Patent API Generic Name API Chemical Name CAS No. Reference Example of Therapeutic Use Example of Indication 1 H-Pyrano [3', 4' : 6, 7] indolizino [1, 2- b] quinoline-3, 14 (4H, 12H)-dione, 4-ethyl-4- hydroxy-11- [2- [ (1-methylethyl) amino] ethyi]-, CKD-602 monchydrochloride, (4S)- [CAS] 213819-48-8 WO 9902530 Anticancer, other Cancer, ovarian cladribine Adenosine, 2-chloro-2'-deoxy- [CAS] 4291-63-8 EP 173059 Anticancer, antimetabolite Cancer, leukaemia, hairy cell Clanobutin 30544-61-7 clarithromycin Erythromycin, 6-O-methyl- [CAS] 81103-11-9 EP 41355 Macrolide antibiotic Infection, respiratory tract, lower Clavulanate, Disodium Clavulanic Acid 58001-44-8 Clebopride 55905-53-8 Clemastine 15686-51-8 Clemizole 442-52-4 Clenbuterol 37148-27-9 Clentiazem 96125-53-0 3, 5-Pyridinedicarboxylic acid, 4- (2, 3- dichlorophenyl)-1, 4-dihydro-2, 6-dimethyl-, clevidipine methyl (1-oxobutoxy) methyl ester () [CAS] 167221-71-8 WO 9512578 Antihypertensive, other Hypertension, general 2, 4 (1 H, 3H)-Pyrimidinedione, 1- (2-deoxy-2- fluoro-ß-L-arabinofuranosyl)-5-methyl- clevudine [CAS] 163252-36-6 Antiviral, other Infection, hepatitis-B virus Clidanac 28968-07-2 Clidinium 3485-62-9 Clinafloxacin 105956-97-6 Clindamycin 18323-44-9 L-threo-Alpha-D-galacto-Octopyranoside, methyl 7-chloro-6, 7, 8-trideoxy-6-[[(1-methyl 4-propyl-2-pyrrolidinyl) carbonyl] amino]-1- thio-, (2S-trans)-+ retinoic acid clindamycin + tretinoin Formulation, fixed-dose combinations Acne Patent API Generic Name API Chemical Name CAS No. Reference Example of Therapeutic Use Example of Indication L-Threo-Alpha-D-galacto-octopyranoside, methyl 7-chloro-6, 7, 8-trideoxy-6-[[(1-methyl- 4-propyl-2-pyrrolidinyl) carbonyl] amino]-1- thio-, 2- (dihydrogen phosphate), (2S-trans)-18323-44-9 clindamycin 24729-96-2 Formulation, parenteral, other Infection, gynaecological Clinofibrate 30299-08-2 Clinprost 88931-51-5 1 H-1, 5-Benzodiazepine-2, 4 (3H, 5H)-dione, clobazam 7-chloro-1-methyl-5-phenyl- [CAS] 22316-47-8 GB 1214662 Anxiolytic Clobenfurol 3611-72-1 Clobenoside 29899-95-4 Clobenzepam 1159-93-9 Clobenzorex 13364-32-4 Clobenztropine 5627-46-3 Pregna-1, 4-diene-3, 20-dione, 21-chloro-9- fluoro-11, 17-dihydroxy-16-methyl-, clobetasol (11 ß, 16ß)- [CAS] 25122-41-2 Formulation, dermal, topical Psoriasis Pregna-1, 4-diene-3, 11, 20-trione, 21-chloro- 9-fluoro-16-methyl-17-(1-oxobutoxy)-, (16ßf 25122-57-0 clobetasone [CAS] 54063-32-0 GB 1253831 Antipruritic/inflamm, allergic Clobutinol 14860-49-2 Clocapramine 47739-98-0 Clocinizine 298-55-5 Cloconazole 77175-51-0 Clocortolone 4828-27-7 Phosphonic acid, (dichloromethylene) bis- Osteoporosis treatment, Anticancer, Pain, cancer, Hypercalcaemia clodronate [CAS] 22560-50-5 hormonal of malignancy Clodronic Acid 10596-23-3 2-chloro-9-(2-deoxy-2-fluoro-ß-D- arabinofurasonyl) adenine Cancer, leukaemia, chronic clofarabine Anticancer, antimetabolite Iymphocytic t Patent API Generic Name API Chemical Name CAS No. Reference Example of Therapeutic Use Example of Indication 3-(p-chloroanilo)-10-(p-chlorophenyl)-2, 10- dihydro-2-(isopropylimino)-phenazine Formulation, optimized, clofazimine 2030-63-9 microencapsulate Infection, tuberculosis Clofenamide 671-95-4 Clofibrate 637-07-0 Clofibric Acid 882-09-7 Cloflucarban 369-77-7 Clofoctol 37693-01-9 Cloforex 14261-75-7 Clomacran 5310-55-4 Clomestrone 4091-75-2 Clometacin 25803-14-9 Clomethiazole 533-45-9 Clometocillin 1926-49-4 Clomiphene 911-45-5 Clomipramine 303-49-1 Clomocycline 1181-54-0 2H-1, 4-Benzodiazepin-2-one, 5- (2- clonazepam chlorophenyl)-1, 3-dihydro-7-nitro- [CAS] 1622-61-3 US 4316897 Antiepileptic Epilepsy, general 1H-Imidazol-2-amine, N- (2, 6- clonidine dichlorophenyl)-4, 5-dihydro- [CAS] 4205-90-7 US 4060084 Formulation, transdermal, patch Hypertension, general Clonitazene 3861-76-5 Clonitrate 2612-33-1 Clonixin 17737-65-4 Clopamide 636-54-4 Clopenthixol 982-24-1 Cloperastine 3703-76-2 Thieno [3, 2-c] pyridine-5 (4H)-acetic acid, 120202-48-4 Alpha- (2-chlorophenyl)-6, 7-dihydro-, methyl 90055-48-4 clopidogrel ester, (S)- [CAS] 113665-84-2 EP 99802 Antithrombotic Infarction, myocardial Clopirac 42779-82-8 Cloprednol 5251-34-3 2-Propanol, 1- (2, 5-dichlorophenoxy)-3- [ (1, 1- 39563-28-5 cloranolol dimethylethyl) amino]- [CAS] 54247-25-5 US 4310549 Antihypertensive, adrenergic Patent API Generic Name API Chemical Name CAS No. Reference Example of Therapeutic Use Example of Indication Clorazepic Acid 23887-31-2 Clorexolone 2127-1-7 Acetic acid, [ [8-chloro-3- [2- (diethylamino) ethyq-4-methyl-2-oxo-2H-1- cloricromene benzopyran-7-yljoxy]-, ethyl ester [CAS] 68206-94-0 US 4349566 Vasodilator, coronary Peripheral vascular disease Clorindione 1146-99-2 Clorprenaline 3811-25-4 Clortermine 10389-73-8 Clospirazine 24527-27-3 Clostebol 1093-58-9 Clothiapine 2058-52-8 2H-Thieno [2, 3-e]-1, 4-diazepin-2-one, 5- (2- chlorophenyl)-7-ethyl-1, 3-dihydro-1-methyi- clotiazepam [CAS] 33671-46-4 US 3849405 Anxiolytic Anxiety, general 1- [ (2-chloraphenyl) diphenylmethyl]-i H- clotrimazole imidazole 23593-75-1 US 3705172 Antifungal Pregna-1, 4-diene-3, 20-dione, 9-fluoro-11- hydroxy-16-methyl-17, 21-bis (1-oxopropoxy)- , (11 ß, 16i3)-, mixt. with 1-[(2- chlorophenyl) diphenylmethyl]-1 H-imidazole clotrimazole + betamethasone [CAS] 92522-91-3 Formulation, fixed-dose combinations Infection, fungal, general Cloxacillin 61-72-3 Oxazolo [3, 2-d] [1, 4] benzodiazepin-6 (5H)- one, 10-chloro-11b- (2-chlorophenyl)- cloxazolam 2, 3, 7, 11 b-tetrahydro- [CAS] 24166-13-0 US 3772371 Anxiolytic Cloxatestosterone 53608-96-1 Cloxyquin 130-16-5 5H-Dibenzo [b, e] [1, 4] diazepine, 8-chloro-11- clozapine (4-methyl-1-piperazinyl)- [CAS] 5786-21-0 US 3539573 Neuroleptic Schizophrenia Trans-2- [3-methoxy-4- (2-p- chlorophenylthio) ethoxy-5- (N'-methyl-N'- hydroxyureidyl) methylphenyl]-5- (3, 4, 5- trimethoxyphenyl) tetrahydrofuran CM 193739-23-0 US 5648486 Antipsoriasis Psoriasis Patent API Generic Name API Chemical Name CAS No. Reference Example of Therapeutic Use Example of Indication 2-Naphthacenecarboxamide, 1, 4, 4a, 5, 5a, 6, 11, 12a-octahydro-3, 10, 12, 12a tetrahydroxy-1, 11-dioxo-, (4aS, 5aR, 12aS)- CMT-3 [CAS] 15866-90-7 US 5837696 Anticancer, other Cancer, sarcoma, Kapos's Decanediamide, N, N'-bis [3, 5-bis [1- [(aminoiminomethyl) hydrazono] ethyl] phenyl] CNI-1493, tetrahydrochloride [CAS] 164301-51-3 US 5750573 Anti-inflammatory Psoriasis N'- [2-chloro-5- (methylthio) phenyl]-N-methyl- CNS-5161 N- [3- (methylthio) phenyi] guanidine [CAS] 160754-76-7 WO 9427591 Analgesic, other Pain, neuropathic Cobamamide 13870-90-1 Cocaethylene 529-38-4 Cocaine 50-36-2 Codeine 76-57-3 52- 28-8 5, 10 methylene-tetrahydrofolate CoFactor Anticancer, antimetabolite Cancer, colorectal Colchicine 64-86-8 1-Hexanaminium, N, N, N-trimethyl-6- (2- propenylamino)-, polymer with (chloromethyl) oxirane, 2-propen-1-amine and N-2-propenyl-1-decanamine, colesevelam hydrochloride [CAS] 182815-44-7 US 5607669 Hypolipaemic/Antiatherosclerosis Hyperlipidaemia, general 1H-Imidazole, 2-methyl-, polymerwith colestilan (chloromethyl) oxirane [CAS] 95522-45-5 JP 59155421 Hypolipaemic/Antiatherosclerosis Hypercholesterolaemia Colestipol 26658-42-4 6- (3-dimethylaminopropionyl) forskolin- colforsin daropate [CAS] 138605-00-2 EP 222413 Cardiostimulant Heart failure 3, 5, 9-Trioxa-4-phosphapentacosan-1- aminium, 4-hydroxy-N, N, N-trimethyl-10-oxo- 7- [ (1-oxohexadecyl) oxy]-, hydroxide, inner 63-89-8 Respiratory distress syndrome, colfosceril salt, 4-oxide, (R)- [CAS] 99732-49-7 US 4826821 Lung Surfactant infant Collagraft 138331-02-9 Formulation, implant Regeneration, bone Colocynthin 1398-78-3 Colpormon 1247-71-8 Patent API Generic Name API Chemical Name CAS No. Reference Example of Therapeutic Use Example of Indication 1-Pyrrolidineacetamide, 2-oxo-N- (5, 6, 7, 8- tetrahydro-2, 3-dimethylfuro [2, 3-b] quinolin-4- coluracetam yi)- [CAS] 135463-81-9 EP 427636 Cognition enhancer Alzheimer's disease disodium combretastatin-A-4-3-O- phosphate combretastatin A-4 prodrug Anticancer, other Cancer, thyroid compound B, Pharmacor US 6362165 Antiviral, anti-HIV Infection, HIV/AIDS [1, 1'-Biphenyl]-2-carboxamide, N- [4- [ (4, 5- dihydro-2-methylimidazo [4, 5-d] [1- benzazepin-6 (1 H)-yl) carbonyl] phenyl]-, conivaptin [CAS] 168626-94-6 WO 9503305 Gi inflammatorylbowel disorders Hyponatraemia Connettivina Hyaluronic acid [CAS] 9004-61-9 Vulnerary Convallatoxin 508-75-8 Coparaffinate 8001-60-3 Corticorelin Ovine Triflutate Corticosterone 50-22-6 Cortisone 53-06-5 Cortivazol 1110-40-3 Cosyntropin 16960-16-0 Cotarnine 82-54-2 Cotinine 486-56-6 Benzenesulfonamide, 4-amino-N-2- pyrimidinyl-, mixt. with 5- [ (3, 4, 5- trimethoxyphenyl) methyl]-2, 4- co-trimazine pyrimidinediamine [CAS] 39474-58-3 Trimethoprim and analogues Infection, urinary tract Coumetarol 4366-18-1 1H-Indene-3-acetamide, 5-fluoro-2-methyl- N- (phenylmethyl)-1- [ (3, 4, 5- CP-248 trimethoxyphenyl) methylene]-, (1Z)- [CAS] 200803-37-8 WO 9747303 Anticancer, other Barrett's oesophagus CP-461 US 5948779 Anticancer, other Cancer, prostate CPC-211 Acetic acid, dichloro-, sodium salt [CAS] 2156-56-1 Neuroprotective Acidosis, lactic CPI-1189 CPI 1189 [CAS] 210475-67-5 WO 9631462 Cognition enhancer Dementia, AIDS-related CRA-0450 WO 0202549 Anxiolytic Unspecified Guanidine, N-methyl-N- (2- creatinol-O-phosphate (phosphonooxy) ethyl]- [CAS] 6903-79-3 Antianginal Patent API Generic Name API Chemical Name CAS No. Reference Example of Therapeutic Use Example of Indication Oxirane, methyl-, polymer with oxirane, CRL-5861 block [CAS] 106392-12-5 US 4837014 Antisickling Anaemia, sickle cell (2R, 6S)-3-[2 (S)-Benzyloxypropyl]-6, 11, 11- trimethyl-1, 2, 3, 4, 5, 6,-hexahydro-2, 6- methano-3-benzazocin-1 0-ol crobenetine WO 9914199 Neuroprotective Ischaemia, cerebral 1H-Imidazole, 1- [1- [2- [ (3- chlorophenyl) methoxy] phenyl] ethenyl]- croconazole [CAS] 77175-51-0 DE 3021467 Antifungal Infection, fungal, general 4H-1-Benzopyran-2-carboxylic acid, 5, 5'- [ (2- hydroxy-1, 3-propanediyl) bis (oxy)] bs4-oxo- cromoglicic acid [CAS] 53736-52-0 Formulation, mucosal, topical Conjunctivitis 4H-1-Benzopyran-2-carboxylic acid, 5, 5'- [ (2- hydroxy-1, 3-propanediyl) bis (oxy)] bis [4-oxo-, 15826-37-6 cromolyn [CAS] 16110-51-3 Formulation, inhalable, solution Asthma Cropropamide 633-47-6 Crotamiton 483-63-6 Crotethamide 6168-76-9 Crystacide US 4557935 Formulation, dermal, topical Infection, dermatological CS-502 EP 799823 Analgesic, other Pain, general 4- [ (1 E, 3E)-4- [trans-5- [ [1 R, 2R)-2- (2, 4- difluorophenyl)-2-hydroxy-1-methyl-3- (1 H- 1, 2, 4-triazol-1-yl) propyl] thio]-1, 3-dioxan-2-yl] 1, 3-butadienyl]-3-fluorobenzonitrile CS-758 Antifungi Infection, fungal, general 1-Azabicyclo [3. 2. 0] hept-2-ene-2-carboxylic acid, 6- [ (1 R)-1-hydroxyethyl]-4-methyl-7-oxo 3- [ [ (3R)-5-oxo-3-pyrrolidinyl] thio]-, (2, 2- dimethyl-1-oxopropoxy) methyl ester, CS-834 (4R, 5S, 6S)- [CAS] 157542-49-9 EP 599512 Beta-lactam antibiotic Infection, general [(2H-benzo [d] 1, 3-dioxalan-5- methyl) amino] [4- (6, 7-dimethoxyquinazolin-4 yl) piperazinyl] methane-1-thione CT-052923-Cardiovascular Restenosis Patent API Generic Name API Chemical Name CAS No. Reference Example of Therapeutic Use Example of Indication N- (4-bromophenyl)-6- (5-chloro-2- methylphenyl)- [1, 3, 5] triazine-2, 4-diamine CT-32228 Anticancer, other Cancer, general Cupric Citrate 866-82-0 Cuproxoline 13007-93-7 Ethanol, 2, 2'- [ [6- [ [ (4- methoxyphenyl) methyl] amino]-9- (1- methylethyl)-9H-purin-2-yl] imino] bis- CVT-2584 [CAS] 199986-75-9 WO 9805335 Cardiovascular Restenosis ((S)-6-amino-5-(6-hydroxy-2, 5, 7, 8- tetramethylchroman-2-carboxamido)-3- methyl-1-phenyl-2, 4- (1 H, 3H)- pyrmidinedione CX-659S Dermatological Eczema, general Cyacetacide 140-87-4 Cyamemazine 3546-03-0 Cyanidin 528-58-5 CYC400 WO 00172745 Anticancer, other Cancer, general Cyclacillin 3485-14-1 Cyclandelate 456-59-7 Cyclazocine 3572-80-3 Cyclexanone 15301-52-7 Cyclexedrine 532-52-5 3-Cyclohexene-1-methanol, 5-hydroxy- cyclidrol Alpha, Alpha, 4-trimethyl- [CAS] 498-71-5 COPD treatment, Respiratory Bronchitis, chronic cyclin D1 inhibitors US 6033843 Anticancer, hormonal Cancer, breast Cyclizine 82-92-8 Cyclobarbital 52-31-3 Cyclobendazole 31431-43-3 1-Propanamine, 3- (5H- dibenzo [a, d] cyclohepten-5-ylidene)-N, N- cyclobenzaprine dimethyl- [CAS] 303-53-7 Formulation, modified-release, other Muscle spasm, general Cyclobutyrol 512-16-3 Cyclocumarol 518-20-7 Cyclodrine 52109-93-0 Patent API Generic Name API Chemical Name CAS No. Reference Example of Therapeutic Use Example of Indication Cyclofenil 2624-43-3 Cycloguanil 516-21-2 Cyclomethycaine 139-62-8 Cyclonium lodide 6577-41-9 Cyclopentamine 102-45-4 Cyclopenthfazfde 742-20-1 Cyclopentobarbital 76-68-6 Cyclopentolate 512-15-2 N, N-Bis (2-chloroethyl) tetrahydro-2H-1, 3, 2- oxazaphosphorin-2-amine-2-oxide monohydrate 50-18-0 cyclophosphamide 6055-19-2 Formulation, parenteral, targeted Cancer, general 2 (1H)-Pyridinone, 6-cyclohexyl-1-hydroxy-4- methyl-, cmpd with 2-aminoethanol (1 : 1) cyclopiroxalamine [CAS] 41621-49-2 Formulation, transdermal, other Vaginitis Cycloserine 68-41-7 Cyclothiazide 2259-96-3 Cyclovalone 579-23-7 Cymarin 508-77-0 Carbamic acid, [4- (1-methylethyl) phenyl]-, (3aS, 8aR)-1, 2, 3, 3a, 8, 8a-hexahydro-1, 3a, 8- cymserine trimethylpyrrolo [2, 3-b] indol-5-yl ester [CAS] 145209-39-8 WO 9902154 Cognition enhancer Alzheimer's disease Cynarin (e) 30964-13-7 CYP26 inhibitors US 6063606 Dermatological Unspecified Cyproheptadine 129-03-3 (1 R. 2ß)-6-Chloro-1, 2-dihydro-17-hydroxy- 3'H-cyclopropa [1, 2] pregna-1, 4, 6-triene-3, 20 Chemotherapy-induced injury, cyproterone dione [CAS] 2098-66-0 Radio/chemoprotective general Cysteamine 60-23-1 [ [4-E3- [ [4- [l- (4-hydroxyphenyl)-l-methyl- ethyl] phenoxy] methyl] phenyl] methoxy]- phenyl] iminomethyl]-, ethyl ester cystic fibrosis ther Cystic fibrosis treatment Cystic fibrosis Patent API Generic Name API Chemical Name CAS No. Reference Example of Therapeutic Use Example of Indication 2 (1H)-Pyrimidinone, 4-amino-1- [5-0- [hydroxy (octadecyioxy) phosphinyi]-ß-D-65093-40-5 cytarabine arabinofuranosyl]-, [CAS] 147-94-4 EP 239015 Anticancer, antimetabolite Myelodysplastic syndrome N- (Pyridin-4-yl)- (1- (4-chlorobenzyl)-indol-3- yl)-glyoxyl-amide) D-24851 Anticancer, other Cancer, general 8-Methoxyquinoline-5- [N- (2, 5- dichloropyridin-3-yl)] carboxamide D4418 Antiasthma Asthma Benzeneacetamide, 4- (2-aminoethoxy)-N- (3 (3, 4-dimethylphenyl) propyl)-3-methoxy-, DA-5018 monohydrochloride [CAS] 174661-97-3 US 5242944 Analgesic, other Pain, musculoskeletal DA-6034 US 6025387 Gl inflammatory/bowel disorders Crohn's disease DA-7867 KR 9957803 Antibacterial, other Infection, general DA-7911 KR 56034 Antiarthritic, other Arthritis, rheumatoid 3- (1-Methyl-7-oxo-3-propyl-6, 7-dihydro-1 H- pyrazolo- [4, 3-d] pyrimidin-5-yi)-N- [2- (1- methylpyrrolidin-2-yl) ethyl]-4- propoxybenzenesulfonamide Sexual dysfunction, male, DA-8159 Sexual dysfunction, male, DA-8159 KR 353014 Male sexual dysfunction general Dacarbazine 4342-3-4 Daclizumab 152923-56-3 Dactinomycin 50-76-0 5, 31-Dichloro-38-de (methoxycarbonyl)-7- demethyl-1 [2-deoxy-2- (10- methylundecanamido)-ß-D- glucopyranurosyl]-38- [N- [3- (dimethylamino) propyl] carbamoyl]-42-O- Alpha-D-mannopyranosyl-N 15- methylristomycin A aglycone dalbavancin 171500-79-1 Peptide antibiotic Infection, dermatological Dalfopristin 112362-50-2 Patent API Generic Name API Chemical Name CAS No. Reference Example of Therapeutic Use Example of Indication Virginiamycin M1, 26-((2- (diethylamino) ethyl) sulfonyl)-26, 27-dihydro-, (26R, 27S)-, mixt with 4- (4- (dimethylamino)- N-methyl-L-phenylalanine)-5-(5-((1- azabicyclo (2. 2. 2) oct-3-ylthio) methyl)-4-oxo- L-2-piperidinecarboxylic acid) virginiamycin Infection, respiratory tract, dalfopristin + quinupristin S1- [CAS] 126602-89-9 EP 248703 Antibiotic, other general dalteparin Heparin-, [CAS] 9041-08-1 US 4303651 Anticoagulant Thromboprophylaxis Daltroban 79094-20-5 d-Aminolevulinic Acid 106-60-5 danaparoid EP 66908 Anticoagulant Thrombosis, venous Pregna-2, 4-dien-20-yno [2, 3-d] isoxazol-17- danazol ol, (17AIpha)- [CAS] 17230-88-5 GB 905844 Menstruation disorders Danthron 117-10-2 Dantrolene 7261-97-4 1, 2, 4-Triazolo [4, 3-a] pyridine, 5, 6, 7, 8- tetrahydro-3- [2- [4- (2-methylphenyl)-l-72822-12-9 dapiprazole piperazinyl] ethyl]- [CAS] 72822-13-0 US 4252721 Ophthalmological Glaucoma 4- [ [4- (2, 4, 6-trimethylphenyl) amino] pyrimidin- 2-yl] amino] benzonitrile dapivirine 244767-67-7 Antiviral, anti-HIV Infection, HIV/AIDS (+)- (S)-N, N-dimethyl-Alpha- [2- (1-naphthyl- dapoxetine oxy) ethyl] benzylamine HCI 119356-77-3 EP 288188 Male sexual dysfunction Premature ejaculation 4, 4'-Sulfonyidianiline dapsone 80-08-0 Formulation, dermal, topical Acne daptomycin Daptomycin [CAS] 103060-53-3 EP 178152 Peptide antibiotic Infection, dermatological Darbepoetin Alfa 3-Pyrrolidineacetamide, 1- [2- (2, 3-dihydro-5- benzofuranyl) ethyl]-Alpha, Alpha-diphenyl-, darifenacin (S)- [CAS] 133099-04-4 EP 388054 Urological Overactive bladder 5, 12-Naphthacenedione, 8-acetyl-10- [ (3- amino-2, 3, 6-trideoxy-Alpha-L-lyxo- hexopyranosyl) oxy]-7, 8, 9, 10-tetrahydro- 6, 8, 11-trihydroxy-1-methoxy-, (8S-cis)- daunorubicin [CAS] 20830-81-3 US 5441745 Formulation, optimized, liposoms Cancer, sarcoma, Kaposi's Patent API Generic Name API Chemical Name CAS No. Reference Example of Therapeutic Use Example of Indication 3-diallyl-8-cyclohexylxanthine DAX, SciClone Cystic fibrosis treatment Cystic fibrosis 7-tert-Butyldimethylsilyl-10- hydroxycamptothecin DB-67 Anticancer, other Cancer, general d-Camphocarboxylic Acid 18530-30-8 DCF-987 Dextran US 5514665 Formulation, other Cystic fibrosis DDT 50-29-3 Deaminooxytocin 113-78-0 Deanol 108-01-0 Debrisoquin 1131-64-2 Decamethonium 541-22-0 Decimemide 14817-09-5 1, 3, 5-Triazin-2 (1H)-one, 4-amino-1- (2- 23339-46-0 decitabine deoxy-13-D-erythro-pentofuranosyl)-[CAS] 2353-33-5 Anticancer, antimetabolite Myelodysplastic syndrome Benzamide, 4-amino-3-chloro-N- (2- declopramide (diethylamino) ethyl)- [CAS] 891-60-1 WO 9732582 Anticancer, other Cancer, colorectal Deferiprone 30652-11-0 Deferoxamine 70-51-9 5'H-Pregna-1, 4-dieno [17, 16-d] oxazol-3, 20- dione, 21-(acetyloxy)-11-hydroxy-2'-methyl-, 14484-47-0 deflazacort (11 ß, 16ß)- [CAS] 74712-90-6 GB 1077393 Hormone Asthma Defosfamide 3733-81-1 N-acetyl-3- (naphtalen-2-yl)-D-alanyl-4- chloro-D-phenylaian-3- (pyridin-3-yi)-D- alanyl-L-seryl-4- [ [ [ (4S)-2, 6- dioxohexahydropyrimidin-4- yl] carbonyl] amino]-L-phenylalanyl-4- (carbamoylamino)-D-phenylalanyl-L-leucyl- N6- (l-methylethyl)-L-lysyl-L-prolyl-D- degarelix alaninamide 214766-78-6 Anticancer, hormonal Cancer, prostate L-threo-2, 3-Hexodiulosonic acid gamma- lactone dehydroascorbic acid 490-83-5 Cognition enhancer Alzheimer's disease Dehydrocholic Acid 81-23-2 Dehydroemetine 4914-30-1 Patent API Generic Name API Chemical Name CAS No. Reference Example of Therapeutic Use Example of Indication Glycine, N-(2, 3-dihydro-1H-inden-2-yl)-N-[N [1- (ethoxycarbonyl)-3-phenylpropyl]-L- 83435-66-9 delapril alanyl]-, (S)- [CAS] 83435-67-0 EP 51391 Antihypertensive, renin system Hypertension, general Glycine, N-(2, 3-dihydro-1 H-inden-2-yl)-N-[N [1- (ethoxycarbonyl)-3-phenylpropyl]-L- alanyl]-, (S)-3, 5-Pyridinedicarboxylic acid, 1, 4-dihydro-2, 6-dimethyl-4- (3-nitrophenyl)-, 2- [4- (diphenylmethyl)-1-piperazinyl] ethyl delapril+manidipine methyl ester [CAS] FR 2733911 Formulation, fixed-dose combinations Hypertension, general Piperazine, 1- [3- [ (1-methylethyl) amino]-2- pyridinyl] ti 15-[(methylsulfonyi) amino]-1 H- delavirdine indol-2-yl] carbonyl]- [CAS] 136817-59-9 WO 9109849 Antiviral, anti-HIV Infection, HIV/AIDS Delmadinone 13698-49-2 Delmopinol 79874-76-3 2H-1, 4-Benzodiazepin-2-one, 7-chloro-5- (2- delorazepam chlorophenyl)-1, 3-dihydm- [CAS] 2894-67-9 CH 408029 Anxiolytic 3, 3-Bis- (m-fluorophenyl)-N- delucemine methylpropylamine [CAS] 186495-99-8 Neuroprotective Ischaemia, cerebral Demanyl 6909-62-2 Demecarium 56-94-0 2-Naphthacenecarboxamide, 7-chloro-4- (dimethylamino)-1, 4, 4a, 5, 5a, 6, 11, 12a- octahydro-3, 6, 10, 12, 12a-pentahydroxy-1, 11 dioxo-, [4S- (4Alpha, 4aAlpha, 5aAlpha, 6ß, 12aAlpha)]- demeclocycline [CAS] 127-33-3 Formulation, modified-release, <=24hr Infection, general Demecolcine 477-30-5 Demegestone 10116-22-0 Demexiptiline 24701-51-7 Benzeneacetic acid, Alpha- (2-ethylbutoxy)- Alpha-phenyl-, 2-(dimethyEamino) ethyl denaverine ester, [CAS] 3321-06-0 DE 4133785 Analgesic, NSAID Pain, musculoskeletal Denileukin Diftitox 173146-27-5 Denopamine 71771-90-9 Denopterin 22006-84-4 Patent API Generic Name API Chemical Name CAS No. Reference Example of Therapeutic Use Example of Indication Deoxycholic Acid 83-44-3 Deoxycorticosterone 64-85-7 56- 47-3 Deoxydihydrostreptomycin 26086-49-7 Deoxyepinephrine 501-15-5 Depreotide 161982-62-3 L-Valine, N- [ (3S, 4E)-3-hydroxy-7-mercapto- 1-oxo-4-heptenyl]-D-valyl-D-cysteinyl- (2Z)-2- amino-2-butenoyl-, (4-1)-lactone, cyclic (1- depsipeptide 2)-disulfide [CAS] 128517-07-7 EP 352646 Anticancer, antibiotic Cancer, general Deptropine 604-51-3 Dequalinium 522-51-0 Benzoic acid, 2-hydroxy-5- [ [4- [3- [4- (2- methyl-1H-imidazol [4, 5-c] pyridin-1- yl] methyl]-1-piperidinyl]-3-oxo-1-phenyl-1- 188913-57-7 dersalazine propenyl] phenyl] azo] (Z) [CAS] 188913-58-8 US 5747477 Anti-inflammatory Colitis, ulcerative Deserpidine 131-01-1 Butanediamide, N'- [5- [ [4- [ [5- (acetylhydroxyamino) pentyl] amino]-1, 4- dioxobutyi] hydroxyamino] pentyl]-N-(5- desferrioxamine aminopentyl)-N-hydroxy- [CAS] 70-51-9 Antidote Poisoning, metal Desflurane 57041-67-5 Desipramine 50-47-5 Deslanoside 17598-65-1 5H-Benzo (5, 6) cyclohepta (1, 2-b) pyridine, 8- chloro-6, 11-dihydro-11- (4-piperidinylidene)- desloratadine [CAS] 100643-71-8 US 5595997 Antiallergic, non-asthma Rhinitis, allergic, perennial Luteinizing hormone-releasing factor (pig), 6-D-tryptophan-9- (N-ethyl-L-prolinamide)- deslorelin 10-deglycinamide- [CAS] 57773-65-6 US 4034082 Releasing hormones Cancer, prostate Vasopressin, 1- (3-mercaptopropanoic acid)- desmopressin 8-D-arginine- [CAS] 16679-58-6 DE 2948345 Hormone Enuresis Desogestrel 54024-22-5 Estra-1, 3, 5 (10)-triene-3, 17-diol (17f5)-, mixt. with (17AIpha)-13-ethyl-11-methylene-18, 19 desogestrel + estradiol inorpregn-4-en-20-yn-17-ol [CAS] 122364-17-4 Menopausal disorders Hormone replacement therapy Patent API Generic Name API Chemical Name CAS No. Reference Example of Therapeutic Use Example of Indication 18, 19-Dinorpregn-4-en-20-yn-17-ol, 13- desogestrel, Akzo Nobel ethyl-11-methylene-, (17Alpha)- [CAS] 54024-55-5 Formulation, oral, other Contraceptive, female 18, 19-Dinorpregn-4-en-20-yn-17-ol, 13-54024-22-5 desogestrel+ethinylestrad (1) ethyl-11-methylene-, (17AIpha)- [CAS] 71138-35-7 US 3927046 Formulation, oral, other Contraceptive, female Desomorphine 427-00-9 Desonide 638-94-8 Desoximetasone 382-67-2 Detaxtran 9015-73-0 Devacade WO 9308176 Analgesic, other Pain, general Pregna-1, 4-diene-3, 20-dione, 9-fluor- 50-02-2 11, 17, 21-trihydroxy-16-methyl-, 2392-39-4 dexamethasone (11 16A 16Alpha)- [CAS] 312-93-6 Formulation, other Inflammation, ocular 6H-Dibenzo [b, d] pyran-9-methanol, 3- (1, 1- dimethylheptyl)-6a, 7, 10, 1 Oa-tetrahydro-1- dexanabinol hydroxy-6, 6-dimethyl-, (6aS-trans)- [CAS] 112924-45-5 EP 427518 Neuroprotective Head trauma Glycine, N-[2-[(acetylthio) methyl]-1-oxo-3- phenylpropyl]-, phenylmethyl ester, (R)- dexecadotril [CAS] 112573-72-5 EP 318377 Alimentary/Metabolic other Unspecified 1H-imidazole, 2- (2-ethyl-2, 3-dihydro-2- 89197-00-2 dexefaroxan benzofuranyl)-4, 5-dihydro- [CAS] 89197-32-0 EP 71368 Cognition enhancer Alzheimer's disease Dexetimide 21888-98-2 Benzeneacetic acid, Alpha-methyl-4- (2- Men U exibuprofen methylpropyi)-, (AlphaS)- [CAS] 51146-56-6 Analgesic, NSAID Pain, general Benzeneacetic acid, 3-benzoyl-Alpha- dexketoprofen methyl-, (S)- [CAS] 22161-81-5 Anti-inflammatory Inflammation, general Pentanoic acid, 4- [ (3, 4- dichlorobenzoyl) amino]-5- [ (3- methoxypropyl) pentylamino]-5-oxo-, (R)- dexioxiglumide [CAS] 119817-90-2 EP 0344184 GI inflammatory/bowel disorders Irritable bowel syndrome 1H-Imidazole, 4- [1- (2, 3- 113775-47-6 dexmedetomidine dimethylphenyl) ethyl]-, (R)- [CAS] 86347-15-1 EP 187471 Hypnotic/Sedative Anaesthesia 2-Piperidineacetic acid, Alpha-phenyl-, methyl ester, (AlphaR, 2R)- dexmethylphenidate 19262-68-1 Psychostimulant Attention deficit disorder Dexpanthenol 81-13-0 2, 6-Piperazinedione, 4, 4'- (1-methyl-1, 2- Chemotherapy-induced injury, dexrazoxane ethanediyl) bis-, (S)- [CAS] 24584-09-6 DE 1910283 Radio/chemoprotective general Patent API Generic Name API Chemical Name CAS No. Reference Example of Therapeutic Use Example of Indication Dextran-1 Dextran [CAS] 9004-54-0 Plasma substitute Dextranomer 56087-11-7 Dextroamphetamine 51-64-9 Morphinan, 3-methoxy-17-methyl-, 6700-34-1 dextromethorphan (9Alpha, 13Alpha, 14Alpha)-, 125-71-3 US 4221788 Formulation, oral, other Cough, Emotional lability Dextromoramide 357-56-2 Benzeneethanol, Alpha- [2- (dimethylamino)- 1-methylethyi]-Alpha-phenyl-, propanoate dextropropoxyphene (ester), [S- (R*, S*)]- [CAS] 469-62-5 Formulation, modified-release, other Pain, general Dezocine 53648-55-8 1 N-Tropyl 7-azaindol-3-ylcarboxamide DF-1012 163220-65-3 WO 9504742 Respiratory Respiratory disease, general di-D-fructofuranose 2, 6' : 6, 2'dianhydride DFA-IV US 5700832 Antianaemic Anaemia, aplastic d-Fenchone 4695-62-9 D-Glucuronolactone 32449-92-6 Diab II Diab II 309956-85-2 US 6153632 Antidiabetic Diabetes, Type II 2-Anthracenecarboxylic acid, 4, 5- bis (acetyloxy)-9, 10-dihydro-9, 10-dioxo- diacerein [CAS] 13739-02-1 US 4244968 Antiarthritic, other Arthritis, rheumatoid Diampromide 552-25-0 Diamthazole 136-96-9 Diathymosulfone 5964-62-5 Diatrizoate 737-31-5 2H-1, 4-Benzodiazepin-2-one, 7-chloro-1, 3- diazepam dihydro-1-methyl-5-phenyl- [CAS] 439-14-5 Formulation, transmucosal, systemic Anxiety, epilepsy, general Diaziquone 57998-68-2 Diazoxide 364-98-7 D-Streptamine, 0-3-amino-3-deoxy-Alpha-D glucopyranosyl- (1-6)-0- [2, 6-diamino-2, 3, 4, 6 tetradeoxy-Alpha-D-erythro-hexopyranosyl-34493-98-6 dibekacin (1-4)]-2-deoxy-, sulfate (salt) [CAS] 58580-55-5 GB 1349302 Aminoglycoside antibiotic Infection, generai Dibenzepin 4498-32-2 Patent Patent API Generic Name API Chemical Name CAS No. Reference Example of Therapeutic Use Example of Indication Dibromopropamidine 496-00-4 Dibucaine 61-12-1 Dichloralphenazone 480-30-8 Dichloramine T 473-34-7 Dichlorisone 7008-26-6 Dichlorobenzyl Alcohol 1777-82-8 Dichlorophen 97-23-4 Dichidrophenarsine 536-29-8 Dichlorphenamide 120-97-8 Hyaluronic acid + benzeneacetic acid, 2- diclofenac + HA [(2, 6-dichlorophenyl) amino]- [CAS] Formulation, transdermal, systemic Keratosis 15307-79-6 Benzeneacetic acid, 2- [ (2, 6- 15307-86-5 diclofenac dichlorophenyl) amino]-, [CAS] 15307-81-0 Formulation, modified-release, <=24hr Pain, general Dicloxacillin 3116-76-5 Dicumarol 66-76-2 Dicyclomine 77-19-0 didanosine Inosine, 2', 3'-dideoxy- [CAS] 69655-05-6 US 4861759 Antiviral, anti-HIV Infection, HIV/AIDS Dideoxyadenosine 4097-22-7 didox Benzamide, N, 3, 4-trihydroxy- [CAS] 69839-83-4 US 4263322 Anticancer, antimetabolite Cancer, general Dienestrol 84-17-3 19-Norpregna-4, 9-diene-21-nitrile, 17- dienogest hydroxy-3-oxo-, (17AIpha)- [CAS] 65928-58-7 GB 1524917 Menstruation disorders Endometriosis 19-Norpregna-4, 9-diene-21-nitrile, 17- hydroxy-3-oxo-, (17Aipha) + Estra-1, 3, 5 (10)- triene-3, 17-diol (1173) dienogest+estradiol Formulation, fixed-dose combinations Contraceptive, female Diethadione 702-54-5 Diethazine 60-91-3 Diethylbromoacetamide 511-70-6 Diethylcarbamazine 90-89-1 1-Propanone, 2-(diethylamino)-1-phenyi- diethylpropion [CAS] 90-84-6 Formulation, modified-release, <=24hr Obesity Diethylstilbestrol 56-53-1 Difemerine 80387-96-8 Patent API Generic Name API Chemical Name CAS No. Reference Example of Therapeutic Use Example of Indication Difenamizole 20170-20-1 Difenoxin 28782-42-5 Difenpiramide 51484-40-3 (5R)-5-Ethyl-9, 10-difluoro-1, 4, 5, 13- tetrahydro-5-hydroxy-3H, 15H- oxepino [3', 4' : 6, indolizino [1, 2-b] quinoline- 3, 15-dione diflomotecan 220997-97-7 Anticancer, other Cancer, general Pregna-1, 4-diene-3, 20-dione, 17, 21- bis (acetyloxy)-6, 9-difluoro-11-hydroxy-16- 33564-31-7 diflorasone methyl-, (6AIpha, 1111, 169)- [CAS] 2557-49-5 US 3980778 Antipsoriasis Difloxacin 98106-17-3 Diflucortolone 2607-6-9 2', 4'-difluoro-4-hydroxy [1, 1'-biphenyl]-3-23674-86-4 diflunisal carboxylic acid 22494-42-4 GB 1175212 Analgesic, NSAID Pain, post-operative Difluprednate 23674-86-4 Digitalin 752-61-4 Digitoxin 71-63-6 Card-20 (22)-enolide, 3-[(0-2, 6-dideoxy-ß-D ibo-hexopyranosyl-(1-4)-0-2, 6-dideoxy-ß-D bo-hexopyranosyi-(1-4)-2, 6-dideoxy-ß-D- ribo-hexopyranosyl) oxy]-12, 14-dihydroxy-, digoxin (311, 5fl, 12R)- [CAS] 20830-75-5 US 4088750 Formulation, oral, enteric-coated Heart failure Dihexyverine 561-77-3 Dihydralazine 484-23-1 Dihydrocodeine 125-28-0 D h drocodeinone Enoi 466-90-0 dihydroergocryptine rgocryptine, dihydro- [CAS] 25447-66-9 Formulation, other Depression, general Ergotaman-3', 6', 18-trione, 9, 10-dihydro-12'- l (phenylmethyl)-, dihydroergotamine (5'Alpha, lOAlpha)- [CAS] 511-12-6 6495535 Formulation, modified-release, other Migraine Dihydromorphine 509-60-4 Dihydrostreptomycin 128-46-1 D ; d ; 67-96-9 Patent API Generic Name API Chemical Name CAS No. Reference Example of Therapeutic Use Example of Indication Dihydroxyaluminum 13682-92-3 539- 68-4 Diisopromine 5966-41-6 Diisopropyl Paraoxon 3254-66-8 Diisopropylamine 660-27-5 Benzoic acid, 3, 4, 5-trimethoxy-, (tetrahydro- 1 H-1, 4-diazepine-1, 4 (5H)-diyl) di-3, 1- dilazep propanediyl ester [CAS] 35898-87-4 JP 51095086 Vasodilator, coronary Dilevalol 75659-07-3 2-Furancarboxylic acid, 4- [(dichloroacetyl) methylamino] phenyi ester 3736-81-0 diloxanide [CAS] 579-38-4 Amoebicide 1, 5-Benzothiazepin-4 (5H)-one, 3- (acetyloxy)-5- [2- (dimethylamino) ethyl]-2, 3- US 4721619 dihydro-2- (4-methoxyphenyl)-, (2S-cis)-33286-22-5 US 5529791 diltiazem [CAS] 42399-41-7 EP 322277 Antianginal Angina, hypertension, general Dimecrotic Acid 7706-67-4 Dimefline 1165-48-6 Dimemorfan 36309-01-0 Dimenhydrinate 523-87-5 Dimenoxadol 509-78-4 Dimepheptanol 545-90-4 Dimercaprol 59-52-9 Dimetacrine 4757-55-5 Dimethadione 695-53-4 Dimethazan 519-30-2 Dimethindene 5636-83-9 Dimethisoquin 86-80-6 Dimethisterone 79-64-1 Dimethocaine 94-15-5 Dimethoxanate 477-93-0 Dimethyl Sulfoxide 67-68-5 Dimethyithiambutene 524-84-5 Dimetofrine 22950-29-4 Dimorpholamine 119-48-2 Patent API Generic Name API Chemical Name CAS No. Reference Example of Therapeutic Use Example of Indication Prosta-5, 13-dien-1-oic acid, 11, 15- dihydroxy-9-oxo-, (5Z, 11Alpha. 13E 15S)- dinoprostone [CAS] 363-24-6 Formulation, modified-release, <=24hr Labour, induction diosmectite Smecta- [CAS] 110070-78-5 FR 2770778 Antidiarrhoeal Diarrhoea, general 4H-1-Benzopyran-4-one, 7- [ [6-0- (6-deoxy- Alpha-L-mannopyranosyl)-. beta.-D- glucopyranosyl] oxy]-5-hydroxy-2- (3-hydroxy- diosmin 4-methoxyphenyl)- [CAS] 520-27-4 DE 2602314 Vasoprotective, systemic Dioxadrol 6495-46-1 Dioxaphetyl 467-86-7 Dioxethedrine 497-75-6 Dioxybenzone 131-53-3 Diphemanil 62-97-5 Diphenadione 82-66-6 Diphencyprone 886-38-4 Diphenhydramine 58-73-1 Diphenidol 972-02-1 Diphenoxylate 915-30-0 Diphenyipyraiine 147-20-6 Diphetarsone 515-76-4 Diphtheria & Tetanus Toxolds And Acellular Pertussis Vaccine Adsorbed Dipipanone 467-83-4 P v15 Propanoic acid, 2, 2-dimethyl-, 4- [1-hydroxy- 2- (methylamino) ethyl]-1, 2-phenylene ester, dipivefrin (+/-)- [CAS] 52365-63-6 US 3809714 Antiglaucoma Glaucoma Dipyridamole 58-32-2 Dipyrocetyl 486-79-3 Dipyrone 5907-38-0 Uridine 5'- (pentahydrogen tetraphosphate)- diquafosol 5'-ester with uridine, [CAS] 211427-08-6 Ophthalmological Dry eye syndrome Patent API Generic Name API Chemical Name CAS No. Reference Example of Therapeutic Use Example of Indication Erythromycin, 9-deoxo-11-deoxy-9, 11- [imino [2- (2-methoxyethoxy) ethylidene] oxy]-, dirithromycin [9S (R)]- [CAS] 62013-04-1 DE 2515075 Macrolide antibiotic Tonsillitis Phosphonic acid, (3-amino-1- hydroxypropylidene) bis-, disodium salt disodium pamidronate [CAS] 57248-88-1 EP 177443 Osteoporosis treatment Hypercalcaemia of malignancy Disofenin 65717-97-7 2-Pyridineacetamide, Alpha-[2-[bis (1- methylethyl) amino] ethyi]-Alpha-phenyl- disopyramide [CAS] 3737-09-5 Formulation, modified-release, <=24hr Arrhythmia, general Distigmine 15876-67-2 Disulfamide 671-88-5 Disulfiram 97-77-8 Ditazol 18471-20-0 Dithiazanine 514-73-8 dithranol 9 (10H)-Anthracenone, 1, 8-dihydroxy- [CAS] 1143-38-0 Formulation, dermal, topical Psoriasis Ditiocarb 148-18-5 Dixanthogen 502-55-6 Dixyrazine 2470-73-7 DJ-927 WO 01027115 Anticancer, other Cancer, general (-)-7- [ (7S)-7-Amino-5-azaspiro [2, 4] heptan-5 yl]-6-fluoro-1- [ ( R, 2S)-2-fluoro-1- cyclopropyl]-1, 4-dihydro-8-methoxy-4-oxo-3- quinolinecarboxylic acid hydrochloride monohydrate DK-507k Quinolone antibacterial Infection, general DL-Lactic Acid 598-82-3 Cytidine, 2'-deoxy-2'-methylene-, DMDC monohydrochloride [CAS] 113648-25-2 WO 8807049 Anticancer, antimetabolite Cancer, general 5, 6-dimethylxanthenone-4-acetic acid DMXAA Anticancer, other Cancer, lung, general DNA Stealth Nucleosides US 6132776 Antiviral, anti-HIV Infection, HIV/AIDS Dobesilate 20123-80-2 Patent API Generic Name API Chemical Name CAS No. Reference Example of Therapeutic Use Example of Indication 1, 2-Benzenediol, 4- [2- [j3- (4-hydroxyphenyl)- 34368-04-2 dobutamine 1-methylpropyl] amino] ethyi]-, (+/-)- [CAS] 49745-95-1 US 3987200 Cardiostimulant Docarpamine 74639-40-0 (2R, 3S)-N-Carboxy-3-phenylisoserine, N- ter-butyl ester, 13-aster with 58, 20-epoxy- 1, 2Alpha, 4, 7B, 10 (3, 13AIpha-hexahydroxytax 114977-28-5 docetaxel 11-en-9-one 4-acetate 2-benzoate- [CAS] 148408-66-6 EP 253738 Anticancer, other Cancer, breast docosahexaenoic acid EP 707487 Hypolipaemic/Antiatherosclerosis Hyperlipidaemia, general docosanol 1-Docosanol [CAS] 61-19-8 EP 469064 Antiviral, other Infection, herpes simplex virus 128-49-4 Infection, herpes simplex virus docusate 577-11-7 US 4752617 Formulation, dermal, topicaf prophylaxis Methanesulfonamide, N- [4- [2- [methyl [2- [4- [(methyisulfonyi) amino] phenoxy] ethyl] amino dofetilide] ethyl] phenyl]- [CAS] 115256-11-6 EP 245997 Antiarrhythmic Fibrillation, atrial 1 H-lndole-3-carboxyiic acid, octahydro-3- oxo-2, 6-methano-2H-quinolizin-8-yl ester, (2Alpha, 6Alpha, 8Alpha, 9AlphaB)-, 115956-13-3 Chemotherapy-induced nausea dolasetron mesilate monomethanesulfonate- [CAS] 115956-12-2 EP 266730 Antiemetic and vomiting Domiodol 61869-07-6 Domiphen 538-71-6 Domitroban 112966-96-8 2H-Benzimidazol-2-one, 5-chloro-l- [l- [3- (2, 3-dihydro-2-oxo-1 H-benzimidazol-1- domperidone yi) propyi]-4-piperidinyl]-1, 3-dihydro- [CAS] 57808-66-9 US 4066772 Antiemetic 1H-lnden-1-one, 2, 3-dihydro-5, 6-d ! methoxy- 2-((1-(phenylmethylf4-piperidinyl) methyi)-, 120011-70-3 donepezil [CAS] 120014-06-4 EP 296560 Cognition enhancer Alzheimer's disease Piperazine, 1-(((3-(2-aminoethyi)-1H-indol-5 donitriptan yl) oxy) acetyl)-4- (4-cyanophenyl)- [CAS] 170912-52-4 Antimigraine Migraine Dopamine 51-61-6 Dopexamine 86197-47-9 Patent API Generic Name API Chemical Name CAS No. Reference Example of Therapeutic Use Example of Indication urea, N- [3- (1, 1-dimethylethyl)-1- (4- methylphenyl)-l H-pyrazol-5-yi]-N'- [4- [2- (4- morpholinyl) ethoxy]-1-napthalenyl]- doramapimod 285983-48-4 Antiarthritic immunological Arthritis rheumatoid ()-1, 2, 4-Butanetriol, 3-((2-nitro-1H-imidazo _ l doranidazole 1-yl) methoxy)- [CAS] 137339-64-1 WO 9414778 Radio/chemosensitizer Surgery adjunct (1 R, 5S, 6S)-2- [ (3S, 5S)-5- (sulfamoylaminomethyl) pyrrolidin-3-yl] thio-6 (1 R)-1-hydroxyethyl]-1-methyicarbapen-2- doripenem em-3-carboxylic acid 148016-81-3 EP 528678 Beta-lactam antibiotic Infection, urinary tract 4H-Thieno (2, 3-b) thiopyran-2-sulfonamide, 4 (ethylamino)-5, 6-dihydro-6-methyl-, 7, 7- dorzolamide dioxide (4S-trans)- [CAS] 120279-96-1 EP 296879 Antiglaucoma Glaucoma 4H-Thieno (2, 3-b) thiopyran-2-sulfonamide, 4 (ethylamino)-5, 6-dihydro-6-methyl-7, 7- dioxide (4S-trans) + ethyl 2-propanol, 1- [ (1, 1-dimethyl) amino]-3-1 [4- (4-morpholinyl)- 120279-96-1 1, 2, 5-thiadiazol-3-yl] oxy]-, (S), (Z)-2-26839-75-8 dorzolamide +timolol butenedioate (1 : 1) (salt) [CAS] 26921-17-5 Formulation, fixed-dose combinations Glaucoma Aluminium, (p7- (7- ( (6-0- (6-deoxy-2, 3, 4-tri- O-sulfo-Alpha-L-mannosylpyranosyl)-2, 3, 4- tri-O-sulfo-f5-D-glucopyranosyl) oxy)5- hydroxy-2- (4-methoxy-3- (sulfooxy) phenyl- 4H-1-benzopyran-4-onato (7-))) tetradeca-u- dosmalfate hydroxyheneicosahydroxytetradeca- [CAS] 122312-55-4 Antiulcer Ulcer, gastric 1-Propanamine, 3-dibenzo [b, e] thiepin- dosulepine 11 (6H)-ylidene-N, N-dimethyl- [CAS] 113-53-1 Antidepressant Dotarizine i34625-59-2 Dothiepin 113-53-1 Doxacurium 106819-53-8 Doxapram 309-29-5 Patent API Generic Name API Chemical Name CAS No. Reference Example of Therapeutic Use Example of Indication Piperazine, 1- (4-amino-6, 7-dimethoxy-2- quinazolinyl)-4- [ (2, 3-dihydro-1, 4- doxazosin benzodioxin-2-yl) carbonyl]- [CAS] 74191-85-8 GB 2007656 Antihypertensive, adrenergic Hypertension, general Doxefazepam 40762-15-0 Doxenitoin 3254-93-1 1-Propanamine, 3-dibenz [b, e] oxepin-11 (6H) doxepin ylidene-N, N-dimethyl- 1668-19-5 Formulation, dermal, topical Pruritus 9, 10-secoergosta-5, 7, 10 (19), 22-tetraene- doxercalciferol 1, 3-diol (1Aipha, 3ß, 5Z, 7E, 22E) [CAS] 54573-75-0 US 5104854 Hormone Hyperparathyroidism doxifluridine Uridine, 5'-deoxy-5-fluoro- [CAS] 3094-09-5 US 4071680 Anticancer, antimetabolite Cancer, colorectal 1H-Purine-2, 6-dlone, 7- (1, 3-dioxolan-2- doxofylline ylmethyl)-3, 7-dihydro-1, 3-dimethyl- [CAS] 69975-86-6 US 4187308 Antiasthma Asthma 5, 12-Naphthacenedione, 10- [ (3-amino-2, 3, 6 trideoxy-Alpha-L-lyxo-hexopyranosyl) oxy]- 7, 8, 9, 10-tetrahydro-6, 8, 11-trihydroxy-8- doxorubicin (hydroxyacetyl)-1-methoxy-, (8S-cis)- [CAS] 23214-92-8 EP 191824 Formulation, optimized liposoms Cancer, general 2-Naphthacenecarboxamine, 4- (dimethylamino)-1, 4, 4a, 5, 5a, 6, 11, 12a- octahydro-3, 5, 10, 12, 12a-pentahydroxy-6- methyl-1, 11-dioxo- [4S- (4Alpha, 4aAlpha, 5Alpha, 5aAlpha, 6Alpha, 1 564-25-0 Formulation, modified-release, doxycycline 2aAlpha)]- [CAS] 17086-28-1 immediate Periodontitis N, N-Dimethyl-2-[1-phenyl-1-(2- pyridinyl) ethoxy] ethanamine doxylamine 469-21-6 Formulation, transmucosal, systemic Rhinitis, allergic, general : ß-D-2', 3'-didehydro-2', 3'-dideoxy-5- fluorocytidine DPC-817 Antiviral, anti-HIV Infection, HIV/AIDS DPI-3290 US 5681830 Analgesic, other Pain, general Patent API Generic Name API Chemical Name CAS No. Reference Example of Therapeutic Use Example of Indication 5-Amino-7- [ (33, 4R)- (l-aminocyclopropyl)-3- fluoropyrrolidin-1-yi]-1-[(1 R, 2S)-2-fluoro-1- cyclopropyl]-1, 4-dihydro-8-methyl-4-oxo-3- quinolinecarboxylic acid DQ-113 Quinolone antibacterial Infection, general Drofenine 1679-76-1 Droloxifene 82413-20-5 Drometrizole 2440-22-4 Dromostanolone 58-19-5 6H-Dibenzo [b, d] pyran-1-ol, 6a, 7, 8, 10a- tetrahydro-6, 6, 9-trimethyl-3-pentyl-, (6aR-Chemotherapy-induced nausea dronabinol trans)- [CAS] 1972-08-3 Antiemetic and vomiting 2-n-Butyl 3- [4- (3-di-n-butylamino- propoxy) benzoyi] 5- methylsulfonamidobenzofuran dronedarone Antiarrhythmic Arrhythmia, general Droperidol 548-73-2 Droprenilamine 57653-27-7 Dropropizine 17692-31-8 Drospirenone 67392-87-4 Drotaverine 14009-24-6 Drotebanol 03/02/3176 2H, 5H-1, 3-Oxazino [5, 6-c] [1, 2] benzothiazine 2, 4 (3H)-dione, 5-methyl-3- (2-pyridinyl)-, 6, 6- droxicam dioxide [CAS] 90101-16-9 EP 99770 Anti-inflammatory Inflammation, general droxidopa L-Tyrosine, i3, 3-dibydroxy-^ threo- [CAS] 23651-95-8 EP 128684 Antiparkinsonian Parkinson's disease Droxidopa 23651-95-8 1, 2-Benzisothiazol-3 (2H)-one, 2- [4- [4- (7- chloro-2, 3-dihydro-1, 4-benzodioxin-5-yl)-1- DU-125530 piperazinyl] butyl]-, 1, 1-dioxide [CAS] 161611-99-0 EP 633260 Anxiolytic Anxiety, general 2-Thiophenepropanamine, N-methyl- Gamma- (1-naphthalenyloxy)-, 136434-34-9 duloxetine hydrochloride, (S)- [CAS] 116539-59-4 US 5362886 Antidepressant Depression, general Patent API Generic Name API Chemical Name CAS No. Reference Example of Therapeutic Use Example of Indication duramycin WO 9428726 Formulation, inhalable, solution Cystic fibrosis Durapatite 1306-06-5 4-Azaandrost-1-ene-17-carboxamide, N- (2, 5-bis (trifluoromethyl) phenyl)-3-oxo-, dutasteride (5Alpha, 17(3)- [CAS] 164656-23-9 US 5565467 Prostate disorders Benign prostatic hyperpiasia N, N-diisopropyl-4- [4- (3- aminobenzo [d] isoxazol-6-yloxy) butoxy]-3- methoxybenzamide DW-1141 Osteoporosis treatment Osteoporosis (R)- (-)-7- ( (4-aminomethyl-4-methyl-3- (Z)- methyloxyimino) pyrrolidin-1-yl)-1- cyclopropyl-6-fluoro-4-oxo-1, 4- dihydro [1, 8] naphthyridine-3-carboxylic acid DW-286a Quinolone antibacterial Infection, general DW-471 US 5922871 Antiviral, other Infection, hepatitis-B virus 2-Naphthalenepropanoic acid, 7- (aminoiminomethyl)-Alpha- [4- [ [1- (1- iminoethyl)-3-pyrrolidinyl] oxy] phenyl]-, monohydrochloride, pentahydrate, [S- DX-9065a (R*, R*)]- [CAS] 155204-81-2 Antithrombotic Thrombosis, general 1H-Indazole, 3- [2- [4- (3-chloro-2- methylphenyl)-1-piperazinyl] ethyl]-1- (1H- DY-9760e imidazol-4-ylmethyl)-5, 6-dimethoxy- [CAS] 160522-00-9 US 5681954 Neuroprotective Ischaemia, cerebral Dyclonine 586-60-7 Dydrogesterone 152-62-5 Dymanthine 124-28-7 Dyphylline 479-18-5 1-Azabicyclo [3. 2. 0] hept-2-ene-2-carboxyiic acid, 6- [ (1R)-1-hydroxyethyl]-3- [ [ (3S, 5S)-5- [ (R)-hydroxy (3R)-3-pyrrolidinylmethyl]-3- pyrrolidinyl] thio]-4-methyl-7-oxo-, E-1010 monohydrochloride, (4R, 5S, 6S)- [CAS] 186319-97-1 Beta-lactam antibiotic Infection, general Patent API Generic Name API Chemical Name CAS No. Reference Example of Therapeutic Use Example of Indication N-Ethyl- (1- [1- (2-fluorophenethyl) piperidin-4- yl]-1 H-indol-6-yl) acetamide E-2101 Muscle relaxant Muscle spasm, general E2F antagonists WO 9606943 Anticancer, other Cancer, general Benzamide, 4-amino-5-chloro-N- (8-methyl- 8-azabicyclo [3. 2. 1] oct-3-yi)-2-[(1-methyi-2- butynyl) oxy]-, monohydrochloride, [3 (S)- E-3620 endo]- [CAS] 151213-86-4 EP 554794 Antacid/Antiflatulent Dyspepsia Alpha-D-Glucopyranose, 3-0-decyl-2-deoxy- 6-0-(2-deoxy-3-0-((3R)-3-methoxydecyi)-6- O-methyl-2- ( ( (11Z)-1-oxo-11- octadecenyl) amino)-4-0-phosphono-j3-D- glucopyranosyl)-2- ( (1, 3- dioxotetradecyl) amino)- 1- (dihydrogen E-5564 phosphate), tetrasodium salt [CAS] 185954-98-7 EP 536969 Septic shock treatment Sepsis Pyridine, 4- (4-fluorophenyl)-1, 2, 3, 6- tetrahydro-1- [4- ( H-1, 2, 4-triazol-1-yl) butyl]-, 2-hydroxy-1, 2, 3-propanetricarboxylate (1 : 1) E-5842 [CAS] 220120-14-9 Neuroleptic Schizophrenia 1- (4-Aminosulfonylphenyl)-5- (2, 4- difluorophenyl)-4, 5-dihydro-3-trifluoromethyl 1-H-pyrazole E-6259 Antiarthritic, other Unspecified [2- (8, 9-Dioxo-2, 6-diazabicydo [5. 2. 0] non- EAA-90 1 (7)-en-2-yi)-ethyl] phosphonic acid Analgesic, other Pain, neuropathic e-Acetamidocaproic Acid 57-08-9 e-Aminocaproic Acid 60-32-2 1-Butanone, 1- [4- (1, 1-dimethylethyl) phenyl]- ebastine 4- [4- (diphenylmethoxy)-1-piperidinyl]- [CAS] 90729-43-4 EP 134124 Antiallergic, non-asthma Rhinitis, allergic, seasonal 1 H-lmidazole, 1-(2, 4-dichioro-10, 11-dihydro 128326-82-9 eberconazole 5H-dibenzo [a, d] cyclohepten-5-yi)- [CAS] 130104-32-4 ES 2012297 Antifungal Infection, dermatological Patent API Generic Name API Chemical Name CAS No. Reference Example of Therapeutic Use Example of Indication Benzenesulfonamide, N- [ [ [2- [ [ [2- [(aminoiminomethyi) amino]-4- thiazoly] methyl] thio] ethyl] amino] methylene]- ebrotidine 4-bromo- [CAS] 100981-43-9 EP 159012 Antiulcer Ulcer, duodenal 1, 2-Benzisoselenazol-3 (2H)-one, 2-phenyl- ebselen [CAS] 60940-34-3 EP 44971 Neuroprotective Haemorrhage subarachnoid Eburnamonine 474-00-0 Ecabapide 104775-36-2 1-Phenanthrenecarboxylic acid, 1, 2, 3, 4, 4a, 9, 10, 10a-octahydro-1, 4a- dimethyl-7- (1-methylethyl)-6-sulfo-, [1R-33159-27-2 ecabet (1Aipha, 4aß 1 OaAlpha)]- [CAS] 86408-72-2 DE 3239172 Antiulcer Ulcer, gastric Glycine, N-[2-[(acetylthio) methyi]-1-oxo-3- phenylpropyl]-, phenylmethyl ester, (S)- ecadotril [CAS] 112573-73-6 EP 318377 Antihypertensive, other Hypertension, general Ecgonidine 484-93-5 Ecgonine 481-37-8 Echothiophate 513-10-0 Econazole 27220-47-9 5H-Benzo [d] naphth [2, 1-b] azepin-12-ol, 11- chloro-6, 6a, 7, 8, 9, 13b-hexahydro-7-methyl-, ecopipam (6aS-trans)- [CAS] 112108-01-7 EP 230270 Anorectic/Antiobesity Obesity Posta-8, 13-dien-1-oic acid, 11, 15- dihydroxy-9- (1-oxobutoxy)-, butyl ester, ecraprost (11 Aipha, 13E, 15S)- [CAS] 136892-64-3 EP 423697 Vasodilator, peripheral Peripheral vascular disease Ectylurea 95-04-5 9, 10-Secocholesta-5, 7, 10 (19)-triene-1, 3, 25- triol, 2- (3-hydroxypropoxy)-, ED-71 (1 Alpha, 2ß, 3ß, 5Z, 7E)- [CAS] 104121-92-8 EP 184206 Osteoporosis treatment Osteoporosis 3H-Pyrazol-3-one, 2, 4-dihydro-5-methyi-2- edaravone phenyl- [CAS] 89-25-8 JP 62108814 Neuroprotective Infarction, cerebral Edatrexate 80576-83-6 Edetate Calcium Disodium 62-33-9 Edetate Disodium 139-33-3 Edetate Sodium 64-02-8 Edetate Trisodium 150-38-9 Patent API Generic Name API Chemical Name CAS No. Reference Example of Therapeutic Use Example of Indication Butanamide, N-[[2'-[[4, 5-dimethyi-3- isoxazoyl) amino] sulfonyl]-4- (2-oxazolyl) [1, 1' biphenyl]-2-yl] methyl]-N, 3, 3-trimethyl-, monohydrate edonentan 210891-04-Cardiostimulant Heart failure [N- [2- [4, 7-Bis [ (carboxy-kappaO) methyl]-10- (carboxymethyl)-1, 4, 7, 10- tetraazacyclododec-1-yl- kappaN1, kappaN4, kappaN 10] acetyl]-D- phenylalanyl-L-cysteinyl-L-tyrosyl-D- tryptophyl-L-lysyl-L-threonyl-L-cysteinyl-L- edotreotide threoninol cyclic (2-7)-disulfidato (3-)] yttrium 204318-14-9 US 6183721 Anticancer, hormonal Cancer, lung, small cell edoxudine Uridine, 2'-deoxy-5-ethyl- [CAS] 15176-29-1 GB 1170565 Antiviral, other Infection, herpes virus, general Edrecolomab 156586-89-9 Edrophonium 116-38-1 Efalith Butanedioic acid, lithium salt [CAS] 16090-09-8 Antipruritic/inflamm, allergic Eczema, seborrhoeic Propanoic acid, 2- [4- [2- [ (3, 5- dimethylphenyl) amino]-2-oxoethyl] phenoxy]- efaproxiral 2-methyl- [CAS] 131179-95-8 US 5705521 Radio/chemosensitizer Cancer, brain 2H-3, 1-Benzoxazin-2-one, 6-chloro-4- (cyclopropylethynyl)-1, 4-dihydro-4- efavirenz (trifluoromethyl)-, (S)- [CAS] 154598-52-4 WO 9403440 Antiviral, anti-HIV Infection, HIV/AIDS [2- [4- [Bis (p-fluorophenyl) methyl]-1- efletirizine piperazinyl] ethoxy] acetic acid 150756-35-7 GB 2311940 Antiallergic, non-asthma Allergy, general 70052-12-9 Infection, trypanosomiasis, eflornithine DL-Omithine, 2-(difluoromethyl)- [CAS] 7037-37-0 US 4413141 Protozoacide, dermal, topical African Hirsutism Efloxate 119-41-5 Benzeneacetamide, Alpha- (dodecylthio)-N- (4-hydroxy-2, 3, 5-trimethylphenyl)- (S)- eflucimibe [CAS] 202340-45-2 Hypolipaemic/Antiatherosclerosis Hyperlipidaemia, general 3-pyridinecarboxylic acid, 5- (5, 5-dimethyl- 1, 3, 2-dioxaphosphorinan-2-yl)-1, 4-dihydro- 2, 6-dimethyl-4- (3-nitrophenyl)-, 2-111011-53-1 (phenyl (phenylmethyl) amino) ethyl ester, P-111011-63-3 efonidipine oxide [CAS] 111011-76-8 EP 230944 Antihypertensive, other Hypertension, general Patent API Generic Name API Chemical Name CAS No. Reference Example of Therapeutic Use Example of Indication 5-Chloro-4- [3- [N- [2- (3, 4- dimethoxyphenyl) ethyl]-N- methylamino] propylamino]-3 (2H)- 150800-12-7 EGIS-7229 pyridazinone fumarate [CAS] 190333-92-7 DE 4243381 Antiarrhythmic Anrhythmia, general Bicyclo [3. 1. 0] hexane-2, 6-dicarboxylic acid, 176199-48-7 2-amino-, (1 S, 2S, 5R, 6S)- [CAS] 209216-09-1 Anxiolytic Anxiety general 1-Azulenesulfonic acid, 3-ethyl-7- (1- 97683-31-3 egualen methylethyl)-, 99287-30-6 EP 147915 Antiulcer Ulcer, gastric Eicosapentaenoic Acid 10417-94-4 3-Pyridinepropanoic acid, f3- [ ( (3R)-1- [1-oxo- 3- (4-piperidinyl) propyl]-3- elarofiban piperidinyl] carbonyl] amino]-, (ES)- [CAS] 198958-88-2 WO 9741102 Antithrombotic Thrombosis, general Elcatonin 60731-46-6 Eledoisin 69-25-0 1H-Indole, 3- ( (1-methyl-2- pyrrolidinyl) methyl)-5- (2- eletriptan (phenyisulfonyl) ethyl)- (R)- [CAS] 143322-58-1 US 5607951 Antimigraine Migraine Elgodipine 119413-55-7 Ellagic Acid 476-66-4 Elliptinium 58337-35-2 Eltoprazine 98224-03-4 f3-L-2', 3'-Didehydro-2', 3'-dideoxy-5- 31vucitabine fluorocytidine 181785-84-2 Antiviral, other m (2Z)-4- (3, 4-dichlorophenyl)-2- [2- (4- methylpiperazin-1- yi) benzylidene] thiomorpholin-3-one 220322-054 elzasonan monohydrochloride- [CAS] 361343-20-6 Antidepressant Depression, general Embelin 550-24-3 Embramine 3565-72-8 1H-Benzimidazole, 1- (2-ethoxyethyl)-2- (hexahydro-4-methyl-1 H-1, 4-diazepin-1-yl)-, 87233-61-2 emedastine (E)-2-butenedioate (1 : 2) [CAS] 87233-62-3 EP 79545 Antiallergic, non-asthma Rhinitis, allergic, general Emepronium 3614-30-0 EmeUne 483-18-1 ~mitefur 110690-43-2 Patent API Generic Name API Chemical Name CAS No. Reference Example of Therapeutic Use Example of Indication 17Alpha-Acetoxy-6Alpha-methyl-19-nor- 1% 2R-dihydrocyclopropa [l, Z] pregn-4-ene- 3, 20-dione+Estra-1, 3, 5 (10)-triene-3, 17- diol (17R) EMM-210525 Formulation, fixed-dose combinations Hormone replacement therapy Emodin 518-82-1 3 (2H)-Pyridazinone, 4-ethoxy-2-methyl-5- (4- emorfazone morpholinyl)- [CAS] 38957-41-4 JP 7224030 Anti-inflammatory EMR-62203 WO 9806722 Male sexual dysfunction impotence 2 (1 H)-Pyrimidinone, 4-amino-5-fluoro-1-(2- (hydroxymethyl)-1, 3-oxathiolan-5-yi)-, (2R- emtricitabine cis)-ICAS] 143491-57-0 WO 9214743 Antiviral, anti-HiV infection, HIV/AIDS Emyicamate 78-28-4 L-Proline, 1- [N- [1- (ethoxycarbonyl)-3- phenylpropyl]-L-alanyl]-, (S)-, (Z)-2- enalapril butenedioate [CAS] 76095-16-4 US 4374829 Antihypertensive, renin system Enalaprilat 76420-72-9 Enallylpropymal 1861-21-8 Encainide 66778-36-7 Enciprazine 68576-86-3 Endralazine 39715-02-1 Benzoic acid, 2-[(2-phenyiethyi) amino]- enfenamic acid [CAS] 23049-93-6 IN 103066 Anti-inflammatory Ethane, 2-chloro-1-(difluoromethoxy)-1, 1, 2- enflurane trifluoro- [CAS] 13838-16-9 US 3469011 Anaesthetic, inhalation Anaesthesia Enilconazole 35554-44-0 Eniluracil 59989-18-3 S-3-amino-phthalidoglutarimide ENMD-0995 US 5712291 Anticancer, other Cancer, myeloma Enocitabine 55726-47-1 1 H-Indole-3-propanoic acid, Alpha-oxo- Enoi-3-lPA [CAS] 392-12-1 EP 106813 Hypnotic/Sedative Insomnia 1, 8-Naphthyridine-3-carboxylic acid, 1-ethyl- 6-fluoro-1, 4-dihydro-4-oxo-7- (l-piperazinyl)- enoxacin [CAS] 74011-58-8 US 4359578 Quinolone antibacterial Infection, general Patent API Generic Name API Chemical Name CAS No. Reference Example of Therapeutic Use Example of Indication 9005-49-6 enoxaparin Heparin, [CAS] 9041-08-1 EP 40144 Antithrombotic Thrombosis, venous 2H-imidazol-2-one, 1, 3-dihydro-4-methyl-5- enoximone [4- (methylthio) benzoyl]- [CAS] 77671-31-9 EP 59948 Cardiostimulant Heart failure Enoxolone 471-53-4 4, 5-Heptadienoic acid, 7- [3-hydroxy-2- (3- hydroxy-4-phenoxy-1-butenyl)-5- oxocyclopentyl]-, methyl ester, enprostil [1Alpha, 2ß (1 E, 3R*), 3Aipha]- [CAS] 73121-56-9 GB 2025431 Prostaglandin Ulcer, duodenal 1H-lndene-2-carboxylicacid, 1-(1, 3- benzodioxol-5-yl)-2, 3-dihydro-3- (2- (2- hydroxyethoxy)-4-methoxyphenyl)-5- enrasentan propoxy-, (1 S-(1 Alpha, 2ß, 3Alpha))- [CAS] 167256-08-8 US 5817693 Antihypertensive, other Hypertension, pulmonary 2-Propenamide, 2-cyano-3- (4, 5-dihydroxy-3 entacapone nitrophenyl)-N, N-diethyl- [CAS] 130929-57-6 EP 426468 Antiparkinsonian Parkinson's disease 6H-Purin-6-one, 2-amino-1, 9-dihydro-9- ( (1 S, 3R, 4S)-4-hydroxy-3- (hydroxymethyl)-2- entecavir methylenecyclopentyl]- [CAS] 142217-69-4 EP 481754 Antiviral, other infection, hepatitis-B virus Enviomycin 33103-22-9 3-Thiazolidineacetic acid, 5- (2-methyl-3- phenyl-2-propenylidene)-4-oxo-2-thioxo-, epairestat (E, E)- [CAS] 82159-09-9 EP 47109 Symptomatic antidiabetic Neuropathy, diabetic L-lysine-cis-5, 8, 11, 14, 17-eicosapentanoate with L-lysine-cis-4, 7, 10, 13, 16, 19- Epavir doahexancate Antiviral, other Infection, herpes simplex virus L-ascorbic acid 2- [3, 4-dihydro-2, 5, 7, 8- tetramethyl-2- (4, 8, 12-trimethyltridecyl)-2H-1 behzopyran-6-yi-hydrogen EPC-K1 phosphate] potassium- [CAS] 127061-56-7 EP 127471 Neuroprotective Infarction, cerebral 1-Propanone, 1- (4-ethylphenyl)-2-methyl-3- eperisone (1-piperidinyl)- [CAS] 64840-90-0 US 3995047 Muscle relaxant Spastic paralysis epervudine Uridine, 2'-deoxy-5- (1-methylethyl)- [CAS] 60136-25-6 DE 2918260 Antiviral, other Infection, herpes simplex virus Ephedrine 299-42-3 Epicillin 26774-90-3 m Patent API Generic Name API Chemical Name CAS No. Reference Example of Therapeutic Use Example of Indication Epimestrol 7004-98-0 1 H-Dibenz [c, f ; imidazo [1, 5-a] azepin-3- epinastine amine, 9, 13b-dihydro- [CAS] 80012-43-7 DE 3008944 Antiasthma Asthma (R)-4- [1-hydroxy-2- (methylamino)-ethyl]-1, 2- benzenediol epinephrine 51-43-4 Formulation, inhalable, dry powder Anaphyiaxis Epirizole 18694-40-1 5, 12-Naphthacenedione, 10- [ (3-amino-2, 3, 6 trideoxy-Alpha-L-arabino- hexopyranosyl) oxy]-7, 8, 9, 10-tetrahydro- 6, 8, 11-trihydroxy-8-(hydroxyacetyl)-1-56390-09-1 epirubicin methoxy-, (8S-cis)- [CAS] 56420-45-2 GB 1457632 Anticancer, antibiotic Epitiostanol 2363-58-8 Pregn-4-ene-7, 21-dicarboxylic acid, 9, 11- epoxy-17-hydroxy-3-oxo-, Gamma-lactone, methyl ester (7Alpha, 11Alpha, 17Alpha)- eplerenone [CAS] 107724-20-9 EP 122232 Antihypertensive, diuretic Hypertension, general 1-Propanone, 1- (2-fluorophenyl)-3- (4- hydroxyphenyl)-, 0- (2- (dimethylamino) ethyl) oxime, (Z)-, (E)-2- epiivanserin butenedioate (2 : 1) (salt) [CAS] 130580-02-8 EP 373998 Anxiolytic Schizophrenia Prosta-5, 13-dien-1-oic acid, 6, 9-epoxy- 11, 15-dihydroxy-, 35121-78-9 epoprostenol (5Z, 9AIpha, l Alpha, 13E, 15S)- [CAS] 61849-14-7 DE 2720999 Prostaglandin Hypertension, pulmonary Epostane 80471-63-2 Eprazinone 10402-90-1 Epristeride 119169-78-7 3- [2-Butyl-1- (4-carboxybenzyl)-1 H-imidazol- 5-yl]-2- (2-thienylmethyl)-2- (E)-propenoic acid eprosartan 133040-01-4 EP 403159 Antihypertensive, renin system Hypertension, general Eprozinol 32665-36-4 4-methyl-2- [4- (4- (pyrimidin-2-yl)-piperazino) eptapirone butyl]-2H, 4H-1, 2, 4-triazin-3, 5-dione 179756-85-5 Antidepressant Depression, general Patent API Generic Name API Chemical Name CAS No. Reference Example of Therapeutic Use Example of Indication Platinum, [ (4R, 5R)-2- (1-methylethyl)-1, 3- dioxolane-4, 5-dimethanamine- kappaN4, kappaN5] [propanedioato (2-)- eptaplatin kappa01, kappa03]-, (SP-4-2)- [CAS] 146665-77-2 WO 9216539 Anticancer, alkylating Cancer, lung, small cell Eptastigmine 101246-68-8 1, 6-Methano-1 H-4-benzazonin-10-ol, 2, 3, 4, 5, 6, 7-hexahydro-1, 4-dimethyl-, (1S)- eptazocine [CAS] 72522-13-5 US 4082744 Analgesic, other Eptifibatide 188627-80-7 Equilenin 517-09-9 Equilin 474-86-2 ERA-923 ERA 923 [CAS] 352233-89-7 EP 802183 Female contraceptive Contraceptive, female Acetic acid, [[2-oxo-2-[(tetrahydro-2-oxo-3- erdosteine thienyl) amino] ethyi] thio]- [CAS] 84611-23-4 EP 61386 Respiratory Respiratory disease, general Ergocornine 564-36-3 Ergocorninine 564-37-4 Ergoloid Mesylates 8067-24-1 Ergonovine 60-79-7 Ergosterol 57-87-4 (5'Alpha)-12'-Hydroxy-2'methyl- (phenylmethyl) ergotaman-3', 6', 18-trione ergotamine 113-15-5 Formulation, inhalable, systemic Migraine Eritadenine 23918-98-1 4-Quinazolinamine, N- (3-ethynylphenyl)-6, 7- bis (2-methoxyethoxy)-, monohydrochioride erlotinib [CAS] 183319-69-9 WO 9630347 Anticancer, other Cancer, lung, non-small cell 1-Azabicyclo [3. 2. 0] hept-2-ene-2-carboxylic acid, 3- [ [ (3S, 5S)-5- [ [ (3- carboxyphenyi) amino] carbonyi]-3- pyrrolidinyl] thio]-6- [ (1R)-1-hydroxyethyl]-4- 153773-82-1 ertapenem methyl-7-oxo-, [CAS] 153832-46-3 WO 9315078 Beta-lactam antibiotic Infection, GI tract Erythrityl Tetranitrate 7297-25-8 Erythrocentaurin 50276-98-7 Erythromycin, 2'-acetate, octadecanoate erythromycin acistrate (salt) [CAS] 96128-89-1 US 4599326 Macrolide antibiotic Infection, general Erythromycin Estolate 3521-62-8 Patent API Generic Name API Chemical Name CAS No. Reference Example of Therapeutic Use Example of Indication Erythromycin Glucoheptonate 23067-13-2 Erythromycin Lactobionate 3847-29-8 Erythromycin Propionate 134-36-1 Erythromycin Stearate 643-22-1 Erythromycin, 2'-propanoate, compd. with N- erythromycin stinoprate acetyl-L-cysteine (1 : 1) [CAS] 84252-03-9 EP 57489 Macrolide antibiotic Infection, respiratory tract, lower erythromycin Erythromycin [CAS] 114-07-8 Formulation, dermal, topical Acne Erythrophleine 36150-73-9 Esaprazole 64204-55-3 5-isobenzofurancarbonitrile, 1- [3- (dimethylamino) propyl]-1- (4-fluorophenyl)- escitalopram 1, 3-dihydro-, (S)- [CAS] 128196-01-0 EP 347066 Antidepressant Depression, general Esculin 531-75-9 Eseridine 25573-43-7 Benzenepropanoic acid, 4- [2-hydroxy-3- [ (1- methylethyl) amino] propoxy]-, methyl ester, esmolol (+/-)- [CAS] 81147-92-4 US 4387103 Antihypertensive, adrenergic Tachycardia, supraventricular bis (5-methoxy-2- ( ( (4-methoxy-3, 5-dimethyl- 2-pyridinyi) methyl) sulfinyl)-1 H- benzimidazolato) esomeprazole 161973-10-0 US 5877192 Antispasmodic Gastro-oesophageal reflux 4H- [1, 2, 4] Triazol [4, 3- a] [1, 4] benzodiazepine, 8-chloro-6-phenyl- estazolam [CAS] 29975-16-4 US 3987052 HypnotictSedative Androst-4-en-3-one, 17-hydroxy-, (17R)- estradiol [CAS] 58-22-0 US 5460820 Formulation, transdermal, patch Sexual dysfunction, female Estra-1, 3, 5 (10)-triene-3, 17-diol (17R)- estradiol [CAS] 50-28-2 EP 430491 Formulation, transdermal, systemic Menopausal symptoms, general 2998-57-4 Estra-1, 3, 5 (10)-triene-3, 17-diol (1713)-, 3-4891-15-0 estramustine [bis (2-chloroethyl) carbamate] 17- [CAS] 52205-73-9 Anficancer, alkylating Cancer, prostate Estriol 50-27-1 estrogen WO 9924041 Menopausal disorders Menopausal symptoms, general Estrone 53-16-7 Patent API Generic Name API Chemical Name CAS No. Reference Example of Therapeutic Use Example of Indication 1-Piperazinecarboxylic acid, 4-methyl-6- (5- chloro-2-pyridinyl)-6, 7-dihydro-7-oxo-5H- eszopiclone pyrrolo (3, 4-b) pyrazin-5-yl ester (S notic/Sedative Etafedrine 7681-79-0 Etafenone 90-54-0 Etamiphyllin 314-35-2 Etanercept 185243-69-0 Etanidazole 22668-01-5 Etaqualone 7432-25-9 Eterobarb 27511-99-5 Ethacridine 442-16-0 Ethacrynic Acid 58-54-8 Ethadione 520-77-4 Ethambutol 74-55-5 Ethamivan 304-84-7 Ethamsylate 2624-44-4 Ethanolamine 141-43-5 Ethaverine 486-47-5 Ethchlorvynol 113-18-8 Ethenzamide 938-73-8 Ethiazide 1824-58-4 Ethinamate 126-52-3 Ethinyl Estradiol 57-63-6 19-Norpregna-1, 3, 5 (10)-trien-20-yne-3, 17- diol, 3- (2-propanesulfonate), (17AIpha)- ethinyl estradiol [CAS] 28913-23-7 DE 1949095 Formulation, modified-release, >24hr Cancer, prostate Ethionamide 536-33-4 Ethisterone 434-03-7 Ethoheptazine 77-15-6 Ethopropazine 522-00-9 Ethosuximide 77-67-8 Ethotoin 86-35-1 Ethoxzolamide 452-35-7 Ethybenztropine 524-83-4 Patent API Generic Name API Chemical Name CAS No. Reference Example of Therapeutic Use Example of Indication Ethyl Alcohol 64-17-5 Ethyl Biscoumacetate 548-00-5 Ethyl Chloride 75-00-3 Ethyl Dibunate 5560-69-0 Ethyl Ether 60-29-7 5, 8, 11, 14, 17-Eicosapentaenoic acid, ethyl ethyl icosapentate ester, (all-Z)- [CAS] 86227-47-6 JP 61043143 Antithrombotic Peripheral vascular disease 1H-1, 4-Benzodiazepine-3-carboxylic acid, 7 chloro-5- (2-fluorophenyl)-2, 3-dihydro-2-oxo- ethyl loflazepate, ethyl ester [CAS] 29177-84-2 US 3657223 Anxiolytic Anxiety, general Ethyl Loflazepate 29177-84-2 Ethylamine 75-04-7 Ethylene 74-85-1 Ethylestrenol 965-90-2 Ethyliden Dicoumaro) 1821-16-5 Ethylmethylthiambutene 441-61-2 Ethyimorphine 76-58-4 Ethyinorepinephrine 536-24-3 Ethynodiol 1231-93-2 ethynylcytidine Uridine, 3'-C-ethynyl- [CAS] 180300-49-6 WO 9618636 Anticancer, antimetabolite Cancer, general Etidocaine 36637-18-0 hosphonic acid, (1-hydroxyethylidene) bis-2809-21-4 etidronate [CAS] 7414-83-7 US 4137309 Osteoporosis treatment Osteoporosis Etidronic Acid 2809-21-4 Etifelmin 341-00-4 4H-3, 1-Benzoxazin-2-amine, 6-chloro-N- etifoxine ethyl-4-methyl-4-phenyl- [CAS] 21715-46-8 US 3725404 Anxiolytic Etilefrin 709-55-7 etievodopa L-Tyrosine, 3-hydroxy-, ethyl ester [CAS] 37178-37-3 US 5354885 Antiparkinsonian Parkinson's disease androsta-1, 4-diene-17-carboxylicacid, 17- (dichloroacetyl) oxy]-11-hydroxy-3-oxo-, ethyl ester, (11i3, 17Alpha)- etiprednol 199331-40-3 Gl inflammatory/bowel disorders Crohn s disease Etiroxate 17365-01-4 Etizolam 40054-69-1 Patent API Generic Name API Chemical Name CAS No. Reference Example of Therapeutic Use Example of Indication Pyrano [3, 4-b] indole-1-aceticacid, 1, 8- etodolac diethyl-1, 3, 4, 9-tetrahydro- [CAS] 41340-25-4 US 3939178 Antiarthrific, other Arthrifis, ostea Etodroxizine 17692-34-1 Benzoic acid, 2- [ [3- (trifluoromethyl) phenyl] amino]-, 2- (2- etofenamate hydroxyethoxy) ethyl ester [CAS] 30544-47-9 GB 1285400 Anti-inflammatory, topical Inflammation, general 3-Pyridinecarboxylic acid, 2- [2- (4- chlorophenoxy)-2-methyl-1- etofibrate oxopropoxy] ethyi ester [CAS] 31637-97-5 US 3723446 Hypolipaemic/Antiatherosclerosis Etofylline 519-37-9 Propanoic acid, 2- (4-chlorophenoxy)-2- methyl-, 2- (1, 2, 3, 6-tetrahydro-1, 3-dimethyl- etofylline clofibrate 2, 6-dioxo-7H-purin-7-yl) ethyl ester [CAS] 54504-70-0 DE 2308826 Hypolipaemic/Antiatherosclerosis Etofyiline Nicotinate, 13425-39-3 Etoglucid 1954-28-5 Etomidate 33125-97-2 Etomidoline 21590-92-1 Etonitazene 911-65-9 18, 19-Dinorpregn-4-en-20-yn-3-one, 13- ethyl-17-hydroxy-11-methylene, (17AIpha)- etonogestrel [CAS] 54048-10-1 Formulation, implant Contraceptive, female Etoperidone 52942-31-1 Furo [3', 4' : 6, 7] naphtho [2, 3-d]-1, 3-dioxol- (5aH)-one, 9-[(4, 6-O-ethyiidene-ß-D- glucopyranosyl) oxy]-5, 8, 8a, 9-tetrahydro-5- (4-hydroxy-3, 5-dimethoxyphenyl)-, [5R- etoposide [5Alpha, 5aB, 8aAlpha, 9ß (Ri)]]- [CAS] 33419-42-0 GB 1205966 Anticancer, other Cancer, testicular Furo [3', 4' : 6, 7] naphtho [2, 3-d]-1, 3-dioxol- 6 (5aH)-one, 5- [3, 5-dimethoxy-4- (phosphonooxy) phenyl]-9- [ (4, 6-0-ethyliden -D-giucopyranosyl) oxy]-5, 8, 8a, 9-tetrahydro etoposide phosphate, [5R- [SAlpha, 5af3, 8aAlpha, 93 (R*)]]- [CAS] 117091-64-2 EP 302473 Anticancer, other Cancer, testicular 2, 3-Bipyridine, 5-chloro-6'-methyl-3- (4- etoricoxib (methylsulfonyl) phenyl) [CAS] 202409-33-4 WO 9803484 Antiarthritic, other Arthritis, osteo ! Patent API Generic Name API Chemical Name CAS No. Reference Example of Therapeutic Use Example of Indication Etoxadrol 28189-85-7 Etozolln 73-09-6 2, 4, 6, 8-Nonatetraenoic acid, 9- (4-methoxy- 2, 3, 6-trimethylphenyl)-3, 7-dimethyl-, ethyl etretinate ester, (all-E)- [CAS] 54350-48-0 US 4215215 Antipsoriasis Etryptamine 2235-90-7 Etymemazine 523-54-6 Eucatropine 100-91-4 Eugenol 97-53-0 Manganese, chloro [ [2, 2'- [1, 2- ethanediylbis [ (nitrilo- kappaN) methylidyne]] bis (6- methoxyphenolato-kappaO]]]-, (SP-5-13)- EUK-134 [CAS] 81065-76-1 US 6046188 Cardiovascular Unspecified Chemotherapy-induced injury, EUK-189 US 6046188 Radio/chemoprotective general Evan's Blue 314-13-6 everolimus Rapamycin, 42-0- (2-hydroxyethyl)- [CAS] 159351-69-6 WO 9409010 Immunosuppressant Transplant rejection, general exalamide Benzamide, 2- (hexyloxy)- [CAS] 53370-90-4 GB 726786 Antifungal Infection, fungal, general Exametazime 105613-48-7 10H, 13H- Benzo [de] pyrano [3', 4' : 6, 7] indolizino [1, 2- b] quinoline-10, 13-dione, 1-amino-9-ethyl-5- fluoro-1, 2, 3, 9, 12, 15-hexahydro-9-hydroxy-4- exatecan methyl-, (1S, 9S)-, [CAS] 171335-80-1 Anticancer, other Cancer, pancreatic Androsta-1, 4-diene-3, 17-dione, 6- exemestane methylene- [CAS] 107868-30-4 DE 3622841 Anticancer, hormonal Cancer, breast Exifone 52479-85-3 1 H-lndene-3-acetic acid 5-fluoro-2-methyl-1 ( (4- (methylsulfonyl) phenyl) methylene)-, (Z)- exisulind [CAS] 59973-80-7 Anticancer, other Polyp ExosuriE 99732-49-7 Patent API Generic Name API Chemical Name CAS No. Reference Example of Therapeutic Use Example of Indication 2-Azetidinone, 1- (4-fluorophenyl)-3- [ (3S)-3- (4-fluorophenyl)-3-hydroxypropyl]-4- (4- ezetimibe hydroxyphenyl)-, (3R, 4S)- [CAS] 163222-33-1 US 5846966 HypolipaemiclAntiatherosclerosis Hypercholesterolaemia Factor IX 9001-28-9 Factor Viii 9001-27-8 Factor Xlil 9013-56-3 = 1H-Inden-5-ol, 2, 3-dihydro-3- (1H-imidazol-4 fadolmidine ylmethyl)-, monohydrochloride [CAS] 189353-32-0 WO 9712874 Analgesic, other Pain, general Fadrozole 102676-47-1 9, 10-Secocholesta-5, 7, 10 (19)-triene-1, 3, 25- triol, 26, 26, 26, 27, 27, 27-hexafluoro-, falecalcitrioi (1 Aipha, 313, 5Z, 7E)- [CAS] 83805-11-2 JP 03099022 Osteoporosis treatment Hyperparathyroidism 1, 3-Propanediol, 2-[2-(2-amino-9H-purin-9- famciclovir yl) ethyl]-, diacetate (ester)- [CAS] 104227-87-4 JP 61085388 Antiviral, other Infection, gynaecological Propanimidamide, 3- [ [ [2- [ (aminoiminomethyl) amino]-4- thiazolyl] methyl] thio]-N- (aminosulfonyl)- famotidine [CAS] 76824-35-6 US 4283408 Antiulcer Ulcer, duodenal fampridine 4-pyridinamine 504-24-5 Neuroprotective Spinal cord injury 3-Quinolinecarboxylic acid, 6-fluoro-1- (5- fluoro-2-pyridinyl)-1, 4-dihydro-7- (4-methyl-1 164150-85-0 fandofloxacin piperazinyl)-4-oxo, [CAS] 164150-99-6 US 5496947 Quinolone antibacterial Infection, urinary tract Fantofarone 114432-13-2 (5R, 6S)-6- [1 (R)-Hydroxyethyl]-2- [2 (R)- tetrahydrofuryl]-2-penem-3-carboxylic acid- faropenem daloxate 5-methyl-2-oxo-1, 3-dioxol-4-ylmethyl ester Beta-lactam antibiotic Infection, general 4-Thia-1-azabicyclo [3. 2. 0] hept-2-ene-2- carboxylic acid, 6-(1-hydroxyethyif7-oxo-3- (tetrahydro-2-furanyl)-, [5R- faropenem [3 (R*), 5Alpha, 6Alpha (Ri)]]-[CAS] 122547-49-3 EP 410727 Beta-lactam antibiotic Infection, ocular L-Alanine, N- [ (2S)-3- (acetylthio)-2- (1, 3- benzodioxol-5-ylmethyl)-l-oxopropyl]-, fasidotril phenylmethyl ester [CAS] 135038-57-2 EP 419327 Antihypertensive, renin system Hypertension, general 1H-1, 4-Diazepine, hexahydro-1- (5- 103745-39-7 fasudil isoquinolinylsulfonyl)- [CAS] 105628-07-7 EP 187371 Neuroprotective Vasospasm, general Patent API Generic Name API Chemical Name CAS No. Reference Example of Therapeutic Use Example of Indication Fazadinium Bromide 49564-56-9 2, 4, 6 (1H, 3H, 5H)-Pyrimidinetrione, 1-[2- [ (aminocarbonyl) oxy]-3-butoxypropyl]-5- febarbamate ethyl-5-phenyl- [CAS] 13246-02-1 US 3075983 Psychostimulant Febuprol 3102-00-9 5-Thiazolecarboxylic acid, 2- [3-cyano-4- (2- febuxostat methylpropoxy) phenyl]-4-methyl- [CAS] 144060-53-7 WO 9209279 Antigout Hyperuricaemia Fedotozine 123618-00-8 1, 3-Propanediol, 2-phenyl-, dicarbamate felbamate [CAS] 25451-15-4 US 4868327 Antiepileptic Epilepsy, general felbinac [1, 1-Biphenyl]-4-acetic acid [CAS] 5728-52-9 EP 127840 Anti-inflammatory, topical 3, 5-Pyridinedicarboxylic acid, 4- (2, 3- dichlorophenyl)-1, 4-dihydro-2, 6-dimethyl-, felodipine ethyl methyl ester [CAS] 72509-76-3 US 4264611 Antihypertensive, other Hypertension, general Felypressin 56-59-7 Femoxetine 59859-58-4 Fenbenicillin 1926-48-3 [1, 1'-Biphenyl]-4-butanoic acid, Gamma-oxo fenbufen [CAS] 36330-85-5 US 3784701 Anti-inflammatory Fenbutrazate 4378-36-3 Fencamfamine 1209-98-9 Fencamine 28947-50-4 Fenclozic Acid 17969-20-9 Fendiline 13042-18-7 Fendosal 53597-27-6 Fenethylline 3736081 Fenfluramine 458-24-2 Fenipentol 583-03-9 Propanoic acid, 2- [4- (4- chlorobenzoyl) phenoxy]-2-methyl-, 1-26129-32-8 fenofibrate methylethyl ester [CAS] 49562-28-9 Formulation, modified-release, <=24hr Hyperlipidaemia, general 1H-3-Benzazepine-7, 8-diol, 6-chloro-2, 3, 4, 5 67227-56-9 fenoldopam tetrahydro-1- (4-hydroxyphenyl)- [CAS] 67227-57-0 EP 22330 Antihypertensive, other Hypertension, general Fenoprofen 31879-05-7 Patent API Generic Name API Chemical Name CAS No. Reference Example of Therapeutic Use Example of Indication Fenoterol 13392-18-2 10H-Phenothiazine, 10- [ [4- (1, 3-benzodioxol fenoverine 5-ylmethyl)-1-piperazinyl] acetyl]- [CAS] 37561-27-6 FR 2092639 Antispasmodic Fenoxazoline 4846-91-7 Fenoxedil 54063-40-0 Fenozolone 15302-16-6 Fenpentadiol 15687-18-0 Fenpiprane 3540-95-2 Fenpiverinium Bromide 125-60-0 Fenproporex 15686-61-0 Fenquizone 20287-37-0 fenretinide Retinamide, N- (4-hydroxyphenyl)- [CAS] 65646-68-6 BE 847942 Anticancer, other Cancer, breast Fenspiride 5053066 Propanamide, N-phenyl-N- [1- (2- fentanyl phenylethyl)-4-piperidinyl]- [CAS] 437-38-7 Formulation, transmucosal, systemic Anaesthesia, adjunct Fentiazac 18046-21-4 Fenticlor 97-24-5 1H-lmidazole, 1-[2-(2, 4-dichiorophenyi)-2-72479-26-6 fenticonazole [ [4- (phenylthio) phenyl] methoxy] ethyl]- [CAS] 73151-29-8 US 4221803 Antifungal Infection, gynaecological Fentonium Bromide 5868064 36981-91-6 Benzenemethanol, Alpha-[[(2-hydroxy-1, 1-67704-50-1 fepradinol dimethylethyl) amino] methyl]-, (+I-)- [CAS] 63075-47-8 Anti-inflammatory, topical Feprazone 30748-29-9 Ferric Sodium Edetate 15708-41-5 Respiratory distress syndrome, ferrioxamine B WO 9426263 Septic shock treatment adult Ferrocholinate 1336-80-7 Ferrous Gluconate 299-29-6 Polyglucose sorbitol carboxymethyl ether- coated non-stoichiometric magnetite ferumoxytol Imaging agent Diagnosis, cancer Patent API Generic Name API Chemical Name CAS No. Reference Example of Therapeutic Use Example of Indication 2-((1 R)-3-(bis (1-methyiethyl) amino)-1- phenylpropyl)-4- (hydroxymethyl) Phenyl ester, (2E)-2-butenedioate (1 : 1) (Salt)- fesoterodine [CAS] 286930-03-8 Urological Incontinence Benzeneacetic acid, 4- [I-hydroxy-4- [4 (hydroxydiphenylmethyl)-1- 153439-40-8 piperidinyl] butyl]-Alpha, Alpha-dimethyl-, 83799-24-0 fexofenadine [CAS] 138452-21-8 US 5375693 Antiallergic, non-asthma Rhinitis, allergic, seasonal Fibrostat CA 2132416 Vulnerary Wound healing Spiro (4H-1-benzopyran-4, 4'-imidazolidine)- 2-carboxamide, 6-fluoro-2, 3-dihydro-2, 5- fidarestat dioxo-, (2S-cis)-, [CAS] 136087-85-9 EP 418834 Symptomaticantidiabetic Neuropathy, diabetic 8-Phenyl-3- [4- [ (3aR, 9bR)-1, 3a, 4, 9b- tetrahydro-9-methoxy [1] benzopyrano [3, 4- c] pyrrol-2 (3H)- yl] butyl] pyrazino [2', 3' : 4, 5] thieno [3, 2- d] pyrimidine-2, 4 (1 H, 3H)-dione fiduxosin 208993-54-8 Prostate disorders Benign prostatic hyperplasia 4-Azaandrost-1-ene-17-carboxamide, N- (1, 1-dimethylethyi)-3-oxo-, (5Aipha, 17ß)- finasteride [CAS] 98319-26-7 EP 155096 Prostate disorders Benign prostatic hyperplasia Benzonitrile, 4- (3- (4-fluorophenyl)-2- hydroxy-1-(1 H-1, 2, 4-triazol-1-yi)-propyi)- finrozole [CAS] 160146-16-7 EP 476944 Urological Urinary retention Fipexide 34161-24-5 N- (4-Acetyl-l-piperazinyl)-4- FK-960 fluorobenzamide monohydrate- [CAS] 133920-70-4 WO 9101979 Cognition enhancer Alzheimer's disease Flavopiridol 146426-40-6 4H-1-Benzopyran-8-carboxylic acid, 3- methyl-4-oxo-2-phenyl-, 2- (1- 15301-69-6 flavoxate piperidinyl) ethyl ester [CAS] 3717-88-2 US 2921070 Urological Benzamide, N- (2-piperldinylmethyl)-2, 5- 54143-55-4 flecainide bis (2, 2, 2-trifluoroethoxy)-, [CAS] 54143-56-5 Formulation, modified-release, <=24hr Fibrillation, atrial 3-Quinolinecarboxylic acid, 6, 8-difluoro-1-(2 fluoroethyl)-1, 4-dihydro-7-(4-methyl-1-79660-S3-0 fieroxacin piperazinyl)-4-oxo- [CAS] 79660-72-3 US 4398029 Quinolone anUbacterial nfection, general ) Patent API Generic Name API Chemical Name CAS No. Reference Example of Therapeutic Use Example of Indication Flesinoxan 98206-10-1 2H-Benzimidazol-2-one, 1, 3-dihydro-1- (2- (4- (3- (trifluoromethyl) phenyl)-1- flibanserin piperazinyl) ethyl)- [CAS] 167933-07-5 Reproductive/gonadal, general Sexual dysfunction, female Benzoic acid, 2- [ [8- (trifluoromethyl)-4- quinolinyl] amino]-, 2, 3-dihydroxypropyl ester floctafenine [CAS] 23779-99-9 US 3644368 Analgesic, NSAID l 5-Oxa-1-azabicyclo [4. 2. 0] oct-2-ene-2- carboxylic acid, 7- [ [ [ (difluoromethyl) thio] acetyl] amino]-3- [ [ [l- (2- hydroxyethyl)l H-tetrazol-5-yi] thio] methyl]-7- 92823-03-5 flomoxef methoxy-8-oxo-, (6R-cis)- [CAS] 99665-00-6 EP 128536 Cephalosporin, injectable Infection, general Flopropione 2295-58-1 Florantyrone 519-95-9 Flosequinan 76568-02-0 Floxacillin 5250-39-5 Floxuridine 50-91-9 Fluacizine 30223-48-4 Fluanisone 1480-19-9 Androst-5-en-17-one, 16-fluoro-, (16Aipha)- fluasterone [CAS] 112859-71-9 EP 246650 Cardiovascular Keratosis 5H-Pregna-1, 4-dieno [17, 16-d] oxazole-3, 20- dione, 21-(acetyloxy)-9-fluoro-11-hydroxy-2 fluazacort methyl-, (11 ß, 1611)- [CAS] 19888-56-3 US 3461119 Antipruritic/inflamm, non-allergic Flucloronide 3693-39-8 1847-24-1 flucloxacillin 34214-51-2 Formulation, other Infection, general 1H-1, 2, 4-Triazole-1-ethanol, Alpha-(2, 4- difluorophenyl)-Alpha- (1 H-1, 2, 4-triazol-1- fluconazole ylmethyl)- [CAS] 86386-73-4 EP 96569 Antifungal Infection, dermatological Flucytosine 2022-85-7 9H-Purin-6-amine, 2-fluoro-9- (5-0- 75607-67-9 Cancer, leukaemia, chronic fludarabine phosphono-fl-D-arabinofuranosyl)- [CAS] 21679-14-1 US 4357324 Anticancer, antimetabolite lymphocytic Fludeoxyglucose F18 105851-17-0 Fludiazepam 3900-31-0 Patent API Generic Name API Chemical Name CAS No. Reference Example of Therapeutic Use Example of Indication Fludrocortisone 127-31-1 Flufenamic Acid 530-78-9 Fluindione 957-56-2 4H-imidazo [1, 5-a] [1, 4] benzodiazepine-3- carboxylic acid, 8-fluoro-5, 6-dihydro-5- flumazenil methyl-6-oxo-, ethyl ester [CAS] 78755-81-4 EP 27214 Neurological Flumecinol 56430-99-0 Flumequine 42835-25-6 Flumethasone 2135-17-3 Flumethiazide 148-56-1 30484-77-6 Piperazine, 1- [bis (4-fluorophenyl) methyl]-4- 52468-60-7 flunarizine (3-phenyl-2-propenyl)-, (E)- [CAS] 27848-84-6 GB 1268710 Antimigraine Pregna-1, 4-diene-3, 20-dione, 6-fluor- 11, 21-dihydroxy-16, 17- [ (1- methylethylidene) bis (oxy)]-, flunisolide (6Alpha, 115, 16Alpha)- [CAS] 3385-03-3 US 3124571 Antiasthma Rhinitis, allergic, general 2H-1, 4-Benzodiazepin-2-one, 5- (2- fluorophenyl)-1, 3-dihydro-1-methyl-7-nitro- flunitrazepam [CAS] 1622-62-4 US 3116203 Hypnotic/Sedative Fiunoxaprofen 66934-18-7 Fluocinolone Acetonide 67-73-2 Fluocinonide 356-12-7 Fluocortin Butyl 41767-29-7 Fluocortolone 152-97-6 Fluorescein 2321-07-5 Fluoresone 2924-67-6 Fluorometholone 426-13-1 Fluorosalan 4776061 fluorouracil 2, 4 (1H, 3H)-Pyrimidinedione, 5-fluor- [CAS] 51-21-8 Formulation, transdermal, enhanced Keratosis Benzenepropanamine, N-methyl-Gamma- [4-54910-89-3 fluoxetine (trifluoromethyl) phenoxy]-, (+/-)- [CAS] 56296-78-7 US 4314081 Antidepressant Depression, general Fluoxymesterone 76-43-7 Flupentixol 2709-56-0 < Patent API Generic Name API Chemical Name CAS No. Patent Example of Therapeutic Use Example of Indication Fluperolone 2119-75-7 Fluphenazine 69-23-8 Carbamic acid, [2-amino-6- [ [ (4- 33400-45-2 fluorophenyl) methyl] amino]-3-pyridinyl]-, 56995-20-1 flupirtine ethyl ester [CAS] 75507-68-5 US 4481205 Analgesic, other Pain, post-operative Fluprednidene Acetate 1255-35-2 Fluprednisolone 53-34-9 Fluproquazone 40507-23-1 Flurandrenolide 1524-88-5 Flurazepam 17617-23-1 [1, 1'-Biphenyl]-4-acetic acid, 2-fluoro-Alpha- flurbiprofen methyl- [CAS] 5104-49-4 US 3793457 Anti-inflammatory Erythromycin, 8-fluoro-mono (ethyl flurithromycin butanedioate) (ester)- [CAS] 82730-23-2 EP 56291 Macro ! ide antibiotic infection, respiratory tract, lower Flurogestone 2529-45-5 Flurothyl 333-36-8 Fluroxene 406-90-6 Fluspirilene 1841-19-6 Propanamide, 2-methyl-N- [4-nitro-3- flutamide (trifluoromethyl) phenyl]- [CAS] 13311-84-7 US 4329364 Anticancer, hormonal Oxazolo [3, 2-d] [1, 4] benzodiazepin-6 (5H)- one, 10-chloro-11b- (2-fluorophenyl)- 2, 3, 7, 11 b-tetrahydro-7- (2-hydroxyethyl)- flutazolam [CAS] 27060-91-9 US 3905956 Anxiolytic Androsta-1, 4-diene-17-carbothioic acid, 6, 9- difluoro-11, 17-dihydroxy-16-methyl-3-oxo-, S- (fluoromethyl) ester, 80474-14-2 fluticasone (6Aipha, 1 1ß, 16Alpha, 17Alpha)- [CAS] 90566-53-3 Formulation, inhalable, solution Asthma 2H-1, 4-Benzodiazepin-2-one, 7-chloro-1- (cyclopropylmethyl)-5- (2-fluorophenyl)-1, 3- flutoprazepam dihydro-[CAS] 25967-29-7 GB 1253368 Anxiolytic Psychosis, general 1H-imidazoXe, 1-[(2-fluorophenyl) (4- flutrimazole fluorophenyl) phenylmethyl]- [CAS] 119006-77-8 EP 352352 Antifungal Infection, dermatological Flutropium Bromide 63516-07-4 Patent API Generic Name API Chemical Name CAS No. Reference Example of Therapeutic Use Example of Indication 6-Heptenoic acid, 7- [3- (4-fluorophenyl)-1- (1 methyiethyi)-1 H-indol-2-yl]-3, 5-dihydroxy-, 93957-55-2 fluvastatin monosodium salt, [R*, S*- (E)]- ()- [CAS] 93957-54-1 EP 114027 Hypolipaemic/Antiatherosclerosis Hypercholesteroiaemia 1-Pentanone, 5-methoxy-1- [4- (trifluoromethyl) phenyl]-O- (2- 54739-18-3 Depression, general, Obsessive fluvoxamine aminoethyl) oxime, (E)- [CAS] 61718-82-9 GB 1535226 Antidepressant compulsive disorder Folic Acid 59-30-3 Folinic Acid 58-05-9 Fomepizole 7554-65-6 Benzamide, N- [3-chloro-2- [Cmethyl [2- (4- morpholinyl)-2-18053-31-1 fominoben oxoethyl] amino] methyl] phenyl]- [CAS] 24600-36-0 US 3661903 Respiratory stimulant Eczema, general Fomivirsen 144245-52-3 Fomocaine 17692-39-6 Fonazine 7456-24-8 Alpha-D-Glucopyranoside, methyl 0-2- deoxy-6-0-sulfo-2- (sulfoamino)-Alpha-D- glucopyranosyl- (1-4)-O-M-D- glucopyranuronosyl- (1-4)-0-2-deoxy-3, 6-di- O-sulfo-2- (sulfoamino)-Alpha-D- glucopyranosyl- (1-4)-0-2-0-sulfo-Alpha-L- idopyranuronosyl- (1-4)-2-deoxy-2- 104993-28-4 fondaparinux (sulfoamino)-, 6- (hydrogen sulfate) [CAS] 114870-03-0 Anticoagulant Thrombosis, venous Formebolone 2454117 formestane Androst-4-ene-3, 17-dione, 4-hydroxy- [CAS] 566-48-3 EP 346953 Anticancer, hormonal Cancer, breast Formocortal 2825-60-7 Formamide, N- [2-hydroxy-5- [1-hydroxy-2- [ [2 (4-methoxyphenyl)-1- methylethyl] amino] ethyl] phenyl]-, (R*, R*)- (+l 43229-80-7 formoterol [CAS] 73573-87-2 GB 1415256 Antiasthma Asthma Patent API Generic Name API Chemical Name CAS No. Reference Example of Therapeutic Use Example of Indication Carbamicacid, ((1S, 2Rk3-(((4- aminophenyi) sulfonyl) (2- methylpropyl) amino)-1- (phenylmethyl)-2- (phosphonooxy) propyl)- C- ( (3S)-tetrahydro- fosamprenavir 3-furanyl ester, [CAS] 226700-81-8 Antiviral, anti-HIV Infection, HIV/AIDS 34156-56-4 Phosphinecarboxylic acid, dihydroxy-, 4428-95-9 foscarnet oxide, trisodium salt [CAS] 63585-09-1 US 4839445 Antiviral, other Infection, cytomegalovirus Fosfestrol 522-40-7 2, 4-difluoro-Alpha, Alpha-bis (1 H-1, 2, 4- triazol-1-ylmethyl) benzyl alcohol, dihydrogen phosphate (ester) fosfluconazole 194798-83-9 Antifungal Infection, fungal, general Phosphonic acid, (3-methyloxiranyl)-, (2R-23155-02-4 fosfomycin cis)- [CAS] 26016-98-8 GB 1223923 Antibiotic, other Infection, general Phosphonic acid, (3-methyloxiranyl)-, (2R- cis)-, compd. with 2-amino-2- (hydroxymethyl)-1, 3-propanediol (1 : 1)- fosfomycin trometamol [CAS] 78964-85-9 EP 27597 Antibiotic, other Infection, urinary tract Fosfosal 6064-83-1 L-Proline, 4-cyclohexyl-1- [ [ [2-methyl-1- (1- oxopropoxy) propoxy] (4- phenyibutyl) phosphinyl] acetyll-, (2Aipha, 4ß) 88889-149 fosinopril [CAS] 98048-97-6 EP 63896 Antihypertensive, renin system Hypertension, general 2, 4-imidazolidinedione, 5, 5-diphenyl-3- 92134-98-0 Epilepsy, generalized, tonic- fosphenytoin [ (phosphonooxy) methyl]- [CAS] 93390-81-9 US 4260769 Antiepileptc clonic Phosphonic acid, [1- [ [ [ (2- chloroethyl) nitrosoamino] carbonyl] amino] et fotemustine hyl]-, diethyl ester [CAS] 92118-27-9 EP 117959 Anticancer, alkylating Cancer, melanoma Fropenem 106560-14-9 1 H-Carbazole-6-carboxamide, 2, 3, 4, 9- frovatriptan tetrahydro-3- (methylamino)-, (R)- [CAS] 158747-02-5 WO 9922730 Antimigraine Migraine Fructose 57-48-7 Fructose-1, 6-diphosphate 488-69-7 2 (1H)-Pyrimidinone, 4-amino-5-fluoro-1-(2- (hydroxymethyl)-1, 3-oxathiolan-5-yl)- (4R) FTC Antiviral, anti-HIV Infection, HIV/AIDS Patent API Generic Name API Chemical Name CAS No. Reference Example of Therapeutic Use Example of Indication 1, 3-Propanediol, 2-amino-2- (2- (4- FTY-720 octylphenyl) ethyl)-, hydrochloride [CAS] 162359-56-0 WO 9408943 Immunosuppressant Transplant rejection, general fudosteine Alanine, 3-((3-hydroxypropyl) thioF [CAS] 13189-98-5 US 5047428 Antitussive Cough Estra-1, 3, 5 (10)-triene-3, 17-diol, 7- [9- [ (4, 4, 5, 5, 5-pentafluoropentyl) sulfinyl] nonyl]-, fulvestrant (7Alpha, 175)- [CAS] 129453-61-8 EP 346014 Anticancer, hormonal Cancer, breast 2, 4, 6, 8-Decatetraenedioic acid, mono [5- methoxy-4- [2-methyl-3- (3-methyl-2- butenyl) oxiranyl]-1-oxaspiro [2. 5] oct-6-yl] ester, [3R- [3Alpha, 4Aipha (2R*. 3R*). 5ß, 6ß (ali-E) B- fumagiline [CAS] 23110-15-8 Protozoacide Infection, GI tract Fumagillin 23110-15-8 Furaltadone 139-91-3 Furazabol 1239-29-8 Furazolidone 67-45-8 Furazolium Chloride 5118-17-2 Furonazide 3460-67-1 Benzoic acid, 5- 4chloro-2- furosemide [(2-furanyimethyl) amino]- [CAS] 54-31-9 Formulation, modified-release, other Hypertension, general Fursultiamine 804-30-8 Furtrethonium 7618-86-2 Fusidic Acid06/03/6990 G1, YM BioSciences 1- (5-bromofur-2-yi)-2-bromo-2-nitroethene Antifungal Infection, gynaecological G25 WO 9804252 Antimalariai Infection maiaria GABA-A Alpha5 inverse agonist, Mer WO 0206285 Cognition enhancer Alzheimer disease Cyclohexaneacetic acid, 1- (aminomethyl)- gabapentin [CAS] 60142-96-3 US 4152326 Antiepileptic Epilepsy, general Benzoic add, 4- [ [6- [(aminoiminomethyl) amino]-1-oxohexyl] oxy]-39492-01-8 gabexate, ethyl ester, monomethanesulfonate [CAS] 56974-61-9 US 3751447 Gl inflammatory/bowel disorders Pancreatitis Patent API Generic Name API Chemical Name CAS No. Reference Example of Therapeutic Use Example of Indication Isoxazolo [5, 4-c] pyridin-3 (2H)-one, 4, 5, 6, 7- gaboxadol tetrahydro- [CAS] 64603-91-4 CA 1125288 Hypnotic/Sedative Sleep disorder, general Gadobenate Dimeglumine 127000-20-8 Gadobutrol 138071-82-6 Gadodiamide 131410-48-5 Gadopentetic Acid 80529-93-7 Gadoteridof 120066-54-8 Gadoversetamide 131069-91-5 Gadoxetic Acid 135326-11-3 (4aS, 6R, 8aS)-6-Hydroxy-3-methoxy-11- methyl-5, 6, 9, 10, 11, 12-hexahydro-4aH- benzofuro [3a, 3, 2-e, fl [2] benzazepine galantamine Formulation, modified-release, other Alzheimer's disease Galanthamine 357-70-0 R-Alanine, 2- [4- [ (2, 6-dideoxy-2-fluoro-Alpha- L-talopyranosyl) oxy]-1, 2, 3, 4, 6, 11-hexahydro 2, 5, 12-trihydroxy-7-methoxy-6, 11-dioxo-2- 140637-82-7 galarubicin naphthacenyl]-2-oxoethyl ester, [CAS] 140637-86-1 EP 424899 Anticancer, antibiotic Cancer, breast Gallamine Triethiodide 65-29-2 Gallic Acid 149-91-7 4H-Pyran-4-one, 3-hydroxy-2-methyl-, gallium complex gallium maltolate Anticancer, other Cancer, myeloma gallium nitrate Nitric acid, gallium salt [CAS] 13494-90-1 US 4529593 Osteoporosis treatment Hypercalcaemia of malignancy Benzeneacetonitrile, Alpha- [3- [ [2- (3, 4- dimethoxyphenyl) ethyl] methylamino] propyl]- 3, 4, 5-trimethoxy-Alpha- (1-methylethyl)- gallopamil [CAS] 16662-47-8 GB 1367677 Antianginal Angina, general g-Aminobutyric Acid 56-12-2 Ganaxolone 38398-32-2 6H-Purin-6-one, 2-amino-1, 9-dihydro-9- [ [2- hydroxy-1- (hydroxymethyl) ethoxy] methyl]- 107910-75-8 ganciclovir [CAS] 82410-32-0 EP 49072 Antiviral, other infection, cytomegalovirus Patent API Generic Name API Chemical Name CAS No. Reference Example of Therapeutic Use Example of Indication [N-Ac-D-Nai, D-pCI-Phe, D-Pal, D- ganirelix hArg (Et) 2, hArg (Et) 2, D-Ala] GnRH- [CAS] 124904-93-4 EP 312052 Releasing hormones Infertility, female Carbamic acid, (2-ethylphenyl)-, (3aS, 8aS)- 1, 2, 3, 3a, 8, 8a-hexahydro-1, 3a, 8- trimethylpyrrolo [2, 3-b] indol-5-yl ester, ganstigmine 223585-99-7 EP 1023297 Cognition enhancer Aizheimer's disease 1-Piperazineacetic acid, 4- [ [ (5R)-3- [4- [imino [ (methoxycarbonyl) amino] methyl] phe yi]-2-oxo-5-oxazolidinyl] methyi]-, ethylester gantofiban [CAS] 183547-57-1 EP 741133 Antithrombotic Thrombosis, general 3-Quinolinecarboxylic acid, 1-cyclopropyl-8- (difluoromethoxy)-7-((1 R)-2, 3-dihydro-1- methyl-1 H-isoindol-5-yl)-1, 4-dihydro-4-oxo- garenoxacin monomethanesulfonate [CAS] 223652-82-2 Quinolone antibacterial Infection, respiratory tract, lower 5-73-macrophage inflammatory protein Chemotherapy-induced injury, garnocestim 2Alpha (human gene gro2)- [CAS] 246861-96-1 Radio/chemoprotective bone marrow, neutropenia 3-Quinolinecarboxylic acid, 1-cyclopropyl-6- fluoro-1, 4-dihydro-8-methoxy-7- (3-methyl-1- Infection, respiratory tract, gatifloxacin piperazinyl)-4-oxo-, (+/-)- [CAS] 112811-59-3 EP 230295 Quinolone antibacterial general Gefarnate 51-77-4 4-Quinazolinamine, N- (3-chloro-4- fluorophenyl)-7-methoxy-6- (3- (4- gefitinib morpholinyl) propoxy) [CAS] 184475-35-2 WO 9633980 Anticancer, other Cancer, lung, non-small cell 6, 6'-oxybis (2, 2-dimethyihexansate) gemcabene 209789-08-2 _ Hypolipaemic/AnUatherosCerosis Hyperlipidaemia, general 122111-03-9 gemcitabine Cytidine, 2'-deoxy-2', 2-difluoro-, [CAS] 95058-81-4 GB 2136425 Anticancer, antimetabolite Cancer, pancreatic Posta-2, 13-dien-1-oicacid, 11, 15- dihydroxy-16, 16-dimethyl-9-oxo-, methyl gemeprost ester, (2E, 11 Alpha, 13E, 15R)- [CAS] 64318-79-2 GB 1540427 Prostaglandin Pentanoic acid, 5- (2, 5-dimethylphenoxy)- gemfibrozil 2, 2-dimethyi- [CAS] 25812-30-0 US 3674836 Hypolipaemic/AntiatherosCerosis Hyperlipidaemia, general Patent API Generic Name API Chemical Name CAS No. Reference Example of Therapeutic Use Example of Indication 1, 8-Naphthyridine-3-carboxylic acid, 7- (3- (aminomethyl)-4- (methoxyimino)-1- pyrrolidinyl)-1-cyclopropyl-6-fluoro-1, 4- Infection, respiratorytract, gemifloxacin dihydro-4-oxo- [CAS] 175463-14-6 US 5869670 Quinolone antibacterial general gentamicin Gentamicin [CAS] 1403-66-3 Formulation, implant Infection, general Gentian Violet 548-62-9 Gentiopicrin 20831-76-9 Gentisic Acid 490-79-9 Gepefrine 18840-47-6 2, 6-Piperidinedione, 4, 4-dimethyl-1- [4- [4- (2- gepirone pyrimidinyl)-1-piperazinyl] butyl]- [CAS] Formulation, modified-release, other Depression, general 18, 19-Dinorpregna-4, 15-dien-20-yn-3-one, 109852-02-0 gestodene 13-ethyl-17-hydroxy-, (17AIpha)- [CAS] 60282-87-3 GB 1569135 Formulation, fixed-dose combinations Contraceptive, female 18, 19-Dinorpregna-4, 15-dien-20-yn-3-one, 13-ethyl-17-hydroxy-, (17Aipha) mixtwith 19 Norpregna-1, 3, 5 (10)-trien-20-yne-13, 17-diol (17Aipha) gestodene + ethinylest Formulation, modified-release, >24hr Contraceptive, female Gestonorone Caproate 1253-28-7 Gestrinone 16320-04-0 g-Hydroxybutyrate 591-81-1 (4S)-11-[(E)-[(1, 1- dimethylethoxy) imino] methyl]-4-ethyl-4- hydroxy-1-12-dihydro-14H- pyrano [3', 4' : 6, 7] indolizino [1, 2-b] quinoline- 3, 14 (4H)-dione gimatecan 292618-32-7 Anticancer, other Cancer, brain Giractide 24870-04-0 Gitoxin 4562-36-1 N, N'-Bis [2- [N- [2- (N2, N5-dimethyl-DL- lysylamino)-ethyl] carbamoyl] 1 H-indol-6-yl]- 1 H-indole-2, 5-dicarboxamide GL-406349 Antifungal Infection, fungal, general Giafenine 3820-67-5 i Patent API Generic Name API Chemical Name CAS No. Reference Example of Therapeutic Use Example of Indication L-Glutamic acid, polymer with L-alanine, L-147245-92-9 Multiple sclerosis, relapsing- glatiramer lysine and L-tyrosine, [CAS] 8704-27-0 WO 5800808 Multiple sclerosis treatment remitting Glibornuride 26944-48-9 Benzenesulfonamide, N- [[(hexahydrocydopenta [c] pyrrol-2 (1 H)- gliclazide yl) amino] carbonyl]-4-methyl- [CAS] 21187-98-4 GB 1153982 Antidiabetic Diabetes, Type II 1H-Pyrrole-1-carboxamide, 3-ethyl-2, 5- dihydro-4-methyl-N- [2- [4- [ [ [ [ (4- methylcyclohexyl) amino] carbonyl] amino] sulf glimepiride onyl] phenyl] ethyl]-2-oxo- [CAS] 93479-97-1 WO 9303724 Antidiabetic Diabetes, Type II g-Linolenic Acid 506-26-3 Pyrazinecarboxamide, N- [2- [4- [[[(cyCohexylamino) carbonyi] amino] sulfonyl glipizide phenyl] ethyl]-5-methyl- [CAS] 29094-61-9 US 3669966 Antidiabetic Benzenesulfonamide, N- [ (cyclohexylamino) carbonyl]-4- [2- (3, 4- dihydro-7-methoxy-4, 4-dimethyl-1, 3-dioxo- gliquidone 2 (1 H)-isoquinolinyl) ethyl]- [CAS] 33342-05-1 GB 1277847 Antidiabetic Diabetes general 3-Isoxazolecarboxamide, N- [2- [4- [ [ [ (cyclohexylamino) carbonyl] amino] sulfonyl glisolamide phenyl] ethyl]-5-methyl- [CAS] 4477-37-0 Antidiabetic Diabetes, general Glisoxepid 25046-79-1 Glucametacin 52443-21-7 Glucoheptonic Acid 87-74-1 Gluconic Acid 526-95-4 29031-19-4 glucosamine D-Glucose, 2-amino-2-deoxy-, [CAS] 3416-24-8 DE 1953689 Antiarthritic, other Arthritis, osteo Glucosulfone 554-18-7 ß-D-Glucopyranose, 1- (N, N'-bis (2- glufosfamide chloroethyl) phosphorodiamidate)- [CAS] 132682-98-5 DE 3835772 Anticancer, alkylating Cancer, general Glutamic Acid 56-86-0 Glutaraldehyde 111-30-8 Glutethimide 77-214 Glyburide 10238-21-8 Glybuthiazol (e) 535-65-9 Glybuzole 1492-02-0 Patent API Generic Name API Chemical Name CAS No. Reference Example of Therapeutic Use Example of Indication Giycero ! 56-81-5 G ! ycocyam ! ne352-97-6 G ! ycot Sa ! icy ! ate87-28-5*'" Glycerol 56-81-5 Glycocyamine 352-97-6 Glycol Salicylate 87-28-5 Glyconiazide 3691-74-5 Giyconlazlde 691-74-5 Glycopyrrolate 596-51-0 Glyhexamide 451-71-8 Glymidine 339-44-6 Glypinamide 1228-19-9 N-acetylglucosaminyl-N-acetylmuramyl GMDP dipeptide Anti-infective, other Infection, general Gold Sodium Thiomalate 12244-574 Gold Sodium Thiosulfate 10233-88-2 Luteinizing hormone-releasing factor (pig), 6-p- (1, 1-dimethylethyl)-D-serine]-10- deglycinamide-, 2- goserelin (aminocarbonyl) hydrazide [CAS] 5807-02-5 US 4100274 Releasing hormones Cancer, prostate L-Proline, 1- (3, 3-dimethyl-1, 2-dioxopentyl)-, GPI-1485 3- (3-pyridinyl) propyl ester [CAS] 186452-09-5 Antiparkinsonian Parkinson's disease 2- (Phosphonomethyl) pentanedioic acid GPI-5693 US 5672592 Analgesic, other Pain, neuropathic Graffskin 1H-lndazole-3-carboxamide, 1-methyl-N-(9- methyl-9-azabicyclo [3. 3. 1] non-3-yi)-, endo-107007-99-8 Chemotherapy-induced nausea [CAS] 109889-09-0 EP 200444 Antiemetic and vomiting Grepafloxacin 119914-60-2 Spiro [benzofuran-2 (3H), 1-[2] cyclohexane]- 3, 4'-dione, 7-chioro-2, 4, 6-trimeth-oxy- griseofulvin 6'methyl-, (1'S-trans)- [CAS] 126-07-8 Formulation, dermal, topical Infection, dermatological Guaiacol 90-05-1 Guaiapate 852-42-ô Guaiazuiene 489-84-9 Guaifenesin 93-14-1 H-1, 3-Benzodioxin-4-one 2-(2- guaimesal methoxyphenoxy)-2-methyl- [CAS] 81674-79-5 GB 2098201 Anti-inflammatory Patent API Generic Name API Chemical Name CAS No. Reference Example of Therapeutic Use Example of Indication Guamecycline 16545-11-2 Guanabenz 5051-62-7 Guanadrel 40580-59-4 Guanethidine 55-65-2 Guanfacine 29110-47-2 Guanoxabenz 24047-25-4 Guanoxan 2165-19-7 gugulipid Pregna-4, 17 (20)-diene-3, 16-dione [CAS] 95975-55-6 EP 447706 HypolipaemictAntiatherosderosis Gusperimus 104317-84-2 (Z)-2-Chlorofumaric acid 1- [3- [- [6, 7- dimethoxy-2 (S)-methyl-1 (R)- (3, 4, 5- trimethoxybenzyl)-1, 2, 3, 4- tetrahydroisoquinolinium-2-yl] propyl] GW-280430A Musde relaxant Anaesthesia, adjunct [2S, 3S, 5R]-2- [3, 5-difluorophenyl]-3, 5- dimethyl-2-morpholinol GW-320659 Anorectic/Antiobesity Obesity (+)-R-2- {3- [N- (2- Benzo [1, 4] dioxanylmethyl) amino]-1-propyl}- GYKI-16084 3 (2H)-pyridazinone hydrochloride US 6194411 Prostate disorders Benign prostatic hyperplasia Hachimycin 1394-02-1 Halazepam 23092-17-3 Halcinonide 3093-35-4 Pregna-1, 4-diene-3, 20-dione, 21-chloro-6, 9 difluoro-11-hydroxy-16-methyl-17- (1- halobetasol oxopropoxy)-, (6Alpha, 11 ß, 16ß)- [CAS] 66852-54-8 US 4619921 Antipsoriasis Psoriasis 9-Phenanthrenemethanol, 1, 3-dichloro- Alpha-[2-(dibutylamino) ethyi]-6-36167-63-2 halofantrine (trifluoromethyl)- [CAS] 69756-53-2 EP 138374 Antimalarial Infection, malaria Pregna-1, 4-diene-3, 20-dione, 2-chloro-6, 9- difluoro-11, 17, 21-trihydroxy-16-methyl-, halometasone (6Alpha, 11 ß, 16Alpha)- [CAS] 50629-82-8 US 4076737 Antipruritic/inflamm, allergic Haloperidol 52-86-8 Halopredone 57781-14-3 I Patent API Generic Name API Chemical Name CAS No. Reference Example of Therapeutic Use Example of Indication Haloprogin 777-11-7 Halopropane 679-84-5 Halothane 151-67-7 Haloxazolam 59128-97-1 2 (R)-Acetamido-N-benzyl-3- methoxypropionamide harkoseride WO 9733861 Antiepileptic Epilepsy, general 16Aipha-Bromo-3ß-hydroxy-5Alpha- androstane-17-one HE-2000 Antiviral, anti-HIV Infection, HIV/AIDS Healos WO 9714376 Musculoskeletal Regeneration, bone Hematoporphyrin 14459-29-1 Hepronicate 7237-81-2 Heptabarbital 509-86-4 Heptaminol 372-66-7 Hetacillin 3511-16-8 Hetastarch 9004-62-0 Hexachlorophene 70-30-4 Hexadimethrine Bromide 28728-55-4 Hexafluorenium Bromide 317-52-2 Hexamethonium 60-26-4 Hexamidine 3811-75-4 Hexapropymate 358-52-1 Hexedine 5980-31-4 Hexestrol 84-16-2 Hexestrol Bis (b-diethylaminoethyl 2691-45-4 ether) Hexethal 144-00-3 Hexetidine 141-94-6 Hexobarbital 56-29-1 Hexobendine 54-03-5 Hexocyclium Methyl Sulfate 115-63-9 Hexoprenaline 3215-70-1 Hextend Hextend [CAS] 235746-51-7 US 5407428 Plasma substitute Surgery adjunct Hexylcaine 532-76-3 = ! Patent API Generic Name API Chemical Name CAS No. Reference Example of Therapeutic Use Example of Indication 11b-hydroxy androstenedione HF-0299 Osteoporosis treatment Osteoporosis Benzeneacetic acid, 4- [2-hydroxy-3- [ (1- methylethyl) amino] propoxy]-, 2- tricyclo [3. 3. 1. 13, 7] dec-1-yiethyl ester, (2Z)-2 HGP-2 butenedioate (1 : 1) (salt) [CAS] 121009-31-2 Antiglaucoma Glaucoma 8-Azoniabicyclo [3. 2. 1] octane, 3- (3-ethoxy- 1, 3-dioxo-2-phenylpropoxy)-8, 8-dlmethyl-, HGP-6A (3-endo)-, methyl sulfate [CAS] 113932-41-5 Antiepileptic Epilepsy, general hidrosmin Hydrosmin- [CAS] 120250-44-4 Vasoprotective, systemic histamine histamine 51-45-6 EP 0493468 Anticancer, immunological Cancer, melanoma Histapyrrodine 493-80-1 Luteinizing hormone-releasing factor (pig), -[1-(phenylmethyi)-D-histidine]-9-(N-ethyi-L histrelin prolinamide)-10-deglycinamide-[CAS] 76712-82-8 EP 217659 Releasing hormones Precocious puberty HM-101 HM 101 [CAS] 217311-70-1 Osteoporosis treatment Osteoporosis E)-4-[2-[2-(p-methoxybenzenesulfonamide) phenyl] ethenyl] pyridine-1-oxide HMN-214 Anticancer, other Cancer, general Homatropine 87-00-3 Homocamfin 535-86-4 Homochlorcyclizine 848-53-3 Hopantenic Acid 18679-90-8 Iycinamide, N-acetyi-L-norieucyl-L- glutaminyl-L-histidyl-D-phenylalanyl-L- HP-228 arginyl-D-tryptophyl- [CAS] 172617-89-9 EP 759770 Analgesic, other Pain, post-operative Huperzine A 102518-79-6 hyaluronan Hyaluronic acid [CAS] 9004-61-9 Formulation, other Restenosis Hycanthone 3105-97-3 Hydnocarpic Acid 459-67-6 Hydralazine 86-54-4 Hydrastine 118-08-1 Hydrastinine 6592-85-4 Patent API Generic Name API Chemical Name CAS No. Reference Example of Therapeutic Use Example of Indication Hydrochlorothiazide 58-93-5 Morphinan-6-one, 4, 5-epoxy-3-hydroxy-17- 466-99-9 hydrocodone methyl-, (5Aipha)- [CAS] 125-29-1 Formulation, modified-release, other Pain, general Hydrocortamate 76-47-1 Pregn-4-ene-3, 20-dione, 21- (acetyloxy)-11- 74050-20-7 hydrocortisone hydroxy-17-(1-oxopropoxy)-, (11 ß)-[CAS] 50-23-7 DE 2826257 Dermatological Unspecified Pregn-4-ene-3, 20-dione, 11-hydroxy-17- (1- oxobutoxy)-21-(1-oxopropoxy)-, (11ß)- hydrocortisone butyrate propio [CAS] 72590-77-3 DE 2910899 Antipruriticlinflamm, allergic Hydroflumethiazide 135-09-1 Morphinan-6-one, 4, 5-epoxy-3-hydroxy-17- methyl-, (5AIpha)-, mixtwith acetamide, N- (4 hydroxyphenyl)-, mixt with morphinan-6- one, 17-(cyclopropylmethyl)-4, 5-epoxy-3, 14- 103-90-2 dihydroxy-, (5AIpha)-16590-41-3 hydromorphone 466-99-9 Formulation, fixed-dose combinations Pain, general Hydroquinidine 1435-55-8 Hydroquinine 522-66-7 Hydroquinone 123-31-9 Hydroxocobalamin 13422-51-0 Hydroxyamphetamine 1518-86-1 Hydroxychloroquine 118-42-3 Hydroxydione 53-10-1 Hydroxypethidine 468-56-4 Hydroxyphenamate 50-19-1 Hydroxypropyl Cellulose 9004-64-2 Hydroxystilbamidine 495-99-8 Hydroxytetracaine 490-98-2 Hydroxyzine 68-88-2 Hytan G-F20 Hymecromone 90-33-5 Patent API Generic Name API Chemical Name CAS No. Reference Example of Therapeutic Use Example of Indication benzeneacetic acid, Alpha (hydroxymethyl)-, 8-methyl-8-azabicyclo [3. 2. 1.] oct-3-yl ester, [3 (S)-endo], hyoscyamine 101-31-5 Formulation, oral, orally-disintegrating Ulcer, GI, general Phenanthro [1, 10, 9, 8-opqra] perylene-7, 14- dione, 1, 3, 4, 6, 8, 13-hexahydroxy-10, 11- hypericin dimethyl- [CAS] 548-04-9 Anticancer, other Cancer, brain IACFT 180468-34-2 Phosphonic acid, [1-hydroxy-3- ibandronic acid (methylpentylamino) propylidene] bis- [CAS] 114084-78-5 EP 252504 Osteoporosis treatment Hypercalcaemia of malignancy Propanoic acid, 2-methyl-, 4- [2- (methylamino) ethyl]-1, 2-phenylene ester- ibopamine [CAS] 66195-31-1 GB 1551661 Cardiostimulant Heart failure Propanoic acid, 2-methyl-, 4- [2- (methylamino) ethyl]-1, 2-phenylene ester- ibopamine [CAS] 66195-31-1 Formulation, mucosal, topical Surgery adjunct Ibritumomab Tiuxetan 206181-63-7 Phosphonic acid, [ [4- [ [ (4-bromo-2- cyanophenyi) amino] carbonyl] phenyi] methyl. ibrolipim).-, diethyl ester [CAS] 133208-93-2 EP 402033 Hypolipaemic/Antiatherosclerosis Hypertriglyceridaemia 1-Propanone, 2-methyl-1- [2- (1- methylethyl) pyrazol [1, 5-a] pyridin-3-yi]- ibudilast [CAS] 50847-11-5 EP 215438 Antiasthma Asthma Ibufenac 1553-60-2 Benzeneacetic acid, Alpha-methyl-4- (2- methylpropyl)-, 2-pyridinyimethyi ester ibuprofen piconol [CAS] 64622-45-3 DE 2658610 Antipruritic/inflamm, non-allergic Eczema, contact Benzeneacetic acid, Alpha-methyl-4- (2- ibuprofen methylpropyl)- [CAS] 15687-27-1 Formulation, modified-release, other Inflammation, general buproxam 53648-05-8 Methanesulfonamide, N- [4- [4- (ethylheptylamino)-1-hydroxybutyl] phenyl]-, 122647-31-8 ibutiiide (+/-)-, [CAS] 122647-32-9 JP 60239458 Antiarrhythmic Fibrillation, atrial ICA-17043 US 6288122 Antisickling Anaemia, sickle cell icodextrin Dextrin- [CAS] 9004-53-9 Urological Renal failure fj Patent API Generic Name API Chemical Name CAS No. Reference Example of Therapeutic Use Example of Indication 5, 12-Naphthacenedione, 9-acetyl-7- [ (3- amino-2, 3, 6-trideoxy-Alpha-L-lyxo- hexopyranosyl) oxy]-7, 8, 9, 10-tetrahydro- 58957-92-9 Cancer, leukaemia, acute idarubicin 6, 9, 11-trihydroxy-, (7S-cis)- [CAS] 86189-66-4 US 4471052 Anticancer, antibiotic lymphocytic Idazoxan 79944-58-4 2- (2, 3-dihydro-2- (4-hydroxy-3- methoxyphenyl)-3- (hydroxymethyl)-1, 4- benzodioxin-6-yi)-2, 3-dihydro-3, 5, 7- trihydroxy-4H-1-benzopyran-4-one IdB-1016 phosphatidylcholine complex 134499-06-2 EP 209038 Anticancer, hormonal Cancer, ovarian 2, 5-Cyclohexadiene-1, 4-dione, 2- (10- hydroxydecyl)-5, 6-dimethoxy-3-methyl- idebenone [CAS] 58186-27-9 EP 58057 Neuroprotective lschaemia, cerebral 4-Hexenoic acid, 3- [ [ (1, 1- dimethylethoxy) carbonyl] amino]-2-hydroxy-5 methyl-, (3aS, 4R, 7R, 8aS, 9S, 10aR, 12aS, 12bR, 13S, 13aS)-7, 12a-bis (acetyloxy)-13- (benzoyloxy)- 3a, 4, 7, 8, 8a, 9, 10, 10a, 12, 12a, 12b, 13- dodecahydro-9-hydroxy-5, 8a, 14, 14- tetramethyl-2, 8-dioxo-6, 13a-methano-13aH- oxeto [2", 3", 5', 6 benzo [1, 2 : 4, 5] cyclodeca IDN-5109 [1, 2-d] dioxyl-4-yl ester, 2R, 3S) [CAS} 186348-05-0 US 5264591 Anticancer, other Cancer, colorectal Idoxifene 116057-75-1 Alpha-D-Glucopyranoside, methyl 0-2, 3, 4- tri-0-methyl-6-0-sulfo-Alpha-D- glucopyranosyi-(1-4)-0-2, 3-di-0-methyl-P ;-D glucopyranuronosyl- (l-4)-0-2, 3, 6-tri-O-sulfo Aipha-D-glucopyranosyi-(1-4)-0-2, 3-di-0- methyl-Alpha-L-idopyranuronosyl- (1-4)-, tris (hydrogen sulfate) nonasodium salt idraparinux [CAS] 149920-56-9 AU 698456 Antithrombotic Thrombosis, venous 2-Propenamide, N- (2-hydroxyethyl)-3- idrocilamide phenyl- [CAS] 6961-46-2 US 3659014 Anti-inflammatory, topical ', Patent API Generic Name API Chemical Name CAS No. Reference Example of Therapeutic Use Example of Indication (7)-2- (4-benzyl piperidino)-i-p-23210-58-4 ifenprodil hydroxyphenylpropanol tartrate 23210-56-2 US 3509164 Neuroprotective 2H-1, 3, 2-Oxazaphosphorin-2-amine, N, 3- ifosfamide bis (2-chloroethyl) tetrahydro-, 2-oxide [CAS] 3778-73-2 US 3732340 Anticancer, alkylating Cancer, lung, general N- [3- (Formylamino)-4-oxo-6-phenoxy-4H- chromen-7-yl] methanesulfonamide iguratimod 123663-49-0 DE 3834204 Antiarthritic, other Arthritis, rheumatoid 1 H-Benåmidazole, 2-(((4-methoxy-3-methyi- 2-pyridinyl) methyl) sulfinyl)-5- (1H-pyrrol-1- ilaprazole yl)- [CAS] 172152-36-2 US 5703097 Antiulcer Uicer, Gl, general Butanediamide, N4-hydroxy-N1- (1- H-indol 3-ylmethyl)-2- (methylamino)-2-oxoethyl)-2- ilomastat (2-methylpropyl)-, (S- (R*, S*))- [CAS] 142880-36-2 US 5892112 COPD treatment Emphysema, smoking-related Ethanone, 1- [4- [3- [4- (6-fluoro-1, 2- benzisoxazol-3-yl)-1-piperidinyl] propoxy]-3- iloperidone methoxyphenyl]- [CAS] 133454-47-4 US 5776963 Neuroleptic Schizophrenia Pentanoic acid, 5- [hexahydro-5-hydroxy-4- (3-hydroxy-4-methyl-1-octen-6-ynyl)-2 (1 H)- iloprost trometamol pentalenylidene]- [CAS] 78919-13-8 DE 3417638 Prostaglandin Peripheral vascular disease 1iL23-7553 1Aipha, 25-Hydroxy-16-yne vitamin D3 Anticancer, other Cancer, general 4- ( (Methyl-1-piperazinyl) methyl)-N- [4-methyl 3-14-(3-pyridinyi)-2-pyrimidinyl] amino]- phenyl] benzamide methanesulfonate Cancer, leukaemia, chronic imatinib 152459-95-5 US 5521184 Anticancer, other myelogenous 4-imidazolidinecarboxylic acid, 3- [2- [ [1- (ethoxycarbonyl)-3-phenylpropyl] amino]-1- oxopropyl]-1-methyl-2-oxo-, [4S-89371-37-9 Antihypertensive, renin system, Hypertension, general, imidapril [3 [R* (R*)], 4R*]]- [CAS] 89396-94-1 EP 95163 Musculoskeletal Cachexia Benzoic acid, 2-hydroxy-, compd. with 1 H- imidazole salicylate imidazole (1 : 1) [CAS] 36364-49-5 US 4329340 Anti-inflammatory Pain, general Patent API Generic Name API Chemical Name CAS No. Reference Example of Therapeutic Use Example of Indication 1-Azabicyclo [3. 2. 0] hept-2-ene-2-carboxylic acid, 6-(1-hydroxyethyi)-3-[[2-64221-86-9 [(iminomethyi) amino] ethyilthio]-7-oxo-, [5R-74431-23-5 imipenem [5AIpha, 6Alpha (R*)]]- [CAS] 81129-83-1 GB 1570990 Beta-lactam antibiotic Infection, general Imipramine 50-49-7 Imipramine N-Oxide 6829-98-7 1H-imidazo [4, 5-c] quinolin-4-amine, 1- (2- Infection, human papilloma imiquimod methylpropyl)- [CAS] 99011-02-6 EP 145340 Antiviral, other virus Imolamine 318-23-0 Benzeneacetamide, Alpha-cyclopentyl-4- ( (2, 4-dimethyl-9H-pyrido (2, 3-b) indol-9- yl) methyi)-N-((1 R)-2-hydroxy-1-phenylethyl)- implitapide (AiphaS)- [CAS] 177469-96-4 EP 705831 Hypolipaemic/Antiatherosclerosis Atherosclerosis Improsulfan 13425-98-4 Inaperisone 99323-21-4 Phosphonic acid, incadronate [(cycloheptylamino) methyiene] bis-, [CAS] 138330-18-4 Musculoskeletal Hypercalcaemia of malignancy Incadronic Acid 124351-85-5 indalpine 63758-79-2 Indanazoline 40507-78-6 4-chloro-N-(2-methylindolin-1-yl)-3- indapamide sulfamoylbenzamide 26807-65-8 GB 1203691 Antihypertensive, diuretic Hypertension, general Indecainide 74517-78-5 Morpholine, 2- [ (1H-inden-7-yloxy) methyl]- 60929-23-9 indeloxazine [CAS] 65043-22-3 JP 52083773 Cognition enhancer Alzheimer disease Indeloxazine 65043-22-3 30190-87-5 2-Propanol, 1- [1 H-inden-4 (or 7)-yloxy]-3- [ (1- 60607-68-3 indenolol methylethyl) amino]- [CAS] 68906-88-7 GB 1290343 Antihypertensive, adrenergic D-erythro-Pentonamide, 2, 3, 5-trideoxy-N- (2, 3-dihydro-2-hydroxy-1 H-inden-1-yl)-5-(2- ( ( (1, 1-dimethylethyl) amino) carbonyl)-4- (3- pyridinylmethyl)-1-piperazinyl)-2- (phenyimethyl), [1S- [lAlpha (R*), 2Alpha]]-, 150378-17-9 indinavir [CAS] 157810-81-6 EP 0541168 Antiviral, anti-HIV Infection, HIV/AIDS Patent API Generic Name API Chemical Name CAS No. Reference Example of Therapeutic Use Example of Indication Acetamide, N-methyl-N- (3- (3- (2- thienylcarbonyl) pyrazol (1, 5-a) pyrimidin-7- indiplon yl) phenyl)- [CAS] 325715-02-4 US 6399621 Hypnotic/Sedative Insomnia 1 H-indazole-3-carboxamide, N- (3, 9- dimethyl-3, 9-diazabicyclo (3. 3. 1) non-7-yi)-, indisetron diendo- [CAS] 160472-97-9 Antiemetic Nausea and vomiting, general 1, 4-Benzenedisulfonamide, N- (3-chloro-1H- indisulam indol-7-yl)- [CAS] 165668-41-7 Anticancer, other Cancer, lung, non-small cell Indobufen 63610-08-2 indocyanine Green 3599-32-4 1 H-indole-3-acetic acid, 1- (4-chlorobenzoyl) indometacin 5-methoxy-2-methyl- [CAS] 53-86-1 Formulation, modified-release, other Inflammation, general indoprofen 31842-01-0 Benzamide, N- [1- [2- (1H-indol-3-yl) ethyl]-4- 26844-12-2 indoramin piperidinyl]- [CAS] 38821-52-2 GB 1218570 Antihypertensive, adrenergic Inducterm US 5993810 Labour inducer Labour, induction Infliximab 170277-31-3 fnosine Pranobex 36703-88-5 Inositol B7-89-8 Inositol Niacinate 6556112 lobenguane 80663-95-2 lobenzamic Acid 3115057 lobitridol 136949-58-1 locarmic Acid 10397-75-8 iocetamic Acid 16034-77-8 lodamide 440-58-4 iodine iodine [CAS] 7553-56-2 Formulation, oral, other Fibrocystic breast disorder lodipamide 606-17-7 lodixanol 92339-11-2 lodoalphionic Acid 577-91-3 5-Chloro-7-iodo-8-quinolinol odochiorhydroxyquin 130-26-7 Cognition enhancer Alzheimer's disease lodoform 75-47-8 lodopyracet 300-37-8 lodopyrrole 87-58-1 Patent API Generic Name API Chemical Name CAS No. Reference Example of Therapeutic Use Example of Indication lodoquinol 83-73-8 lofetamine 1231 75917-92-9 toglycamic Acid 2618-25-9 fohexol 66108-95-0 lomeglamic Acid 25827-76-3 lomeprol 78649-41-9 lopamidol 60166-93-0 lopanoic Acid 96-83-3 lopentol 89797-00-2 lophendylate 99-79-6 lophenoxic Acid 96-84-4 lopromide 73334-07-3 lopronic Acid 41473-08-9 lopydol 5579-92-0 lopydone 5579-93-1 lothalamic Acid 2276-90-6 lotrolan 79770-24-4 loversol 87771-40-2 loxaglic Acid 59017-64-0 loxilan 107793-72-6 IP-751 (3R, 4R)-(delta6)-THC-DMH-11-oic acid WO 9401429 Analgesic, other Pain, neuropathic ipidacrine _ 62732-44-9 Stigmastan-15-one, 22, 29-epoxy-3, 4, 6, 7, 29- pentahydroxy-, (3Alpha, 413, 5Alpha, 6Aipha, 7ß, 14ß, 22S)- IPL-576092 [CAS] 137571-30-3 US 6046185 Antiasthma Asthma Ipodate 5587-89-3 66985-17-9 Chronic obstructive pulmonary ipratropium bromide 22254-24-6 Formulation, inhalable, solution disease (endo, syn)- ()-3- (3-Hydroxy-1-oxo-2- phenylpropoxy)-8-methyl-8- (1-methylethyl)- 8-azoniabicyclo [3. 2. 1] octane ipratropium Formulation, inhalable, topical Asthma Patent API Generic Name API Chemical Name CAS No. Reference Example of Therapeutic Use Example of Indication Hydrazinecarboxamide, 2- [1, 2, 3, 6- tetrahydro-3-hydroxy-1- (1-methylethyl)-6- iprazochrome oxo-5H-indol-5-yiidene]- [CAS] 7248-21-7 Haemostatic 4H-1-Benzopyran-4-one, 7- (l-methylethoxy) ipriflavone 3-phenyl- [CAS] 35212-22-7 EP 214647 Osteoporosis treatment Osteoporosis iprindole 5560-72-5 Iproclozide 3544-35-2 iproniazid 54-92-2. Ipsapirone 95847-70-4 2-n-butyl-4-spirocyclopentane-1-[((2- tetrazol-5-yl) biphenyl-4-yl) methyl]-2- irbesartan imidazolin-5-one 138402-11-6 WO 9114679 Antihypertensive, renin system Hypertension, general Butanedioic acid, mono [2- [2- (acetylthio) ethyl]-2, 3-dihydro-4, 6, 7-trimethyl- IRFI-042 5-benzofuranyl] ester, (+I-)- [CAS] 134867-62-2 US 5114966 Cardiovascular Atherosclerosis N-Cyclopentyl-1-methylimidazo [1, 2- a] quinoxalin-4-amine IRFI-165 191349-26-5 EP 865442 Antidepressant Depression, general Iridomyrmecin 485-43-8 -Imidazolidinone, 1- [2- [4- [3- (4-fluorophenyl)- 2, 3-dihydro-1 104113-57-7 irindalone iperazinyl] ethyl]-, (1R-trans)-[CAS] 96478-43-2 EP 183349 Antidepressant Depression, general Irinotecan 97682-44-5 Spiro [cyclopropane-1, 5'- [5H] inden]-7' (6'H)- irofulven one, 6'-hydroxy-2', 4', 6'-trimethyl-, (R)- [CAS] 125392-76-9 US 5563176 Anticancer, other Cancer, prostate Iron Sorbitex 1338-16-5 57381-26-7 1, 3, 5-Triazine-2, 4-diamine, 6- (2, 5- 57381-28-9 irsogladine dichlorophenyl)- [CAS] 57381-33-6 US 4657907 Antihypertensive, diuretic Hypertension, general Cyclohexanecarboxamide, N- [2- [ (ethylsulfonyl) amino]-5- (trifluoromethyl)-3- IS-741 pyridinyl)- [CAS] 141283-87-6 EP 465913 Gi inflammatorylbowel disorders Pancreatitis 2, 4-Thiazolidinedione, 5-[[6-[(2- fluorophenyl) methoxy]-2- isaglitazone naphthaienyilmethyl]-[CAS] 161600-01-7 US 5594016 Antidiabetic Diabetes, Type II , Patent API Generic Name API Chemical Name CAS No. Reference Example of Therapeutic Use Example of Indication ISAtx-247 NZ 502362 Immunosuppressant Transplant rejection, general Isbogrel 89667-40-3 D-Streptamine, 0-6-amino-6-deoxy-Alpha-D glucopyranosyl- (1-4)-O- [3-deoxy-4-C-methyl 3-(methylamino)-ß-L-arabinopyranosyi-(1- 6) J-N1- (3-amino-2-hydroxy-1-oxopropyi)-2- 58152-01-5 isepamicin deoxy-, (S)- [CAS] 58152-03-7 US 4029882 Aminoglycoside antibiotic Infection, dermatological isoaminile 77-51-0 Isobutyl p-Aminobenzoate 94-14-4 Isocarboxazid 59-63-2 1- [2- (2-6-dichlorobenzyloxy)-2- (2-, 4- 24168-96-5 isoconazole dichlorophenyl) ethyl] 27523-40-6 GB 1244530 Antifungal Infection, fungal, general Isoetharine 530-08-5 1-Piperazineethanol, 4- [3-fluoro-10, 11- 106819-39-0 dihydro-8- (1-methylethyl) dibenzo [b, flthiepin- 106819-41-4 isofloxythepin 10-yi]- [CAS] 70931-18-9 GB 2010843 Neuraleptic Ethane, 2-chloro-2- (difluoromethoxy)-1, 1, 1- isoflurane trifluor- [CAS] 26675-46-7 US 3535388 Anaesthetic, inhalation Anaesthesia Isoflurophate 55-91-4 Isoladol 530-34-7 lsomethadone 466-40-0 Isometheptene 503-01-5 Isoniazid 54-85-3 Isonixin 57021-61-1 Isopromethazine 303-14-0 lsopropamide lodide 71-81-8 Isopropyl Alcohol 67-63-0 5-Heptenoic acid, 7- (3, 5-dihydroxy-2- (3- oxodecyl) cyclopentyl)-, 1-methylethylester, isopropyl unoprostone (1R-(1Aipha (Z), 211, 3Alpha, 5Alpha))- [CAS] 120373-24-2 EP 289349 Prostaglandin Glaucoma Isoproterenol 7683-59-2 isosorbide 652-67-5 = Patent API Generic Name API Chemical Name CAS No. Reference Example of Therapeutic Use Example of Indication D-Glucitol, 1, 4 : 3, 6-dianhydro-, dinitrate isosorbide nitrate [CAS] 87-33-2 Formulation, modified-release, other Angina, general D-Glucitol, 1, 4 : 3, 6-dianhydro-, 5-nitrate isosorbide mononitrate [CAS] 16051-77-7 Formulation, modified-release, other Angina, general Isothipendyl 482-15-5 isotretinoin Retinoic acid, 13-cis- [CAS] 4759-48-2 US 4843096 Antiacne Acne isovaleryl Diethylamide 533-32-4 Isoxepac 55453-87-7 Isoxicam 34552-84-6 Isoxsuprine 395-28-8 3, 5-Pyridinedicarboxylic acid, 4- (4- benzofurazanyl)-1, 4-dihydro-2, 6-dimethyl-, isradipine methyl 1-methylethyl ester [CAS] 75695-93-1 GB 2037766 Antihypertensive, other Hypertension, general 6H-Thieno [3, 2-f [1, 2, 4] triazol [4, 3- a] [1, 4] diazepine, 4- (2-chlorophenyl)-6, 9- dimethyl-2- [2- [4- (2- israpafant methylpropyl) phenyl] ethyl]- [CAS] 117279-73-9 EP 268242 Antiasthma Asthma ISV-403 US 5447926 Formulation, mucosai, topical Conjunctivitis Itasetron 123258-84-4 ITF-282 ITF 282 [CAS] 93615-44-2 GB 2115821 Antianaemic Anaemia, general Benzamide, N- [ [4- [2- (dimethylamino) ethoxy] phenyl] methyl]-3, 4- itopride dimethoxy-, monohydrochloride [CAS] 122892-31-3 EP 306827 Gastroprokinetic Gastritis 3H-1, 2, 4-Triazol-3-one, 4- [4- [4- [4- [ [2- (2, 4- dichlorophenyl)-2- (1 H-1, 2, 4-triazol-1- ylmethyl)-1, 3-dioxolan-4-yl] methoxy] phenyl]- I-piperazinyl] phenyl]-2, 4-dihydro-2- (l- itraconazole methylpropyl)- [CAS] 84625-61-6 EP 6711 Antifungal Infection, fungal, general Itramin 13445-63-1 1-Naphthalenepropanoic acid, R- [2- [ [2- (8- azaspiro [4. 5] dec-8-ylcarbonyl)-4, 6- dimethylphenyl] amino]-2-oxoethyl]-, (aR)- itriglumide [CAS] 201605-51-8 WO 9800404 Anxiofytic Anxiety, general ! a Patent API Generic Name API Chemical Name CAS No. Reference Example of Therapeutic Use Example of Indication D-Aianinamide N-acetyl-3- (2-naphthalenyl)- D-alanyl-4-chloro-D-phenylalanyl-3- (3- py (idinyl)-D-alanyl-L-seryi-N6- (3- pyridinylcarbonyl)-L-lysyl-N6- (3- pyridinylcarbonyl)-D-lysyl-L-leucyl-N6- (1- iturelix methyiethyl)-L-iysyi-L-proly.- [CAS] 112568-12-4 WO 8901944 Fertility enhancer Infertility, female 7, 8-dimethoxy-3- (3- [ [ (1 S) (4, 5- dimethoxybenzocyclobutan-1- yl) methyl] methylamino] propyl)-1, 3, 4, 5- ivabradine tetrahydro-2H-benzazepin-2-one Antianginal Angina, general 17-Oxa-4-azabicyclo (14. 1. 0) heptadecane- 5, 9-dione, 7, 11-dihydroxy-8, 8, 10, 12, 16- pentamethyl-3- (1-methyl-2- (2-methyl-4- thiazolyl) ethenyl, ixabepilone ( R, 3S, 7S, 10R, 11S, 12S, 16R) [CAS] 219989-84-1 Anticancer, other Cancer, breast 5H-Cyclopenta [b] pyridine-6-carboxylic acid, 5-(1, 3-benzodioxo.-5-yl)-2-butyi-7-[2 [(2S)-2- carboxypropyl]-4-methoxyphenyl]-6, 7- J-104132 dihydro-, (5S, 6R, 7R)- [CAS] 198279-45-7 WO 9737665 Antihypertensive, other Heart failure 5H-Indolo (2, 3-a) pyrrolo (3, 4-c) carbazole- 5, 7 (6H)-dione, 1 2-ß-D-giucopyranosyi- 12, 1 3-dihydro-2, 1 0-dihydroxy-6-((2-hydroxy- J-107088 1- (hydroxymethyl) ethyl) amino- [CAS] 174402-32-5 Anticancer, other Cancer, bladder 1-[(3R, 4R)-1-Cyclooctyimethyl-3- hydroxymethyl-4-piperidyl]-3-ethyl-1, 3- dihydro-2H-benzimidazole-2-one J-113397 Analgesic, other Pain, general Phenol, 4- [ (6, 7-dimethoxy-4- Janex-1 quinazolinyl) amino]- [CAS] 202475-60-3 Anticancer, other Cancer, leukaemia, general Leucomycin V, 3-acetate 4B- (3- josamycin methylbutanoate) [CAS] 16846-24-5 JP 41021759 Macrolide antibiotic Infection, general 1, 4-Benzothiazepine, 2, 3, 4, 5-tetrahydro-7- methoxy-4- [I-oxo-3- [4- (phenyimethyl)-l- JTV-519 piperidinyl] propyl]- [CAS] 145903-06-6 WO 9212148 Cardiovascular infarction, myocardial Patent API Generic Name API Chemical Name CAS No. Reference Example of Therapeutic Use Example of Indication Infection, trypanosomiasis, K-777 US 6287840 Protozoacide American Kainic Acid 487-79-6 Kalimate Kalimate- [CAS] 92354-70-6 Urological Kallidin 342-10-9 Acetic acid (2, 6-diXodo-4-((2-methyi-3- KB-130015 benzofuranyl) methyl) phenoxy)- [CAS] 147030-48-6 Antiarrhythmic Arrhythmia, general Methanesulfonamide, N- [3-amino-4- [2- [ [2- (3, 4- dimethoxyphenyl) ethyl] methylamino] ethoxy] KCB-328 phenyl]-, monohydrochloride [CAS] 177596-55-3 WO 9604231 Antiarrhythmic Arrhythmia, general Kebuzone 853-34-9 2- (2-Chlorophenyl)-2- (methylamino)- cyclohexanone hydrochloride ketamine 6740-88-1 Formulation, transmucosal, nasal Pain, post-operative 2, 4 (1H, 3H)-Quinazolinedione, 3- [2- [4- (4- 74050-98-9 ketanserin fluorobenzoyl)-1-piperidinyl] ethyl]- [CAS] 83846-83-7 EP 13612 Antihypertensive, other Hypertension, general 4H- [1, 3] Oxazino [3, 2-d] [1, 4] benzodiazepine- 4, 7 (6H)-dione, 11-chloro-8, 12b-dihydro-2, 8- ketazolam dimethyl-12b-phenyl- [CAS] 27223-35-4 GB 1222294 Anxiolytic Kethoxal 27762-78-3 Ketobemidone Piperazine, 1-acetyl-4- [4- [ [2- (2, 4- dichlorophenyl)-2-(1 H-imidazol-1-yimethyl)- 1, 3-dioxolan-4-yl] methoxy] phenyl]-, cis- ketoconazole [CAS] 65277-42-1 US 4335125 Antifungal Infection, fungal, general mono (3-benzoyl-Alpha- ketoprofen methylbenzeneacetate) [CAS] 173011-11-5 EP 502502 Formulation, transdermal, systemic Pain, general 1 H-Pyrrolizine-1-carboxylic acid, 5-benzoyl-74103-06-3 ketorolac 2 ; 3-dihydro-, (+/-)- [CAS] 74103-07-4 EP 53021 Analgesic, NSAID Ketorolac Tromethamine 10-H-Benzo [4, 5] cyclohepta [1, 2-b] thiophen- 10-one, 4, 9-dihydro-4- (1-methyl-4- piperidinylidene)-, (E)-2-butenedioate (1 : 1)- 34580-13-7 ketotifen [CAS] 34580-14-8 GB 1355539 Antiasthma Asthma Khellin 82-02-0 Patent API Generic Name API Chemical Name CAS No. Reference Example of Therapeutic Use Example of Indication kinetin 9001-29-0 Dermatological Photodamage 4-Thiazolidinecarboxamide, N- (1, 1- dimethylethyl)-3- [2-hydroxy-3- [ [2- [ [ (5- isoquinolinyloxy) acetyl] amino]-3- (methylthio)-1-oxopropyi] amino]-1-oxo-4- phenylbutyl]-, [4R- [3 [2S*, 3S* (R*)], 4R*]]- KNI-272 [CAS] 147318-81-8 US 5644028 Antiviral, anti-HIV Infection, HIV/AIDS (R, R)-2- (2, 4-Difluorophenyl)-3- (4- methylenepiperidin-1-ytE1-(1, 2, 4-triazol-1- KP-103 yl)-2-butanol Antifungal Infection, general KP-157 US 6110961 Antidepressant Depression, general KP-544 WO 9919305 Cognition a Unspecified L-glycero-R-L-manno- Heptopyranosylamine, 4-deoxy-4-[[[[(2E, 4E) 1-oxo-2, 4- tetradecadienyl] amino] acetyl] amino]-N-1 H- KRN-5500 purin-6-yl- [CAS] 151276-95-8 WO 9015811 Anticancer, antibiotic Cancer, colarectal Aipha-D-Gtucopyranoside, ß-D- fructofuranosyi, mixt. with 1-ethenyl-2- pyrrolidinone homopolymer compd. with KT-136 iodine [CAS] 121602-88-8 Formulation, dermal, topical Ulcer, decubitus (-)-2- [ (2S)-1, 2, 3, 4-tetrahydro-2- [ [ (2R)-2- hydroxy-2- (4- hydroxphenyl) ethyl] amino] naphthalen-7- yloxy]-N, N-dimethylacetamide hydrochloride monohydrate KUL-7211 Urological Urinary calculus 6H-Pyrazolo [4, 5, 1-de] acridin-6-one, 5- [ (3- aminopropyl) amino]-7, 10-dihydroxy-2- [ [ (2- hydroxyethyl) amino] methyl]-, KW-2170 dihydrochloride [CAS] 207862-44-0 Anticancer, alkylating Cancer, lung, non-small cell 1H-Purine-2, 6-dione, 8- (2- (3, 4- dimethoxyphenyl) ethenyl)-1, 3-diethyl-3, 7- KW-6002 dihydro-7-methyl- (E)- [CAS] 155270-99-8 Antiparkinsonian Parkinson's disease Patent API Generic Name API Chemical Name CAS No. Reference Example of Therapeutic Use Example of Indication 3, 3, 3-Trifluoro-2-hydroxy-2-methyl-N- (10- oxo-4, 10-dihydrothieno [3, 2-C] [1] benzothiepin-9-yl) propanamide 5, 5 dioxide KW-7158 Urological Incontinence Urea, N- (2, 3-dihydro-1-methyl-2-oxo-5- phenyl-1 H-1, 4-benzodiazepin-3-yl)-N'- (3- L-365260 methylphenyl)-, (R)- [CAS] 118101-09-0 EP 284256 Anticancer, other Cancer, general L-5-hydroxytryptophan L-Tryptophan, 5-hydroxy- [CAS] 4350-09-8 Metabolic and enzyme disorders Unspecified Methanesulfonamide, N- [6- [ (2, 4- difluorophenyl) thio]-2, 3-dihydro-1-oxo-1 H- L-745337 inden-5-yl]- [CAS] 158205-05-1 WO 9413635 Analgesic, NSAID Pain, general Phosphonic acid, [3- [ [ (2R, 3S)-2-. (. (1 R)-1- [3, 5-bis (trifluoromethyl) phenyl] ethoxy]-3- (4- fluorophenyl)-4-morpholinyl] methyl]-2, 5- Chemotherapy-induced nausea L-758298 dihydro-5-oxo-1 H-1, 2, 4-triazol-1-yl]- [CAS] 172673-20-0 WO 9523798 Antiemetic and vomiting L-826141 WO 9722585 Antiasthma Unspecified 5- [1-hydroxy-2- [ (1-methyl-3- 32780-64-6 labetalol phenylpropyl) amino] ethyl] salicylamide HCI 36894-69-6 US 4012444 Antihypertensive, adrenergic 3, 5-Pyridinedicarboxyiic acid, 4- [2- [3- (1, 1- dimethylethoxy)-3-oxo-1-propenyl] phenyl]- 1, 4-dihydro-2, 6-dimethyl-, diethyl ester, (E)- lacidipine [CAS] 103890-78-4 GB 2164336 Antihypertensive, other Hypertension, general Lactic Acid D-Glucitol, 4-O-f3-D-galactopyranosyl- lactitoi [CAS] 585-86-4 Hepatoprotective Infection, neurological Lactulose 4618-18-2 Acetamide, 2- [ (2-furanylmethyl) sulfinyl]-N-14 [ [4- (1-piperidinylmethyl)-2-pyridinyl] oxy]-2- 118288-08-7 lafutidine butenyl]-, (Z- [CAS] 169899-19-8 EP 282077 Antiulcer Ulcer, gastric Lamifiban 144412-49-7 2 (1H)-Pyrimidinone, 4-amino-1-[2- (hydroxymethyl)-1, 3-oxathiolan-5-yl]-, (2R- lamivudine cis)- [CAS] 134678-17-4 EP 513917 Antiviral, anti-HIV Infection, HIV/AIDS Patent API Generic Name API Chemical Name CAS No. Reference Example of Therapeutic Use Example of Indication 1, 2, 4-Triazine-3, 5-diamine, 6- (2, 3- lamotrigine dichlorophenyl)- [CAS] 84057-84-1 EP 21121 Antiepileptic Epilepsy, partial (focal, local) Benzenepropanoic acid, 4-[2-hydroxy-3-[[2- [ (4- morpholinylcarbonyl) amino] ethyl] amino] pro poxy]-, (2, 2-dimethyl-1, 3-dioxolan-4- y) methyl ester, [S- (R*, R*)]- HCL landiolol 133242-30-5 EP 397031 Antiarrhythmic Tachycardia, general (S)-Alpha-phenyl-2-pyridine ethanamine lanicemine dihydrochloride 153322-05-5 Neurological Unspecified Methyl 6, 11-dihydro-11- [1- [2- [4- (-2- quinolylmethoxy) phenyl] ethyl]-4- piperidinylidene]-5H-imidazo [2, 1- b] [3] benzazepine-3-carboxylate laniquidar 197509-46-9 WO 9734897 Radio/chemosensitizer Cancer, general 1 H-Imidazole-1-acetonitrile, Alpha- [4- (2- chlorophenyl)-1, 3-dithiolan-2-ylidene]-, (E)- lanoconazole [CAS] 101530-10-3 US 4738976 Antifungi Infection, fungal, general Lanoteplase 171870-23-8 Lanreotide 108736-35-2 1 H-Benzimidazole, 2- [ [ [3-methyl-4- (2, 2, 2- trifluoroethoxy)-2-pyridyi] methyl] sulfinyi]- lansoprazole [CAS] 103577-45-3 EP 174726 Antiulcer Ulcer, duodenal Carbonic acid, lanthanum (3+) salt lanthanum carbonate (3 : 2) [CAS] 587-26-8 US 5968976 Urological Hyperphosphataemia 4-Quinazolinamine, N- [3-chloro-4- [ (3- fiuorobenzyl) methoxy phenyl]-6- [5- [ [ [2- [methylsulfonyl] ethyl] amino] methyl] furan-2- Yi] lapatinib 388082-78-8 Anticancer, other Cancer, breast laquinimod 248281-84-7 Multiple sclerosis treatment Multiple sclerosis, general 2-Naphthalenol, 5, 6, 7, 8-tetrahydro-6-phenyl 5- (4- (2- (1-pyrrolidinyl) ethoxy) phenyl- (5R- cis)-, (S- (R*, R*))-2, 3- lasofoxifene dihydroxybutanedioate [CAS] 190791-29-8 WO 9716434 Menopausal disorders Hormone replacementtherapy Patent API Generic Name API Chemical Name CAS No. Reference Example of Therapeutic Use Example of Indication 5-Oxa-1-azabicyclo [4. 2. 0] oct-2-ene-2- carboxylic acid, 7-[[carboxy (4- hydroxyphenyl) acetyl] amino]-7-methoxy-3- [[(1-methyl-1 H-tetrazol-5-yi) thio] methyl]-8-64952-97-2 latamoxef oxo- [CAS] 64953-12-4 GB 1547351 Beta-lactam antibiotic Infection, general 5-Heptenoic acid, 7- (3, 5-dihydroxy-2- (3- hydroxy-5-phenylpentyl) cyclopentyl)-, 1- methylethyl ester, (1R- latanoprost (1Alpha (Z), 211 (R*), 3Alpha, 5Alpha))- [CAS] 130209-82-4 WO 9002553 Prostaglandin Glaucoma Lauroguadine 135-43-3 Laurolinium Acetate 146-37-2 Lawsone 83-72-7 1- (Z, Z, Z, Z, Z-eicosa-5, 8, 11, 14, 17- pentaenoyloxy)-3- (Z, Z, Z, Z, Z-eicosa- LAX-111 5, 8, 11, 14, 17-pentaenoyloxy)-propane Neuroleptic Schizophrenia Lazabemide 103878-84-8 Benzenecarboximidic acid, 4- [ (2S)-3- (cyclopentylmethylamino)-2- [ (2- naphthalenylsulfonyl) amino]-3-oxopropyl]-, LB-30057 hydrazide [CAS] WO 9749673 Antithrombotic Thrombosis, venous L-Cystine Lefetamine 7262-75-1 4-Isoxazolecarboxamide, 5-methyl-N- [4- ieflunomide (trifluoromethyl) phenyl]-[CAS] 75706-12-6 EP 13376 Antiarthritic, immunological Arthritis, rheumatoid 4-Isoxazolecarboxamide, 5-methyl-N- [4- 104981-93-3 leflunomide (trifluoromethyl) phenyl]- [CAS] 75706-12-6 US 5610173 Anticancer, other Cancer, ovarian Leiopyrrole 5633-16-9 4-Thia-1-azabicyclo [3. 2. 0] heptane-2- carboxylic acid, 6- [(aminophenylacetyl) amino]-3, 3-dimethyl-7- oxo-, (5-methyl-2-oxo-1, 3-dioxol-4-yl) methyl 80734-02-7 lenampicillin ester, [2S-[2Alpha, 5Alpha, 6ß (S*)]]- [CAS] 86273-18-9 EP 61206 Penicillin, oral Infection, general lentinan Lentinan [CAS] 37339-90-5 Anticancer, immunological Cancer, stomach Lepirudin Patent API Generic Name API Chemical Name CAS No. Reference Example of Therapeutic Use Example of Indication 3, 5-Pyridinedicarboxylic acid, 1, 4-dihydro- 2, 6-dimethyl-4- (3-nitrophenyl)-, 2- [ (3, 3- diphenylpropyl) methylamino]-1, 1- dimethylethyl methyl ester-, hydrochloride 100427-26-7 lercanidipine [CAS] 132866-11-6 US 4705797 Antihypertensive, other Hypertension general 1 H-Benzimidazole, 1- (phenylmethyl)-2- (1- lerisetron piperazinyl)- [CAS] 143257-98-1 US 5256665 Antiemetic Nausea and vomiting, general Lesopitron 132449-46-8 Benzoic acid, 4- ( (3- (1, 6-dihydro-6-oxo-9H- purin-9-yi)-1-oxopropyl) amino)-, leteprinim monopotassium salt [CAS] 138117-50-7 US 6338963 Antiparkinsonian Parkinson's disease 4-Thiazolidinecarboxylic acid. 2-[2-[(2- letosteine ethoxy-2-oxoethyl) thio] ethyl]- [CAS] 53943-88-7 US 4032534 COPD treatment Bronchitis, chronic Benzonitrile, 4, 4'- (1H-1, 2, 4-triazol-1- letrozole ylmethylene) bis- [CAS] 112809-51-5 EP 236940 Anticancer, hormonal Cancer, breast Leucocyanidin 480-17-1 Leuprolide 53714-56-0 Luteinizing hormone-releasing factor (pig), 6-D-leucine-9- (N-ethyl-L-prolinamide)-10- 53714-56-0 leuprolide acetate deglycinamide-, monoacetate (salt) [CAS] 74381-53-6 Formulation, implant Cancer, prostate Luteinizing hormone-releasing factor (pig), 6-D-leucine-9- (N-ethyl-L-prolinamide)-10- leuprorelin deglycinamide- [CAS] 53714-56-0 Formulation, implant Cancer, prostate Levallorphan 152-02-3 Imidazo [2, 1-b] thiazole, 2, 3, 5, 6-tetrahydro-6- 14769-73-4 levamisole phenyl-, (S)- [CAS] 16595-80-5 US 4584305 Anthelmintic Infection, helminth, general Levcromakalim 94535-50-9 1-Pyrrolidineacetamide, Alpha-ethyl-2-oxo-, levetiracetam (S)- [CAS] 102767-28-2 EP 162036 Ant epileptic Epilepsy, general 2'Propanol, 1- (4- (2- (cyclopropyimethoxy) ethyl) phenoxy)-3-((1- levobetaxolol methylethyl) amino) hydrochloride [CAS] 116209-55-3 Formulation, mucosal, topical Glaucoma 1 (2H)-Naphthalenone, 5- [3- [ (1, 1- dimethylethyl) amino]-2-hydroxypropoxy]-3, 4- 27912-14-7 levobunolol dihydro-, (S)- [CAS] 47141-42-4 US 3641152 Formulation, mucosal, topical Glaucoma Patent API Generic Name API Chemical Name CAS No. Reference Example of Therapeutic Use Example of Indication 2-Piperidinecarboxamide, 1-butyl-N- (2, 6- levobupivacaine dimethylphenyl)-, (S)- [CAS] 27262-47-1 WO 9510276 Anaesthetic, injectable Anaesthesia 4-Piperidinecarboxylic acid, 1- [4-cyano-4- (4- 79449-98-2 fluorophenyl) cyclohexyl]-3-methyl-4-phenyl-, 79516-68-0 levocabastine [3S- [1 (cis), 3Alpha, 4ß]]- [CAS] 79547-78-7 US 4369184 Antiallergic, non-asthma Rhinitis, allergic, general Acetic acid, (2- (4- ( (4- chlorophenyl) phenylmethyl)-1- levocetirizine piperazinyi) ethoxy)-, (R)- [CAS] 130018-77-8 WO 9406429 Antiallergic, non-asthma Allergy, general Levodopa 59-92-7 1, 2-Propanediol, 3- (4-phenyl-l-piperazinyl)- levodropropizine, (S)- [CAS] 99291-25-5 EP 147847 Antitussive Cough l 7H-Pyrido [1, 2, 3-de]-1, 4-benzoxazine-6- carboxylic acid, 9-fluoro-2, 3-dihydro-3- methyl-1 0- (4-methyl-l-piperazinyl)-7-oxo-, 100986-85-4 levofloxacin (S)- [CAS] 138199-71-0 EP 206283 Quinolone antibacterial Infection, respiratory tract, lower Levomethadyl Acetate 1477-40-3 27058-84-0 2-Propanol, 1- (2-methoxyphenoxy)-3- [ (1- 5741-22-0 levomoprolol methylethyl) amino]-, (S)- [CAS] 77164-20-6 EP 15418 Antihypertensive, adrenergic 18, 19-Dinorpregn-4-en-20-yn-3-one, 13- levonorgestrel ethyl-17-hydroxy-, (17AIpha)- [CAS] 797-63-7 Formulation, implant Contraceptive, female Levophacetoperane 24558-01-8 Levopropoxyphene 2338-37-6 Levorphanol 77-07-6 Propanedinitrile, [ [4- (1, 4, 5, 6-tetrahydro-4- methyl-6-oxo-3-131741-08-7 levosimendan pyridazinyl) phenyl] hydrazono]-, (R)- [CAS] 141505-33-1 EP 383449 Cardiostimulant Heart failure Benzamide, 5- (aminosulfonyl)-N- [ (1-ethyl-2- levosulpiride pyrrolidinyl) methyi]-2-methoxy-, (S)-[CAS] 3672-07-3 GB 2014990 Antiemetic Dyspepsia Levothyroxine 1-fl-L-ribofuranosyl-1, 2, 4-triazole-3- carboxamide levovirin Antiviral, other Infection, hepatiUs-C virus Patent API Generic Name API Chemical Name CAS No. Reference Example of Therapeutic Use Example of Indication L-Leucine, N-methyl-N-14-[(2-methyl-1 H- imidazo [4, 5-c] pyridin-1- yl) methyl] phenyi] sulfonyl]-, ethyl ester- lexipafant [CAS] 139133-26-9 WO 9203423 Neurological Dementia, AIDS-related LF-15-0195 WO 9624579 Immunosuppressant Lupus erythematosus, general 2-Pyrrolidinecarboxamide, N- [3- [ [4- (aminoiminomethyl) benzoyl] amino] propyl]-1 [[2, 4-dichloro-3-[[(2, 4-dimethyl-8- quinolinyl) oxy] methyl] phenyl] sulfonyl]-, (2S)- LF-16-0687 [CAS] 209733-45-9 FR 2756562 Neuroprotective Head trauma 2, 4, 6-Octatrienoic acid, 7- (3, 5-bis (1, 1- dimethylethyl) phenyl)-3-methyl- (2E, 4E, 6E)- LGD-1550 [CAS] 178600-20-9 Anticancer, other Cancer, cervical LH 9002-67-9 LH-RH 9034-40-6 1H-Benzimidazole, 5- [ (3-chlorophenyl)-1H- 115575-11-6 liarozole imidazol-1-ylmethyl]- [CAS] Formulation, other Psoriasis 1 H-Pyrrolizine-5-acetic acid, 6- (4- chlorophenyl)-2, 3-dihydro-2, 2-dimethyl-7- licofelone phenyl- [CAS] 156897-06-2 Antiarthritic, other Arthritis, osteo Licostinel 153504-81-5 Phosphonic acid, [1-amino-3- lidadronate (dimethylamino) propylidene] bis- [CAS] 63132-38-7 WO 9702827 Urological Unspecified Lidamidine 66871-56-5 Acetamide, 2- (diethylamino)-N- (2, 6- lidocaine dimethylphenyl)- [CAS] 137-58-6 Formulation, transdermal, patch Pain, post-herpetic Lidofenin 59160-29-1 Lidoflazine 3416-26-0 Prosta-2, 13-dien-1-oicacid, 11, 15- dihydroxy-17, 20-dimethyl-9-oxo- limaprost, (2E, 11 Alpha, 13E, 15S, 17S)-, [CAS] 74397-12-9 GB 2041368 Prostaglandin Buerger's syndrome Lincomycin 154-21-2 Lindane 58-89-9 Acetamide, N- ( (3- (3-fluoro-4- (4- morpholinyl) phenyl)-2-oxo-5- linezoiid oxazolidinyl) methyl)-, (S)- [CAS] 165800-03-3 WO 9507271 Antibiotic, other Infection, dermatological Patent API Generic Name API Chemical Name CAS No. Reference Example of Therapeutic Use Example of Indication LinoleicAcid 60-33-3 Linolenic Acid 463-40-1 Liothyronine 6893023 Lipase 9001-62-1 Pregna-1, 4-diene-3, 20-dione, 9-fluor- 11, 17-dihydroxy-16-methyl-21-[(1- Lipo-dexamethasone palmitate oxohexadecyl) oxy]-, (1113, 16Alpha)- [CAS] 14899-36-6 Formulation, optimized, microemulsion Arthritis, rheumatoid [1, 1'-Biphenyl]-4-acefic acid, 2-fluoro-Alpha- lipo-flurbiprofen methyl-, 1- (acetyloxy) ethyl ester [CAS] 91503-79-6 JP 60208910 Formulation, optimized, microemulsion Pain, cancer Lipogel HA EP 525655 Formulation, optimized, Iiposomes Unspecified Respiratory distress syndrome, LiquiVent perfluorooctylbromide 423-55-2 US 5437272 Lung Surfactant adult Carbamothioic acid, (6-methoxy-2- pyridinyl) methyl-, 0- (5, 6, 7, 8-tetrahydro-2- liranaftate naphthalenyl) ester [CAS] 88678-31-3 GB 2124617 Antifungal Infection, dermatological L-Proline, 1- [N2- (1-carboxy-3-phenylpropyl)- 76547-98-3 lisinopril L-lysyl]-, (S)- [CAS] 83915-83-7 EP 12401 Antihypertensive, renin system Hypertension, general Lisofylline 100324-81-0 19875-60-6 Urea, N'- [ (8Afpha)-9, 10-didehydro-6- 305-13-5 iisuride methylergolin-8-yi]-N, N-diethyi-, [CAS] 18016-80-3 Antiprolactin Acromegaly Lithium Citrate 919-16-4 lithium Carbonic acid, dilithium salt [CAS] 554-13-2 Formulation, modified-release, <=24hr Depression, bipolar l Benzamide, N- [3-chloro-4- (5H-pyrrolo [2, 1- c] [1, 4] benzodiazepin-10 (11 H)- lixivaptan ylcarbonyl) phenyl]-5-fluoro-2-methyl- [CAS] 168079-32-1 US 5736540 Cardiovascular Heart failure LJP-1082 US 6207160 Immunosuppressant Thrombosis, venous S-2, 7, 8-Trimethyl-6- (Il-carboxyethyl)-6- hydroxychroman LLUAlpha Antihypertensive, other Hypertension, general LMP-160 US 5643893 Antiasthma Asthma LMP-420 US 5643893 Antiarthritic, other Arthritis, rheumatoid Patent API Generic Name API Chemical Name CAS No. Reference Example of Therapeutic Use Example of Indication Platinum, (1, 2-cyclobutanedimethanamine- N, N') [2-hydroxypropanoato (2-)-01, 02]-, [SP lobaplatin 4-3- (S), (trans)]- [CAS] 135558-11-1 DE 4115559 Anticancer, alkylating Cancer, lung, small cell Lobeline 90-69-7 Lobenzarit 63329-53-3 2, 2'- ( (2-chloro-5-cyano-1, 3- phenylene) diimino) bis (2-oxoacetate) : 2- amino-2- (hydroxymethyl)-1, 3-propanediol 63610-09-3 lodoxamide (1 : 2) 53882-12-5 US 4439445 Antiasthma Asthma Lofentanil 61380-40-3 Ethanone, 1- (4-chlorophenyl)-2- [ [3- (10, 11- dihydro-5H-dibenz [b, fRazepin-5-23047-25-8 lofepramine yl) propyl] methylamino]- [CAS] 26786-32-3 GB 1177525 Antidepressant 1 H-Imidazole, 2- (1- (2, 6- lofexidine dichlorophenoxy) ethyl]-4, 5-dihydro- [CAS] 31036-80-3 GB 1181356 Antihypertensive, adrenergic Hypertension, general Loflucarban 790-69-2 3-Quinolinecarboxylic acid, 1-ethyl-6, 8- difluoro-1, 4-dihydro-7- (3-methyl-1- 98079-51-7 lomefloxacin piperazinyl)-4-oxo- [CAS] 98079-52-8 EP 140116 Quinone antibacterial lnfecfion, respiratory tract, lower Piperazine, 1-[bis (4-fluorophenyi) methyl]-4-101477-54-7 lomerizine [ (2, 3, 4-trimethoxyphenyl) methyl]-, [CAS] 101477-55-8 EP 159566 Antimigraine Migraine lomifylline 7- (5-oxohexyl) theophylline 10226-54-7 DE 2207860 Neurological Urea, N- (2-chloroethyl)-N'-cyclohexyl-N- lomustine nitroso- [CAS] 13010-47-4 JP 48075526 Anticancer, alkylating 1-Piperidinecarboxamide, 4- [2- [4- [ (11R)- 3, 10-dibromo-8-chloro-6, 11-dihydro-5H- benzo [5, 6] cyclohepta [1, 2-b] pyridin-11-yl]-1- lonafarnib piperidinyl]-2-oxcethyl]- [CAS] 193275-84-2 US 5874442 Anticancer, other Cancer, lung, non-small cell Lonapalene 91431-42-4 Lonazolac 53808-88-1 1 H-indazole-3-carboxylic acid, 1-[(2, 4-_ lonidamine dichlorophenyl) methyl]- [CAS] 50264-69-2 DE 2310031 Radio/chemosensitizer Cancer, breast 4- (p-chlorophenyl)-4-hydroxy-N, N-dimethyl- Alpha, Alpha-diphenyl-1-piperidine 34552-83-5 loperamide butyramide HCI 53179-11-6 US 3714159 Antidiarrhoeal Diarrhoea, general Patent API Generic Name API Chemical Name CAS No. Reference Example of Therapeutic Use Example of Indication 1-Piperidinebutanamide, 4- (4-chlorophenyl) 4-hydroxy-N, N-dimethyl-Alpha, Alpha- loperamide oxide diphenyl-, 1-oxide, trans- [CAS] 106900-12-3 EP 219898 Antidiarrhoeal Diarrhoea, general 1 H-lmidazo [1, 2-a] [1, 4] benzodiazepin-1-one, 61197-73-7 6- (2-chlorophenyl)-2, 4-dihydro-2- [ (4-methyl- 61197-93-1 loprazolam 1-piperazinyl) methylene]-8-nitro- [CAS] 70111-54-5 GB 1496426 Hypnotic/Sedative Loprinone 106730-54-5 1-Azabicyclo [4. 2. 0] oct-2-ene-2-carboxylic acid, 7- [ (aminophenylacetyl) amino]-3-chloro 76470-66-1 loracarbef 8-oxo- [6R-[6Aipha 7ß (R*)]]- [CAS] 121961-22-6 EP 14475 Cephalosporin, oral Infection, respiratory tract, lower Lorajmine 47562-08-3 1-Piperidinecarboxylic acid, 4- (8-chloro-5, 6- dihydro-11 H-benzo [5, 6] cyclohepta [1, 2- loratadine b] pyridin-11-ylidene)-, ethyl ester- [CAS] 79794-75-5 EP 42544 Antiallergic, non-asthma Rhinitis, allergic, general 2H-1, 4-Benzodiazepin-2-one, 7-chloro-5- (2- lorazepam chlorophenyl)-1, 3-dihydro-3-hydroxy- 846-49-1 Formulation, oral, orally-disintegrating Epilepsy, general Benzeneacetamide, N- (4-chlorophenylrN- 58934-46-6 lorcainide [1- (1-methylethyl)-4-piperidinyl]- [CAS] 59729-31-6 DE 2642856 Antiarrhythmic 2H-1, 4-Benzodiazepin-2-one, 7-chloro-5- (2- chlorophenyl)-1, 3-dihydro-3-hydroxy-1- lormetazepam methyl- [CAS] 848-75-9 US 3296249 Hypnotic/Sedative Insomnia 2H-Thieno [2, 3-e]-1, 2-thiazine-3- carboxamide, 6-chloro-4-hydroxy-2-methyl- lornoxicam N-2-pyridinyl-, 1, 1-dioxide- [CAS] 70374-39-9 EP 313935 Analgesic, NSAID Pain, post-operative 1H-Imidazole-5-methanol, 2-butyl-4-chloro- 1- [ [2'- (1H-tetrazol-5-yl) [1, 1'-biphenyl]-4- 124750-99-8 losartan yl] methyl]-, [CAS] 114798-26-4 EP 253310 Antihypertensive, renin system Hypertension, general Androsta-1, 4-diene-17-carboxylicacid, 17- [(ethoxycarbonyl) oxy]-11-hydroxy-3-oxo-, loteprednol chloromethyl ester, (11f3, 17Alpha)- [CAS] 82034-46-6 GB 2079755 Anti-inflammatory, topical Uveitis Patent API Generic Name API Chemical Name CAS No. Reference Example of Therapeutic Use Example of Indication Lotrafiban 171049-14-2 Lovastatin 75330-75-5 Loxapine 10/02/1977 Pentanoic acid, 4- [ (3, 4- dichlorobenzoyl) amino]-5- [ (3- methoxypropyl) pentylamino]-5-oxo-, foxiglumide [CAS] 107097-80-3 WO 8703869 G inflammatory/bowel disorders Pancreatitis 68767-14-6 Benzeneacetic acid, Alpha-methyl-4- [ (2- 80382-23-6 loxoprofen oxocyclopentyl) methyl]- [CAS] 87828-36-2 EP 55588 Antiarthritic, other Arthritis, rheumatoid 1-p [ [2- [5-chloro-i- (4-fluorophenyl)-3-lH- indolyl] ethyl] methylamino] propyl]-2- Lu-35-138 imidazolidinone hydrochloride WO 9516684 Neuroleptic Psychosis, general Lubeluzole 144665-07-6 (-)-7- [ (2R, 4aR, 5R, 7aR)-2- (1, 1- difluoropentyl)-2-hydroxy-6- oxooctahydrocyclopenta [b] pyran-5- yl] heptanoic acid lubiprostone 136790-76-6 Laxative Constipation Thioxanthen-9-one, 1- ( (2- lucanthone (diethylamino) ethyl) amino-4-methyl- [CAS] 479-50-5 Radio/chemosensitizer Cancer, brain Lucanthone 548-57-2 Lumefantrine 82186-77-4 Benzeneacetic acid, 2-((2-chloro-6- lumiracoxib fluorophenyl) amino)-5-methyl- [CAS] 220991-20-8 Analgesic, NSAID Pain, general 11 H-1, 4-Dioxino [2, 3- g] pyrano [3', 4' : 67iindolizino [12-b] quinoline 9, 12 [8H, 14H]-dione, 8-ethyl-2, 3-dihydro-8- hydroxy-15- [ [4-methyl-l-piperazinyllmethyq- lurtotecan [CAS] 155773-58-3 Formulation, optimized, liposoms Cancer, ovarian Lutetium, bis (acetato-O) [9, 10-diethyl-20, 21- bis- [2- [2- (2-methoxyethoxy) ethoxy] ethoxy]- 15-dimethyi-8, 11-imino-3, 6 : 16, 13-dinitrilo- 1, 18-benzodiazacycloeicosine-5, 14- dipropanolato-N1, N18, N23, N24, N25]-, (PB- iutetium texaphyrin 7-11-233 2 4)- [CAS] 156436-90-7 WO 9906411 Radiolchemosensitizer Atherosclerosis Patent API Generic Name API Chemical Name CAS No. Reference Example of Therapeutic Use Example of Indication LV-216 Zinc [2-(2, 6-dichloroanilino) phenyi] acetate Anti-inflammatory Arthritis, rheumatoid Hexadecanamide, N- [4- [ [2- [2- [2- [ [O- (N- acetyl-Alpha-neuraminosyl)- (2-3)-O-f5-D- galactopyranosyl- (1-4)-O- [6-deoxy-Alpha-L- galactopyranosyi-(1-3)]-ß-D- glucopyranosyl] oxy] ethoxy] ethoxy] ethoxy] m LX-104 ethyl] phenyl]-2-tetradecyl- [CAS] 158792-45-1 Cognition enhancer Dementia, senile, general LY-156735 ß-methyl-6-chloromeiatonin EP 655243 Hypnotic/Sedative Sleep disorder, general Benzoic acid, 2- [3- [3- [ (5-ethyl-4'-fluoro-2- hydroxy [1, 1'-biphenyl]-4-yl) oxy] propoxy]-2- LY-293111 propylphenoxy]- [CAS] 161172-51-6 Anticancer, other Cancer, melanoma 3-Isoquinolinecarboxylic acid, decahydro-6- [2- (1H-tetrazol-5-yl) ethyl]-, [3S- LY-293558 (3Alpha., 4aAlpha, 6i3, 8aAipha.)]- [CAS] 154652-83-2 Analgesic, other Pain, neuropathic 1, 4-Dioxa-8, 11-diazacyclohexadec-13-ene- 2, 5, 9, 12-tetrone, 10- [ (3-chloro-4- methoxyphenyl) methyl]-6, 6-dimethyl-3- (2- methylpropyl)-16- [ (lS)-I- [ (2S, 3R)-3- phenyloxiranyl] ethyl]-, (3S, 10R, 13E, 16S)- LY-355703 [CAS] 18256-67-7 WO 9707798 Anticancer, other Cancer, lung, non-small cell Lyapolate 25053-27-4 Lymecycline 992-21-2 Lynestrenol 52-76-6 Lypressin 50-57-7 Lysine Acetylsalicylate 62952-06-1 lysine salicylate L-Lysine, 2-hydroxybenzoate [CAS] 59535-08-9 WO 9624331 Analgesic, NSAID l l Iysophospholipids WO 9843093 Diagnostic Diagnosis, cancer Patent API Generic Name API Chemical Name CAS No. Reference Example of Therapeutic Use Example of Indication Dichloro [(4aR, 13aR, 17aR, 21aR)- 1, 2, 3, 4, 4a, 5, 6, 12, 13, 13a, 14, 15, 16, 17, 17a, 1 8, 19, 20, 21, 21 a-eicosahydro-1, 7-nitrilo-7H- dibenzo [b, h] [1, 4, 7, 10] tetraazacyclo- heptadecine- kappaN5, kappaN 13, kappaN 18, kappaN21, k appaN22] manganese M-40403 US 6180620 Anticancer, other Unspecified Benzeneacetamide, N- (2-hydroxyethyl)- Alpha-methyl-4- (2-methylpropyl)-, (+/-)- mabuprofen [CAS] 82821-47-4 DE 3121595 Anti-inflammatory Mabuterol 56341-08-3 Macrophage Colony-Stimulating 81627-83-0 Factor MADU 840-50-6 Benzenesulfonamide, 4- (aminomethyl)- 13009-99-9 mafenide monoacetate [CAS] 138-39-6 Vulnerary Burns Ethanesulfonic acid, 2- [ [2- [bis (2- chloroethyl) amino] tetrahydro-2H-1, 3, 2- oxazaphosphorin-4-yl] thio]-, P-oxide, cis-(+) 88859-04-5 mafosfamide [CAS] 98845-64-8 EP 393575 Anticancer, alkylating Cancer, renal Aluminum magnesium hydroxide sulfate magaldrate (A ! 5Mg10 (OH) 31 (S04) 2), hydrate [CAS] 74978-16-8 US 2923660 Antacid/Antiflatulent Magenta I 632-99-5 Magnesium Acetylsalicylate 132-49-0 Magnesium Carbonate 39409-82-0 Hydroxide magnesium chloride Magnesium chloride (MgCl2) [CAS] 7786-30-3 Formulation, oral, enteric-coated Nutrition Magnesium Citrate 3344-18-1 D-Gluconic acid, magnesium salt (2 : 1) magnesium gluconate [CAS] 3632-91-5 Formulation, other Hypertension, general Magnesium Lactate 18917-93-6 Magnesium Salicylate 18917-89-0 Malathion 121-75-5 Malotilate 59937-28-9 Mandelic Acid 90-64-2 Patent API Generic Name API Chemical Name CAS No. Reference Example of Therapeutic Use Example of Indication MandelicAcid isoamyl Ester 5421045 Mangafodipir 118248-94-5 (free acid) ; 155319-91-8 (hexahydrogen) 3, 5-Pyridinedicarboxylic acid, 1, 4-dihydro- 2, 6-dimethyl-4- (3-nitrophenyl)-, 2- [4- (diphenylmethyl)-1-piperazinyl] ethyl methyl 89226-50-6 manidipine ester [CAS] 89226-75-5 EP 94159 Antihypertensive, other Hypertension, general Mannomustine 551-74-6 mannose-6-phosphate mannose-6-phosphate Vulnerary Wound healing Maprotiline 10262-69-8 1H-Benzimidazol-2-amine, 5, 6-dichloro-N- maribavir (1-methylethyl)-1-ß-L-ribofuranosyi- [CAS] 176161-24-3 Antiviral, other Infection, cytomegaiovirus N- [2, 2-Dimethyl-I (S)- (N- methylcarbamoyl) propyl]-N, 3 (S)-dihydroxy- marimastat 2 (R)-isobutylsuccinamide 154039-60-8 WO 9402447 Anticancer, other Cancer, pancreatic 1, 3-Cyclohexanediol, 4-methylene-5- (2- (octahydro-1- (1- (3-hydroxy-3- methylbutoxy) ethyl)-7a-methyl-4H-inden-4- ylidene) ethylidene)-, (1S- (1Aipha (R*), 3aR, 4E (1S*, 3R*, 5Z), 7aAipha))- maxacalcitol [CAS] 103909-75-7 US 4891364 Hormone Hyperparathyroidism 3H-Imidazo [2, 1-a] isoindol-5-ol, 5-(4- mazindol chlorophenyl)-2, 5-dihydro- [CAS] 22232-71-9 US 3763178 Anorectic/Antiobesity Obesity Mazipredone 13085-08-0 MC-5723 US 6043259 Cardiovascular Unspecified (2-amino-6- (4-methoxyphenylthio)-9- [2- (phosphonomethoxy) ethyl] purine bis (2, 2, 2- trifluoroethyl) ester) MCC-478 Antiviral, other Infection, hepatitis-B virus 3 (2H)-Pyridazinone, 4, 5-dihydro-6- [4- (4- pyridinylamino) phenyl]-, monohydrochloride 98326-32-0 MCI-154 [CAS] 98326-33-1 EP 145019 Cardiostimulant Heart failure m-Cresyl Acetate 122-46-3 i Patent API Generic Name API Chemical Name CAS No. Reference Example of Therapeutic Use Example of Indication Gamma-Methylene-10-deazaaminopterin MDAM Anticancer, antimetabolite Cancer, general MDI-101 US 4885311 Antiacne Acne MDI-403 403849-94-5 US 4677120 Antiacne Acne 4-Piperidinemethanol, Aipha-(2, 3- dimethoxyphenyl)-1- (2- (4- MDL-100907 fluorophenyl) ethyl)-, (R)- [CAS] 139290-65-6 Hypnotic/Sedative Sleep disorder, general methyl-5-benzoylbenzimidazole-2- mebendazole carbamate 31431-39-7 GB 1307306 Anthelmintic Benzoic acid, 3, 4-dimethoxy-, 4- [ethyl [2- (4- Benzoic acid, 3, 4-dimethoxy-, 4-[ethyi [2-(4- methoxyphenyl)-1-methylethyl] amino] butyl mebeverine ester [CAS] 3625-06-7 Antispasmodic Irritable bowel syndrome Mebhydroline 524-81-2 Mebrofenin 78266-06-5 Mebutamate 64-55-1 Bicyclo (2. 2. 1) heptan-2-amine, N, 2, 3, 3- mecamylamine tetramethyl- [CAS] 60-40-2 Neurological Unspecified Mechlorethamine 51-75-2 Mechlorethamine Oxide 302-70-5 4-Thia-1-azabicyclo [3. 2. 0] heptane-2- carboxylic acid, 6-[[(hexahydro-1H-azepin-1 yl) methylene] amino]-3, 3-dimethyi-7-oxo-, 32887-01-7 mecillinam [2S- (2Alpha, 5Alpha, 6. beta.)]- [CAS] 32887-03-9 GB 1293590 Penicillin, injectable Infection, general Meclizine 569-65-3 Medocycline 2013-58-3 Benzoic acid, 2-[(2, 6-dichloro-3- methylphenyl) amino]-, monosodium salt 6385-02-0 medofenamate [CAS] 644-62-2 Antiarthritic, other Arthritis, osteo Meclofenamic Acid 644-62-2 Medofenoxate 51-68-3 Mecloqualone 340-57-8 Mecysteine 18598-63-5 Medazepam 12/06/2898 Ethanamine, N, N-dimethyl-2, 2-diphenoxy- medifoxamine [CAS] 32359-34-5 FR M5498 Antidepressant Patent API Generic Name API Chemical Name CAS No. Reference Example of Therapeutic Use Example of Indication Medrogestone 977-79-7 Medronic Acid 1984-15-2 Pregn-4-ene-3, 20-dione, 17- (acetyloxy)-6- methyl-, (6Alpha) 71-58-9 medroxyprogesterone 520-85-4 Formulation, fixed-dose combinations Contraceptive, female Medrysone 2668-66-8 Mefenamic Acid 61-68-7 Mefenorex 17243-57-1 Mefexamide 1227-61-8 51773-92-3 4-Quinolinemethanol, Alpha-2-piperidinyi-53230-10-7 mefloquine 2, 8-bis (trifluoromethyl)-, (R*, S*)- ()- [CAS] 69191-18-0 GB 1594282 Antimalarial Mefruside 7195-27-9 Megestrol 595-33-5 Megestrol 595-33-5 Meglumine 22154-43-4 131- 49-7 2-hydroxy-2-methyl-1, 3-propandicarboxylic meglutol acid 503-49-1 US 3629449 Hypolipaemic/Antiatherosclerosis Hyperlipidaemia, general Glycine, N-1 (1R)-2-[(2S)-2-[[[[4- (aminoiminomethyl) phenyl] methyqamino] car bonyl]-1-azetidinyl]-1-cyclohexyl-2-oxoethyl]- melagatran [CAS] 159776-70-2 WO 9616671 Antithrombotic Thrombosis, general N- [ (3R)-1, 2, 3, 4-Tetrahydroisoquinolinium-3- ylcarbonyl]- (1 R)-1- (4-chlorobenzyl)-2- [4- cyclohexyl-4- (1 H-1, 2, 4-triazol-1- ylmethyl) piperidin-1-yl]-2-oxoethylamine (1) melanocortin-4 agonist Anorectic/Antiobesity Obesity Melarsoprol 494-79-1 Melengestrol 5633-18-1 Alanine, 3- (3, 4-dihydroxyphenyl)- melevodopa methylester [CAS] 7101-51-1 EP 252290 Antiparkinsonian Parkinson's disease Melinamide 14417-88-0 Melitracen 5118-29-6 Patent API Generic Name API Chemical Name CAS No. Reference Example of Therapeutic Use Example of Indication 2H-1, 2-Benzothiazine-3-carboxamide, 4- hydroxy-2-methyl-N- (5-methyl-2-thiazolyl)-, meloxicam 1, 1-dioxide- [CAS] 71125-38-7 US 4233299 Antiarthritic, other Arthritis, rheumatoid 1-Butanone, 1- (4-fluorophenyl)-4- (4-methyl- 1622-79-3 melperone 1-piperidinyl)- [CAS] 3575-80-2 BE 651144 Neuroleptic Melphalan 148-82-3 Benzenemethanol, 2-chloro-Alpha- ( ( (1, 1- dimethylethyl) amino) methyi)-4-hydroxy-, (R) , (R*, R*))-2, 3-dihydroxybutanedioate (1 : 1) meluadrine (salt) [CAS] 134865-37-5 EP 420120 Labour inhibitor Labour, preterm Tricyclo [3. 3. 1. 13, 7] decan-1-amine, 3, 5-41100-52-1 memantine dimethyl [CAS] 19982-08-2 EP 392059 Cognition enhancer Dementia, AIDS-related Acetamide, 2-[[[(5R, 6S)-6-[(1R)-1- hydroxyethyl]-2-methyi-7-oxo-4-thia-1- azabicyclo [3. 2. 0] hept-2-en-3- MEN-10700 yl] methyl] methylamino]- [CAS] 195874-55-6 WO 9406803 Beta-lactam antibiotic Infection, general 5, 12-Naphthacenedione, 7- [ [4-0- (3-amino- 2, 3, 6-trideoxy-Alpha-L-lyxo-hexopyranosyl)- 2, 6-dideoxy-Alpha-L-lyxo- hexopyranosyl] oxy]-7, 8, 9, 10-tetrahydro- 6, 9, 11-trihydroxy-9-(hydroxyacetyl)-, MEN-10755 hydrochloride, (7S, 9S)- [CAS] 169317-77-5 WO 9509173 Anticancer, antibiotic Cancer, breast Menadiol 481-85-6 Menadione 58-27-5 Menadoxime 573-01-3 Menbutone 3562-99-0 Menogaril 71628-96-1 7Aipha-Methyl-19-nortestosterone MENT Formulation, transdermal, systemic Contraceptive, male Cyclohexanol, 5-methyl-2- (1-methlethyl)- 1490-04-6 menthol [CAS] 89-78-1 Formulation, dermal, topical Pruritus Menthyl Valerate 89-47-4 Meobentine 46464-11-3 Meparfynol 77-75-8 mepartricin Partricin, methyl ester [CAS] 11121-32-7 US 3780173 Antifungal Infection, Candida, general Patent API Generic Name API Chemical Name CAS No. Reference Example of Therapeutic Use Example of Indication Mepazine 60-89-9 Mepenzolate Bromide 76-90-4 Meperidine 57-42-1 Mephenesin 59-47-2 Mephenoxalone 70-07-5 Mephentermine 100-92-5 Mephenytoin 50-12-4 Mephobarbital 115-38-8 Mepindolol 23694-81-7 Mepitiostane 21362-69-6 N-(2, 6-Dimethylphenyl)-1-methyl-2-96-88-8 piperidinecarboxamide mepivacaine Formulation, modified-release, >24hr Pain, post-operative Mepixanox 17854-59-0 Meprednisone 1247-42-3 Meprobamate 57-53-4 Bufa-4, 20, 22-trienolide, 3-[(6-deoxy-4-O- methyl-Aipha-L-mannopyranosyl) oxy]-14- meproscillarin hydroxy-, (3ß)- [CAS] 33396-37-1 DE 1910207 Cardiostimulant Heart failure Phenol, 3- (3-ethylhexahydro-1-methyl-1 H-54340-58-8 meptazinol azepin-3-ylf [CAS] 59263-76-2 GB 1285025 Analgesic, other Pain, general 10H-Phenothiazine, 10- (1- mequitazine azabicyclo [2. 2. 2] oct-3-ylmethyl)- [CAS] 29216-28-2 GB 1250534 Antiallergic, non-asthma Meralein 4386-35-0 Meralluride 8069-64-5 Merbromin 129-16-8 Mercaptomerin 21259-76-7 Mercumallylic Acid 86-36-2 Mercuric Chloride, Ammoniated 10124-48-8 Mercuric Oleate 1191-80-6 Mercuric Oxycyanide 1335-31-5 Patent API Generic Name API Chemical Name CAS No. Reference Example of Therapeutic Use Example of Indication Carbamic acid, ( (3- ( ( ( (3-methoxy-4- (5- oxazolyl) phenyl) amino) carbonyl) amino) phe nyl) methyl)- (3S)-tetrahydro-3-furanyi ester menmepodfb [CAS] 198821-22-6 US 5807876 Antiviral, other Infection, hepatitis-C virus 1-Azabicyclo [3. 2. 0] hept-2-ene-2-carboxylic acid, 3- [ [5- [ (dimethylamino) carbonyl]-3- pyrrolidinyl] thio]-6- (1-hydroxyethyl)-4-methyl 7-oxo-, [4R-[3 (3S*, 5S*), 4Alpha, 5ß, 6ß (R*)]]- meropenem [CAS] 96036-03-2 EP 126587 Beta-lactam antibiotic Infection, respiratory tract, lower Mersalyl 492-18-2 Mesalamine 89-57-6 mesalazine Benzoic acid, 5-amino-2-hydroxy- [CAS] 89-57-6 WO 5541170 Formulation, oral, other Colitis, ulcerative Mesna 19767-45-4 Mesoridazine 5588-33-0 Mestanolone 521-11-9 Mesterolone 1424-00-6 Mestranol 72-33-3 Mesuffen 135-58-0 Metaclazepam 84031-17-4 Metampicillin 6489-97-0 Metapramine 21730-16-5 Metaproterenol 586-06-1 Metaraminof 54-49-9 Metazocine 3734-52-9 17692-51-2 Carbamic acid, [ [ (8f5)-1, 6-dimethylergolin-8- 21631-37-8 metergoline yl] methyl]-, phenylmethyl ester [CAS] 2706-42-5 GB 1401935 Antiprolactin Amenorrhoea Imidodicarbonimidic diamide, N, N-dimethyl- metformin [CAS] 657-24-9 Formulation, modified-release, <=24hr Diabetes, Type II Methacholine 62-51-1 Methacycline 914-00-1 Methadone 76-99-3 Methafurylene 531-06-6 Methamphetamine 537-46-2 Patent API Generic Name API Chemical Name CAS No. Reference Example of Therapeutic Use Example of Indication Methandriol 521-10-8 Methandrostenolone 72-63-9 Methantheline 53-46-3 Methapyrilene 91-80-5 Methaqualone 72-44-6 Metharbital 50-11-3 Methazolamide 554-57-4 Methdilazine 1982-37-2 Methenamine 100-97-0 Methenolone 153-00-4 Methestrol 130-73-4 Methetoin 5696-06-0 Methicillin 132-92-3 Methimazole 60-56-0 Methiodal 126-31-8 Methionic Acid 503-40-2 Methionine 63-68-3 Methisazone 1910-68-5 Methitural 467-43-6 Methixene 02/02/4969 Methocarbamol 532-03-6 Methohexital 22151-68-4 L-Glutamic acid, N- [4- [ [ (2, 4-diamino-6- pteridinyl) methyi] methylamino] benzoyl]- methotrexate [CAS] 59-05-2 US 2512572 Anticancer, antimetabolite Cancer, general Methotrimeprazine 60-99-1 Methoxamine 390-28-3 Methoxsalen 298-81-7 Methoxyflurane 76-38-0 Methoxyphenamine 93-30-1 Methoxypromazine 61-01-8 Methscopolamine 155-41-9 Methsuximide 77-41-8 Methyciothiazide-35-07-9 = i Patent API Generic Name API Chemical Name CAS No. Reference Example of Therapeutic Use Example of Indication Methyl Blue 28983-564 Methyl Nicotinate 93-60-7 Methyl Propyl Ether 557-17-5 Methyl Salicylate 119-36-8 Methyl tert-Butyl Ether 1634-04-4 Methyibenzethonium Chloride 25155-18-4 Methylcobalamin 13422-55-4 methyidopa L-Tyrosine, 3-hydroxy-Alpha-methyl- [CAS] 555-30-6 Formulation, modified-release, <=24hr Hypertension, general Methylene Blue 61-73-4 Methylergonovine 113-42-8 Methylhexaneamine 105-41-9 2-Piperidineacetic acid, Alpha-phenyl-, 113-45-1 methylphenidate methyl ester [CAS] 298-59-9 Formulation, modified-release, multi Attention deficit disorder Methylprednisolone 83-43-2 Pregna-1, 4-diene-3, 20-dione, 21- (acetyloxy)-11-hydroxy-6-methyl-17- (1- methylprednisolone aceponate oxopropoxy)-, (6Alpha, 11ß)- [CAS] 86401-95-8 EP 72547 Antipruritic/inflamm, allergic Pruritus Pregna-1, 4-diene-3, 20-dione, 11, 17- dihydroxy-6-methyl-21- [ [8- [methyl (2- sulfoethyl) amino]-1, 8-dioxooctyi] oxy]-, methylprednisolone suleptanate monosodium salt, (6Alpha, 11 ß)- [CAS] 90350-40-6 JP 59137500 Antiasthma Asthma Methylthiouracil 56-04-2 Methyltrienolone 965-93-5 Methyprylon 125-64-4 Methysergide 361-37-5 Metiazinic Acid 13993-65-2 Phenol, 4- [2-hydroxy-3- [ (1- methylethyl) amino] propoxy]-2, 3, 6-trimethyi-, metipranolol 1-acetate [CAS] 22664-55-7 GB 1206148 Antihypertensive, adrenergic Benzamide, 4-amino-5-chloro-N- [2- metoclopramide (diethylamino) ethyl]-2-methoxy- [CAS] 364-62-5 Formulation, modified-release, <=24hr Gastro-oesophageal reflux Metocurine lodide 7601-55-0 Metofenazate 388-51-2 ! Patent API Generic Name API Chemical Name CAS No. Reference Example of Therapeutic Use Example of Indication 6-Quinazolinesulfonamide, 7-chloro-1, 2, 3, 4- tetrahydro-2-methyl-3- (2-methylphenyl)-4- metolazone oxo- [CAS] 17560-51-9 US 4517179 Antihypertensive, diuretic Metopimazine 14008-44-7 Metopon 143-52-2 51384-51-1 2-Propanol, 1- [4- (2-methoxyethyl) phenoxy]- 56392-17-7 metoprolol 3- [ (1-methylethyi) amino]-, (+/-)- [CAS] 37350-58-6 Formulation, modified-release, other Hypertension, general Metralindole 54188-38-4 Metrizamide 31112-62-6 Metrizoic Acid 1949-45-7 Metron S 13946-02-6 Metyrapone 54-36-4 Metyrosine 672-87-7 Mexazolam 31868-18-5 Mexenone 1641-17-4 Mexiletine 31828-71-4 4-Thia-1-azabicyclo [3. 2. 0] heptane-2- carboxylic acid, 3, 3-dimethyl-6- [ [ [ [ [3- (methylsulfonyl)-2-oxo-1- imidazolidinyl] carbonyl] amino] phenylacetyl] 42057-22-7 amino]-7-oxo-, [2S-[2Aipha, 5Alpha, 6ß (Si)]]-51481-65-3 mezlocillin [CAS] 72539-76-5 GB 1301961 Penicillin, injectable Infection, general Benzenecarboximidic acid, 3, 4, 5-trihydroxy- MFH-244, ethyl ester, hydrochloride 95933-76-9 US 4623659 Cardiovascular Reperfusion injury Dibenzo [c, fjpyrazino [1, 2-a] azepine, 21535-47-7 mianserin 1, 2, 3, 4, 10, 14b-hexahydro-2-methyl- [CAS] 24219-97-4 GB 1173783 Antidepressant Depression, general Mibefradil 116644-53-2 Miboplatin 103775-75-3 Micafungin 235114-32-6 1 H-Imidazole, 1- (2, 4-dichlorophenyl)-2 [2, 4- dichlorophenyl) methoxy] ethyl] miconazole 22916-47-8 Formulation, modified-release, other Infection, Candida, general Micronomicin 52093-21-7 ; Patent API Generic Name API Chemical Name CAS No. Reference Example of Therapeutic Use Example of Indication 1 H-Purine-2, 6-dione, 8- (1- aminocyclopentyl)-3, 7-dihydro-1, 3-dipropyl- midaxifylline [CAS] 151159-23-8 US 5378844 Cardiovascular Unspecified 4H-imidazo [1, 5-a] [1, 4] benzodiazepine, 8-59467-70-8 midazolam chloro-6- (2-fluorophenyl)-l-methyl- [CAS] 59467-94-6 US 4280957 Anaesthetic, injectable midecamycin Leucomycin V, 3, 4B-dipropanoate [CAS] 35457-80-8 US 3761588 Macrolide antibiotic Infection, general Leucomycin V, 3B, 9-diacetate 3, 4B- midecamycin acetate dipropanoate [CAS] 55881-07-7 JP 49124087 Macrolide antibiotic Infection, general 2-Thiophenecarbothioic acid, S- [1-methyl-2- oxo-2- [ (tetrahydro-2-oxo-3- midesteine thienyl) amino] ethyl] ester [CAS] 94149-41-4 EP 120534 COPD treatment Emphysema, general Acetamide, 2-amino-N- [2- (2, 5- 42318-56-0 midodrine dimethoxyphenyl)-2-hydroxyethyl]- [CAS] 42794-76-3 EP 164571 Urological Incontinence Benzamide, N- (2, 3, 10, 11, 12, 13-hexahydro- 10-methoxy-9-methyl-1-oxo-9, 13-epoxy- 1 H, 9H-diindolo [1, 2, 3-gh : 3', 2', 1'- im] pyrrolo [3, 4-j] [1, 7] benzodiazonin-11-yl)-N-Cancer, leukaemia, acute midostaurin methyl-, (9Alpha, 10ß, 11 ß, 13Aipha)- [CAS] 120685-11-2 EP 296110 Anticancer, other myelogenous Estra-4, 9-dien-3-one, 11- [4- (dimethylamino) phenyl]-17-hydroxy-17- (1- mifepristone propynyl)-, (im, 17H)- [CAS] 84371-65-3 EP 57115 Aborrifacient Abortion 3, 4, 5-Piperidinetriol, 1- (2-hydroxyethyl)-2- (hydroxymethyl)-, [2R- miglitol (2Alpha, 3ß, 4Aipha, 5ß)]- [CAS] 72432-03-2 EP 55431 Antidiabetic Diabetes, Type I 3, 4, 5-Piperidinetriol, 1-butyl-2- (hydroxymethyl)-(2R-(2Aipha, 3ß, 4Alpha, migiustat 5ß)) [CAS] 72599-27-0 DE 2758025 Metabolic and enzyme disorders Gaucher's disease Hydrazinium, 2- (2-carboxyethyl)-1, 1, 1- mildronate trimethyl-, innersalt- [CAS] 76144-81-5 WO 8001068 Cardiostimulant Heart failure Cyclopropanecarboxamide, 2- (aminomethyl)-N, N-diethyl-1-phenyl-, cis- (). 101152-94-7 milnacipran [CAS] 92623-85-3 US 4478836 Antidepressant Depression, general IMiloxacin 37065-29-5 l Patent API Generic Name API Chemical Name CAS No. Reference Example of Therapeutic Use Example of Indication [3, 4'-Bipyridine]-5-carbonitrile, 1, 6-dihydro-2 milrinone methyl-6-oxo- [CAS] 78415-72-2 US 4313951 Cardiostimu Heart failure Ethanaminium, 2- [ [ (hexadecyloxy) hydroxyphosphinylloxy]- 53949-20-5 miltefosine N, N, N-trimethyl-, hydroxide, inner salt [CAS] 58066-85-6 EP 225608 Anticancer, other Cancer, skin, general 4-Morpholineethanamine, N- (4-methyl-6- 25905-77-5 minaprine phenyl-3-pyridazinyl)- [CAS] 25953-17-7 GB 1345880 Antidepressant Depression, general 2-Naphthacenecarboxamide, 4, 7- bis (dimethylamino)-1, 4, 4a, 5, 5a, 6, 11, 12a- octahydro-3, 10, 12, 12a-tetrahydroxy-1, 11- dioxo-, [4S- (4Alpha, 4aAlpha, 5a. alpha., 12aAlpha)]- minocycline [CAS] 10118-90-8 Formulation, optimized, microparticles Infection, oral Phosphonic acid, (1-hydroxy-2-imidazo (1, 2- minodronic acid a) pyridin-3-yiethylidene) bis-, [CAS] 180064-38-4 EP 354806 Anticancer, other Cancer, myeloma 2, 4-Pyrimidinediamine, 6- (1-piperidinyl)-, 3- minoxidil oxide [CAS] 38304-91-5 US 4139619 Vasodilator, peripheral Hypertension, general Miokamycin 55881-07-7 Pyrazin [2, 1-a] pyrido [2, 3-c] [2] benzazepine, 85650-52-8 mirtazapine 1, 2, 3, 4, 10, 14b-hexahydro-2-methyl- [CAS] 61337-67-5 GB 1543171 Antidepressant Depression, general rost-13-en-1-oic acid, 11, 16-dihydroxy-16- methyl-9-oxo-, methyl ester, (11Alpha, 13E)-59122-46-2 misoprostol ()- [CAS] 59122-48-4 US 4301146 Prostaglandin Ulcer, gastric Erythromycin, 8, 9-didehydro-N-demethyi-9- deoxo-6, 11-dideoxy-6, 9-epoxy-12-O-methyl- N- (1-methylethyl)-11-oxo-, (2E)-2- mitemcinal butenedioate (2 : 1) [CAS] 154802-96-7 WO 9324509 Gastroprokinetic Gastro-oesophageal reflux Calcium (2S)-2-benzyl-3- (cis-hexahydro-2- isoindolinylcarbonyl) propionate, dihydrate- mitiglinide [CAS] 145525-41-3 EP 507534 Antidiabetic Diabetes, Type II Mitobronitol 488-41-5 Mitoguazone 459-86-9 Patent API Generic Name API Chemical Name CAS No. Reference Example of Therapeutic Use Example of Indication mitolactol Galactitol, 1, 6-dibromo-1, 6-dideoxy- [CAS] 10318-26-0 US 3993781 Anticancer, alkylating Cancer, cervical Azirino [Z, 3 : 3, 4] pyrrolo [1, 2-a] indole-4, 7- dione, 6-amino-8- [ [ (aminocarbonyl) oxy] methyl]-1, 1 a, 2, 8, 8a, 8b hexahydro-8a-methoxy-5-methyi-, [1aS- mitomycin (1aAlpha, 8ß, 8aAlpha, 8bAlpha)]- [CAS] 50-07-7 Formulation, parenteral, other Cancer, stomach Mitotane 53-19-0 9, 10-Anthracenedione, 1, 4-dihydroxy-5, 8- bisft2- [ (2-hydroxyethyl) aminolethyllamino]- 65271-80-9 mitoxantrone [CAS] 70476-82-3 US 4197249 Anticancer, other Cancer, breast 9, 10-Anthracenedione, 1, 4-dihydroxy-5, 8- bis [ [2- [ (2-hydroxyethyl) amino] ethyl] amino]- 65271-80-9 mitoxantrone [CAS] 70476-82-9 Formulation, optimized, liposoms Cancer, general MIV-210 (3'-Fiuoro-2'-3'-dideoxy guanosine) Antiviral, other infection, hepatitis-B virus Isoquinolinium, 2, 2'- [ (1, 8-dioxo-4-octene- 1, 8-diyl) bis (oxy-3, 1-propanediyi)] bis [1, 2, 3, 4- ! tetrahydro-6, 7-dimethoxy-2-methyi-1-[(3, 4, 5- trimethoxyphenyl) methyi]-, dichloride, [R- mivacurium [R*, R*- (E)]]]- [CAS] 106861-44-3 EP 181055 Muscle relaxant Anaesthesia, adjunct Mivazerol 125472-02-8 4 (1 H)-Pyrimidinone, 2- [ [1- [1- [ (4- fluorophenyl) methyi]-t H-benzimidazol-2-yl]- mizolastine 4-piperidinyl] methylamino]- [CAS] 108612-45-9 EP 217700 Antiallergic, non-asthma Rhinitis, allergic, general Mizoribine 50924-49-7 (R)-N- (3-quinuclidinyl)-7-oxo-4, 7- dihydrothienc [3, 2-b] pyridine-6-carboxamide MKC-733 hydrochloride 194093-42-0 JP 09216888 Gastroprokinetic Gastro-oesophageal reflux 6-Oxa-2-azabicyclo [3. 2. 0] heptane-3, 7- dione, 1- [ (IS)-l-hydroxy-2-methylpropyl]-4- MLN-519 propyl-, (1R, 4R, 5S)- [CAS] 211866-70-5 WO 9915183 Neuroprotective Ischaemia, cerebral 4-Methoxy-benzo [a] phenazine-11- carboxylic acid (2-(dimethylamino)-1-(R)- methyiethyi)-amide MLN-576 Anticancer, other Cancer, general I Patent API Generic Name API Chemical Name CAS No. Reference Example of Therapeutic Use Example of Indication Benzamide, 4-chloro-N- [2- (4- moclobemide morpholinyl) ethyl]- [CAS] 71320-77-9 EP 326023 Antidepressant Depression, general Acetamide, 2- [ (diphenylmethyl) sulfinyl]- modafinil [CAS] 68693-11-8 DE 2809625 Psychostimulant Narcolepsy 3-Isoquinolinecarboxylic acid, 2- [2- [ [1- (ethoxycarbonyl)-3-phenylpropyl] amino]-1- oxopropyl]-1, 2, 3, 4-tetrahydro-6, 7-dimethoxy 103775-10-6 moexipril (3S- (2 (R* (R*)), 3R*))- [CAS] 103775-14-0 US 4344949 Antihypertensive, renin system Hypertension, general Mofarotene 125533-88-2 Mofebutazone 2210-63-1 Mofegiline 119386-96-8 5-Isoxazoleacetic acid, 3, 4-bis (4- mofezolac methoxyphenyl)- [CAS] 78967-07-4 EP 26928 Analgesic, NSAID Pain, post-operative N- [4- (aminomethyl) benzyl]-8 (S)- [1- [4- [2- (4- aminophenyl)-acetamido] butyryi] piperidin-4- yl]-2- (naphthalen-1-ylmethyl)-1, 3-dioxo- 2, 3, 5, 8-tetrahydro-1 H- [1, 2, 4] triazolo [1, 2-a]- pyridazine-5 (R)-carboxamide MOL-6131 Antiasthma Asthma Molindone 7416-34-4 Sydnone imine, N- (ethoxycarbonyl)-3- (4- molsidomine morpholinyl)- [CAS] 25717-80-0 US 3769283 Vasodilator, coronary Pregna-1, 4-diene-3, 20-dione, 9, 21-dichloro- 11, 17-dihydroxy-16-methyl-, (11 ß, 16Alpha)-105102-22-5 mometasone [CAS] 83919-23-7 EP 57401 Antipruritic/inflamm, allergic Psoriasis Monatepil 103377-41-9 Monobenzone 103-16-2 Dodecanoic acid, monoesterwifh 1, 2, 3- monolaurin propanetriol [CAS] 27215-38-9 US 4885282 Dermatological Ichthyosis Cyclopropaneacetic acid, 1- [ [ [1- [3- [2- (7- Chloro-2-quinolinyl) ethenyl] phenyl]-3- [2- (1- hydroxy-1- methylethyl) phenyl] propyl] thio] methyl-, 151767-02-1 montelukast [CAS] 158966-92-8 Antiasthma Asthma Monteplase 122007-85-6 Moperone 1050-79-9 t Patent API Generic Name API Chemical Name CAS No. Reference Example of Therapeutic Use Example of Indication Mopidamol 13665-88-8 Moprolol 5741-22-0 Carbamic acid, [10- [3- (4-morpholinyl)-1- oxopropyl]-10H-phenothiazin-2-yl]-, ethyl 29560-58-5 moracizine ester [CAS] 31883-05-3 US 3864487 Antiarrhythmic Tachycardia, ventricular Morazone 6536-18-1 Moricizine 31883-05-3 Moroxydine 3731-59-7 Morphazinamide 952-54-5 57-27-2 Morphinan-3, 6-diol, 7, 8-didehydro-4, 5- 6055-06-7 morphine epoxy-17-methyi- (5Aipha, 6Aiphak, [CAS] 64-31-3 Formulation, parenteral, other Pain, cancer morphine-6-glucuronide morphine-6-glucuronide Formulation, inhalable, systemic Pain, general Spiro [imidazo [1, 2-a] pyridine-3 (2H), 4'- piperidin]-2-one, 1'- [3- (3-chloro-10, 11- dihydro-5H-dibenz [b, f] azepin-5- 89419-40-9 mosapramine yl) propyl] hexahydro-, (+/-)- [CAS] 98043-60-8 US 4337260 Neuroleptic Benzamide, 4-amino-5-chloro-2-ethoxy-N- ( (4- ( (4-fluorophenyl) methyl)-2- 112886-41-3 mosapride morpholinyl) methyl)- [CAS] 112885-42-4 EP 243959 GI inflammatory/bowel disorders Gastritis Gadolinium, bis (acetetato-kappa0) (9, 10- diethyl-20, 21-bis (2- (2- (2- methoxy) ethoxy) ethoxy)-4, 15-dimethyl-8, 11- imino-3, 16 : 16, 13-dinitrilo-1, 18- benzodiazacycloeicosine-5, 14- dipropanalato-kappaN 1, kappaN 18, kappaN23, kappaN24, kappaN25), (PB-7- motexafin gadolinium 11-233'2'4) [CAS] 246252-06-2 Radio/chemosensitizer Cancer, brain Motretinide 56281-36-8 Moveltipril 85856-54-8 Moxalactam 64952-97-2 Moxastine 3572-74-5 Moxaverine 10539-19-2 Moxestrol 34816-55-2 f Patent API Generic Name API Chemical Name CAS No. Reference Example of Therapeutic Use Example of Indication 3-Quinolinecarboxylic acid, 1-cyclopropyl-6- fluoro-1, 4-dihydro-8-methoxy-7- (octahydro- 6H-pyrrolo (3, 4-b) pyridin-6-yl)-4-oxo-, 186826-86-8 Infection, respiratory tract, moxifloxacin hydrochloride (4aS-cis)- [CAS] 151096-09-2 DE 19546249 Quinolone antibacterial general Phenol, 4- [2- (dimethylamino) ethoxy]-2- methyl-5- (1-methylethyl)-, acetate (ester), 964-52-3 moxisylyte [CAS] 54-32-0 Mate sexual dysfunction Impotence 5-Pyrimidinamine, 4-chloro-N- (4, 5-dihydro- 1 H-imidazol-2-yl)-6-methoxy-2-methyl- moxonidine [CAS] 75438-57-2 DE 2849537 Antihypertensive, other Hypertension, general (-)- (S)-2-Methyl-2- (1-oxo-2, 3-dihydro-1 H- isoindol-2-yl) pentanedioic acid M-PGA US 5712291 Anticancer, other Cancer, general Platinum diamminedichloro-, (SP-4-2) + (R)- 4- [1-hydroxy-2- (methylamino)-ethyl]-1, 2- benzenediol MPI-5010 US 6224883 Formulation, parenteral, other Cancer, head and neck MPI-5020 2, 4 (1H, 3H)-Pyrimidinedione, 5-fluoro- [CAS] 51-21-8 US 5750146 Formulation, parenteral, other Cancer, breast MPL 198076-81-2 Immunostimulant, other Vaccine adjunct MRS-1754 US 6060481 Antiasthma Asthma 1-Piperazineethanol, 4- (diphenylacetyl)- Alpha- [ (5-quinolinyloxy) methyl]-, (2E)-2- MS-209 butenedioate (2 : 3) (salt) [CAS] 158681-49-3 Radio/chemosensitizer Cancer, breast N- (2-Aminophenyl)-4- [N- (pyridin-3-yl- methoxycarbonyl) aminomethyl] benzamide MS-275 Anticancer, antimetabolite Cancer, lung, general MS-325 201688-00-8 MS-377 EP 839805 Neuroleptic Schizophrenia Mupirocin 12650-69-0 Muscarine 300-54-9 Muzolimine 55294-15-0 MX-1013 US 6153591 Hepatoprotective Unspeciñed ! Patent API Generic Name API Chemical Name CAS No. Reference Example of Therapeutic Use Example of Indication 4-Hexenoic acid, 6- (1, 3-dihydro-4-hydroxy-6 methoxy-7-methyl-3-oxo-5-isobenzofuranyl)- 4-methyl-, 2- (4-morpholinyl) ethyl ester, (E)-116680-01-4 mycophenolate mofetil [CAS] 128794-94-5 WO 9119498 immunosuppressant Transplant rejection, general 4-hexanoic acid, 6- (1, 3-dihydro-4-hydroxy-6- methoxy-7-methyl-3-oxo-5-isobenzofuranyl) 4-methyl-, 37415-62-6 mycophenolic acid 24280-93-1 Formulation, oral, enteric-coated Transplant rejection, general Myrophine 467-18-5 N- (Hydroxymethyl) nicotinamide 3569-99-1 83-81-8 N, N, N¢, N¢-83-81-8 Tetraethylphthalamide N2-Formylsulfisomidine 795-13-1 N4-b-D-Glucosylsulfanilamide 53274-53-6 N4-Suifanilylsuifanilamide 547-52-4 Nabilone 51022-71-0 2-Butanone, 4- (6-methoxy-2-naphthalenyl)- nabumetone [CAS] 42924-53-8 GB 1476721 Anti-inflammatory Arthritis, osteo N-acetylcysteine L-Cysteine, N-acetyl- [CAS] 616-91-1 Anticancer, other Cancer, general N-Acetylmethionine 65-82-7 1 H, 5H-Benzo [ij] quinolizine-2-carboxylic acid, 9-fluoro-6, 7-d) hydro-8- (4-hydroxy-1- nadifloxacin piperidinyl)-5-methyl-1-oxo-, (+/-)- [CAS] 124858-35-1 US 4399134 Quinolone antibacterial Acne 2, 3-Naphthalenediol, 5- [3- [ (1, 1- dimethylethyl) amino]-2-hydroxypropoxy]- nadolol 1, 2, 3, 4-tetrahydro- [CAS] 42200-33-9 US 4346106 Antihypertensive, adrenergic Nadoxclol 54063-51-3 Benzoic acid, 4-[(aminoiminomethyl) amino]-80251-32-7 ; 6- (aminoiminomethyl)-2-naphthalenyl ester 81525-10-2 nafamostat [CAS] 82956-11-4 EP 450232 GI inflammatory/bowel disorders Pancreatitis Luteinizing hormone-releasing factor (pig), 76932-56-4 nafarelin 6- [3- (2-naphthalenyl)-D-alanine]- [CAS] 86220-42-0 EP 21234 Releasing hormones Endometriosis Patent API Generic Name API Chemical Name CAS No. Reference Example of Therapeutic Use Example of Indication Nafcillin 147-52-4 Nafronyl 31329-57-4 2-Furanpropanoic acid, tetrahydro-Aipha-(1- naphthalenyimethyl)-, 2- (diethylamino) ethyl ester naftidrofuryl 31329-57-4 Formulation modified-release, other Unspecified 1-Naphthalenemethanamine, N-methyl-N- (3 65472-88-0 naftifine phenyl-2-propenyl)-, (E)- [CAS] 65473-14-5 US 4282251 Antifungal Infection, dermatological 1-Piperazineethanol, 4- (2-methoxyphenyi)- naftopidil Alpha- [ (1-naphthalenyloxy) methyl]- [CAS] 57149-07-2 US 3997666 Antihypertensive, adrenergic Hypertension, general Morphinan-3, 6, 14-triol, 17- (cyclobutylmethyl)-4, 5-epoxy-, 20594-83-6 nalbuphine (5AIpha, 6Alpha)- [CAS] 23277-43-2 US 3393197 Analgesic, other Pain, general Nalidixic Acid 389-08-2 Morphinan-3, 14-diol, 17- (cyclopropylmethyl) nalmefene 4, 5-epoxy-6-methylene-, (5Alpha)-[CAS] 55096-26-9 JP 56167687 Dependence treatment Poisoning, drug Nalorphine 62-67-9 Morphinan-6-one, 17-allyl-4, 5Alpha-epoxy-357-08-4 naloxone 3, 14-dihydroxy-, hydrochloride [CAS] 465-65-6 Septic shock treatment Morphinan-6-one, 17- (cyclopropyimethyl)- 16590-41-3 naltrexone 4, 5-epoxy-3, 14-dihydroxy-, (5AIpha)- [CAS] 16676-29-2 US 3332950 Dependence treatment Addiction, narcotic/opiate Imidazolium trans (imidazole) (dimethylsulfoxide) tetrachlo NAMI roruthenate (111) Anticancer, other Cancer, general Guanidine, N-cyano-N'- (4-cyanophenyl)-N"- naminidil [ (1R)-1, 2, 2-trimethylpropyl]- [CAS] 220641-11-2-Dermatological Alopecia, general Nandrolone 434-22-0 Naphazoline 835-31-4 Naphthalene 91-20-3 Methanaminium, 1-carboxy-N, N, N- trimethyl-saltwith (R)-6-methoxy-Alpha- methyl-2-naphthaleneacetic acid (1 : 1), naproxen betainate sodium salt [CAS] 104124-26-7 US 4672077 Antiarthritic, other Arthritis, rheumatoid I t Patent API Generic Name API Chemical Name CAS No. Reference Example of Therapeutic Use Example of Indication 2-Naphthaleneacetic acid, 6-methoxy-Alpha 26159-34-2 naproxen methyl-, [CAS] 22204-53-1 GB 1211134 Analgesic, NSAID Pain, general 1H-Indole-5-ethanesulfonamide, N-methyl-3 naratriptan (1-methyl-4-piperidinyl)- [CAS] 121679-13-8 EP 303507 Antimigraine Migraine Narceine 131-28-2 Narcobarbital 125-55-3 Natamycin 7681-93-8 D-phenylalanine, N- ( (4- (1- methylethyl) cyclohexyl) carbonyl)-, trans- nateglinide [CAS] 105816-04-4 EP 196222 Antidiabetic Diabetes, Type II N-Butyldeoxynojirimycin 72599-27-0 N-Butylscopolammonium 149-64-4 Bromide NC-503 US 5643562 Anti-inflammatory Amyloidosis NC-531 US 5643562 Cognition enhancer Alzheimer's disease NCX-1000 WO 0061604 Hepatoprotective Cirrhosis, hepatic Benzoic acid, 2- (acetyloxy)-, 2-Insulin-related metabolic NCX-4016 ((nitrooxy) methyl) phenyl ester [CAS] 175033-36-0 WO 9716405 Symptomatic antidiabetic syndrome Benzoic acid, 5-amino-2-hydroxy-, 4- NCX-456 (nitrooxy) butyl ester [CAS] 256499-26-0 Gl inflammatory/bowei disorders inflammatory bowei disease Alpha'- [ [ (1, 1-dimethylethyl) amino] methyl]-4- hydroxyl-1, 3-benzenedimethanol nitrate NCX-950 Antiasthma Asthma n-Docosanol 661-19-8 Benzeneethanamine, 4-methoxy-3- (2- phenylethoxy)-N, N-dipropyl-, hydrochloride NE-100 [CAS] 149409-57-4 WO 9307113 Neuroleptic Schizophrenia Nealbarbital 561-83-1 2H-1-Benzopyran-2-methanol, Alpha, Alpha'- [iminobis (methylene)] bis [6-fluoro-3, 4- 118457-14-0 nebivolol dihydro]-, (2R* (R* (R* (S*))))- (1+)- [CAS] 99200-09-6 EP 145067 Antihypertensive, adrenergic Hypertension, general nebostinel N1- (4, 4-Dimethylcyclohexyl)-L-isoglutamine 163000-63-3 EP 0688312 Cognition enhancer Unspecified Nebracetam 97205-34-0 Patent API Generic Name API Chemical Name CAS No. Reference Example of Therapeutic Use Example of Indication Platinum, diammine [hydroxyacetato (2-)- nedaplatin 01, 02]-, (SP-4-3)- [CAS] 95734-82-0 EP 216362 Anticancer, alkylating 4H-Pyrano [3, 2-g] quinoline-2, 8-dicarboxylic acid, 9-ethyl-6, 9-dihydro-4, 6-dioxo-10- 69049-73-6 Rhinitis, allergic, general, nedocromil propyl- [CAS] 69049-74-7 EP 555718 Antiasthma, Ophthalmological Ocular disorder, general 3H-1, 2, 4-Triazol-3-one, 2- [3- [4- (3- chlorophenyl)-1-piperazinyl] propyl]-5-ethyl- 82752-99-6 nefazodone 2, 4-dihydro-4- (2-phenoxyethyl)-, [CAS] 83366-66-9 US 4338317 Antidepressant Depression, general 1-Pyrrolidineacetamide, N- (2, 6- nefiracetam dimethylphenyl)-2-oxo- [CAS] 77191-36-7 US 4341790 Cognition enhancer Dementia, senile, general 1H-2, 5-Benzoxazocine, 3, 4, 5, 6-tetrahydro-5 13669-70-0 nefopam methyl-i-phenyl- [CAS] 23327-57-3 US 3487153 Analgesic, NSAID Negamycin 33404-78-3 3-lsoquinolinecarboxamide, N-(1, 1- dimethylethyl) decahydro-2-(2-hydroxy-3-((3- hydroxy-2-methylbenzoyl) amino)-4- (phenylthio) butyl)-, (3S-159989-65-8 nelfinavir (2 (2S*, 3< 159989-64-7 Antiviral, anti-HIV Infection, HiV/AIDS Nemonapride 75272-39-8 Neostigmine 59-99-4 Cyclo [3-amino-L-alanyl-L-leucyl-N- [2- (acetyiamino)-2-deoxy-ß-D-glucopyranosyl]- L-asparaginyl-L-Alpha-aspartyl-L-tryptophyl- nepadutant L-phenylalanyl], (4-1)-lactam [CAS] 183747-35-5 WO 9628467 Antiasthma Asthma 1, 3, 3, 5, 5-pentamethylcyclohexylamine 202807-80-5 neramexane 219810-59-0 Dependence treatment Addiction, alcohol Phosphonic acid, (6-amino-1- neridronic acid hydroxyhexylidene) bis- [CAS] 79778-41-9 Musculoskeletal Osteogenesis imperfecta Neriifolin 466-07-9 N-Ethylamphetamine 457-87-4 1 H-lmidazole, 1-[2-(methylthio)-1-[2- (pentyloxy) phenyl] ethenyl]-, 130773-02-3 neticonazole monohydrochloride, (E)- [CAS] 130726-68-0 EP 445540 Antifungal Infection, Candida, general ! 1 Patent API Generic Name API Chemical Name CAS No. Reference Example of Therapeutic Use Example of Indication D-Streptamine, 0-3-deoxy-4-C-methyl-3- (methylamino)-ß-L-arabinopyranosyl-(1-6)- 0-[2, 6-diamino-2, 3, 4, 6-tetradeoxy-Alpha-D- glycero-hex-4-enopyranosyl- (1-4)]-2-deoxy- 56391-56-1 netilmicin N1-ethyl- [CAS] 56391-57-2 GB 1473733 Aminoglycoside antibiotic Infection, general 6H-Dipyrido [3, 2-b : Z, 3'-e] [1, 4] diazepin-6- one, 11-cyclopropyl-5, 11-dihydro-4-methyl- nevirapine [CAS] 129618-40-2 EP 429987 Antiviral, anti-HIV Infection, HIV/AIDS NGD-98-2 WO 9635689 Anxiolytic Anxiety, general Nialamide 51-12-7 Niaprazine 27367-90-4 Nicametate 3099-52-3 3-Pyridinecarboxamide, N, N'- (1-methyl-1, 2- nicaraven ethanediyl) bis- [CAS] 79455-30-4 EP 29602 Neuroprotective Haemorrhage, subarachnoid 3, 5-Pyridinedicarboxylic acid, 1, 4-dihydro- 2, 6-dimethyl-4- (3-nitrophenyl)-, methyl 2- [methyl (phenylmethyl) amino] ethyl ester 54527-84-3 nir, ardipine [CAS] 55985-32-5 US 3985758 Neuroprotective Hypertension, general Ergoline-8-methanol, 10-methoxy-1, 6- dimethyl-, (8/b)-, 5-bromo-3- pyridinecarboxylate (ester) nicergoline 27848-84-6 Formulation, modified-release, other Unspecified Niceritrol 5868053 Niclosamide 5D-65-7 Nicoclonate 10571-59-2 Nicofuranose 15351-13-0 Nicomol 27959-26-8 Nicomorphine 639-48-5 3-Pyridinecarboxamide, N-[2-(nitrooxy) ethyl] nicorandil [CAS] 65141-46-0 US 4792564 Vasodilator, coronary Hypertension, general Nicotinamide 98-92-0 Pyridine, 3- (1-methyl-2-pyrrolidinyl)-, (S)- nicotine [CAS] 54-11-5 Formulation, inhalable, other Addiction, nicotine Nicotinic Acid 59-67-6 Nicotinic Acid Benzyl Ester 94-44-0 Nicotinyl Alcohol 100-55-0 Patent API Generic Name API Chemical Name CAS No. Reference Example of Therapeutic Use Example of Indication 4- (2'-nitrophenyl)-2, 6-dimethyl-3, 5- dicarbomethoxy-1, 4-dihydropyridine nifedipine 21829-25-4 GB 1173862 Vasodilator, coronary Hypertension, general 2, 4 (1H, 3H)-Pyrimidinedione, 6-[[2-[(2- hydroxyethyl) [3- (4- nitrophenyl) propyl] amino] ethyl] amino]-1, 3- 130636-43-0 nifekalant dimethyl-, [CAS] 130656-51-8 EP 369627 Antiarrhythmic Arrhythmia, general Nifenalol 7413-36-7 Niflumic Acid 4394-00-7 Nifuratel 4936-47-4 Nifurfoline 3363-58-4 Nifuroxazide 965-52-6 Nifuroxime 6236051 Nifurpirinol 13411-16-0 Nifurprazine 1614-20-6 Nifurtimox 23256-30-6 Nifurtoinol 1088-92-2 2-Thiophenecarboxylic acid, 5-nitro-, [3- (5- nitro-2-furanyl>2-propenylidene] hydrazide nifurzide [CAS] 39978-42-2 US 3847911 Antidiarrhoeal Infection, Gl tract NIK-254 Gentamicin, sulfate (salt) [CAS] 1405-41-0 Formulation, other Infection, general Nikethamide 59-26-7 2, 4-Imidazolidinedione, 5, 5-dimethyl-3- [4- nilutamide nitro-3- (trifluoromethyl) phenyl]- [CAS] 63612-50-0 US 4472382 Anticancer, hormonal Cancer, prostate 3, 5-Pyridinedicarboxylic acid, 2-cyano-1, 4- dihydro-6-methyl-4- (3-nitrophenyl)-, 3- nilvadipine methyl 5- (1-methylethyl) ester [CAS] 75530-68-6 US 4338322 Antihypertensive, other Hypertension, general Methanesulfonamide, N- (4-nitro-2- nimesulide phenoxyphenyl)- [CAS] 51803-78-2 US 3840597 Anti-inflammatory Pain, general Nimetazepam 2011-67-8 3, 5-Pyridinedicarboxylic acid, 1, 4-dihydro- 2, 6-dimethyl-4- (3-nitrophenyl)-, 2- nimodipine methoxyethyl 1-methylethyl ester [CAS] 66085-59-4 EP 533014 Neuroprotective Nimorazole 6506-37-2 i Patent API Generic Name API Chemical Name CAS No. Reference Example of Therapeutic Use Example of Indication Urea, N'- [ (4-amino-2-methyl-5- 103745-00-2 pyrimidinyl) methyl]-N- (2-chloroethyl)-N- 42471-28-3 nimustine nitroso- [CAS] 55661-38-6 GB 1374344 Anticancer, alkylating Cancer, brain Ninopterin 2179-16-0 N- [4 (S)- (Cyclopropylamino)-3- (R)-hydroxy- 2, 2-dimethyl-7-nitro-3, 4-dihydro-2H-1- benzopyran-6-yl]-4- methoxybenzeneacetamide NIP-142 WO 9804542 Antiarrhythmic Fibrillation, atrial N'- [3, 5-Bis (trifluoromethyl) benzyl]-N- [3- [N- [1 (4-fluorobenzyl) benzimidazol-2-yl]- amino] propyl-N-methylurea hydrochloride NIP-531 Antipruritic/inflamm, allergic Eczema, atopic N- [2- [ [5- [ (dimethylamino) methyl] furfuryl] thio] ethyl]-2- niperotidine nitro-N'-piperonyl-1, 1-ethenediamine 84845-75-0 GB 2104071 Antiulcer Ulcer, Gl, generai 2H-1-Benzopyran-3-ol, 3, 4-dihydro-8- [2- hydroxy-3- [ (1-methylethyl) amino] propoxy]-, 81486-22-8 nipradilol 3-nitrate [CAS] 86247-86-1 EP 42299 Formulation, mucosal, topical Glaucoma Niridazole 61-57-4 3, 5-Pyridinedicarboxylic acid, 1, 4-dihydro- 2, 6-dimethyl-4- (2-nitrophenyl)-, methyl 2- nisoldipine methylpropyl ester- [CAS] 63675-72-9 GB 1516793 Antihypertensive, other Hypertension, general Benzamide, 2- (acetyloxy)-N- (5-nitro-2- nitazoxanide thiazolyl)- [CAS] 55981-09-4 US 5387598 Protozoacide Infection, GI tract 1, 3-Cyclohexanedione, 2- [2-nitro-4- nitisinone (trifluoromethyl) benzoyl]- [CAS] 104206-65-7 EP 186118 Metabolic and enzyme disorders Cirrhosis, hepatic 1, 3-Propanediamine, N, N-dimethyl-N'- (1- 4533-39-5 nitracrine nitro-9-acridinyl)- [CAS] 6514-85-8 FR 1458183 Anticancer, other Cancer, ovarian Nitrazepam 146-22-5 3, 5-Pyridinedicarboxylicacid, 1, 4-dihydro- 2, 6-dimethyl-4- (3-nitrophenyl)-, ethyl methyl nitrendipine ester- [CAS] 39562-70-4 GB 1358951 Antihypertensive, other Hypertension, general l 1 Patent API Generic Name API Chemical Name CAS No. Reference Example of Therapeutic Use Example of Indication (1, 1'-Biphenyl)-4-acetic acid, 2-fluoro-Alpha- nitroflurbiprofen methyl-, 4- (nitrooxy) butyl ester [CAS] 158836-71-6 EP 670825 Urological Incontinence Nitrofurantoin 67-20-9 Nitrofurazone 59-87-0 nitroglycerin 1, 2, 3-Propanetriol, trinitrate [CAS] 55-63-0 Formulation, transdermal, patch Angina, general Nitromersol 133-58-4 2-Napthaleneacetic acid, 6-methoxy-Alpha- methyi 4- (nitrooxy) butyl ester (AlphaS)- nitronaproxen [CAS] 163133-43-5 WO 9509831 Analgesic, NSAID Pain, post-operative D ! benz [b, flow, 4] oxazepin-11 (10H)-one, 10- [3 (dimethylamino) propyl]-2-nitro-, nitroxazepine monohydrochloride [CAS] 16398-39-3 NL 6608671 Antidepressant Nitroxoline 4008-48-4 1, 1-Ethenediamine, N-[2-[[[2- dimethylamino) methyi]-4- thiazolyl] methyl] thio] ethyl]-N'-methyl-2-nitro- nizatidine [CAS] 76963-41-2 EP 49618 Antiulcer Ulcer, duodenal Nizofenone 54533-85-6 j 3- (2-methylcarboxymethyl)-6-methoxy-8- ydroxy-isocoumarin NM-3 JP 08176138 Anticancer, other Cancer, general 4-Bromo-5- (3-pyridylmethylamino)-6- [3- (4- chlorophenyl) propoxy]-3 (2H) pyridazinone hydrochloride NM-702 Antithrombotic Peripheral vascular disease N-Methylephedrine 552-79-4 N-Methylepinephrine 554-99-4 N-Methylglucamine 6284-40-8 6-chloro-3- (1-methylcyclopropylamino)-4H- thieno [3, 2-e]- [1, 2, 4] thiadiazine-1, 1-dioxide NN-414 Antidiabetic Diabetes, Type II (R)-1- (3- (10, 11-dihydro-5H- dibenzo [a, d] cyclohepten-5-ylidene)-1- ropyl)-3-piperidine carboxylic acid NNC-05-1869 Symptomatic antidiabetic Neuropathy, diabetic, ) Patent API Generic Name API Chemical Name CAS No. Reference Example of Therapeutic Use Example of Indication Nogalamycin 1404-15-5 4 ( H)-Quinazolinone, 2-amino-6-methyl-5- 152946-68-4 nolatrexed (4-pyridinylthio)-, [CAS] 147149-76-6 WO 9320055 Anticancer, antimetabolite Cancer, liver Propanoic acid, 2-methyl-, 5, 6, 7, 8- tetrahydro-6- (methylamino)-1, 2- naphthaienediyl ester, hydrochloride, nolomirole [CAS] 138531-51-8 WO 9529147 Cardiostimulant Heart failure 1-Azoniabicyclo [2. 2. 2] octane, 1- [2- [3- (3, 4- dichlorophenyl)-1- [ [3- (1- methylethoxy) phenyl] acetyl]-3- piperidinyl] ethyl]-4-phenyl-, chloride, (S)- nolpitantium [CAS] 153050-21-6 EP 591040 G inflammatory/bowel disorders Inflammatory bowel disease 19-Norpregna-4, 6-diene-3, 20-dione, 17- nomegestrol (acetyloxy)-6-methyl- [CAS] 58652-20-3 DE 2522533 Menstruation disorders Menstrual disorder, general Nomifensine 24526-64-5 Noprylsulfamide 576-97-6 Norbolethone 1235-15-0 Nordazepam 1088-11-5 Nordefrin 6539-57-7 (unspecified) ; 74812-63-8 (R*, S*) ()-form Nordihydroguaiaretic Acid 2i686-84-6 (meso- form) ; 500-38-9 (unspecified) Norelgestromin, Ethinyl Estradiol Norepinephrine 51-41-2 Norethandrolone 52-78-8 Norethindrone 68-22-4 Norethynodrel 68-23-5 Norfenefrine 536-21-0 3-Quinolinecarboxylic acid, 1-ethyl-6-fluoro-68077-27-0 norfloxacin 1, 4-dihydro-4-oxo-7- (1-piperazinyl)- [CAS] 70458-96-7 US 4146719 Quinolone antibacterial Infection, general Norgesterone 13563-60-5 ! Patent API Generic Name API Chemical Name CAS No. Reference Example of Therapeutic Use Example of Indication Norgestimate 35189-28-7 Norgestrel 6533-00-2 Norgestrienone 848-21-5 Norlevorphanol 1531-12-0 Normethadone 467-85-6 Normethandrone 514-61-4 Normorphine 466-97-7 Norphenazone 89-25-8 Norpipanone 561-48-8 Norpseudoephedrine 492-39-7 Nortriptyline 72-69-5 Norvinisterone 6795-60-4 Noscapine 128-62-1 Novembichin 1936-40-9 Novobiocin 303-81-1 Noxiptilin 3362-45-6 Noxythiolin 15599-39-0 Butanoic acid, 2- [ [ [5- [4- [ (dimethylamino) sulfonyl] phenyl]-1, 2, 6, 7, 8, 9- hexahydro-8-methyl-2-oxo-3H-pyrrolo [3, 2- h] isoquinolin-3-ylidene] amino] oxy]-3- NS-1209 hydroxy- [CAS] 254751-28-5 WO 9426747 Antiepileptic Epilepsy, general 5- (4-chlorophenyl)-6, 7, 8, 9-tetrahydro-1H- pyrolo- (3, 2-h] naphthalene-2, 3-dione-3- oxime NS-1231 Neuroprotective Ischaemia, cerebral NS-126 US 5063222 Antiallergic, non-asthma Rhinitis, allergic, general 2-Methyl-c-5- [4- [5-methyl-2- (4- methylphenyl)-4-oxazolyl] butyl]-1, 3-dioxane- r-2-carboxylic acid NS-220 Hypolipaemic/Antiatherosclerosis Atherosclerosis NS-2330 NS 2330 [CAS] 402856-42-2 Cognition enhancer Alzheimer's disease NS5A inhibitors US 6030785 Antiviral, other infection, hepatitis-C virus Pyrimidine, 4- (4-fluorophenyi)-2-methyl-6- [ [5- (1-piperidinyl) pentyl] oxy]-, NS-7 monohydrochloride [CAS] 178429-67-9 WO 9607641 Neuroprotective Ischaemia, cerebral Patent API Generic Name API Chemical Name CAS No. Reference Example of Therapeutic Use Example of Indication 2-Amino-5- (2-fluorophenyl)-4-methyl-1 H- pyrrole-3-carbonitrile NS-8 Urological Incontinence 17-Allylaminogeldanamycin NSC-330507 Anticancer, antibiotic Cancer, general l NSC-619534 2-chloroethyl phenyl selenone Anticancer, alkylating Cancer, general l 2, 5-diazinidinyi-3-[hydroxymethyi] 6-methyl- 1, 4-benzoquinone NSC-697726 Anticancer, antibiotic Cancer, general l N-Sulfanilyi-3, 4-xylamide 120-34-3 2, 4-Pyrimidinediamine, 6- NU-6027 (cyclohexylmethoxy)-5-nitroso- [CAS] 220036-08-8 Anticancer, other Cancer, general 2, 4, 6 (1H, 3H, 5H)-Pyrimidinetrione, 5-ethyl-5- NV-07 sec-pentyl-, 2-oxime [CAS] 53745-16-7 US 6455032 Antipruritic/inflamm, non-allergic Keratosis ( [3R, 4aR, 1 OaR]-1, 2, 3, 4, 4a, 5, 10, 1 Oa- Octahydro-6-methoxy-1-methyl- benz [g] quinoline-3-carboxylic acid-4- (4- nitrophenyl) piperazine amide, hydrogen maleate NVP-SRA880 Neurological Unspecified (S)- (+)-2- [4- (2- fluorobenzyloxy) benzylamino] propanamide methansulfonate NW-1029 Analgesic, other Pain, general NXY-059 CPI 22 [CAS] 168021-79-2 US 5780510 Neuroprotective Ischaemia, cerebral Nylidrin 447-41-6 1-lmidazolidineaceUc acid, 3- [ (3- NZ-314 nitrophenyl) methyl]-2, 4, 5-trioxo- [CAS] 128043-99-2 EP 353198 Symptomatic antidiabetic Neuropathy, diabetic NZ-419 5-hydroxy-1-methylimidazolidine-2, 4-dione EP 412940 Urological Renal failure Obidoxime Chloride 114-90-9 OC-108 OC 108 [CAS] 162602-62-2 Vasoprotective, topical Venous insufficiency Methanone, 2-pyridinyi [7- (4- pyridinyl) pyrazol [1, 5-a] pyrimidin-3-yi]- ocinaplon [CAS] 96604-21-6 EP 129847 Anxiolytic Generalized anxiety disorder Octabenzone 1843-05-6 Octacaine 13912-77-1 I Patent API Generic Name API Chemical Name CAS No. Reference Example of Therapeutic Use Example of Indication Octamoxin 4684-87-1. Octaverine 549-68-8 70775-75-6 1-Octanamine, N, N'- (1, 10-decanediyldi- 71251-02-0 octenidine 1 (4H)-pyridinyl-4-ylidene) bis- [CAS] 86767-75-1 WO 8705501 Stomatological Periodontitis Octodrine 543-82-8 Octopamine 104-14-3 Octotiamine 137-86-0 L-Cysteinamide, D-phenylalanyl-L-cysteinyl- L-phenylalanyl-D-tryptophyl-L-lysyl-L- threonyl-N-[2-hydroxy-1- (hydroxymethyl) propyl]-, cyclic (2-7)- octreotide disulfide, [R- (R*, R*)]- [CAS] 83150-76-9 Formulation, fixed-dose combinations Cancer, general Octyl Methoxycinnamate 5466-77-3 7H-Pyrido [1, 2, 3-de]-1, 4-benzoxazine-6- carboxylic acid, 9-fluoro-2, 3-dihydro-3- methyl-10- (4-methyl-1-piperazinyl)-7-oxo-, ofloxacin (+/-)- [CAS] 82419-36-1 EP 47005 Quinone antibacterial o-iodchippurate 133-17-5 10H-Thieno (2, 3-b) (1, 5) benzodiazepine, 2- olanzapine methyl4-(4-methyi-1-piperamnyl)- [CAS] 132539-06-1 EP 454436 Neuroleptic Schizophrenia Oleandrin 465-16-7 Oleic Acid 112-80-1 1 H-Imidazole-5-carboxylic acid, 4- (1- hydroxy-1-methyiethyl)-2-propyi-1-((2-(1 H- tetrazol-5-yi) (1, 1-biphenyi) 4-yi) methyl)-. (5- methyl-2-oxo-1, 3-dioxol-4-yl) methyl ester olmesartan medoxomil [CAS] 144689-63-4 EP 503785 Anthypertensive, renin system Hypertension, general 11- [ (Z)-3- (Dimethylamino) propAidene]-6, 1 1- dihydrodibenz [b, e] oxepin-2-acetic acid, monohydrochloride 113806-05-6 olopatadine 140462-76-6 EP 235796 Ophthalmological Conjunctivitis Monosodium 3-dimethyiamino-1- (hydroxypropylidene)-1, 1-bisphosphonate olpadronic acid 63132-39-8 WO 9619998 Osteoporosis treatment Osteoporosis ! Patent API Generic Name API Chemical Name CAS No. Reference Example of Therapeutic Use Example of Indication 15722-48-2 olsalazine Benzoic acid, 3, 3'-azobis [6-hydroxy- [CAS] 53200-51-4 US 4559330 GI inflammatorylbowel disorders Colitis, ulcerative 3H-1, 2-Dithiole-3-thione, 4-methyl-5- oltipraz pyrazinyl- [CAS] 64224-21-1 DE 2705641 Anticancer, other Cancer, general 2- [3 (R)- (Dodecanoyloxy) tetradecanamido]- N- [4- [3 (R)-hydroxytetradecanamido]-5- (phosphonooxy) pentyi]-4- (phosphonooxy) butyramide OM-294DP Anticancer, immunological Unspecified ethyl (5Z, 8Z, 11Z, 14Z, 17Z)-eicosa- 5, 8, 11, 14, 17-pentaenoate + ethyl (4Z, 7Z, 10Z, 13Z, 16Z, 19Z)-docosa- 4, 7, 10, 13, 16, 19-hexaenoate 81926-94-5 Omacor 86227-47-6 Hypolipaemic/Antiatherosclerosis Hypertriglyceridaemia 7H-Pyrido (2, 1-b) (1, 3) thiazepine-7- carboxylic acid, octahydro-4- ( (2-mercapto-1 oxo-3-phenylpropyl) amino)-5-oxo, (4S- omapatrilat (4Alpha (R*), 7AIpha, 1029))- [CAS] 167305-00-2 US 5508272 Antihypertensive, renin system Hypertension, general 1 H-Benzimidazole, 5-methoxy-2- [ [ (4- methoxy-3, 5-dimethyl-2- omeprazole pyridinyl) methyl] sulfinyl]- [CAS] 73590-58-6 US 4255431 Antiulcer Ulcer, GI, general Ethanone, 2- [ (3R, 4S)-3- [ (1, 3-benzodioxol-5- yloxy) methyl]-4- (4-fluorophenyl)-1- omiloxetine piperidinyl]-1- (4-fluorophenyl)-, rel- [CAS] 176894-09-0 Antidepressant Depression, general 1 H-Imidazole, 1- [2- [2- (4- chlorophenoxy) ethoxy]-2-(2, 4- dichlorophenyl)-1-methylethenyl]-, (Z)- omoconazole [CAS] 74512-12-2 EP 8804 Antifungal Infection, dermatological Onapristone 96346-61-1 4H-Carbazol-4-one, 1, 2, 3, 9-tetrahydro-9- methyi-3-[(2-methyl-1 H-imidazol-1-99614-01-4 Chemotherapy-induced nausea ondansetron yl) methyl]- [CAS] 99614-02-5 US 4847281 Antiemetic and vomiting I i i Patent API Generic Name API Chemical Name CAS No. Reference Example of Therapeutic Use Example of Indication Benzoic acid, 4- [ (l E)-3- [ (2-ethoxy-2- oxoethyl)-2-propenylamino]-2-methyl-3-oxo- 1-propenyl]-, 4- (aminoiminomethyl) phenyl ONO-3403 ester, monomethanesulfonate [CAS] 181586-07-2 GI inflammatory/bowel disorders Unspecified 1, 4, 9-Triazaspiro (5. 5) undecane-2, 5-dione, 1-butyl-3- (cyclohexylmethyl)-9- ( (2, 3-dihydro- ONO-4128 1, 4-benzodioxin-6-yl) methyl- [CAS] 342394-93-8 Antiviral, anti-HIV Infection, HIV/AIDS _ L-lysine (Z)-7- [ (1 R, 2R, 3R, 5R)-5-chloro-3- hydroxy-2- [ (E)- (S)-4- (1-ethylcyclobutyl)-4- hydroxy-1-butenyl] cyclopentyl]-5-heptenoate ONO-8815 Ly Labour inhibitor Labour, preterm ONT-093 US 5756527 Radio/chemosensitizer Cancer, general 2 (1H)-Quinolinone, 1- [3- [4- (3-chlorophenyl)- 1-piperazinyl] propyl]-3, 4-dihydro-5-methoxy- OPC-14523 [CAS] 145969-30-8 EP 512525 Antidepressant Depression, general Benzamide, N- [4- [ [5- (dimethylamino)- 2, 3, 4, 5-tetrahydro-1 H-1-benzazepin-1- OPC-31260 yi] carbonyi] phenyl]-2-methyl-37975-06-5 WO 9105549 Urological Unspecified (5R)-2- [1- (2-chloro-4- (1-pyrolidinyl) benzoyl)- 2, 3, 4, 5-tetrahydro-1 H-1-benzazepin-5-yi]-N OPC-51803 isopropylacetamide Antidiabetic Diabetes, insipidus 2-Pyridinecarboxylic acid, 6- [2- (3, 4- OPC-6535 diethoxyphenyl)-4-thiazolyl]- [CAS] 145739-56-6 WO 9209586 Gi inflammatory/bowel disorders Inflammatory bowel disease Opiniazide 2779-55-7 2- (4-trifluoromethylphenyl)-N-methyl- [1- phenyl-2- (1-pyrolidinyl) ethylacetamide opioid analgesics Analgesic, other Pain, general Opipramol 315-72-0 Orazamide 2574-78-9 2, 4-Pentanedione, 3- ( (4- orazipone methylsulfonyl) phenyl) methylene)- [CAS] 137109-78-5 EP 440324 Antiasthma Unspecified I Patent API Generic Name API Chemical Name CAS No. Reference Example of Therapeutic Use Example of Indication Piperazine, 1- [6-chloro-5- (trifluoromethyl)-2- Org-12962 pyridinyl]-, monohydrochloride [CAS] 210821-63-9 Antidepressant Depression, general Org-24448 US 6166008 Neuro) Schizophrenia Vancomycin, 22-0- (3-amino-2, 3, 6-trideoxy- 3-C-methyl-Alpha-L-arabino-hexopyranosyl) N3"- [ (4'-chloro [1, 1'-biphenyl]-4-yl) methyl]- oritavancin, (4"R)- [CAS] 171099-57-3 US 5840684 Peptide antibiotic infection, dermatological L-Leucine, N-formyl-, 1- [ (3-hexyl-4-oxo-2- oxetanyl) methyl] dodecyl ester, [2S- orlistat [2Alpha (R*), 3ß]]- [CAS] 96829-58-2 EP 129748 Anorectic/Antiobesity Obesity Pyrrolidine, 1- [2- (p- (7-methoxy-2, 2-dimethyl- 3-phenyl-4-chromanyl) phenoxy) ethyl]-, trans ormeloxifene [CAS] 31477-60-8 DE 2329201 Female contraceptive Contraceptive, female Ornidazole 16773-42-5 Ornipressin 3397-23-7 Ornithine 70-26-8 Prost-13-en-1-oicacid, 11, 15-dihydroxy- 17, 20-dimethyl-6, 9-dioxo-, methyl ester, ornoprostil (11 Alpha, 13E, 15S, 17S)- [CAS] 70667-26-4 US 4278688 Prostaglandin Ulcer, gastric Orotic Acid 65-86-1 Orphenadrine 83-98-7 Orthocaine 536-25-4 Osalmid 526-18-1 Acetamide, N- [1- [3- [ (3R)-1-benzoyl-3- (3, 4- dichlorophenyl)-3-piperidinyi] propyl]-4- osanetant phenyl-4-piperidinyl]-N-methyl- [CAS] 160492-56-8 EP 673928 Neuroleptic Schizophrenia 2-Oxapregna-4, 6-diene-3, 20-dione, 17- osaterone (acetyloxy)-6-chloro- [CAS] 105149-00-6 EP 193871 Prostate disorders Benign prostatic hyperplasia 1-Cyclohexene-1-carboxylic acid, 4- (acetylamino) 5-amino-3- (1-ethylpropoxy)-, ethyl ester, (3R-(3Alpha, (4iN, 5Aipha))- oseltamivir [CAS] 196618-13-0 WO 9626933 Antiviral, other Infection, influenza virus 4'-Th) o-R-D-arabinofuranosyicytosine OSI-7836 Anticancer, antimetabolite Cancer, general I Patent API Generic Name API Chemical Name CAS No. Reference Example of Therapeutic Use Example of Indication Pentanedioic acid, 2- [5- [ [ (1, 2-dihydro-3- methyl-1-oxobenzo [flquinazolin-9- yl) methyl] amino]-1, 3-dihydro-1-oxo-2H- OSI-7904 isoindol-2-yl]-, (S)- [CAS] 139987-54-5 WO 9119700 Formulafion, opfimized, liposomes Cancer, general Ethanol, 2- [4- [ (1Z)-4-chioro-1, 2-diphenyi-1- ospemifene butenyl] phenoxy]- [CAS] 128607-22-7 WO 9607402 Menopausal disorders Osteoporosis Ethanaminium, N, N-diethyl-N-methyl-2- [ [4- [ [2- (octyloxy) benzoyl] amino] benzoyl] oxy]-, otilonium bromide bromide [CAS] 26095-59-0 GB 1181406 Antispasmodic Irritable bowel syndrome Ouabain 630-60-4 Oxaceprol 33996-33-7 Oxacillin 66-79-5 Oxaflozane 26629-87-8 Platinum, (1, 2-cyclohexanediamine- N, N') [ethanedioato (2-)-O, O']-, [SP-4-2- (1R- oxaliplatin trans)]- [CAS] 61825-94-3 EP 393575 Anticancer, alkylating Cancer, colorectal 1, 2, 3-Propanetricarboxylic acid, 2-hydroxy-, Oxalyt-C potassium sodium salt [CAS] 28060-67-5 DE 2249274 Urological Oxamarin 15301-80-1 Oxametacine 27035-30-9 Oxamniquine 21738-42-1 2-Oxaandrostan-3-one, 17-hydroxy-17-Sex-chromosome abnormality, oxandrolone methyí-, (5Alpha, 17ß)- [CAS] 53-39-4 US 3128283 Reproductive/gonadal, general Turner's syndrome Oxantel 36531-26-7 Oxapropanium 541-66-2 2-Oxazolepropanoic acid, 4, 5-diphenyl- oxaprozin [CAS] 21256-18-8 GB 1206403 Antiarthritic, other Arthritis, osteo 2H-Benzimidazol-2-one, 1- [3- [4- (diphenylmethyl)-1-piperazinyl] propyl]-1, 3- oxatomide dihydro- [CAS] 60607-34-3 GB 1579365 Antiallergic, non-asthma Rhinitis, allergic, general 7-Chloro-1, 3-dihydro-3-hydroxy-5-phenyl- 2H-1, 4-benzodiazepin-2-one oxazepam 604-75-1 Formulation, oral, orally-disintegrating Anxiety, general Patent API Generic Name API Chemical Name CAS No. Reference Example of Therapeutic Use Example of Indication Oxazolo [3, 2-d] [1, 4] benzodiazepin-6 (5H)- 27167-30-2 one, 10-chloro-2, 3, 7, 11b-tetrahydro-2- oxazolam methyl-11b-phenyl- [CAS] US 3772371 Anxiolytic 5H-Dibenz [b, f azepine-5-carboxamide, 28721-07-5 oxcarbazepine 10, 11-dihydro-10-oxo- [CAS] 29331-92-8 DE 2011087 Antiepileptic Epilepsy, general Oxeladin 468-61-1 Oxendolone 33765-68-3 Oxethazaine 126-27-2 Oxetorone 26020-55-3 Ethanone, 1-(2, 4-dichlorophenyl)-2-(1H- imidazol-1-yi)-, 0-[(2, 4- oxiconazole dichlorophenyl) methyl] oxime, (Z)- [CAS] 64211-45-6 GB 1514870 Antifungal Infection, fungal, general Oxidronic Acid 15468-10-7 Oxiniacic Acid 2398-81-4 Oxiracetam 62613-82-5 3-Oxa-9-azoniatricyclo [3. 3. 1. 02, 4] nonane, 9 ethyl-7- (3-hydroxy-1-oxo-2-phenylpropoxy)- 9-methyl-, bromide, [7 (S)- oxitropium (1Aipha, 213, 4ß, 5Alpha, 7ß)]- [CAS] 30286-75-0 GB 1178305 Antiasthma Oxolamine 959-14-8 Oxolinic Acid 14698-29-4 Oxophenarsine 538-03-4 Oxprenolol 6452-71-7 Oxybenzone 131-57-7 Benzeneacetic acid, Alpha-cyclohexyl- Alpha-hydroxy-, 4- (diethylamino)-2-butynyl oxybutynin ester- [CAS] 5633-20-5 Formulation, modified-release, other Incontinence Oxycinchophen 485-89-2 Morphinan-6-one, 4, 5-epoxy-14-hydroxy-3- methoxy-17-methyl-, (5AIpha)- oxycodone 76-42-Formulation, transmucosal, nasal Pain, general Oxyfedrine 15687-41-9 Patent API Generic Name API Chemical Name CAS No. Reference Example of Therapeutic Use Example of Indication Octane, 1-bromo- 1, 1, 2, 2, 3, 3, 4, 4, 5, 5, 6, 6, 7, 7, 8, 8, 8- Oxygent heptadecafluoro- [CAS] 423-55-2 Haematological Surgery adjunct Oxymesterone 145-12-0 Oxymetazoline 1491-59-4 Androstan-3-one, 17-hydroxy-2- (hydroxymethylene)-17-methyl-, oxymetholone (5Alpha, 17ß)- [CAS] 434-07-1 Hormone Anaemia, general Oxymethurea 140-95-4 (5Alpha)4, 5-Epoxy-3, 14-dihydroxy-17-Formulation, modified-reiease, oxymorphone methylmorphinan-6-one [CAS] 76-41-5 immediate Pain, general Oxypendyl 5585-93-3 Oxypertine 153-87-7 Oxyphenbutazone 129-20-4 Oxyphencyclimine 125-53-1 Oxyphenisatin 115-33-3 Oxyphenonium 50-10-2 Oxypinocamphone 10136-65-9 1 H-Pyrazolo [3, 4-d] pyrimidine-4, 6 (5H, 7H)- oxypurinol dione [CAS] 2465-59-0 Antigout Hyperuricaemia Oxytetracycline 79-57-2 2-Propenoic acid, 3- [4- (l H-imidazol-I-78712-43-3 ozagrei methyl) phenyl]-, (E)- [CAS] 82571-53-7 GB 2025946 Antithrombotic Vasospasm, cerebral p- (Benzylsulfonamido) benzoic 536-95-8 Acid P-100 US 6313177 Antiviral anti-HIV Infection, HIV/AIDS Pentanoic acid, 5-amino-4-oxo, methyl P-1202 ester, hydrochloride [CAS] 79416-27-6 US 6034267 Dermatological Keratosis Di- (3N- [ (2S, 3S)-2-amino-3-methyl- pentanoyl]-1, 3-thiazolidine) fumarate P32/98 Antidiabetic Diabetes, Type II PA-824 WO 9701562 Antimycobacterial Infection, tuberculosis Pituitary adenyiate cydase-acUvating PACAP 38 peptide-38 [CAS] 128606-20-2 US 5128242 Neuroprotective Nerve injury, general ! Patent API Generic Name API Chemical Name CAS No. Reference Example of Therapeutic Use Example of Indication 5ß, 20-Epoxy-1, 2Alpha, 4, 7fl, 10ß, 13Alpha- hexahydroxytax-11-en-9-one4, 10-diacetate 2-benzoate-13- (Alpha-phenylhippurate) paclitaxel 33069-62-4 Formulation, optimized, nanoparticles Cancer, breast PADRE US 6413935 Immunostimulant, other Vaccine adjunct 1H-Isoindol-1-one, 2- (7-chloro-1, 8- naphthyridin-2-yl)-2, 3-dihydro-3- (5-methyl-2 pagoclone oxohexyl)- (R)- [CAS] 133737-32-3 US 4960779 Anxiolytic Panic disorder PAI inhibs WO 9404512 Antithrombotic Thrombosis, venous 8H-1, 4-dioxin [2, 3-e] indol-8-one, 2, 3, 7, 9- tetrahydro-2- [ (phenylmethyl) aminoJmethyl]-, 2 (S)-, (2E)-2-butendioate (1 : 1) palindore 189681-71-8 Neuroleptic Schizophrenia Palivizumab 188039-54-5 3aS-2-[(S)-1-Azabicyclo [2. 2. 2] oct-3-yl]- 2, 3, 3a, 4, 5, 6-hexahydro-1-oxo-1 H- benz [de] isoquinoline hydrochioride Chemotherapy-induced nausea palonosetron 135729-62-3 US 5202333 Antiemetic and vomiting Pamabrom 606-04-2 Pamaquine 491-92-9 1 H-Pyrrole-1-acetic acid, 2- [4, 5-bis (4- methoxyphenyl)-2-thiazolyl]-, ethyl ester pamicogrel [CAS] 101001-34-7 EP 159677 Antithrombotic Thrombosis, cerebral (3-Amino-1- hydroxypropylidene) diphosphonic acid- pamidronate [CAS] 40391-99-9 Formulation, implant Hypercalcaemia of malignancy p-Aminobenzoic Acid 150-13-0 p-Aminohippuric Acid 61-78-9 p-Aminoproplophenone 70-69-9 p-Aminosalicylic Acid 65-49-6 4, 4'-isopropylidenedithiobis-2, 6-di-t- Panavir butylphenol Neuroprotective Vasospasm, cerebral Pancuronium 15500-66-0 Panipenem 87726-17-8 Patent API Generic Name API Chemical Name CAS No. Reference Example of Therapeutic Use Example of Indication Pantethine 16816-67-4 1H-Benzimidazole, 5- (difluoromethoxy)-2- [ [ (3, 4-dimethoxy-2-pyridinyl) methyl] sulfinyl]- pantoprazole [CAS] 102625-70-7 EP 166287 Antiulce Ulcer, duodenal Pantothenic Acid 79-83-4 Papain Papaverine 58-74-2 Formulation, oral, other, modified- paracetamol Acetamide, N- (4-hydroxyphenyl)- [CAS] 103-90-2 release Pain, general Paraflutizide 1580-83-2 Paraldehyde 123-63-7 Paramethadione 115-67-3 Paramethasone 53-33-8 Paranyline 1729-61-9 Parathyroid Hormone 9002-64-6 Propanamide, N- ( (4- (5-methyl-3-phenyl-4- isoxazolyl) phenyl) sulfonyl)-, sodium salt parecoxib [CAS] 198470-85-8 WO 9738986 Analgesic, NSAID Pain, post-operative Parethoxycaine 94-23-5 Pargyline 555-57-7 19-Nor-9, 10-secoergosta-5, 7, 22-trine- paricalcitol 1, 3, 25-triol, (1Alpha, 3ß, 7E, 22E)- [CAS] 131918-61-1 EP 387077 Hormone Hyperparathyroidism 0-2-Amino-2-deoxy-Alpha-D- lucopyranosyi-(14)-0-[0-2, 6-diamino-2, 6- ideoxy-ß-L-idopyranosyi-(1-3)-ß-D- ribofuranosyl- (l-5)]-2-deoxy-D-streptamine paromomycin 7542-37-2 Protozoacide Infection, leishmaniasis Piperidine, 3- [ (1, 3-benzodioxol-5- yloxy) methyl]-4- (4-fluorophenyl)-, (3S-trans)-Antidepressant, formulation, oral, orally- paroxetine [CAS] 61869-08-7 EP 223403 disintegrating Depression, general Paroxypropione 70-70-2 Parsaimide 30653-83-9 4-Bromothenylguanine PaTrin-2 Radio/chemosensitizer Cancer, melanoma Pazinaclone 103255-66-9 t Patent API Generic Name API Chemical Name CAS No. Reference Example of Therapeutic Use Example of Indication 7H-Pyrido [1, 2, 3-de]-1, 4-benzoxazine-6- carboxylic acid, 10- (1-aminocyclopropyl)-9- 127045-41-4 fluoro-2, 3-dihydro-3-methyl-7-oxo-, (S)-127046-45-1 pazufloxacin [CAS] 136905-87-8 DE 3913245 Quinolone antibacterial Infection, general p-Bromoacetanilide 103-88-8 PC-NSAIDs US 4918063 Formulation, other Arthritis, general 6- (2, 6-Dichlorophenyl)-2- [4- (diethylamino- ethoxy)-phenylamino]-8-pyrido [2, 3- D] pyrimidine-7-one PD-0166285 Anticancer, other Cancer, general Pecilocin 19504-77-9 3-Quinolinecarboxylic acid, 1-ethyl-6-fluoro- 1, 4-dihydro-7- (4-methyl-1-piperazinyl)-4-oxo pefloxacin [CAS] 70458-92-3 GB 1598915 Quinone antibacterial Infection, urinary tract Somatotropin (18-aspartic acid, 21- asparagine, 120-lysine, 167-asparagine, 168-alanine, 171-serine, 172-arginine, 174- serine, 179-threonine (human), pegylated pegvisomant [CAS] 218620-50-9 Somatostatin Acromegaly Pelletierine 4396-1-4 L-Glutamic acid, N- [4- [2- (2-amino-4, 7- dihydro-4-oxo-1 H-pyrrolo [2, 3-d] pyrimidin-5- 137281-23-3 pemetrexed yl) ethyl] benzoyl]-, disodium salt [CAS] 150399-23-8 US 5248775 Anticancer, antimetabolite Cancer, mesothelioma 4H-Pyrido [1, 2-a] pyrimidin-4-one, 9-methyl-3 100299-08-9 pemirolast (1 H-tetrazol-5-yl)- [CAS] 69372-19-6 US 4457932 Antiasthma Asthma Pemoline 2152-34-3 Pempidine 79-55-0 Infection, human papilloma PEN-203 US 5955446 Antiviral, other virus Penamecillin 983-85-7 2-Propanol, 1- (2-cyclopentylphenoxy)-3- [ (1, 1-dimethylethyl) amino]-, (S)-, sulfate 38363-32-5 penbutolol (2 : 1) (salt) [CAS] 38363-40-5 GB 1215751 Antihypertensive, adrenergic , _|_ 6H-Purin-6-one, 2-amino-1, 9-dihydro-9- [4- penciclovir hydroxy-3- (hydroxymethyl) butyl]- [CAS] 39809-25-1 JP 60058982 Antiviral, other Infection, herpes simplex virus Penethamate 808-71-9 I i Patent API Generic Name API Chemical Name CAS No. Reference Example of Therapeutic Use Example of Indication 4-Piperidinol, 1- [4, 4-bis (4- fluorophenyl) butyl]-4- [4-chloro-3- penfluridol (trifluoromethyl) phenyl]- [CAS] 26864-56-2 DE 2040231 Neuroleptic Penicillamine 52-67-5 Penicillin G 61-33-6 Penicillin G Benzathine 1538-09-6 Penicillin G Procaine 6130-64-9 Penicillin N 525-94-0 Penicillin 0 87-09-2 Penicillin V 87-08-1 Penimepicycline 4599-60-4 Penntuss US 4221778 Formulation, modified-release, other Rhinitis, allergic, general Pentaerythritol Chloral 78-12-6 Pentaerythritol Dichlorohydrin 2209-86-1 Pentaerythritol 597-71-7 Pentagastrin 5534-95-2 Pentagestrone 7001-56-1 PentaLyte Starch, 2-hydroxyethyl ether [CAS] 9005-27-0 US 5407428 Plasma substitute Surgery adjunct Pentamethonium 541-20-8 Benzenecarboximidamide, 4, 4'- [1, 5- Infection, Pneumocystis jiroveci pentamidine pentanediylbis (oxy)] bis- [CAS] 100-33-4 Formulation, inhalable, systemic prophylaxis Pentazocine 359-83-1 Pentetate 12111-24-9 Pentetic Acid 67-43-6 Pentetreotide 138661-02-6 Penthienate 60-44-6 Pentifyiline 1028-33-7 Pentigetide 62087-72-3 Pentisomide 78833-03-1 Pentobarbital 76-74-4 Pentolinium 52-62-0 Pentorex 434-43-5 pentosan Xylan, [CAS] 37319-17-8 US 5180715 Urological Inflammation, urinary tract l Patent API Generic Name API Chemical Name CAS No. Reference Example of Therapeutic Use Example of Indication imidazo [4, 5-d] [1, 3] diazepin-8-ol, 3-(2-deoxy- ß-D-erythro-pentofuranosyi)-3, 6, 7, 8- pentostatin tetrahydro-, (R)- [CAS] 53910-25-1 US 3923785 Anticancer, antimetabolite Cancer, leukaemia, hairy cell 1H-Purine-2, 6-dione, 3, 7-dihydro-3, 7- pentoxifylline dimethyl-1- (5-oxohexyl)- [CAS] Neuroprotective Amyotrophic lateral sclerosis Pentoxyl 147-61-5 Pentrinitrol 1607-17-6 Pentylenetetrazole 54-95-5 Bleomycinamide, N1- [3- [ (1- peplomycin phenylethyl) amino] propyl]-, (S)- [CAS] 68247-85-8 US 4195018 Anticancer, antibiotic Perazine 84-97-9 Perflubron 423-55-2 Perfosfamide 62435-42-1 ; 39800-16-3 (unspecified) Ergoline, 8-[(methylthio) methyl]-6-propyi-, 66104-22-1 pergolide (8ß)-, monomethanesulfonate- [CAS] 66104-23-2 US 4797405 Antiparkinsonian Parkinson's disease Perhexiline 6621-47-2 Pericyazine 2622-26-6 Piperidinium, 4- [[hydroxy (octadecyioxy) phosphinyi ; oxy]-1, 1- perifosine dimethyl-, inner salt [CAS] 157716-52-4 EP 594999 Anticancer, other Cancer, prostate 1-Cyclohexene-1-methanol, 4- (1- perillyl alcohol methylethenyl)- [CAS] 536-59-4 US 5110832 Anticancer, other Cancer, breast Perimethazine 13093-88-4 1 H-Indole-2-carboxylic acid, 1- [2- [ [1- (ethoxycarbonyl) butyl], amino]-1- oxopropyi] octahydro-, [2S-107133-36-8 [1 [R* (R*)], 2Aipha, 3aR. 7aB]]-, compd. with 2-82834-16-0 perindopril methyl-2-propanamine (1 : 1) [CAS] 95153-31-4 EP 49658 Antihypertensive, renin system Hypertension, general Periodyl 53586-99-5 1-Piperidineethanol, Alpha- (5-phenyl-3- isoxazolyi)-, 2-hydroxy-1, 2, 3- 2139-25-5 perisoxal propanetricarboxylate (2 : 1) (salt) [CAS] 2055-44-9 JP 04217925 Anti-inflammatory Periapine 11977-11-3 Permethrin 52645-53-1 = Patent API Generic Name API Chemical Name CAS No. Reference Example of Therapeutic Use Example of Indication 1H-Isoindole-1, 3 (2H)-dione, 2- [4- [4- (1, 2- benzisothiazol-3-yl)-1-129273-38-7 perospirone piperazinyl] butyl] hexahydro-, cis- [CAS] 150915-41-6 CA 2167004 Neuroleptic Schizophrenia Perphenazine 58-39-9 Petroleum Benzin 8030-30-6 PH-10 US 6331286 Antipsoriasis Psoriasis Phanquinone 84-12-8 Pharmaprojects No. 4994 WO 9638482 Immunological Unspecified Pharmaprojects No. 5325 WO 9703986 Neuroleptc Schizophrenia Pharmaprojects No. 5972 WO 0204426 Antiasthma Asthma Pharmaprojects No. 6362 US 6057346 Antiviral, anti-HIV Infection, HIV/AIDS (R)-N- [4- [2-Q2-Hydroxy-2- (3- pyridinyi) ethyllamino] ethyl] phenyl]-4- [4- [4- (trifluoromethyl) phenyi] thiazol-2- yl] benzenesulfonamide Pharmaprojects No. 6446 Anorectic/Antiobesity Obesity Pharmaprojects No. 6590 WO 0206223 Psychostimulant Attention deficit disorder Pharmaprojects No. 6656 US 6455026 Genomics-based drug discovery Cancer, brain' Pharmaprojects No. 6691 US 6299900 Formulation, other Pain, general 3- (6-Aminopyridin-3-yi)-N-methyl-N- [ (l- methyl-1 H-indol-2-yl) methyl] acrylamide Pharmaprojects No. 6743 Antibacterial, other infection, general 1, 2, 3, 4, 10, 14b-Hexahydro-6-methoxy-2- methyidibenzo [c, flpyrazino [1, 2-a] azepin Pharmaprojects No. 6748 Antidepressant Depression, general Phenacaine 620-99-5 Phenacemide 63-98-9 Phenacetin 62-44-2 Phenadoxone 467-84-5 Phenallymal 115-43-5 Phenamet 3819-34-9 Phenazocine 127-35-5 Phenazopyridine 136-40-3 Phenbutamide 3149-00-6 Patent API Generic Name API Chemical Name CAS No. Reference Example of Therapeutic Use Example of Indication Phencyclidine 77-10-1 Phendimetrazine 634-03-7 Phenelzine 51-71-8 Phenesterine 3546-10-9 Phenetharbital 357-67-5 Phenethicillin 132-93-4 Pheneturide 90-49-3 Phenformin 114-86-3 Phenglutarimide 1156-05-4 Phenindamine 82-88-2 Phenindione 83-12-5 Pheniprazine 55-52-7 Pheniramine 86-21-5 Phenmetrazine 134-49-6 Phenobarbital 50-06-6 Phenobutiodil 554-24-5 Phenocoll 103-97-9 Phenoctide 78-05-7 Phenolphthalein 77-09-8 Phenolphthalol 81-92-5 Phenolsulfonphthalein 143-74-8 Phenoltetrachlorophthalein 639-44-1 Phenoperidine 562-26-5 Phenosulfazole 515-54-8 Phenoxybenzamine 59-96-1 Phenoxypropazine 3818-37-9 Phenprobamate 673-31-4 Phenprocoumon 435-97-2 Pyrrolo (2, 3-b) indol-5-ol, 1, 2, 3, 3a, 8, 8a- hexahydro-1, 3a, 8-trimethyl-, phenserine phenylcarbamate (ester), (3aS-cis)- [CAS] 101246-66-6 Cognition enhancer Alzheimer's disease Phensuximide 86-34-0 Phentermine 122-09-8 = i Patent API Generic Name API Chemical Name CAS No. Reference Example of Therapeutic Use Example of Indication Phentetiothalein 18265-54-8 Phenol, 3- ( ( (4, 5-dihydro-1 H-imidazol-2- yl) methyl) (4-methylphenyl) amino)-, 65-28-1 phentolamine monomethanesulfonate (salt) [CAS] 50-60-2-Formulation, oral, other impotence Phenyl Acetylsalicylate 134-55-4 Phenyl Aminosalicylate 133-11-9 Phenyl Salicylate 118-55-8 Phenylbutazone 50-33-9 Phenylephrine 61-76-7 Phenylethanolamine 7568-93-6 Phenylmercury 102-98-7 Phenylmethylbarbituric Acid 76-94-8 Benzenemethanol, Alpha- (1-aminoethyl)-, Anorectic/Antiobesity, formulation, phenylpropanolamine (R7, Si/-)- [CAS] 14838-15-4 optimized, microparticles Phenylpropylmethylamine 93-88-9 Phenyltoloxamine 92-12-6 Phenyramidol 553-69-5 phenytoin 2, 4-lmidazolidinedione, 5, 5-diphenyl- [CAS] 57-41-0 Formulation, oral, other Epilepsy, general Phethenylate 510-34-9 Phloroglucinol 108-73-6 Pholcodine 509-67-1 Pholedrine 370-14-9 Phosphocreatine 67-07-2 Phosphocysteamine 5746-40-7 Phosphorylcholine 107-73-3 Phthalylsulfacetamide 131-69-1 Phthalyisulfathiazole 85-73-4 p-Hydroxyephedrine 365-26-4 Phylloquinone 84-80-0 Physostigmine 57-47-6 Phytic Acid 83-86-3 ! Patent API Generic Name API Chemical Name CAS No. Reference Example of Therapeutic Use Example of Indication D-Mannose, 0-6-O-phosphono-Alpha-D- mannopyranosyl- (1-3)-O-Alpha-D- mannopyranosyf- (1-3)-O-Alpha-D- mannopyranosyl- (1-3)-O-Alpha-D- mannopyranosyl- (1-2)- hydrogen sulphate PI-88 [CAS] 185077-23-0 Anticancer, other Cancer, melanoma Piberaline 39640-15-8 2H- (1, 3) 0xazino (3, 2-a) indole-10- carboxamide, N- ( (1-butyl-4- piboserod piperidinyl) methyl)-3, 4-dihydro- [CAS] 152811-62-6 WO 9318036 Antiarrhythmic Fibrillation, atrial Picilorex 62510-56-9 Picloxydine 5636-92-0 Picoperine 21755-66-8 Picosulfate 10040-45-6 Picotamide 32828-81-2 Picumast 39577-19-0 4-Thiazolidinecarboxylic acid, 3- [ (S-oxo-2- pidotimod pyrrolidinyl) carbonyl]- [CAS] 121808-62-6 EP 276752 Immunomodulator, anti-infective Infection, respiratory tract, lower Pifarnine 56208-01-6 Benzeneacetamide, 3-benzoyl-Alpha- piketoprofen methyl-N- (4-methyl-2-pyridinyl)- [CAS] 60576-13-8 GB 1436502 Anti-inflammatory, topical Pildralazine 64000-73-3 2 (3H)-Furanone, 3-ethyldihydro-4- [ (1- methyl-1H-imidazol-5-yl) methyl]-, (3S-cis)- pilocarpine [CAS] 92-13-7 Formulation, implant, Stomatological 2-Propenoic acid, 2-methyl-, dodecyl ester, polymer with 2-propenoicacid, compd. with (3S-cis)-3-ethyldihydro-4- [ (1-methyl-1 H- Piloplex imidazol-5-yl) methyl]-2 (3H)-furanone [CAS] 62783-28-2 DE 2636559 Formulation, mucosal, topical Glaucoma 1H-Pyrrolizine-7a (5H)-acetamide, N- (2. 6- dimethylphenyl) tetrahydro-, 88069-49-2 pilsicainide monohydrochloride [CAS] 88069-67-4 US 4564624 Antiarrhythmic Arrhythmia, general Pimecione 534-84-9 = i Patent API Generic Name API Chemical Name CAS No. Reference Example of Therapeutic Use Example of Indication 15, 19-Epoxy-3H-pyrido (2, 1- c) (1, 4) oxaazacyclotricosine- 1, 7, 20, 21 (4H, 23H)-tetrone, 3- (2- (4-chloro-3- methoxycyclohexyl)-1-methyletheny)-8-ethyl 5, 6, 8, 11, 12, 13, 14, 15, 16, 17, 18, 19. 24, 25, 26, 26a-hexadecahydro-5, 19-dihydroxy-14, 16- dimethoxy-4, 10, 12, 18-tetramethyl- (3S- (3R*E (1 S*, 3S*, 4R*)), 4S*, 5R*, 8S*, 9E*, 12R*, 14R*, 5S*, 16R*, 18S8 pimecrolimus, 19S*, 26aR*))- [CAS] 137071-32-0 EP 626385 Antipruritic/inflamm, allergic Eczema, atopic Pimefylline 10001-43-1 Acetic acid, [2- [octahydro-5-hydroxy-6- (3- hydroxy-5-methyl-1-nonenyl)-2- pentalenyl] ethoxy]-, methyl ester, [2R- [2Aipha, 3Aipha, 4Aipha (1 E, 3S*, 5S*), 5 l, 6aA pimilprost Ipha]]- [CAS] 139403-31-9 Dermatological Ulcer, general Piminodine 13495-09-5 Pimobendan 74150-27-9 2H-Benzimidazol-2-one, 1- [1- [4, 4-bis (4- fluorophenyl) butyl]-4-piperidinyl]-1, 3-dihydro pimozide [CAS] 2062-78-4 FR M3695 Neuroleptic Pinacidil 85371-64-8 Morpholinium, 4-[(2-bromo-4, 5- dimethoxyphenyl) methyl]-4- [2- [2- (6, 6- dimethylbicyclo [3. 1. 1] hept-2-yi) ethoxy] ethyl]- 53251-94-8 pinaverium, [CAS] 59995-65-2 EP 406743 Antispasmodic Irritable bowel syndrome 2H-1, 4-Benzodiazepin-2-one, 7-chloro-1, 3- pinazepam dihydro-5-phenyl-1- (2-propynyl)- [CAS] 52463-83-9 DE 2339790 Anxiolytic Pindolol 13523-86-9 2, 4-Thiazolidinedione, 5- [ [4- [2- (5-ethyl-2- pyridinyl) ethoxy] phenyl] methyl]-, 111025-46-8 pioglitazone monohydrochloride (+/-)- [CAS] 112529-15-4 EP 193256 Antidiabetic Diabetes, Type II Pipacycline 1110-80-1 Pipamazine 84-04-8 Pipamperone 1893-33-0 Patent API Generic Name API Chemical Name CAS No. Reference Example of Therapeutic Use Example of Indication Pipazethate 2167-85-3 Pipebuzone 27315-91-9 Pipecurium 52212-02-9 Piperazinium, 4, 4'- [(2ß, 3Aipha, 5Alpha, 16ß, 17i3)-3, 17- bis (acetyloxy) androstane-2, 16-diyl] bis [1, 1]- 52212-02-9 pipecuronium dimethyl-, [CAS] 68399-57-5 GB 1398050 Muscle relaxant Anaesthesia, adjunct Pyrido [2, 3-d] pyrimidine-6-carboxylic acid, 8- ethyl-5, 8-dihydro-5-oxo-2- (1-piperazinyl)- pipemidic acid [CAS] 51940-44-4 GB 1451911 Antibacterial, other Infection, urinary tract Pipenzolate Bromide 125-51-9 Piperacetazine 3819-00-9 4-Thia-1-azabicyclo [3. 2. 0] heptane-2- carboxylic acid, 6-[[[[(4-ethyl-2, 3-dioxo-1- piperazinyl) carbonyl] amino] phenylacetyl] ami no]-3, 3-dimethyl-7-oxo-, [2S- 59703-84-3 piperacillin [2Alpha, 5Alpha, 6f5 (S*)]]- [CAS] 61477-96-1 GB 1508062 Penicillin, injectable Infection, general Piperazine Adipate 142-88-1 Piperidione 77-03-2 Piperidolate 82-98-4 Piperilate 4546-39-8 piperine analogues WO 002544 Dermatological Vitiligo Piperocaine 136-82-3 Piperonal 120-57-0 Piperoxan 59-39-2 Piperylone 25 31-4-6 Pipobroman 54-91-1 Piposulfan 2608-24-4 Hexadecanoic acid, 2- [1- [3- [2- [ (dimethylamino) sulfonyl]-10H-phenothiazin- 37517-26-3 pipotiazine 10-yl] propyl]-4-piperidinyl] ethyl ester [CAS] 39860-99-6 US 4782077 Neuroleptic Pipoxolan 18174-58-8 Pipradrol 467-60-7 1 I Patent API Generic Name API Chemical Name CAS No. Reference Example of Therapeutic Use Example of Indication Acetic acid, [3-ethyl-4-oxo-5- (1-piperidinyl)- piprozolin 2-thiazolidinylidene]-, ethyl ester [CAS] 17243-64-0 US 3971794 Gi inflammatory/bowel disorders Motility dysfunction, GI, general Piracetam 7491-74-9 5, 12-Naphthacenedione, 10- [ [3-amino-2, 3, 6 trideoxy-4-0- (tetrahydro-2H-pyran-2-yi)- Alpha-L-lyxo-hexopyranosyl] oxy]-7, 8, 9, 10- tetrahydro-6, 8, 11-trihydroxy-8- hydroxyacetyl)-1-methoxy-, [8S- pirarubicin [8Alpha, 10Alpha (S*)]]- [CAS] 72496-41-4 US 4303785 Anticancer, antibiotic Cancer, breast Pirazolac 71002-09-0 2, 6-Pyridinedimethanol, Alpha6-[[(1, 1-38029-10-6 dimethylethyl) amino] methyl]-3-hydroxy-, 38677-81-5 pirbuterol monoacetate (salt) [CAS] 65652-44-0 US 3786160 Antiasthma Asthma Pirenoxine 1043-21-6 6H-Pyrido [2, 3-b] [1, 4] benzodiazepin-6-one, 5, 11-dihydro-11- [ (4-methyl-1- 28797-61-7 pirenzepine piperazinyl) acetyl]- [CAS] 29868-97-1 FR 1505795 Antiulcer Benzoic acid, 3- (aminosulfonyl)-4-phenoxy- piretanide 5- (1-pyrrolidinyl)- [CAS] 55837-27-9 US 4010273 Antihypertensive, diuretic Hypertension, general pirfenidone 2 (1H)-Pyridinone, 5-methyl-1-phenyl- [CAS] 53179-13-8 Respiratory Fibrosis, pulmonary Pyrimidine, 2- [4- (1, 3-benzodioxol-5- piribedil ylmethyl)-1-piperamnyi]- [CAS] 3605-01-4 US 3299067 Vasodilator, peripheral Parkinson's disease Piridocaine 87-21-8 Pirifibrate 55285-45-5 Piritramide 302-41-0 Piritrexim 72732-56-0 H-Pyrazino [3, 2, 1-jk] carbazole, 2, 3, 3a, 4, 5, 6 16154-78-2 pirlindole hexahydro-8-methyl- [CAS] 60762-57-4 SU 276060 Antidepressant Depression, general (2-Pyridinemethanol, Alpha- [3- (2, 6-dimethyl 1-piperidinyl) propyl]-. Alpha. phenyl-, cis- (+)- 61477-94-9 pirmenol [CAS] 68252-19-7 US 4112103 Antiarrhythmic Tachycardia, supraventricuiar Piroctone 50650-76-5 Piroheptine 16378-21-5 i Patent API Generic Name API Chemical Name CAS No. Reference Example of Therapeutic Use Example of Indication Piromidic Acid 19562-30-2 2H-1, 2-Benzothiazine-3-carboxamide, 4- hydroxy-2-methyl-N-2-pyridinyl-, 1, 1-dioxide piroxicam [CAS] 36322-90-4 US 3862319 Anti-inflammatory ß-Cyclodextrin, compd. with 4-hydroxy-2- methyl-N-2-pyridinyl-2H-1, 2-benzothiazine- 121696-62-6 piroxicam betadex 3-carboxamide 1, 1-dioxide- [CAS] 96684-39-8 EP 153998 Formulation, other Pain, musculoskeletal 2-Propenoic acid, 3-phenyl-, 2-methyl-3-[(2- pyridinylamino) carbonyl]-2H-1, 2- piroxicam cinnamate benzothiazin-4-yl ester, S, S-dioxide [CAS] 87234-24-0 EP 79639 Antiarthritic, other Inflammation, general Pirozadil 54110-25-7 Pirprofen 31793-07-4 6-Heptenoic acid, 7- [2-cyclopropyl-4- (4- fluorophenyl)-3-quinolinyl]-3, 5-dihydroxy-, pitavastatin calcium salt (2 : 1), [S- [R*, S*- (E)]]- [CAS] 147526-32-7 EP 304063 Hypolipaemic/Antiatherosclerosis Hyperlipidaemia, general pivagabine N-trimethylacetyl-4-aminobutyric acid 69542-93-4 Neurological Anxiety, general Butanoic acid, (2, 2-dimethyl-1- pivaloyloxymethyl oxopropoxy) methyl ester [CAS] 122110-53-6 EP 302349 Anticancer, other Cancer, lung, non-small cell Pivalylbenzhydrazine 306-19-4 Pivampicillin 33817-20-8 pivampicillin/pivmecillinam 98445-47-7 Penicillin, oral Infection, general Pivcefalexin 63836-75-9 4-Thia-1-azabicyclo [3. 2. 0] heptane-2- carboxylic add, 6-[[(hexahydro-1 H-azepin-1 yl) methylene] amino]-3, 3-dimethyl-7-oxo-, (2, 2-dimethyl-1-oxopropoxy) methyl ester, pivmecillinam [2S- (2Alpha, 5Alpha, 6f5)]- [CAS] 32886-97-8 GB 1293590 Penicillin, oral Infection, general Benz [g] isoquinoline-5, 10-dione, 6, 9-bis [ (2- aminoethyl) amino]-, (2Z)-2- butenedioate (1 : 2) Cancer, lymphom, non- pixantrone [CAS] 144675-97-8 EP 503537 Anticancer, other Hodgkin's l Patent API Generic Name API Chemical Name CAS No. Reference Example of Therapeutic Use Example of Indication 4- (9, 10-dihydro-4H- benzo [4, 5] cyclohepta [1, 2-b] thien-4-ylidene)- pizotifen 1-methylpiperidine 15574-96-6 DE 2346747 Antimigraine Pizotyline 15574-96-6 Phenol, 4-(4-(((1 R)-1-phenyiethyi) amino)- PKI-166 1 H-pyrrolo (2, 3-d) pyrimidin-6-yl)- [CAS] 187724-61-4 Anticancer, other Cancer, general p-Lactophenetide 539-08-2 Plafibride 63394-05-8 plasminogen activator Plasminogen activator [CAS] 105913-11-9 EP 151996 Fibrinolytic Infarction, myocardial Plasmocid 551-01-9 Platonin 3571-88-8 Plaunotol 64218-02-6 Cyclopentanecarboxylic acid, 2-amino-4- PLD-118 methylene-, (1R, 2S)- [CAS] 198022-65-0 EP 805145 Antifungal Infection, Candida, general (OC-6-43)-Bis (acetato) (1- adamantylamine) ammine-dichlorc-platinum (IV) PLD-147 Anticancer, alkylating Cancer, general 1, 2, 4-Oxadiazole, 3- (3, 5-dimethyl-4- (3- (3- methyl-5-isoxazolyl) propoxy) phenyl)-5- Infection, respiratory tract, pleconarfi (trifluoromethyl)- [CAS] 153168-05-9 US 5464848 Antiviral, other general Plicamycin 18378-89-7 p-Methyidiphenhydramine 19804-27-4 PMS-601 WO 0001677 Antiviral, anti-HIV Infection, HIV/AIDS Pneumococcal Vaccine, Diphtheria Conjugate Pneumococcal Vaccine, Polyvalent N- [ [ (5s)-3 [4 [(1, 1-dioxido-4- thiomorpholinyl) 3, 5-difluorophenyl]-2-oxo-5- oxazolidinyl] methyl] acetamide] PNU-288034 Antibiotic, other Infection, general Podophyllotoxin 518-28-5 Zinc, bis (N-ß-aianyl-L-histidinato- polaprezinc N3, 0Alpha)-, (T-4)- [CAS] 107667-60-7 EP 303380 Antiulcer Ulcer, duodenal Poldine Methylsulfate 545-80-2 i Patent API Generic Name API Chemical Name CAS No. Reference Example of Therapeutic Use Example of Indication Policresulen 9011-2-3 Polidexide 9064-92-0 Polyethylene glycol monododecyl ether 3055-99-0 polidocanol 9002-92-0 Vasoprotective, systemic Venous insufficiency Poliovirus Vaccine Inactivated Poliovirus Vaccine Inactivated poly-ADPRT inhibitors WO 9845253 Anticancer, other Cancer, general Polyestradiol Phosphate 28014-46-2 Infection, human papilloma Polyphenon E Polyphenon E [CAS] 188265-33-0 Antiviral, other virus Polythiazide 346-18-9 porfimer Photofrin [CAS] 87806-31-3 US 4882234 Anticancer, other Cancer, lung, non-small cell Porfiromycin 801-52-5 D-threo-Pentitol, 2, 5-anhydro-1, 3, 4-trideoxy- 2-C- (2, 4-difluorophenyl)-4- ( (4- (4- (4- (1 (1 S, 2S)-1-ethyi-2-hydroxypropyi)-1, 5- dihydro-5-oxo-4H-1, 2, 4-triazol-4-yl) phenyl)- 1-piperazinyl) phenoxy) methyl)-1- (1 H-1, 2, 4- posaconazole triazol-1-yl)- [CAS] 171228-49-2 US 5714490 Antifungal Infection, fungai, general Posatirelin 78664-73-0 potassium chloride Potassium chloride (KCI) [CAS] 7447-40-7 Formulation, oral, enteric-coated Potassium Gluconate 299-27-4 Potassium Guaiacolsuifonate 1321-14-8 Potassium p-Aminobenzoate 138-84-1 Potassium Permanganate 7722-64-7 Povidone 9003-39-8 Povidone-lodine 25655-41-8 PP-117 3-Pyridinemethanol, hydrofluoride [CAS] 62756-44-9 DE 2633028 Formulation, oral, other Unspecified (-)- (E)- [4- (2, 4-dichlorophenyl)-1, 3-dithiolan- 2-ylidene]-1-imidazolylacetonitrile PR-2699 Antifungal Infection, fungal, general t Patent API Generic Name API Chemical Name CAS No. Reference Example of Therapeutic Use Example of Indication (S)- (-)-1- [4, 4-bis (4-fluorophenyl) butyl]-4- (2- . hydroxy-3-phenylaminopropyl) piperazine PR-608 trihydrochloride Antiparkinsonian Parkinson's disease Practolol 6673-35-4 Prajmaline 35080-11-6 Pralidoxime 51-15-0 6H-Pyridazino (1, 2-a) (1, 2) diazepine-1- carboxamide, N- ( (2R, 3S)-2- ethoxytetrahydro-5-oxo-3-furanyl) octahydro- 9- ( (1-isoquinolinylcarbonyl) amino)-6, 10- pralnacasan dioxo-, (1S, 9S)- [CAS] 192755-52-5 Antiarthritic, immunological Arthritis, rheumatoid 2, 6-Benzothiazolediamine, 4, 5, 6, 7- pramipexole tetrahydro-N6-propyl-, (S)- [CAS] 104632-26-0 EP 186087 Antiparkinsonian Parkinson's disease 1-Pyrrolidineacetamide, N-[2-[bis (1-68497-62-1 methylethyl) amino] ethyl]-2-oxo-, 72869-16-0 pramiracetam monohydrochloride [CAS] 75733-50-5 US 4145347 Cognition enhancer Amnesia Pramiverin 14334-40-8 1, 2-Dithia-5, 8, 11, 14, 17- pentaazacycloeicosane, cyclic peptide pramlintide deriv. [CAS] 151126-32-8 US 5124314 Antidiabetic Diabetes, Type I Pramoxine 140-65-8 3, 5-Pyridlnedicarboxylic acid, 1, 4-dihydro- 2, 6-dimethyl-4- (3-nitrophenyl)-, methyl 3- pranidipine phenyl-2-propenyl ester, (E)- [CAS] 99522-79-9 EP 173126 Antihypertensive, other Hypertension, general Praniukast 103177-37-3 5H- [1] Benzopyrano [2, 3-b] pyridine-7-acetic pranoprofen acid, Alpha-methyl- [CAS] 52549-17-4 Formulation, mucosal, topical Ocular disorder, general Androst-5-en-17-one, 3-hydroxy-, (33)- prasterone [CAS] 53-43-0 Labour inducer 4 (3H)-Cycloheptimidazolone, 5, 6, 7, 8- tetrahydro-2-propyl-3-[[2-(1 H-tetrazoi-5- pratosartan yi) [1, 1'-biphenyl]-4-yl] methyl]- [CAS] 153804-05-8 US 5409947 Antihypertensive, renin system Hypertension, general 1 Patent API Generic Name API Chemical Name CAS No. Reference Example of Therapeutic Use Example of Indication 1-Naphthaleneheptanoic acid, 1, 2, 6, 7, 8, 8a- hexahydro-g, delta, 6-trihydroxy-2-methyl-8- 2-methyi-1-oxobutoxy)-, monosodium salt, 1S- 1Alpha (ßS*, deltaS*), 2Aipha, 6Alpha, 8ß (Ri), 81093-37-0 pravastatin 8aAlpha]]- [CAS] 81131-70-6 US 4346227 Hypolipaemic/Antiatherosclerosis Atherosclerosis Prazepam 2955-38-6 4H-Pyrazino [2, 1-a] isoquinolin-4-one, 2- (cyclohexylcarbonyl)-1, 2, 3, 6, 7, 11b- praziquantel hexahydro- [CAS] 55268-74-1 US 4001411 Schistosomicide Piperazine, 1- (4-amino-6, 7-dimethoxy-2- 19216-56-9 prazosin quinazolinyl)-4- (2-furanylcarbonyl)- [CAS] 19237-84-4 US 4092315 Antihypertensive, adrenergic Hypertension, general Prednicarbate 73771-04-7 Pregna-1, 4-diene-3, 20-dione, 21- [4- [4- [bis (2-chloroethyl) amino] phenyl]-1- prednimustine oxobutoxy]-11, 17-dihydroxy-, (11ß)- [CAS] 29069-24-7 GB 1272841 Anticancer, alkylating Prednisolone 50-24-8 Prednisolone 21-5626-34-6 Diethyiaminoacetate Pregna-1, 4-diene-3, 20-dione, 11, 17- dihydroxy-21- [ (3, 7, 11-trimethyl-1-oxo-2, 6, 10 prednisolone famesil odecatrienyl) oxy]-, [im, 21 (2E, 6E)]- [CAS] 118244-44-3 EP 332143 Antiarthritic, other Arthritis, rheumatoid Prednisolone Sodium Phosphate 125-02-0 Prednisone 53-03-2 Prednival 15180-00-4 Prednylidene 599-33-7 Hexanoic acid, 3- (aminomethyl)-5-methyl, pregabalin (S)- [CAS] 148553-50-8 Antiepileptic Epilepsy, general Pregnan-3a-ol-20-one 128-20-1 Estra-4, 9-dien-3-one, 17- (2-hydroxy-1- Premarin + trimegestone oxopropyl)-17-methyl-, [17a (S)]- [CAS] 74513-62-5 Menopausal disorders Hormone replacement therapy Phenol, 4- [2-hydroxy-3- [ (1- methylethyi) amino] propoxy]-, hydrochloride, 7526-81-5 prenalterol (S)- [CAS] 61260-05-7 GB 1470039 Cardiostimulant l Patent API Generic Name API Chemical Name CAS No. Reference Example of Therapeutic Use Example of Indication Prenoxdiazine 982-43-4 Prenylamine 390-64-7 Cuprate (1-), (N2- (N-glycyl-L-histidyl)-L- lysinato) (N2- (N-glycyl-L-histidyl)-L- prezatide lysinato (2-))-, hydrogen, [CAS] 130120-57-9 Vulnerary Wound healing Pridinol 511-45-5 Prifinium 4630-95-9 Prilocaine 721-50-6 Primaquine 90-34-6 Primidone 125-33-7 Prinomastat 192329-42-3 PRO-2000 US 5614599 Antiviral, anti-HIV Infection, HIV prophylaxis Probenecid 57-66-9 Probucol 23288-49-5 Benzamide, 4-amino-N- [2- 51-06-9 procainamide (diethylamino) ethyl]- [CAS] 614-39-1 Formulation, other Arrhythmia, general Procaïne 59-46-1 Procarbazine 671-16-9 I 2 (1H)-Quinolinone, 8-hydroxy-5- [1-hydroxy- 59828-07-8 2- [ (1-methylethyl) amino] butyl]-, 60443-17-6 procaterol monohydrochloride [CAS] 72332-33-3 GB 1496766 Antiasthma 10H-Phenothiazine, 2-chloro-10- [3- (4-methyl 58-38-8 prochlorperazine 1-piperazinyl) propyl]-, (Z)-2-butenedioate 84-02-6 Formulation, oral, other Nausea and vomiting, general procodazol 23249-97-0 ES 407882 Anticancer, immunological Cancer, general Procyclidine 77-37-2 Procymate 13931-64-1 Prodipine 31314-38-2 Proflavine 92-62-6 Progabide 62666-20-0 progesterone Pregn-4-ene-3, 20-dione [CAS] 57-83-0 Formulation, transmucosal, systemic Amenorrhoea ! Patent API Generic Name API Chemical Name CAS No. Reference Example of Therapeutic Use Example of Indication 1H-indole-3-aceticacid, 1- (4-chlorobenzoyl) 5-methoxy-2-methyl-, 2- (4- (3- ( (4- (benzoylamino)-5- (dipropylamino)-1, 5- dioxopentyl) oxy) propyl)-1- 57132-53-3 proglumetacin piperazinyl) ethylester, (+/-)- [CAS] 59209-40-4 GB 1467568 Anti-inflammatory Inflammation, general Pentanoic acid, 4- (benzoylamino)-5- proglumide (dipropylamino)-5-oxo-, (+/-)- [CAS] 6620-60-6 DE 1518125 Antiulcer Ulcer, gastric Proheptazine 77-14-5 Prolactin 9002-62-4 Prolintane 493-92-5 Prolonium 123-47-7 Promazine 58-40-2 Promedol 64-39-1 Promegestone 34184-77-5 Estra-1, 3, 5 (10)-triene, 17-methoxy-3- promestriene propoxy-, (17fol)- [CAS] 39219-28-8 GB 1337198 Reproductive/gonadal, general Acne Promethazine 60-87-7' Pronethalol 54-80-8 Glycine, N, N-diethyl-, 4- (acetylamino) phenyl 66532-85-2 propacetamol ester [CAS] 66532-86-3 US 4127671 Formulation, parenteral, other 1-Propanone, 1- [2- [2-hydroxy-3- (propylamino) propoxy] phenyl]-3-phenyl- propafenone [CAS] 54063-53-5 GB 1307455 Antiarrhythmic Fibrillation, ventricular Propagermanium 12758-40-6 Propallylonal 545-93-7 Propamidine 104-32-5 propane-1, 2-diol 1, 2-propanediol 57-55-6 Formulation, dermal, topical Infection, fungal, general Propanidid 1421-14-3 Propantheline 50-34-0 Proparacaine 499-67-2 Propatyl 2921-92-8 ethyl trans-Alpha-acetyl-l-methyl-5- propenidazole nitroimidazole-2-acrylate 76448-31-2 Antifungal Infection, trichomoniasis 1H-Purine-2, 6-dione, 3, 7-dihydro-3-methyl- propentofyiline 1-(5-oxohexyl)-7-propyl- [CAS] 55242-55-2 GB 1470220 NeuroprotecUve ischaemia, cerebrai i 7 i Patent API Generic Name API Chemical Name CAS No. Reference Example of Therapeutic Use Example of Indication Propicillin 551-27-9 Propiomazine 362-29-8 Propionic Acid 79-09-4 1-Propanaminium, 3-carboxy-N, N, N- trimethyl-2- (I-oxopropoxy)-, chloride, (R)-119793-66-7 propionyl L-carnitine [CAS] 20084-19-1 GB 2008578 Vasodilator, peripheral Peripheral vascular disease Propipocaine 3670-68-6 Propiram 15686-91-6 2, 2-diphenyl-2- (1-propoxy) acetic acid (1-54556-98-8 propiverine methylpiperid-4-yl) ester hydrochloride 60569-19-9 Urological Incontinence Propizepine 10321-12-7 propofol Phenol, 2, 6-bis (1-methylethyl)- [CAS] 2078-54-8 US 4056635 Anaesthetic, injectable Anaesthesia Propoxycaine 550-83-4 Propoxyphene 469-62-5 2-Propanol, 1- [ (1-methylethyl) amino]-3- (1- 318-98-9 propranolol naphthalenyloxy)- [CAS] 525-66-6 Formulation, modified-release, <=24hr Hypertension, general Propylhexedrine 101-40-6 Propyliodone 587-61-1 ( Propylthiouracil 51-52-5 Proscillaridin 466-06-8 Proquazone 22760-18-5 Proscillaridin 466-06-8 Prostacyclin 35121-78-9 Prostaglandin E1 745-65-3 Prostaglandin E2 363-24-6 Prosc ! i ! aridin''466-06-8 Prostacydin 35121-78-9 Prostagiandin E1745-65-3 Prostaglandin F2a 551-11-1 Prosultiamine 59-58-5 Protein C 60202-16-6 Protheobromine 50-39-5 Prothipendyl 303-69-5 Protiofate 58416-00-5 Protionamide 14222-60-7 = i ! Patent API Generic Name API Chemical Name CAS No. Reference Example of Therapeutic Use Example of Indication 1OH-Phenothiazine-2-acetic acid, 7- protizinic acid methoxy-Alpha, 10-dimethyl-, (+/-)- [CAS] 13799-03-6 US 3450698 Anti-inflammatory Protoanemonin 108-28-1 Protokylol 136-70-9 Protoporphyrin IX 553-12-8 Protriptyline 438-60-8 Pro-Urokinase 82657-92-9 Proxazole 5696-9-3 Proxibarbal 2537-29-3 Propanoic acid, 3, 3'- (1, 3-dioxo-1, 3- proxigermanium digermoxanediyl) bis- [CAS] 12758-40-6 FR 2005110 Antiviral, other Infection, hepatitis-B virus Proxyphylline 603-00-9 Prozapine 3426-8-2 Prucalopride 179474-81-8 1 H, 4H- [1, 3] Thiazeto [3, 2-a] quinoline-3- carboxylic acid, 6-fluoro-1-methyl-7- [4- [ (5- methyl-2-oxo-1, 3-dioxol-4-yl) methyl]-1- Infection, respiratory tract, prulifloxacin piperazinyl]-4-oxo- [CAS] 123447-62-1 EP 315828 Quinolone antibacterial general Pseudococaine 478-73-9 Benzenemethanol, Alpha- [1- (methylamino) ethyl]-, hydrochloride, [S- (R*, R*)]-, mixt. with (E)-2- [1- (4- methylphenyl)-3- (I-pyrrolidinylyi- pseudoephedrine + triprolidine propenyl] pyridine monohydrochloride [CAS] Formulation, modified-release, other Rhinitis, allergic, general Benzenemethanol, Alpha- [1- 90-82-4, 8054-27-Infection, respiratory tract, pseudoephedrine (methylamino) ethyl]-, [S- (R*, R*)]- [CAS] 1, 345-78-8 Formulation oral other general Psilocybin 520-52-5 Benzonitrile, 4- [3- (4-hydroxybutyl)-4, 4- dimethyl-2, 5-dioxo-1-imidazolidinyl]-2- PSK-3841 (trifluoromethyl)- [CAS] 154992-24-2 Dermatological Alopecia, general p-Sulfanilylbenzylamine 4393-19-5 PT-141 US 6051555 Male sexual dysfunction Impotence Pteropterin 89-38-3 _ Puromycin 53-79-2 I Patent API Generic Name API Chemical Name CAS No. Reference Example of Therapeutic Use Example of Indication 1-Methylpropyl 2-mercaptoimidazolyl disulfide PX-12 Anticancer, other Cancer, general Pyrantel 15686-83-6 Pyrazinamide 98-96-4 Pyridinol Carbamate 1882-26-4 Pyridostigmine Bromide 101-26-8 Pyridoxal 5-Phosphate 54-47-7 Pyridoxine 58-56-0 Pyrilamine 91-84-9 Pyrimethamine 58-14-0 Pyrinoline 1740-22-3 Pyrisuccideanol 33605-94-6 Pyrithione 1121-30-8 Pyrithyidione 77-04-3 = Pyritinol 1098-97-1 Pyrocatechol 120-80-9 Pyrogallol 87-66-1 Pyronaridine 74847-35-1 Pyrovalerone 3563-49-3 Pyroxylin 9004-70-0 Pyrrobutamine 91-82-7 Pyrrocaine 2210-77-7 Pyrrolnitrin 1018-71-9 Pyrvinium Pamoate 3546-41-6 2H-1, 4-Benzodiazepine-2-thione, 7-chloro-5 (2-fluorophenyl)-1, 3-dihydro-1-(2, 2, 2- quazepam trifluoroethyl)- [CAS] 36735-22-5 US 3845039 Hypnotic/Sedative Insomnia Quercetin 117-39-5 Ethanol, 2- [2- (4-dibenzo [b, fj [1, 4] thiazepin- 11-yl-1-piperazinyl) ethoxy]-, (E)-2-111974-69-7 quetiapine butenedioate (2 : 1) (salt) [CAS] 111974-72-2 EP 240228 Neuroleptic Schizophrenia Quinacillin 1596-63-0 Patent API Generic Name API Chemical Name CAS No. Reference Example of Therapeutic Use Example of Indication N-(6-Chloro-2-methoxy-9-acridinyi)-N, N-83-89-6 diethyl-1, 4-pentanediamine + 10H- Phenothiazine-10-propanamine, 2-chloro- N, N-dimethyl quinacrine Neurological Creutzfeldt-Jakob disease Sulfamide, N, N-diethyl-N'- (1, 2, 3, 4, 4a, 5, 10, 10a-octahydro-6-hydroxy-1- 87056-78-8 propylbenzo [g] quinolin-3-yl)-, 94424-50-7 quinagolide (3Alpha, 4aAlpha, 10aß)- (+/-)- [CAS] 97805-49-7 EP 77754 Antiprolactin Hyperprolactinaemia 3-Isoquinolinecarboxylic acid, 2- [2- [ [1- (ethoxycarbonyi)-3-phenylpropyl] amino]-1-82586-55-8 oxopropyl]-1, 2, 3, 4-tetrahydro-, [3S-85441-61-8 quinapril [2 [R* (R*)], 3R*]]- [CAS] 90243-99-5 EP 49605 Antihypertensive, renin system Hypertension, general 3-Isoquinolinecarboxylic acid, 2- [2- [ (1- carboxy-3-phenylpropyl) amino]-1-oxopropyl] 1, 2, 3, 4-tetrahydro-, [3S- [2 [R* (R*)], 3R*]]- quinaprilat [CAS] 82768-85-2 EP 46953 Antihypertensive, renin system Hypertension, general Quinapyramine 20493-41-8 Quinbolone 2487-63-0 Quinestradiol 1169-79-5 Quinestrol 152-43-2 Quinethazone 73-49-4 2-Furancarboxylic acid, 1- (dichloroacetyl)- quinfamide 1, 2, 3, 4-tetrahydro-6-quinolinyl ester [CAS] 62265-68-3 US 3997542 Amoebicide Cinchonan-9-ol, 6'-methoxy-, (9S)-, sulfate 747-45-5 quinidine (1 : 1) (salt) [CAS] 56-54-2 Formulation, modified-release, other Arrhythmia, general Quinine Quinine 130-95-0 Quinocide 525-61-1 Quinupramine 31721-17-2 Quinupristin 120138-50-3 cis-2, 3, 3a, 8-tetrahydro-N, N- dimethyidibenz [c, fjisoxazolo [2, 3-a] azepin- R-107500 2-methanamine WO 9614320 Anxiolytic Anxiety, general R-667 WO 0204439 COPD treatment Emphysema, general ; ) i Patent API Generic Name API Chemical Name CAS No. Reference Example of Therapeutic Use Example of Indication 1H-Benzimidazole, 2- [ [ [4- (3- methoxypropoxy)-3-methyl-2- pyridinyljmethyllsulfina-, sodium salt-117976-89-3 rabeprazole [CAS] 117976-90-6 EP 268956 Antiulcer Ulcer, gastric Glycine, N-[2-[(acetyithio) methyi]-1-oxo-3- phenylpropyl]-, phenylmethyl ester, (+/-)-112573-72-5 racecadotril [CAS] 81110-73-8 EP 38758 Antidiarrhoeal Diarrhoea, general Racemethorphan 510-53-2 Methanone, [6-hydroxy-2- (4- hydroxyphenyl) benzo [b] thien-3-yl] [4- [2- (1- piperidinyl) ethoxy] phenyl]-, hydrochloride 82640-04-8 raloxifene [CAS] 84449-90-1 EP 62503 Osteoporosis treatment Osteoporosis L-glutamic acid, N- [ [5- [ [ (1, 4-dihydro-2- methyl-4-oxo-6- quinazolinyi) methyl] methylamino]-2- raititrexed thienyl] carbonyl]- [CAS] 112887-68-0 EP 239362 Anticancer, antimetabolite Cancer, colorectal 9H-Carbazole-9-propanoic acid, 3- [ [ (4- fluorophenyl) sulfonyl] amino]-1, 2, 3, 4- ramatroban tetrahydro-, (R)- [CAS] 116649-85-5 EP 242518 Antiallergic, non-asthma Rhinitis, allergic, perennial Ramifenazone 3615-24-5 Cyclopenta [b] pyrrole-2-carboxyiic acid, 1-[2- [ [I- (ethoxycarbonyl)-3-phenylpropyt] amino]- 1-oxopropyl] octahydro-, [2S-87269-97-4 ramipril [1 [R* (R*)], 2Alpha, 3al3, 6aß]]-[CAS] 87333-19-5 EP 79022 Antihypertensive, renin system Heart failure Methanone, (1-methyl-1H-indol-3-yl) (4, 5, 6, 7 tetrahydro-1H-benzimidazol-5-yl)-, 132907-72-3 ramosetron monohydrochloride, (R)- [CAS] 132036-88-5 EP 381422 Antiemetic Nausea and vomiting, general Ramot project No. 1097 US 5730992 Dermatological Unspecified Ranimustine 58994-96-0 1, 1-Ethenediamine, N- [2- [ [ [5- [ (dimethylamino) methyl]-2- furanyl] methyl] thio] ethyl]-N'-methyl-2-nitro- ranitidine [CAS] 66357-35-5 US 4128658 Antiulcer Ulcer, duodenal ) Patent API Generic Name API Chemical Name CAS No. Reference Example of Therapeutic Use Example of Indication 1, 2, 3-Propanetricarboxylic acid, 2-hydroxy- bismuth (3+) salt (1 : 1), compd. with N- (2- ( ( (5 ((dimethyiamino) methyl)-2- furanyl) methyl) thio) ethyl)-N-methyl-2-ni1- ranitidine bismuth citrate ethenediamine (1 : 1)- [CAS] 128345-62-0 EP 533281 Antiulcer Ulcer, duodenal 1-Piperazineacetamide, N-(2, 6- dimethylphenyl)-4- [2-hydroxy-3- (2- 95635-55-5 ranolazine methoxyphenoxy) propyi]-, (+/-)- [CAS] 95635-56-6 EP 126449 Antianginal Angina, general Ranpirnase 133737-96-9 Rapacuronium 156137-99-4 1H-Inden-1-amine, 2, 3-dihydro-N-2- rasagiline propynyl-, (R)-, [CAS] 161735-79-1 US 5457133 Antiparkinsonian Parkinson's disease Raubasine 483-04-5 Benzonitrile, 4- [2- [ (1R, 2R)-2- (2, 4- difluorophenyl)-2-hydroxy-1-methyl-3- (1 H- ravuconazole 1, 2, 4-triazol-1-yl) propyl]-4-thiazolyi]- [CAS] 182760-06-1 Antifungal Infection, meningitis, general 2-Benzofuranacetic acid, 5- (acetyloxy)-2, 3- raxofelast dihydro-4, 6, 7-trimethyl-, (+)- [CAS] 128232-14-4 US 4999350 Symptomatic antidiabetic Nephropathy, diabetic 2, 6-Piperazinedione, 4, 4'- (1-methyl-1, 2- 21416-67-1, 21416 razoxane ethanediyl) bis- [CAS] 87-5 GB 1234935 Anticancer, other Cancer, general Tetradecanoic acid (1 R)-1-(2-((2-((2-deoxy- 3-0-((3R)-1-oxo-3-((1- oxotetradecyl) oxy) tetradecyl) amino-4-0- phosphono-ß-D- glucopyranosyl) oxy) ethyl) amino)-2- oxoethyl) dodecyl ester, compd. with N, N- RC-529 diethylethanamine (1 : 1) [CAS] 216014-46-9 Immunostimulant, other Vaccine adjunct 4-Quinolinepropanoic acid, Alpha- [ (4- chlorobenzoyl) amino]-1, 2-dihydro-2-oxo- rebamipide [CAS] 90098-04-7 DE 3324034 Antiulcer L-Valinamide, N-((2S)-2-mercapto-1-oxo-4- (3, 4, 4-trimethyl-2, 5-dioxo-1- imidazol butyl)-L-leucyl-N, 3-dimethyl- rebimastat [CAS] 259188-38-0 Anticancer, other Cancer, lung, non-small cell Morpholine, 2- [ (2- ethoxyphenoxy) phenylmethyl]-, (R*, S*)- 71620-89-8, 98769- reboxetne [CAS] 81-4 US 4229449 Antidepressant Depression, general t Patent API Generic Name API Chemical Name CAS No. Reference Example of Therapeutic Use Example of Indication Remacemide 128298-28-2 1-Piperidinepropanoic acid, 4- (methoxywarbonyi)-4-((1- oxopropyl) phenylamino)-methyl ester-132539-07-2, remifentanil [CAS] 132875-61-7 EP 383579 Analgesic, other Pain, general Tricyclo [3. 3. 1. 13, 7] decane-2-carboxylic add, 2-[[[1-(7-chloro-4-quinolinyl)-5-(2, 6- dimethoxyphenyl)-1 H-pyrazol-3- reminertant yl] carbonyl] amino]- [CAS] 146362-70-1 EP 699438 Neuroleptic Schizophrenia Remoxipride 80125-14-0 Benzamide, 4-amino-N-1- azabicyclo [3. 3. 1] non-4-yi-5-chloro-2-109872-41-5 renzapride methoxy- [CAS] 88721-77-1 JP 58188885 Gastroprokinetic Irritable bowel syndrome Benzoic acid, 2-ethoxy-4- [2- [ [3-methyl-1- [2- (1-piperidinyi) phenyl] butyl] amino]-2- repaglinide oxoethyl]-, (S)- [CAS] 135062-02-1 WO 9300337 Antidiabetic Diabetes, Type II 2 (R)-4-lsobutylphenylpropionyl methanesulfonamide L-lysine salt repertaxin L-lysine salt WO 0024710 Cardiovascular Reperfusion injury 1, 2-Benzisothiazol-3 (2H)-one, 2- (4- ( ( (3, 4- dihydro-2H-1-benzopyran-2- yl) methyl) amino) butyl)-, 1, 1-dioxide, 144980-29-0 repinotan monohydrochloride [CAS] 144980-77-8 US 5137901 Neuroprotective Ischaemia, cerebral 4H-Pyrano [3, 2-c] quinoline-2-carboxylic acid, 5, 6-dihydro-7, 8-dimethyl-4, 5-dioxo-, 3- repirinast methylbutyl ester [CAS] 73080-51-0 US 4298610 Antiasthma Reposal 3625-25-0 1H-Purine-2, 6-dione, 7- [3- [ [2- (3, 5- dihydroxyphenyl)-2- hydroxyethyi] amino] propyl]-3, 7-dihydro-1, 3- 13055-82-8 reproterol dimethyl- [CAS] 54063-54-6 FR M5969 Antiasthma Asthma Rescimetol 73573-42-9 Rescinnamine 24815-24-5 Reserpiline 131-02-2 Reserpine 50-55-5 Resibufogenin 465-39-4 = l Patent API Generic Name API Chemical Name CAS No. Reference Example of Therapeutic Use Example of Indication 1 H-imidazo (4, 5-c) quinoline-1- ethanol (ethoxymethyi)-Alpha, Alpha- resiquimod dimethyl- [CAS] 144875-48-9 US 5389640 Antiviral, other Infection, hepatitis-C virus Resorcinol 108-46-3 Reteplase 133652-38-7 Carbamic acid, (2-amino-4- ( ( (4- fluorophenyl) methyl) amino) phenyl)-, ethyl retigabine ester [CAS] 150812-12-7 DE 4200259 Antiepileptic Epilepsy, general Cancer, leukaemia, acute retinoic acid Retinoic acid [CAS] 302-79-4 Formulation, parenteral, other myelogenous Revimid US 6281230 Anticancer, other Cancer, myeloma [1, 1-Biphenyl]-4-acetic acid, 2-fluoro-Alpha- methyl R-flurbiprofen 5104-49-4 Anticancer, other Cancer, prostate Rho (D) Immune Globulin (Human) Rho-kinase inhibitors WO 0156988 Antiasthma Unspecified 1H-1, 2, 4-Triazole-3-carboxamide, 1-ß-D- ribavirin ribofuranosyl- [CAS] 36791-04-5 US 4211771 Antiviral, other Infection, haemorrhagic fever Riboflavin 146-17-8 D-Streptamine, 0-2, 6-diamino-2, 6-dideoxy- Alpha-D-glucopyranosyl- (1-4)-O- [f3-D- ribostamycin ribofuranosyl- (1-5)]-2-deoxy- [CAS] 25546-65-0 GB 1254883 Aminoglycoside antibiotic Infection, general Ricinoleic Acid 141-22-0 Ridogrel 110140-89-1 Rifamycin XIV, 1', 4-didehydro-1-deoxy-1, 4- Infection, Mycobacterium avium rifabutin dihydro-5-(2-methyipropyi)-1-oxo-[CAS] 72559-06-9 US 4219478 Antimycobacterial complex Rifamycin Vlil, 1, 4-didehydro-1-deoxy-1, 4-129791-92-0 dihydro-3'-hydroxy-5'- [4- (2-methylpropyl)-1- 129791-94-2 rifaiazil piperazinyl]-1-oxo- [CAS] 133633-12-2 EP 366914 Antimycobacterial Infection, tuberculosis Rifamycin, 3- [ [ [1- (diethylamino) ethylidene] hydrazono] methyi]- rifametane [CAS] 94168-98-6 EP 119571 Antimycobacterial Infection, general Rifamide 2750-76-7' I Patent API Generic Name API Chemical Name CAS No. Reference Example of Therapeutic Use Example of Indication Rifamycin, 3-[[(4-methyi-1- piperazinyi) imino] methyl]-, mixt. with 5- [ (3, 4, 5-trimethoxyphenyl) methyl]-2, 4- rifampicin + trimethoprim pyrimidinediamine [CAS] 61498-94-Formulation, fixed-dose combinations Infection, general Rifampin 13292-46-1 Rifamydn SV 6998-60-3 Rifamycin, 3-[[(4-cyclopentyi-1- rifapentine piperazinyl) imino] methyi]- [CAS] 61379-65-5 DE 2608218 Antibiotic, other Infection, tuberculosis Epoxypentadeca [1, 11, 13] trienimino) benzof uro [4, 5-e]-pyrido [1, 2-a] benzimidazole- 1, 15 (2H)-dione, 25- (acetyloxy)-5, 6, 21, 23- tetrahydroxy-27-methoxy- 2, 4, 11, 16, 20, 22, 24, 26-octamethyl-, [2S- (2R*, 16Z, 18E, 20R*, 22S*, 23S*, 24S*, 25R*, 2 6S*, 27R*, 28E)] rifaximin80621-81-4 GB 2079270 Antibiotic, other Infection, Gi tract 4-deoxy-4'-methylpyrido [1', 2'- rifaximine cream 1, 2] imidoazo [5, 4-c] rifamycin SV 80621-81-4 BE 888895 Formulation, dermal, topical Infection, dermatological Rilmazafone 99593-25-6 2-Oxazolamine, N-(dicyclopropyimethyi)-4, 5 54187-04-1 rilmenidine dihydro- [CAS] 54249-57-9 DE 2362754 Antihypertensive, adrenergic Hypertension, general 2-Benzothiazolamine, 6-(trifluoromethoxy)- riluzole [CAS] 1744-22-5 EP 50551 Neuroprotective Amyotrophic lateral sclerosis Rimantadine 13392-28-4 4H-Pyrido [1, 2-a] pyrimidinium, 3- (ethoxycarbonyl)-6, 7, 8, 9-tetrahydro-1, 6- 28610-84-6 rimazolium dimethyl-4-oxo-, [CAS] 35615-72-6 DE 2461349 Analgesic, NSAID Androsta-1, 4-dien-3-one, 11-hydroxy-16, 17- dimethyl-17- (I-oxopropyl)-, mexolone (11ß, 16Alpha, 1713)- [CAS] 49697-38-3 DE 2301317 Ophthalmological Inflammation, ocular Rimiterol 32953-89-2 1 H-Pyrazole-3-carboxamide, 5- (4- chlorophenyl)-1-(2, 4-dichlorophenyi)-4- methyl-N-1-piperidinyl-, monohydrochloride rimonabant [CAS] 158681-13-1 US 5624941 Anorectic/Antiobesity Obesity riodoxol 1, 3-Benzenediol, 2, 4, 6-triiodo- [CAS] 19403-92-0 US 3755251 Antiviral, other Patent API Generic Name API Chemical Name CAS No. Reference Example of Therapeutic Use Example of Indication Rioprostil 77287-05-9 Phosphonic acid, (1-hydroxy-2- (3- risedronate pyridinyl) ethylidene) bis-, monosodium salt 115436-72-1 EP 304961 Osteoporosis treatmentPaget's disease Risedronic Acid 105462-24-6 4H-Pyrido [1, 2-a] pyrimidin-4-one, 3- [2- [4- (6- fluor-1, 2-benzisoxazol-3-yl)-1- piperidinyl] ethyl]-6, 7, 8, 9-tetrahydro-2-methyl Neuroleptic, formulation, optimized, risperidone [CAS] 106266-06-2 EP 196132 microencapsulate Schizophrenia Ritanserin 87051-43-2 Ritipenem 84845-57-8 Benzenemethanol, 4-hydroxy-Alpha- [1- [ [2- (4-hydroxyphenyl) ethyl] amino] ethyl]-, 23239-51-2 ritodrine (R*, S*)- [CAS] 26652-09-5 US 3410944 Labour inhibitor Labour, preterm 2, 4, 7, 12-Tetraazatridecan-13-oic acid, 10- hydroxy-2-methyl-5- (1-methylethyl)-1- (2- (1- methylethyl)-4-thiazolyl)-3, 6-dioxo-8, 11- bis (phenylmethyl)-, 5-thiazolyl-methyl ester, ritonavir (5S- (5R*, 8R*, 10R*, 11 R*))- [CAS] 155213-67-5 WO 9414436 Antiviral, anti-HIV Infection, HIV/AIDS Rituximab 174722-31-7 Carbamic acid, ethylmethyl-, 3- [l- (dimethylamino) ethyl] phenyl ester, (S)-123441-03-2 rivasfigmine [CAS] 129101-54-8 DE 3805744 Cognition enhancer Alzheimer's disease 145202-66-0 1H-lndoie-3-ethanamine, N, N-dimethyl-5-159776-67-7 rizatriptan (1H-1, 2, 4-triazol-1-ylmethyl)-, [CAS] 144034-80-0 EP 497512 Antimigraine Migraine 3-Buten-1-amine, N-methyl-4- (3-pyridinyl)-, RJR-2403 (3E)-, (2E)-2-butenedioate (1 : 1) [CAS] 183288-99-5 Cognition enhancer Alzheimer's disease 5-Formyluridine RNA Stealth Nucleosides Antiviral, other Infection, hepatitis-C virus 2', 3'-Di-O-acetyl-5'-vinylcytidine Ro-0094889 Anticancer, antimetabolite Cancer, general i 1 Patent API Generic Name API Chemical Name CAS No. Reference Example of Therapeutic Use Example of Indication 2-Pyridinesulfonamide, N- [6- (2- hydroxyethoxy)-5- (2-methoxyphenoxy)-2- [2- (1 H-tetrazol-5-yl)-4-pyridinyl]-4-pyrimidinyl]- Ro-61-1790 5-methyl- [CAS] 180384-56-9 WO 9619459 Cardiovascular Haemorrhage, subarachnoid Rociverine 53716-44-2 Pyrrolidinium, 1-104855-17-6 [(2ß, 3Aipha, 5Alpha, 16ß, 17ß)-17-(acetyloxy) 104884-91-S 3-hydroxy-2- (4-morpholinyl) androstan-16-yl] 119302-91-9 rocuronium 1- (2-propenyl)-, bromide- [CAS] 143558-00-3 EP 287150 Muscle relaxant Muscle spasm, general 2 (5H)-Furanone, 4- (4- rofecoxib (methylsulfonyl) phenyl)-3-phenyl- [CAS] 162011-90-7 US 5474995 Analgesic, NSAiD Arthritis, osteo Benzamide, 3- (cyclopropylmethoxy)-N- (3, 5- dichioro-4-pyridinyi)-4-(difluoromethoxy)-Chronic obstructive pulmonary roflumilast [CAS] 162401-32-3 WO 9501338 COPD treatment disease Leucomycin V, 4B-butanoate 3B- rokitamycin propanoate [CAS] 74014-51-0 US 4242504 Macrolide antibiotic Infection, general Rolipram 61413-54-5 Rolitetracycline 751-97-3 Romurtide 78113-36-7 Ronifibrate 42597-57-9 2H-Indol-2-one, 4- [2- (dipropylamino) ethyl]- 91374-20-8 ropinirole 1, 3-dihydro-, monohydrochloride- [CAS] 91 i74-21-9 EP 266033 Antiparkinsonian Parkinson's disease 2-Piperidinecarboxamide, N- (2, 6- 84057-95-4 ropivacaine dimethylphenyl)-1-propyl-, (S)- [CAS] 98717-15-8 EP 239710 Anaesthetic, local Anaesthesia Roquinimex 84088-42-6 Cyclopentaneheptanoic acid, 2-hexyl-5- rosaprostol hydroxy- [CAS] 56695-65-9 GB 1523355 Prostaglandin Rosaramicin 35834-26-5 Rose Bengal 632-68-8 2, 4-Thiazolidinedione, 5- ( (4- (2- (methyl-2- pyridinylamino) ethoxy) phenyl) methyl)-, (Z)-2 122320-73-4 rosiglitazone butenedioate (1 : 1) [CAS] 155141-29-0 US 5002953 Antidiabetic Diabetes, Type II 3-Quinolinecarboxylic acid, 1-ethyl-1, 4-, rosoxacin dihydro-4-oxo-7- (4-pyridinyl)- [CAS] 40034-42-2 US 3753993 Quinoione antibacterial Infection, gonorrhoea i Patent API Generic Name API Chemical Name CAS No. Reference Example of Therapeutic Use Example of Indication Tin, dichloro [ethyl 3, 4, 20, 21-tetradehydro- 4, 9, 14, 19-tetraethyl-18, 19-dihydro-3, 8, 13, 18 tetramethyl-20-phorbinecarboxylato (2-)- kappaN23, kappaN24, kappaN25, kappaN26] rostaporfin, (OC-6-13)- [CAS] 114494-17-6 Ophthalmological Macular degeneration 6-Heptenoic acid, 7- (4- (4-fluorophenyl)-6- (1 methylethyl)-2- (methyl (methylsulfonyl) amino)-5-pyrimdinyl) rosuvastatin 3, 5-dihydroxy- (S- (R*, S*- (E))) [CAS] 147098-20-2 JP 2648897 Hypolipaemic/Antiatherosclerosis Hyperlipidaemia, general 1-Naphthalenol, 5, 6, 7, 8-tetrahydro-6- rotigotine [propyl [2-(2-thienyl) ethyl] amino]-, (S)- [CAS] 99755-59-6 US 4564628 Antiparkinsonian Parkinson's disease Rotraxate 92071-51-7 Roxarsone 121-19-7 Acetamide, 2- (acetyloxy)-N- [3- [3- (1- 78628-28-1 roxatidine piperidinylmethyl) phenoxy] propyl]-, [CAS] 93793-83-0 EP 24510 Antiulcer Ulcer, gastric L-Alanine, 3- ( ( (3- (4- (aminoiminomethyi) phenyl)-4, 5-dihydro-5- isoxazolyl) acetyl) amino)-N- (butoxycarbonyl) roxifiban methyl ester, (R)-, [CAS] 176022-59-6 US 5849736 Antithrombotic Thrombosis, general Roxindole 112192-04-8 Erythromycin, 9- [0- [ (2- 80214-83-1 roxithromycin methoxyethoxy) methyl] oxime] [CAS] 80214-86-4 EP 33255 Macrolide antibiotic infection, general Patent API Generic Name API Chemical Name CAS No. Reference Example of Therapeutic Use Example of Indication i Benzenepropanoic acid, ß-(((1, 1- dimethylethoxy) carbonyl) amino)-Alpha- hydroxy- (1 S, 2S, 4S, 7R, 8aR, 9aS, 10aR, 12aS, 12bR)- 7, 12a-bis (acetyloxy)-1- (benzoyloxy)- 1, 3, 47, 8, 9, 9a, 10, 10a, 12, 12a, 12b- dodecahydro-2-hydroxy-5, 13, 13-trimethyl-8- oxo-2, 6-methano-2H-cyclodeca (3, 4) cyclopropa (4, 5) benz (1, 2-b) oxet-4-yl RPR-109881A ester, dihydrate Alpha R, betaS [CAS] 192573-38-9 Anticancer, other Cancer, lung, general 4, 9-Ethano-3aH-benz [flisoindole-3a- carboxylicacid, 1, 2, 3, 4, 9, ga-hexahydro-2- [2- (2-methoxyphenyl)-1-oxo-2-propenyl]-9- (4- RPR-130401 methylphenyl)-, (3aR, 4S, 9S, 9aR)-rel- [CAS] 210282-69-2 WO 9829390 Anticancer, other Cancer, general R-roscovitine US 6316456 Anticancer, other Cancer, lung, non-small cell N'N'-bis (3-hydroxyphenyl) pyridazine-3, 6- diamine RS-0406 Neuroprotective Alzheimer's disease RSR-13 131179-95-8 Rubijervine 79-58-3 1 H-Pyrano (3', 4' : 6, 7) indolizino (1, 2- b) quinoline-3, 14 (4H, 12H)-dione, 4-ethyl-4- rubitecan hydroxy-10-nitro-, (S)- [CAS] 91421-42-0 US 6485514 Anticancer, other Cancer, pancreatic 9H, 18H-5, 21 : 12, 17- Dimethenodibenzo (e, k) pyrrolo (3, 4- h) (1, 4, 13) oxadiazacyclohexadecine- 18, 20 (19H)-dione, 9- ( (dimethylamino) methyl)-6, 7, 10, 11- ruboxistaurin tetrahydro-, (S)- [CAS] 169939-94-0 Symptomaticantidiabetic Retinopathy, diabetic Rufinamide 106308-44-5 7H-Pyrido [1, 2, 3-de]-1, 4-benzothiazine-6- 101363-10-4 carboxylic acid, 9-fluoro-2, 3-dihydro-10- (4- 102052-47-1 rufloxacin methyl-1-piperazinyl)-7-oxo- [CAS] 106017-08-7 EP 165375 Quinolone antibacterial Infection, general i Patent API Generic Name API Chemical Name CAS No. Reference Example of Therapeutic Use Example of Indication 5H-Benzo [5, 6] cyclohepta [1, 2-b] pyridine, 8- chloro-6, 11-dihydro-11- [1- [ (5-methyl-3- pyridinyl) methyl]-4-piperidinylidene]-, rupatadine trihydrochloride- [CAS] 156611-76-6 EP 0577957 Antiallergic, non-asthma Rhinitis, allergic, seasonal Rutin 153-18-4 5-Thia-1-azabicyclo [4. 2. 0] oct-2-ene-2- carboxylic acid, 7-[[(2Z)-(2-amino-5-chioro-4 thiazolyi) (hydroxyimino) acetyl] amino]-3- [ (3- [[(2-aminoethyi) thio] methyi]-4-pyridinyi] thio]-Infection, beta-lactamase RWJ-54428 8-oxo-, (6R, 7R)- [CAS] 189448-35-9 WO 9713772 Cephalosporin, injectable resistant Olean-12-en-28-oic acid, 27- [ [3- [5-hydroxy- 2- [ (4-methoxy-1, 4-dioxo-2- butenyl) amino] phenyl]-1-oxo-2- S-0139 propenyl] oxy]-3-oxo- [CAS] 193969-54-9 WO 9727314 Cardiovascular Ischaemia, cerebral Piperazine, 1- (2, 3-dihydro-1, 4-benzodioxin- S-15535 5-yl)-4-(2, 3-dihydro-1 H-inden-2-yl)- [CAS] 146998-34-7 Cognition enhancer Cognitive disorder, general 1-Napthalenepropanoic acid, 6-(((4- chlorophenyl) sulfonyl) amino)-5, 6, 7, 8- S-18886 tetrahydro-2-methyl [CAS] 165537-73-5 Antithrombotic Thrombosis, general 7-chloro-6-sulfamoyl-2- ( H)-quinoleinone-3- phosphonic acid S-34730 Neuroprotective Unspecified 711- [2- (5-amino-1, 2, 4-thiadiazol-3-yl)-2 (Z)- ethoxyiminoacetamido]-3- (1- (N- rriethylaminopropyl)-1 H-imidazo [4, 5- b] pyridinium-4-methyl-3-cephem-4- carboxylate monosulfate S-3578 Cephalosporin, injectable Infection, general 2- {N- [4- (4-Chlorophenyisulfonylamino) butyl] N- {3- [ (4-isopropylthiazol-2- yl) methyloxy] benzyl} sulfamoyl} benzoic acid 1 S-36496Ant ! asthmaAsthma r Patent API Generic Name API Chemical Name CAS No. Reference Example of Therapeutic Use Example of Indication 2- {N- [4- (4-Chlorophenyisulfonylamino) butyl] N- {3- [2- (4-cyclobutylthiazol-2- yl) ethyl benzyl} sulfamoyl} benzoic acid S-36527 Antiasthma Asthma (1 R, 2R, 3S, 5S)-7- [2- (5- Hydroxybenzothiophen-3-ylcarboxamido)- 6, 6-dimethylbicyclo [3. 1. 1] hept-3yi]-5 (Z)- heptenoic acid S-5751 Antiallergic, non-asthma Allergy, general imidazo [4, 5-d] pyrano [4, 3-b] pyridine, 1, 6, 7, 9- tetrahydra-2- (3-isoxazolyi)-, phosphate (1 : 1) S-8510 [CAS] 151466-23-8 EP 556008 Cognition enhancer Alzheimer's disease 2-Naphthalenecarboxylic acid, 1- (3, 4- dimethoxyphenyl)-3- (3-ethyl-1-oxopentyl)-4- hydroxy-6, 7, 8-trimethoxy-, methyl ester S-8921 [CAS] 151165-96-7 WO 9308155 Hypolipaemic/Antiatherosclerosis Hypercholesterolaemia Sabcomeline 159912-53-5 Sabeluzole 104383-17-7 S-Adenosyimethionine 29908-03-0 (S)- (+)-2- [4- (3- fluorobenzyloxy) benzylamino] propanamide safinamide methansulfonate 133865-89-1 AU 711309 Antiepileptic Epilepsy, general Salacetamide 487-48-9 Salazosulfadimidine 2315-8-4 1, 3-Benzenedimethanol, Aipha1-[[(1, 1- dimethylethyl) amino] methyl]-4-hydroxy- Formulation, inhalable, topical, dry salbutamol [CAS] 18559-94-9 EP 451745 powder Asthma Salicin 138-52-3 Salicyl Alcohol 90-01-7 Salicylamide 65-45-2 Salicylamide O-Acetic Acid 25395-22-6 Salicylanilide 87-17-2 Salicylic Acid 69-72-7 Salicylsulfuric Acid 89-45-2 Salinazid 495-84-1 ! Patent API Generic Name API Chemical Name CAS No. Reference Example of Therapeutic Use Example of Indication 1, 3-Benzenedimethanol, 4-hydroxy-Alphal- [ [ [6- (4-phenylbutoxy) hexyl] amino] methyl-, ()-1-hydroxy-2-naphthalenecarboxylate 89365-50-4 salmeterol [CAS] 94749-08-3 WO 9006775 Antiasthma Asthma Salsalate 552-94-3 Salverine 6376-26-7 Samarium 153Sm Lexidronam 154427-83-5 L-Tyrosine, N2- (methylsulfonyl)-L-lysyl-1- [ (2S)-3-amino-2- sampatrilat carboxypropyl] cyclopentanecarbonyl- [CAS] 129981-36-8 EP 358398 Antihypertensive, renin system Hypertension, general Sancycline 808-26-4 Saperconazole 110588-57-3 4 (1 H)-Pteridinone, 2-amino-6- (1, 2- dihydroxypropyl)-5, 6, 7, 8-tetrahydro-, 69056-38-8 62989- sapropterin dihydrochloride, [6R- [6R* (1R*, 2S*)]]- [CAS] 33-7 EP 191335 Antidepressant Hyperphenylalaninaemia Butanediamide, N1- [3- [3- [ [ (1, 1- dimethylethyl) amino] carbonyl] octahydro- 2 (1 H)-isoquinolinyl]-2-hydroxy-1- (phenylmethyl) propyl]-2- [ (2- quinolinylcarbonyl) amino]-, [3S- saquinavir [2 [1R* (R*), 2S*], 3Alpha, 4aß, 8aß]]- [CAS] 127779-20-8 EP 432695 Antiviral, anti-HIV Infecflon, HIV/AIDS Saraiasin 34273-10-4 Benzamide, N- [4- [4- (acetylamino)-4-phenyl- 1-piperidinyl]-2- (3, 4-dichlorophenyl) butyl]-N- saredutant methyl-, (S)- [CAS] 142001-63-6 EP 474561 Antiasthma Asthma 3-Pyridinemethanamine, N-((3, 4-dihydro-2H 1-benzopyran-2-yl) methyl)-5- (4- sarizotan fluorophenyl)- [CAS] 177975-08-5 Antiparkinsonian Parkinson's disease Butanedioic acid, mono [2- (dimethylamino)- - [ [2- [2- (3- methoxyphenyl) ethyl] phenoxy] methyl] ethyl] sarpogrelate ester [CAS] 125926-17-2 EP 398326 Antithrombotic Satigrel 111753-73-2 Patent API Generic Name API Chemical Name CAS No. Reference Example of Therapeutic Use Example of Indication Platinum, bis (acetato- O) amminedichloro (cyclohexanamine)-, (OC satraplatin 6-43)- [CAS] 129580-63-8 EP 328274 Anticancer, alkylating Cancer, prostate Satumomab 144058-40-2 N- [3- [ [2- (3, 4- dimethoxyphenyl) ethyl] amino] propyl]-4- nitrobenzamide, HCI SB-237376 Antiarrhythmic Fibriliation atriaí (5 (-2-phenylamino-4-pyrimidinyl)-4-) (4- fluorophenyl)-1- (4-piperidinyl) imidazole SB-238039 Anticancer, other Cancer, general trans-N- [4- [2- (6-Cyano-1, 2, 3, 4- tetrahydroisoquinolin-2-yl) ethyl] cyclohexyl]- 4-quinolinecarboxamide SB-277011 Neuroleptic Schizophrenia Scarlet Red 85-83-6 Benzonitrile, 4- [2- [3, 6-dihydro-4- (1, 4, 5, 6- tetrahydro-6-oxo-3-pyridazinyl)-1 (2H)- SCH-00013 pyridinyl]-1-hydroxyethyl]- [CAS] 217963-18-3 EP 618204 Cardiostimulant Heart failure (2- [10, 11-Dihydro-5-ethoxy-5H-dibenzo [a, d] cyclohepten-S-yl]-N, N-dimethyl- ethanamine Sch-23863 Immunosuppressant Inflammation, general 1-Piperazineacetonitrile, 4-cyclohexyl-alpha [4-[(S)-(4-methoxyphenyi) sulfinyi] phenyl]- Sch-57790 [CAS] 221660-80-6 Cognition enhancer Alzheimer's disease 7H-Pyrazolo [4, 3-e] [1, 2, 4] triazol [1, 5- c] pyrimidin-5-amine, 2- (2-furanyl)-7- (3- Sch-63390 phenylpropyl)- [CAS] 174648-45-4 Antiparkinsonian Parkinson's disease Scillarenin 465-22-5 Scopolamine 51-34-3 Scopolamine N-Oxide 97-75-6 Patent API Generic Name API Chemical Name CAS No. Reference Example of Therapeutic Use Example of Indication Benzeneacetic acid, Alpha- (hydroxymethyl)- , 9-methyl-3-oxa-9- azatricyclo [3. 3. 1. 02, 4] non-7-yl ester, [7 (S)- scopolamine (1Alpha, 2ß, 4ß, 5Alpha, 7ß)]- [CAS] 51-34-3 US 4262003 Formulation, transdermal, other Nausea and vomiting, general SCS technology US 6046188 Antiasthma Unspecified 9, 10-Secocholesta-5, 7, 10 (19)-triene- secalciferol 3, 24, 25-triol, (335, 5Z, 7E, 24R)- [CAS] 55721-11-4 EP 301167 Osteoporosis treatment Osteodystrophy 1H-Imidazole-1-ethanol, Alpha, 2-dimethyl-5- secnidazole nitro- [CAS] 3366-95-8 FR M3270 Protozoacide Infection, trichomoniasis Secobarbital 309-43-3 Benzeneethanamine, N, Alpha-dimethyl-N-2- selegiline propynyl-, (R)- [CAS] 14611-51-9 GB 1153578 Antiparkinsonian Selenomethionine 1464-42-2 Sematilide 101526-83-4 Semotiadil 116476-13-2 1, 3-Cyclohexanediol, 5- ( (1- (6-ethyl-6- hydroxy-l-methyl-2, 4-octadienyl) octahydro- 7a-methyl-4H-inden-4-ylidene) ethylidene)-4- methylene-, (1 R- (1Aipha (1R*, 2E, 4E), 3aS. 4E (1R*, 3S*, 5Z), 7a seocalcitol Alpha))- [CAS] 134404-52-7 WO 9100855 Anticancer, other Cancer, liver Sepimostat 103926-64-3 Benzeneheptanoic acid, zeta- (2, 4, 5- trimethyl-3, 6-dioxo-1, 4-cyclohexadien-1-yi)-, 103187-07-1 seratrodast (+/-)- [CAS] 112665-43-7 EP 232089 Antiasthma Asthma 1H-lmidazole, 1-[2-[(7-chiorobenzo [b] thien- 3-yl) methoxy]-2- (2, 4-dichlorophenyl) ethyl]- sertaconazole [CAS] 99592-32-2 EP 151477 Antifungal Infection, dermatological 2-Imidazolidinone, 1- [2- [4- [5-chloro-1- (4- fluorophenyl)-1 H-indol-3-yl]-1- sertindole piperidinyl] ethyl]- [CAS] 106516-24-9 EP 392959 Neuroleptic Schizophrenia 1-Naphthalenamine, 4- (3, 4-dichlorophenyl)- 79559-97-0 1, 2, 3, 4-tetrahydro-N-methyl-, (1S-cis)-79617-96-2 sertraline [CAS] 79617-97-3 EP 30081 Antidepressant Depression, general Setastine 64294-95-7 = ! Patent API Generic Name API Chemical Name CAS No. Reference Example of Therapeutic Use Example of Indication 2-Propen-1-amine polymer with 152751-57-0 sevelamer (chloromethyl) oxirane, hydrochloride [CAS] 52757-95-6 US 5496545 Urological Renal failure Propane, 1, 1, 1, 3, 3, 3-hexafluoro-2- sevoflurane (fluoromethoxy)- [CAS] 28523-86-6 DE 1954268 Anaesthetic, inhalation Anaesthesia 2H-1, 4-Benzothiazine-2-acetic acid, 3, 4- dihydro-3-oxo-4- ( (4, 5, 7-trifluro-2- SG-210 benzothiazolyl) methyl)- [CAS] 143162-65-6 Symptomatic antidiabetic Neuropathy, diabetic Cyclobutanemethanamine, 1- (4- chlorophenyl)-N, N-dimethyl-Alpha- (2- 106650-56-0 ibutramine methyipropyi)- [CAS] 84485-00-7 GB 2098602 Anorectic/Antiobesity Obesity (4aS- (4aAipha, 6alpha, 11bAlpha, 13aR*, 13bAlph a))-1, 2, 3, 4, 4a, 5, 6a, 11 b, 13b-decahydro- 4, 4, 6a, 9-tetramethyl-13H-benzo [a] furo [2, 3, 4 siccanin mn] xanthen-11-ol 22733-60-4 JP 37003548 Antifungal Piperazine, 1-((3-(4, 7-dihydro-1-methyl-7- oxo-3-propyl-1 H-pyrazolo (4, 3-d) pyrimidin-5- yl)-4-ethoxyphenyl) sulfonyl)-4-methyi, 2- hydroxy-1, 2, 3-propanetricarboxylate- (1 : 1) 171599-83-0 sildenafil [CAS] 139755-83-2 WO 9428902 Male sexual dysfunction Impotence 1 H-Indole-7-carboxamide, 2, 3-dihydro-1- (3- hydroxypropyl)-5-[(2R)-2-[[2-[2-(2, 2, 2- trifluoroethoxy) phenoxy] ethyl] amino] propyi]- silodosin [CAS] 160970-54-7 EP 600675 Urological Dysuria Silver Lactate 128-00-7 Silver Picrate 146-84-9 N-2-pyrimidinyisuifanilamide monosilver 22199-08-2 silver suffadiazine salt 68-35-9 Anti-infective, other Infection, general Simetride 154-82-5 Simflbrate 14929-11-4 Patent API Generic Name API Chemical Name CAS No. Reference Example of Therapeutic Use Example of Indication Butanoic acid, 2, 2-dimethyl-, 1, 2, 3, 7, 8, 8a- hexahydro-3, 7-dimethyl-8- [2- (tetrahydro-4- hydroxy-6-oxo-2H-pyran-2-yl) ethyi]-1- naphthalenyl ester, [1S- [1Alpha, 3Alpha, 7ß, 8R (2S*, 4S*), 8aft]]- simvastatin [CAS] 79902-63-9 US 4444784 Hypolipaemic/Antiatherosclerosis Hyperlipidaemia, general Sincalide 25126-32-3 Sintropium Bromide 79467-19-9 Sisomicin 32385-11-8 3-Quinolinecarboxylic acid, 7- (7-amino-5- azaspiro [2. 4] hept-5-yi)-8-chloro-6-fluoro-1- (2-fluorocyclopropyl)-1, 4-dihydro-4-oxo-, sitafloxacin [1 R- Alpha (S*), 2Alpha]]-, hydrate 127254-12-0 EP 341493 Quinolone antibacterial Infection, general 1, 6-Hexanediamine, N, N-diethyl-N-(6-5330-29-0 sitamaquine methoxy-4-methyl-8-quinolinyl)- [CAS] 57695-04-2 Protozoacide Infection, leishmaniasis N- (4-Chlorc-3-methyl-5-iscxazolyl)-2-1 [4, 5- (methylenedioxy)-o-toly] acetyl]-3- thiophenesulfonamide sitaxsentan 184036-34-8 US 5464853 Antihypertensive, other Hypertension, pulmonary Glycine, N-[2-[[[4-(2, 2-dimethyl-1- oxopropoxy) phenyl] sulfonyl] amino] benzoyl]- Systemic inflammatory sivelestat [CAS] 127373-66-4 EP 347168 Respiratory response syndrome Butanamide, 2- [ [ (4- fluorophenyl) sulfonyl] amino]-N-[(1 S)-1- formyi-3-methyibutyl.).-3-methyl-, (2S)- SJA-6017 [CAS] 190274-53-4 EP 771565 Ophthalmological Cataract 6-Fluoro-9-methyl-2-phenyl-4-pyrrolidin-1- ylcarbonyl)-2, 9-dihydro-1 H-pyrido [3, 4- b] indole-1-one SL-65-1498 EP 607076 Anxiolytic Anxiety, general (3S, 2'R)-3- [1- [2'- (Ethoxycarbonyl)-4'-phenyl- butyl-]-cyclopentan-1-carbonylamino]- 2, 3, 4, 5-tetra-hydro-2-oxo-1 H-benzapin-1- SLV-306 acetic acid Antihypertensive, diuretic Hypertension, general i Patent API Generic Name API Chemical Name CAS No. Reference Example of Therapeutic Use Example of Indication 2 (3H)-Benzoxazolone, 7- (4-methyl-1- piperazinyl)-, monohydrochloride SLV-308 269718-83-4 Antiparkinsonian Parkinson's disease Samarate (5-)-153Sm, ( ( (1, 2- ethanediylbis (nitrilobis (methylene))) tetrakis ( phosphonato)) (8-)-N, N', OP, OP', OP", OP)-, Sm1531exidronam pentasodium, (OC-6-21)- [CAS] 160369-78-8 Analgesic, other Pain, cancer S-Methylmethionine 4727-40-6 N- (Aminoiminomethyl)-11-chloro-5, 6, 7, 8- tetrahydro-8-oxo-4H-pyrrolo [3, 2, 1- ki] [1] benzazocine-2-carboxamide monomethanesulfonate monohydrate SMP-300 Antianginal Angina, general (4S)-4, 7, 11-triethyl-3, 4, 12, 14-tetrahydro- 4, 10-dihydroxy-3, 14-dioxo-1 H- pyrano [3', 4' : 6, 7] indolizino [1, 2-b] quindin-9-yl SN-38 100286-90-6 Formulation, optimized, liposomes Cancer, colorectal ( (+)-methyl (4S)-3- (3- {4- [3- (acetylamino) phenyl]-1- piperidinyl} propyl) amino] carbonyl}-4- (3, 4- difluorophenyl)-6- (methoxymethyl)-2-oxo- 1, 2, 3, 4-tetrahydro-5-pyrimidinecarboxylate hydrochloride) SNAP-7941 Anxiolytic Anxiety, general 2-Naphthalenecarboxamide, N- [2- [4- (diphenylmethoxy)-1-piperidinyl] ethyl]-3- SOA-132 hydroxy-5- (3-pyridinylmethoxy)- [CAS] 143964-80-1 Formulation, inhalable, topical Asthma L-valinamide, N, N-dimethyl-L-valyl-N- [2- methoxy-4-[2-[1-methoxy-2-methyi-3-oxo-3- [(2-phenylethyi) amino] propyl]-1-pyrrolidinyll- ; 1- (2-methylpropyl)-4-oxobutyl]-N-methyl-, soblidotin [2S- [1 [1R* (R*), 2S*], 2R* (1S*, 2S*)]]- [CAS] 149606-27-9 WO 9303054 Anticancer, other Cancer, lung, non-small cell Sobrerol 498-71-5 f Patent API Generic Name API Chemical Name CAS No. Reference Example of Therapeutic Use Example of Indication Carbonic acid, 1, 2-ethanediylbis [ (2, 6-dioxo- r 4, 1-piperazinediyl) methyiene] bis (2- sobuzoxane methylpropyl) ester [CAS] 98631-95-9 EP 140327 Anticancer, other Cancer, lymphoma, T-cell Sodium Arsanilate 127-85-5 Sodium Arsphenamine 1936-28-3 Sodium Chloride Sodium Dibunate 14992-59-7 Sodium Folate 6484-89-5 Sodium Formaidehydesulfoxylate 149-44-0 Sodium Glycerophosphate 1334-74-3 Sodium Hyaluronate Sodium lodomethamate 519-26-6 Sodium Nitrite7632-00-0 Sodium Nitroprusside 14402-89-2 Butyric acid, 4-hydroxy monosodium salt sodium oxybate [CAS] 502-85-2 Psychostimulant Narcolepsy Sodium Phenotsuifonate 1300-51-2 sodium phenylbutyrate Butyric acid, 4-phenyl-, sodium salt- [CAS] 1716-12-7 Formulation, other Hyperammonaemia Sodium phosphate monobasic monohydrate + sodium phosphate dibasic sodium phosphate anhydrous US 6162464 Formulation, oral, other Surgery adjunct 3R-hydroxy-5-androsten-17-one (sodium sodium prasterone sulfate sulfate dihydrate) EP 380036 Formulation, mucosai, topical Labour, induction Sodium Propionate 137-40-6 Benzoic acid, 2-hydroxy-, monosodium salt sodium salicylate [CAS] 54-21-7 Formulation, oral, solubility-enhanced Pain, general Sodium Tetradecyl Sulfate 139-88-8 Acetic acid, [5- [ (3-methyl-2-butenyl) oxy]-2- [3- [4- [ (3-methyl-2-butenyl) oxy] phenyi]-1-oxo sofalcone 2-propenyl] phenoxy]- [CAS] 64506-49-6 GB 1523241 Antiulcer Solasulfone 133-65-3 Patent API Generic Name API Chemical Name CAS No. Reference Example of Therapeutic Use Example of Indication Butanedioic acid compd with (1S)- (3R)-1- azabicyclo (2. 2. 2) octyl 3, 4-dihydro-1- phenyl-2 (1H)-isoquinolinecarboxylate (1 : 1) solifenacin [CAS] 242478-38-2 Urological Overactive bladder D-Glucitol, hexa-3-pyridinecarboxylate Sorbinicate [CAS] 6184-06-1 BE 883352 Hypolipaemic/Antiatherosclerosis Sorbitol 50-70- Sorivudine 77181-69-2 Methanesulfonamide, N- [4- [1-hydroxy-2- [ (1- 3930-20-9 , otaioi methyiethyl) amino] ethyl] phenyi]- [CAS] 959-24-0 Antiarrhythmic Soterenol 13642-52-9 Sozoiodolic Acid 554-71-2 L-Glutamic acid, N- (N-acetyl-L-Alpha- 3106-85-2 spaglumic acid aspav)- [CAS] 80619-64-3 Formulation, mucosal, topical Conjunctivitis 3-Quinolinecarboxylic acid, 5-amino-1- cyclopropyl-7-(3s5-dimethyi-1-piperazinyl)-infedion, respiratory tract, sparfloxacin 6, 8-difluoro-1, 4-dihydro-4-oxo-, cis- [CAS] 110871-86-8 EP 221463 Quinolone antibacterial general Sparteine 90-39-1 1 Candicin D, 18-decarboxy-40-demethyf-3, 7- dideoxo-N3'- ( (dimethylamino) acetyl)-18- ( ( (2- (dimethylamino) ethyl) amino) carbonyl)-3, 7- dihydroxy-N47-methyl-5-oxo cyclic 15, 19- hemiacetal, comp with L-ascorbic acid (1 : 2) SPA-S-843 [CAS] 202748-83-2 US 5298495 Antifungal Infection, fungal, general Spasmolytol 25333-96-4 2 (1H)-Pyrimidinone, 4-amino-1- (2- (hydroxymethyl)-1, 3-oxathiolan-4-yi- (2R- cis)- SPD-754 160707-69-7 US 6228860 Antiviral, anti-HIV Infection, HIV/AIDS Spectinomycin 1695-77-8 4- [3- (4-Oxo-4, 5, 6, 7-tetrahydroindol- yl) propionylamino] benzoic acid ethyl ester SPI-339 Cognition enhancer Aizheimers disease Patent API Generic Name API Chemical Name CAS No. Reference Example of Therapeutic Use Example of Indication Spiperone 749-02-0 1, 4-Dithia-7-azaspiro [4. 4] nonane-8- carboxylic acid, 7- [2- [ [1- (ethoxycarbonyl)-3- phenylpropyl] amino]-1-oxopropyl]-, [8S- spirapril [7 [R* (R*)], 8R*]]- [CAS] 83647-97-6 EP 50800 Antihypertensive, renin system Hypertension, general Spirogermanium 41992-23-8 Pregn-4-ene-21-carboxylic acid, 7- (acetylthio)-17-hydroxy-3-oxo-, Gamma- spironolactone lactone, (7Alpha, 17Alpha)- [CAS] 52-01-7 EP 124147 Formulation, dermal, topical Acne Benzamide, N- (1, 1-dimethylethyl)-4- [ [cis-5'- ethoxy-4- [2- (4-morpholinyl) ethoxy]-2'- oxospiro [cyclohexane-1, 3-[3H] indol]-1 (2 H SR-121463 yl] sulfonyl]-3-methoxy- [CAS] 185913-78-4 WO 9715556 Cardiostimulant Heartfailure Morpholine, 4-benzoyl-2- (3, 4- difluorophenyl)-2- [2- [4- [[(dimethyiamino) carbonyi] amino]-4-phenyi- SR-144190 1-piperidinyl] ethyl]-, (2R)- [CAS] 201152-86-5 WO 9623787 Anxiolytic Anxiety, general 1 H-lndole-1-acetic acid, 2-[[[4-(4-chloro-2, 5- dimethoxyphenyl)-5- (2-cyclohexylethyl)-2- thiazoXyl] amino] carbonyi]-5, 7-dimethyi- SR-146131 [CAS] 221671-61-0 WO 9915525 Anorectic/Antiobesity Obesity N- [1- [2- (diethylamino) ethylamino]-7- methoxy-9-oxo-9H-thioxanthen-4- ylmethyl] formamide SR-271425 Anticancer, alkylating Cancer, general 1H-Indole-1-acetic acid, 2- [ [ [4- (2- chlorophenyl)-2-thiazolyl] amino] carbonyl]- SR-27897 [CAS] 136381-85-6 EP 432040 Anticancer, other Cancer, pancreatic Cyclohexanamine, N- (3- (3-chloro-4- cyclohexylphenyl)-2-propenyl)-N-ethyl-, SR-31747 hydrochloride, (Z)- [CAS] 132173-07-0 EP 376850 Anticancer, other Cancer, myeloma Acetic acid, [ [ (7S)-7- [ [ (2R)-2- (3- chlorophenyl)-2-hydroxyethyl] amino]-5, 6, 7, 8 tetrahydro-2-naphthalenyl] oxy]-, ethyl ester, SR-58611 hydrochloride [CAS] 121524-09-2 EP 303546 Gi inflammatory/bowel disorders Irritable bowel syndrome Patent API Generic Name API Chemical Name CAS No. Reference Example of Therapeutic Use Example of Indication SS732 US 5385900 Formulation, mucosal, topical Infection, ocular (R)- (-)-2- (2, 4-difluorophenyl)-1- (ethylsulfonyl)-1, 1-difluoro-3- (1 H-1, 2, 4- triazol-1-yl)-2-propanol SS-750 US 6083968 Antifungal Infection, fungal, general Propanamide, N, N' (dithiodi-2, 1- ß-alethine ethanediyi) bis (3-amino)- [CAS] 646-08-2 Anticancer, immunological Cancer, myeloma (2S, 4R)-1- [5-chloro-1- [ (2, 4- dimethoxyphenyl) sulfonyl]-3- (2-methoxy- phenyi)-2-oxo-2, 3-dihydro-1 H-indol-3-yl]-4- hydroxy-N, N-dimethyi-2-pyrrolidine carboxamide SSR-149415 WO 0155130 Antidepressant Depression, general 2- (7-chloro-5-methyl-4-oxo-3-phenyl-4, 5- dihydro-3H-pyridazino [4, 5-6] indoi-1-yi)-N, N- dimethylacetamide SSR-180575 Neuroprotective Unspecified (3-Exo)-8-benzoyl-N-[[(2S)-7-chloro-2, 3- dihydro-1, 4-benzodioxin-2-yl] methyl]-8- azabicyclo [3. 2. 1] octane-3-methanamine HCI SSR-181507 US 6221879 Neuroleptic Schizophrenia (5aS, 8S, 10aR)-5a, 6, 9, 10-tetrahydro, 7H, 11H-8, 10a- methanopyrido [2', 3' : 5, 6] pyrano [2, 3- d] azepine SSR-591813 Dependence treatment Addiction, nicotine D-Glucitol, 1, 4 : 3, 6-dianhydro-, nitrate SST-101 [CAS] 87-33-2 Formulation, transdermal, other Angina, general (-)- (R)-3-Methyl-3- (methylsulfonyl)-1- (1, 2, 4- triazol-i-yi)-2- [4- (tdfluoromethyI) phenyl]-2- SSY-726 butanol US 5147886 Antifungal Infection, fungal, general 1-Propanaminium, 2- (acetyloxy)-3-carboxy- ST-200 N, N, N-trimethyl-, chloride, (R)- [CAS] 5080-50-2 DE 3015635 Cognition enhancer Dementia, senile, general stachyfiin WO 9711947 Antiviral, other Infection, influenza virus Stallimycin 636-47-5 Stampidine US 6350736 Antiviral, anti-HIV Infection, HIV/AIDS Patent API Generic Name API Chemical Name CAS No. Reference Example of Therapeutic Use Example of Indication Stannous Pyrophosphate 15578-26-4 (OC-6-13)-Dihydrogen dichloro [7, 12-diethyl- 3, 8, 13, 17-tetramethyl-21 H, 23H-porphine- 2, 18-dipropanoato (4-)- N21, N22, N23, N24] stannate (2-) stannsoporfin 106344-20-1 Hepatoprotective Hyperbilirubinaemia Stanolone 521-18-6 Stanozolol 10418-03-8 (2¢H form) ; 302-96-5 (1¢H form) Staph aureus ther US 6376652 Genomics-based drug discovery Infection, MRSA STAT4 inhibitors WO 9629341 Immunosuppressant Unspecified stavudine Thymidine, 2', 3'-didehydro-3'-deoxy- [CAS] 3056-17-5 EP 501511 Antiviral, anti-HiV infection, HIV/AIDS Stenbolone 5197-58-0 Glycine, N- [1-oxo-2- [ (2- stepronin thienyicarbonyi) thio] propyl]- [CAS] 72324-18-6 US 4242354 Antitussive Cough Stibocaptate 27279-76-1 Stibophen 15489-16-4 Stilbamidine 122-06-5 1-Penten-3-ol, 1- (1, 3-benzodioxol-5-yl)-4, 4- stiripentol dimethyl- [CAS] 49763-96-4 Antiepileptic Epilepsy, general Streptodornase 37340-82-2 Streptomycin 57-92-1 Streptonicozid 5667-71-0 Streptonigrin 3930-19-6 Streptozocin 18883-66-4 3-Thiopheneacetic acid, 5- [bis (carboxymethyl) amino]-2-carboxy-4- strontium ranelate cyano-, strontium salt (1 : 2)- [CAS] 135459-87-9 EP 415850 Osteoporosis treatment Osteoporosis strontium-89 chloride Strontium chloride (89SrC12) [CAS] 38270-90-5 Analgesic, other Pain, cancer uccimer 304-55-2 Succinimide 123-56-8 Succinylcholine 55-94-7 Succinylcholine 71-27-2 SucCnylsulfathiazole 116-43-8 Patent API Generic Name API Chemical Name CAS No. Reference Example of Therapeutic Use Example of Indication Succisulfone 5934-14-5 Suclofenide 30279-49-3 Aluminium, hexadeca-p- hydroxytetracosahydroxy (p8- (1, 3, 4, 6-tetra- O-sulfo-ß-D-fructofuranosyi-Aipha-D- glucopyranoside tetrakis (hydrogen sucralfate sulfat) (8-))) hexadeca- [CAS] 54182-58-0 JP 58208233 Antiulcer, Formulation, oral, other Ulcer, general Propanamide, N- [4- (methoxymethyf)-l- [2- (2- sufentanil thienyl) ethyl]-4-piperidinyl]-N-phenyl- [CAS] 56030-54-7 US 3998834 Analgesic, other, formulation implant Pain, general 4-Thia-1-azabicyclo [3. 2. 0] heptane-2- carboxylic acid, 3, 3-dimethyl-7-oxo-, 4, 4- sulbactam dioxide, (2S-cis)- [CAS] 68373-14-8 GB 2000138 Antibiotic, other Infection, general sulbactam + ampicillin 117060-71-6 US 4234579 Antibiotic, other Infection, general 4-Thia-1-azabicyclo [3. 2. 0] heptane-2- carboxylic acid, 3, 3-dimethyl-7-oxo-6- [(phenyisulfoacetyl) amino]-, [2S-28002-18-8 sulbenicillin [2Alpha, 5Alpha, 6f (S*) B- [CAS] 41744-40-5 GB 1289358 Penicillin, injectable Infection, pseudomonal Sulbentine 350-12-9 Propanoic acid, 2-methyl-, dithiobis [3- [1- [ [ (4 amino-2-methyi-5- pyrimidinyl) methyl] formylamino] ethylidene]- 3286-46-2 sulbutiamine 3, 1-propanediyl] ester [CAS] 67-16-3 Neurological Unspecified 1H-imidazole, 1- [2- [ [ (4- chlorophenyl) methyl] thio]-2- (2, 4- 61318-90-9 sulconazole dichlorophenyl) ethyl]-, [CAS] 61318-91-0 US 4055652 Antifungal Infection, fungal, general Suiesomab 167747-19-5 Sulfabenzamide 127-71-9 Sulfacetamide 144-80-9 Sulfachlorpyridazine 80-32-0 Sulfachrysoidine 485-41-6 Sulfacytine 17784-12-2 Sulfadiazine 68-35-9 Sulfadicramide 115-68-4 Sulfadimethoxine 122-11-2 Sulfadoxine 2447-57-6 j Patent API Generic Name API Chemical Name CAS No. Reference Example of Therapeutic Use Example of Indication Sulfaethidole 94-19-9 Sulfaguanidine 57-67-0 Sulfaguanole 27031-08-9 Sulfalene 152-47-6 Sulfaloxic Acid 14376-16-0 Sulfamerazine 127-79-7 Sulfameter 651-06-9 Sulfamethazine 57-68-1 Sulfamethizole 144-82-1 Sulfamethomidine 3772-76-7 Sulfamethoxazole 723-46-6 Suifamethoxypyridazine 80-35-3 Sulfametrole 32909-92-5 Sulfamidochrysoidine 103-12-8 Sulfamoxole 729-99-7 Sulfanilamide 63-74-1 Sulfanilic Acid 121-57-3 Sulfanilylurea 547-44-4 Sulfaperine 599-88-2 Sulfaphenazole 526-08-9 Sulfaproxyline 116-42-7 Sulfapyrazine 116-44-9 Sulfapyridine 144-83-2 Sulfarside 1134-98-1 Sulfarsphenamine 618-82-6 Benzoic acid, 2-hydroxy-5- [ [4- [ (2- sulfasalazine pyridinylamino) sulfonyl] phenyl azo]- [CAS] 599-79-1 Formulation, oral, enteric-coated Arthritis, rheumatoid Sulfasomizole 632-00-8 Sulfasymazine 1984-94-7 Sulfathiazole 72-14-0 Sulfathiourea 515-49-1 Sulfinalol 66264-77-5 Sulfinpyrazone 57-96-5 = i Patent API Generic Name API Chemical Name CAS No. Reference Example of Therapeutic Use Example of Indication Sulfiram 95-05-6 Sulfisomidine 515-64-0 Sulfisoxazole 127-69-5 Sulfobromophthalein 71-67-0 Sulfonethylmethane 76-20-0 Sulfoniazide 3691-81-4 Sulfonmethane 115-24-2 Sulforidazine 14759-06-9 Sulfoxone 144-75-2 cis-5-fluoro-2-methyl-1-[(p- methylsulflnyl) benzySidene] indene-3-acetic sulindac acid 38194-50-2 US 3725548 Anti-inflammatory Inflammation, general Sulisatin 54935-03-4 Sulisobenzone 4065-45-6 Sulmarin 29334-07-4 Sulmazole 73384-60-8 Suloctidil 54063-56-8 Sulphan Blue 129-17-9 Benzamide, 5- (aminosulfonyl)-N- [ (1-ethyl-2- suipiride pyrrolidinyl) methyl]-2-methoxy- [CAS] 15676-16-1 Aiimentary/MetaboXic, other 5-Heptenamide, 7- [3-hydroxy-2- (3-hydroxy- 4=phenoxy-1-butenyl)-5-oxocyclopentyl]-N- (methylsulfonyl)-, [1 R- sulprostone [1Alpha (Z), 2ß (1E, 3R*), 3Alpha]]- [CAS] 60325-46-4 US 4024179 Prostaglandin Abortion 4-Thia-1-azabicyclo (3. 2 0) heptane-2- carboxylic acid, 6- ( (aminophenylacetyl) amino)-3, 3-dimethyl-7- oxo-, (((3, 3-dimethyl-7-oxo-4-thia-1- azabicyclo (3. 2. 0) hept-2- yl) carbonyl) oxy) methyl ester, S, S-dioxide, (2S- (2. alpha. (2R*, 5S*), 5, alpha., 6. beta. (S*)))- 117060-71-6 sultamicillin [CAS] 76497-13-7 GB 2044255 Penicillin, oral Infection, general Sulthiame 61-56-3 = Patent API Generic Name API Chemical Name CAS No. Reference Example of Therapeutic Use Example of Indication Benzamide, N- [ (1-ethyl-2- pyrrolidinyl) methyl]-5- (ethylsulfonyl)-2- suitopride methoxy- [CAS] 53583-79-2 FR M5916 Neuroleptic Psychosis, general Sultosilic Acid 57775-26-5 4H-imidazo [4, 5, 1-ij] quinolin-2 (1H)-one, 5, 6- dihydro-5- (methylamino)-, (5R)-, (2Z)-2- sumanirole butenedioate (1 : 1) [CAS] 179386-44-8 WO 9514020 Antiparkinsonian Parkinson's disease 1H-Indole-5-methanesulfonamide, 3- [2- (dimethylamino) ethyl]-N-methyl-, 103628-46-2 sumatriptan butanedioate (1 : 1)- [CAS] 103628-48-4 EP 147107 Antimigraine Migraine 1- (4-amino-2, 3, 5-trimethylphenoxy)-3- {4- [4- (4-fluorobenzyl) phenyl] piperazin-1- yl} propan-2 (s)-ol dimethanesulfonate SUN-N8075 Neuroprotective Infarction, cerebral Sulfonium, [3- [ [4- (3-ethoxy-2- hydroxypropoxy) phenyl] amino]-3- suplatast oxopropyl] dimethyl-, [CAS] 94055-76-2 JP 59167564 Antiasthma Asthma Suprofen 40828-46-4 Suramin 129-46-4 Respiratory distress syndrome, surfactant TA Beractant [CAS] 108778-82-1 WO 9117766 Lung Surfactant general Suriclone 53813-83-5 Suxibuzone 27470-51-5 SYM-1010 US 5830998 Antiepileptic Epilepsy, general SYM-2081 L-Glutamic acid, 4-methyl-, (4R)- [CAS] 31137-74-3 Analgesic, other Pain, general 4- (Aminophenyl)-1-methyl-6, 7- (methylenedioxy)-N-butyl-1, 2- SYM-2207 dihydrophthalazine-2-carboxamide Neuroprotective Ischaemia, cerebral Symclosene 87-90-1 1-cyclopropyl-6-fluoro-8-methoxy-7- [3- (4- methyl-1, 2, 3-triazol-1-yl) pyrrolidin-1-yi]-4- Syn-1253 oxo-1, 4-dihydroquinoline 3-carboxylic add Quinolone antibacterial Infection, peritoneum 1-Azetidinesuifonic acid, 3- [ [ (2E)- [ [ (1, 4- dihydro-1, 5-dihydroxy-4-oxo-2- pyridine) methoxy] imino]-2- thienylacetyl] amino]-2-methyl-4-oxo, Syn-2190 (2S, 3S)- [CAS] 214963-75-4 WO 9847895 Antibacterial, other infection, general 1 i Patent API Generic Name API Chemical Name CAS No. Reference Example of Therapeutic Use Example of Indication 3H-1, 2, 4-Triazoi-3-one, 4-(4-(4-((1R, 2R)-2- (2, 4-difluorophenyl)-2-hydroxy-1-methyl-3- (1H-1, 2, 4-triazol-1-yl) propyl)-1- piperazinyl) phenyl)-2, 4-dihydro-2 ( (4- Syn-2869 (trifluoromethoxy) phenyl) methyl)- [CAS] 210562-98-4 US 6153616 Antifungal Infection, Aspergillus Synephrine 94-07-5 Syrosingopine 84-36-6 = 1-Propanone, 3-(5-benzofuranylf 1-(2- hydroxy-6-((6-O-methoxycarbonyi)-ß-D- T-1095 glucopyranosyl) oxy)-4-methylphenyl- [CAS] 209746-59-8 EP 850948 Antidiabetic Diabetes, general L-Phenylalaninamide, N-acetyl-L-tryptophyl- L-glutaminyl-L-Alpha-glutamyl-L-tryptophyl- L-Alpha-glutamyl-L-glutaminyl-L-lysyl-L- isoleucyl-L-threonyl-L-alanyl-L-leucyl-L- leucyl-L-Alpha-glutamyl-L-glutaminyl-L- alanyl-L-glutaminyl-L-isoleucyl-L-glutaminyl- L-glutaminyl-L-Alpha-glutamyl-L-lysyl-L- Alpha-glutamyl-asparaginyl-L-tyrosyl-L- Alpha-glutamyl-L-leucyl-L-glutaminyl-L-lysyl- L-leucyi-L-Alpha-aspar yl-L-lysyl-l-trytophyl- L-ananyl-L-seryl-L-leucyl-L-trytophyl-L- T-1249 Aipha-glutamyl-L-tryptophyl- [CAS] 251562-00-2 WO 9959615 Antiviral, anti-HIV Infection, HIV/AIDS 1-cyclopropyl-8-methyl-7- [5-methyl-6- (methylamino)-3-pyridinyl]-4-oxo-1, 4- dihydro-3-quinolinecarboxylic acid T-3912 Quinolone antibacterial Infection, dermatological Benzo (b) thiophene-5-methanol, Alpha-((2- (diethylamino) ethoxy) methyl)- T-588 hydrochloride, (R)- [CAS] 142935-03-3 EP 565965 Cognition enhancer Alzheimer's disease Benzenesulfonamide, 2, 3, 4, 5, 6-pentafluoro- T-67 N- (3-fluoro-4-methoxyphenyl)- [CAS] 195533-53-0 Anticancer, other Cancer, liver T-82 US 5190951 Cognition enhancer Alzheimers disease i ; I Patent API Generic Name API Chemical Name CAS No. Reference Example of Therapeutic Use Example of Indication 2 (1H)-Quinolinone, 8-hydroxy-5- [1-hydroxy- 2-[[2-(4-methoxyphenyi)-1- methylethyl] amino] ethyl]-, TA-2005 monohydrochloride, [R- (R*, R*)]- [CAS] 137888-11-0 US 4579854 Antiasthma Asthma 2 (1H)-Quinolinone, 8-hydroxy-5- [1-hydroxy- 2-[[2-(4-methoxyphenyi)-1- methylethyl] amino] ethyl]-, TA-2005 monohydrochloride, [R- (R*, R*)]- [CAS] WO 189480 Formulation, inhalable, solution Asthma 1, 5-Benzothiazepin-4 (5H>one, 3- (acetyloxy)-5- [2- (dimethylamino) ethyl]-2, 3- dihydro-8-methyl-2- (4-methylphenyl)-, TA-993 (2R, 3R)-rel-(-)-, (2Z)-2-butenedioate [CAS] 122024-98-0 JP 01045376 Antithrombotic Peripheral vasculardisease (R)-Alpha- [ (E)-5-Amino-N, 5-dimethyl-2- hexenamido]-N-methyi-N-[(R)-Alpha- (methylcarbamoyl) phenethyl]-2- napthalenepropionamide 170851-70-4 tabimorelin 193079-69-5 Releasing hormones Growth hormone deficiency 9. 10-Secocholesta-5, 7, 10 (19)-triene-1, 3, 24- 57333-96-7 tacalcitol triol, (1 Aipha, 3ß, 5Z, 7E, 24R)- [CAS] 93129-94-3 EP 129003 Antipsoriasis Keratosis Benzamide, 4- (acetylamino)-N- (2- tacedinaline aminophenyl)- [CAS] 112522-64-2 DE 3613571 Anticancer, other Cancer, pancreatic 1684-40-8 tacrine 9-Acridinamine, 1, 2, 3, 4-tetrahydro- [CAS] 321-64-2 EP 332147 Cognition enhancer Alzheimer's disease Tacrolimus 104987-11-3 Pyrazino (1', 2' : 1, 6) pyrido (3, 4-b) indole1, 4- dione, 6- (1, 3-benzodioxol-5-yi)- 2, 3, 6, 7, 12, 12a-hexahydro-2-methyl-, (6R- tadalafil trans) [CAS] 171596-29-5 US 6143746 Male sexual dysfunction Impotence 1., 4-Pentanediamine, N4- [2, 6-dimethoxy-4- 106635-80-7 methyl-5- [3- (trifluoromethyl) phenoxy]-8- 106635-81-8 tafenoquine quinolinyl]- [CAS] 80065-55-0 US 4617394 Antimalarial Infection, malaria tafluposide 179067-42-6 WO 9612727 Anticancer, other Cancer, general (S)-N- [2- (1, 6, 7, 8-Tetrahydro-2H-indeno- [5, 4 b] furan-8-yi)] propionamide TAK-375 Hypnotic/Sedative Insomnia ! I Patent API Generic Name API Chemical Name CAS No. Reference Example of Therapeutic Use Example of Indication 2- [6- [ [3- [4- (Diphenylmethoxy)- piperidino] imidazo [1, 2-b] pyridazin-2-yl-2- methylpropionic acid dihydrate TAK-427 Antipruritic/inflamm, allergic Eczema, atopic (E)-4-t4- [5-Methyl-2-phenyl-1, 3-oxazol-4- yl) methoxy] benzyloxyimino}-4-phenylbutyric acid TAK-559 Antidiabetic Diabetes, general Taka-Diastase 9001-19-8 7H-1, 3-Dioxolo [4, 5-h] [2, 3] benzodiazepine, 7- acetyl-5- (4-aminophenyl)-8, 9-dihydro-8- talampanel methyl-, (8R)- [CAS] 161832-65-1 US 5639751 Antiepileptic Epilepsy, general Talampicillin 47747-56-8 N-[[(2S, 3S)-18-Carboxy-2-(2-carboxy-ethylf 13-ethyl-2, 3-dihydro-3, 7, 12, 17-tetramethyl-8 vinyl porphyrin-20-yl] acetyl]-L-aspartic acid talaporrin 220201-34-3 Radio/chemosensitizer Cancer, lung, general Talastine 16188-61-7 ! Talbutal 115-44-6 Talinolol 57460-41-0 4H-Thiazolo [4, 5-d] azepin-2-amine, 5, 6, 7, 8- 101626-70-4 talipexole tetrahydro-6- (2-propenyl)- [CAS] 36085-73-1 DE 3503963 Antiparkinsonian Schizophrenia 4-Quinolinecarboxamide, 3-hydroxy-2- talnetant phenyl-N- [ (1S)-1-phenylpropyl]- [CAS] 174636-32-9 WO 9532948 GI inflammatory/bowel disorders Irritable bowel syndrome 3-Pyridinecarboxylic acid, 2- [ [3- (trifluoromethyl) phenyl] amino]-, 1, 3-dihydro- talniflumate-oxo-1-isobenzofuranyl ester [CAS] 66898-62-2 BE 858864 Anti-inflammatory Inflammation, ocular L-Prolinamide, N-[(hexahydro-1-methyl-2, 6- dioxo-4-pyrimidinyl) carbonyl]-L-histidyl-, (S)- taltirelin CAS] 103300-74-9 JP 61033197 Neurological Dyskinesia, general Ethanamine, 2- [4- (1, 2-diphenyl-1- tamoxifen utenyl) phenoxy]-N, N-dimethyl-, (Z)- [CAS] 10540-29-1 US 4536516 Anticancer, hormonal Patent API Generic Name API Chemical Name CAS No. Reference Example of Therapeutic Use Example of Indication Benzenesußfonamide, 5-[2-[[2-(2- ethoxyphenoxy) ethyl] amino] propyl]-2- 106133-20-4 tamsulosin methoxy-, (R)- [CAS] 80223-99-0 EP 34432 Prostate disorders Benign prostatic hyperplasia 4, 7-Methano-1 H-isoindole-1, 3 (2H)-dione, hexahydro-2- [4- [4- (2-pyrimidinyl)-1- piperazinyilbutyi]-, (3aAlpha, 4ß, 7ß, 7aAipha) , 2-hydroxy-1, 2, 3-propanetricarboxylate 112457-95-1 tandospirone (1 : 1) [CAS] 87760-53-0 EP 82402 Anxiolytic Anxiety, general Tannoform 9010-29-1 Taprostene 108945-35-3 3-Quinolinecarboxamide, N-[2-[[[4-[2-(3, 4- dihydro-6, 7-dimethoxy-2 (1 H)- isoquinolinyl) ethyl] phenyl] amino] carbonyl]- tariquidar 4, 5-dimethoxyphenyl]- [CAS] 206873-63-4 WO 9817648 Radio/chemosensitizer Cancer, lung, non-small cell 6- [ [2- (Dimethyl-amino) ethyl] amino]-3- hydroxy-7H-indeno [2, 1-c] quinolin-7-one dihydrochloride TAS-103 174634-09-4 WO 9532187 Anticancer, other Cancer, lung, non-small cell Tasosartan 145733-36-4 Taurocholic Acid 81-24-3 Taurolidine 19388-87-5 Acetic acid, oxo [ [3- (1 H-tetrazol-5- tazanolast yl) phenyl] amino]-, butyl ester [CAS] 82989-25-1 US 4778816 Antiasthma 3-Pyridinecarboxylic acid, 6- [ (3, 4-dihydro- 4, 4-dimethyl-2H-1-benzothiopyran-6- tazarotene yl) ethynyl]-, ethyl ester [CAS] 118292-40-3 EP 284288 Antipsoriasis Psoriasis Tazobactam 89786-04-9 tazobactam + piperacillin jp 58225091 Antibiotic, other Infection, general TBC-3711 374680-51-0 Cardiovascular Heart failure N-Methyl-N-propargyl-10-aminomethyl- TCH-346 dibenzo (b, f) oxepin Neuroprotective Amyotrophic lateral sclerosis 5-Hexenoic acid, 4-hydroxy-, polymer with 4 tebipenem ethenyl-1 H-imidazole [CAS] 82200-24-6 Beta-lactam antibiotic infection, streptococcal Adenosine, N- [ (3R)-tetrahydro-3-furanyi]- tecadenoson [CAS] 204512-90-3WO 9808855 Antiarrhythmic Tachycardia, supraventricuiar Patent API Generic Name API Chemical Name CAS No. Reference Example of Therapeutic Use Example of Indication 1H-Benzimidazol-2-amine, 1- ( (4- tecastemizole fluorophenyl) methyi>N-4-piperidinyl- [CAS] 75970-99-9 US 4219559 Antiallergic, non-asthma Rhinitis, allergic, seasonal Technetium 99mTc Bicisate 121281-41-2 Technetium 99mTc Mertiatide 125224-05-7 ; 104348-91-6 Technetium 99mTc Sestamibi 109581-73-9 Technetium 99mTcTeboroxime 104716-22-5 Teclothiazide 4267-5-4 Teclozan 5560-78-1 Spiro [cyclopentane-1, 9'- [3, 7] diazabicyclo [3. 3. 1] nonane], 3', 7'- tedisamil bis (cyclopropylmethyl)- [CAS] 90961-53-8 EP 102833 Antiarrhythmic Fibrillation, atrial Teflurane 124-72-1 2, 4 (1 H, 3H)-Pyrimidinedione, 5-fluoro-1- tegafur (tetrahydro-2-furanyl)- [CAS] 17902-23-7 GB 1168391 Anticancer, antimetabolite Cancer, general 2, 4 (1 H, 3H)-Pyrimidinedione, 5-fluoro-1- (tetrahydro-2-furanyl)-, mixt. with 2, 4 (1H, 3H) tegafur + uracil pyrimidinedione- [CAS] 74578-38-4 EP 224885 Anticancer, antimetabolite Cancer, breast Hydrazinecarboximidamide, 2- ( (5-methoxy- 1 H-indol-3-yi) methylene)-N-pentyl-, (Z)-2-189188-57-6 tegaserod butenedioate [CAS] 145158-71-0 G inflammatory/bowel disorders Irritable bowel syndrome Teicoplanin 61036-64-4 ß-L-2-deoxythymidine telbivudine 3424-98-4 Antiviral, other infection, hepatitis-B virus Telenzepine 80880-90-6 3-De ((2, 6-dideoxy-3-C-methyi-3-O-methyi- Aipha-L-ribo-hexopyranosyl) oxy)-11, 12- dideoxy-6-O-methyl-3-oxo-12, 11- (oxycarbonyl ( (4- (4- (3-pyridinyl)-1 H-imidazol-Infection, respiratory tract, telithromycin 1-yl) butyl) imino))- [CAS] 191114-48-4 EP 680967 Macrolide antibiotic general 3, 4-Thiazolidinedicarboxylic acid, 3-ethyl mes ine ester, (R)- [CAS] 122946-43-4 COPD treatment Bronchitis, chronic (1, 1-Biphenyi)-2-carboxylic acid, 4-((1, 4- dimethyl-2'-propyl (2, 6'-bi-1 H-benzimidazol)- telmisartan 1'-yl) methyl)- [CAS] 144701-48-4 EP 502314 Antihypertensive, renin system Hypertension, general Patent API Generic Name API Chemical Name CAS No. Reference Example of Therapeutic Use Example of Indication telomerase inhibs WO 9941261 Anticancer, other Cancer, general 7-chloro-1, 3-dihydro-3-hydroxy-1-methyi-5- temazepam phenyl-2H-1, 4-benzodiazepin-2-one 846-50-4 US 3197467 Hypnotic/Sedative Insomnia Benzeneacetic acid, Alpha-cyclohexyl- Alpha-hydroxy-, 4- (diethylamino)-1, 1- temiverine dimethyl-2-butynyl ester, [CAS] 129927-33-9 GB 2222828 Urological Pollakisuria i 1, 4-Thiazepine-4 (5H)-acetic acid, 6-11- (ethoxycarbonyl)-3-102090-90-4 phenylpropyl] amino] tetrahydro-5-oxo-2- (2- 110221-44-8 temocaprif thienyi)-, [2S-[2Alpha, 6ß (R*)]]- [CAS] 111902-57-9 US 4495188 Antihypertensive, renin system Hypertension, general Temocillin 66148-78-5 Phenol, 3, 3', 3", 3"'- (2, 3-dihydro-21 H, 23H- temoporfin porphine-5, 10, 15, 20-tetrayl) tetrakis- [CAS] 122341-38-2 EP 337601 Radio/chemosensitizer Cancer, head and neck Imidazo [5, 1-d]-1, 2, 3, 5-tetrazine-8- carboxamide, 3, 4-dihydro-3-methyl-4-oxo- temozolomide [CAS] 85622-93-1 DE 3231255 Anticancer, aikylating Cancer brain general 1 H-imidazo (4, 5-b) pyridine, 5-methoxy-2- ( ( (4 methoxy-3, 5-dimethyl-2- tenatoprazole pyridinyl) methyl) sulfinyl)- [CAS] 113712-98-4 US 4808596 Antiulcer Ufcer, gastric Tenecteplase 191588-94-0 Tenidap 120210-48-2 Furo [3', 4' : 6, 7] naphtho [2, 3-d]-1, 3-dioxol- 6 (5aH)-one, 5, 8, 8a, 9-tetrahydro-5- (4- hydroxy-3, 5-dimethoxyphenyi)-9-[[4, 6-0-(2- thienyimethylene)-ß-D-glucopyranosyi] oxy]-, Cancer, lymphom, non- teniposide [5R- [5Alpha, 5af3, 8aAlpha, 95 (R*)]]- [CAS] 29767-20-2 US 3524844 Anticancer, other Hodgkin's Phosphonic acid, ( ( (1R)-2- (6-amino-9H- tenofovir purin-9-yl)-1-methylethoxy) methyl)- [CAS] 147127-20-6 Antiviral, anti-HIV Infection, HIV/AIDS j Patent API Generic Name API Chemical Name CAS No. Reference Example of Therapeutic Use Example of Indication 2, 4, 6, 8-tetraoxa-5-phosphanonanedioic acid, 5-(2-(6-amino-9H-purin-9-yi)-1- methylethoxymethyl) bis (1- ; methylethyl) ester, 5-oxide (R)-, (E)-2- butenedioate tenofovir disoproxil 202138-50-9 Antiviral, anti-HIV Infection, HIV/AIDS Tenonitrozole 3810-35-3 2H-Thieno [2, 3-e]-1, 2-thiazine-3- carboxamide, 4-hydroxy-2-methyl-N-2- tenoxicam pyridinyl-, 1, 1-dioxide [CAS] 59804-37-4 GB 1519811 Antiarthritic, other Tenuazonic Acid 610-88-8 5, 9, 13, 17-Nonadecatetraen-2-one, 3796-63-2 teprenone 6, 10, 14, 18-tetramethyl- [CAS] 6809-52-5 Antiulcer Pipera7ine, 1- (4-amino-6, 7-dimethoxy-2- 63074-08-8 quinazolinyl)-4- [ (tetrahydro-2- 63590-64-7 terazosin furanyl) carbonyi]- [CAS] 70024-40-7 US 4112097 Antihypertensive, adrenergic Hypertension, general __ ___ 1-Naphthalenemethanamine, N-(6, 6- dimethyl-2-hepten-4-ynyl)-N-methyl-, (E)-78628-80-5 terbinafine [CAS] 91161-71-6 EP 24587 Antifungal Infection, dermatological 1, 3-Benzenediol, 5- [2- [ (1, 1- terbutaline dimethylethyl) amino]-1-hydroxyethyl]- [CAS] 23031-25-6 Formulation, mucosal, topical Dysmenorrhoea Piperazine, 1- [4-ff2- (2, 4-dichlorophenyl)-2- (1 H-1, 2, 4-triazol-1-ylmethyl)-1, 3-dioxolan-4- yl] methoxy] phenyl]-4- (1-methylethyl)-, cis- terconazole [CAS] 67915-31-5 US 4358449 Antifungal Vaginitis 1-Piperidinebutanol, Alpha- [4- (1, 1- dimethylethyl) phenyl]-4- terfenadine (hydroxydiphenylmethyl)- [CAS] 50679-08-8 US 3878217 Antiallergic, non-asthma Urea, N, N-diethyl-N'- [ (8Alpha)-6- terguride methylergolin-8-yl]- [CAS] 37686-84-3 EP 159522 Antiprolactin Hyperprolactinaemia Terlipressin 14636-12-5 Terodiline 15793-40-5 Terofenamate 29098-15-5 Terpin 80-53-5 Patent API Generic Name API Chemical Name CAS No. Reference Example of Therapeutic Use Example of Indication 2-Propanol, 1- [ (3, 4-dihydro-2H-1- benzothiopyran-8-yl) oxy]-3- [ (1, 1- 33580-30-2 dimethylethyl) amino]-, hydrochloride, (+\-)-83688-84-0 34784- tertatolol [CAS] 64-0 GB 1308191 Antihypertensive, adrenergic Hypertension, general tert-Pentyl Alcohol 75-85-4 (2S)-2-ethoxy-3- [4- [2- [4- [ (methylsulfonyl) oxy] phenyl] ethoxy] phenyl] propanoic acid tesaglitazar Antidiabetic Diabetes, Type lí Ethanamine, N, N-Diethyl-2- (4- tesmilifene (phenylmethyl) phenoxy)- [CAS] 92981-78-7 Radio/chemosensitizer Cancer, breast Testolactone 968-93-4 Testosterone androst-4-en-3-one, 17-hydroxy-, (17ß)-58-22-0 5949-44-0 [CAS] Formulation, transdermal, systemic Hormone replacement therapy tetrabamate 60763-47-5 DE 2748794 Anxiolytic Addiction, alcohol Tetrabarbital 76-23-3 Tetrabenazine 58-46-8 Tetracaine 136-47-0 Tetrachloroethylene 127-18-4 Benzoic add, 4-(butylamino)-, 2- tetracine (dimethylamino) ethyl ester [CAS] 94-24-6 Formulation, transdermal, systemic Pain, general 2-Naphthacenecarboxamide, 4- (dimethylamino)-1, 4, 4a, 5, 5a, 6, 11, 12a- octahydro-3, 6, 10, 12, 12a-pentahydroxy-6- methyl-1, 11-dioxo-, [4S- (4Aipha, 4aAipha, 5aAlpha, 6ß, 1 2aAlpha)]- tetracycline [CAS] 60-54-8 Formulation, oral, other Infection, oral Tetrahydrozoline 84-22-0 Tetrandrine 518-34-3 Tetrantoin 52094-70-9 Tetrazepam 10379-14-3 Tetrofosmin 127502-06-1 2, 4-Pyrimidinediamine, 5- [ [3, 5-dimethoxy-4- 53808-87-0 tetroxoprim (2-methoxyethoxy) phenyi] methyl]-[CAS] 74515-38-1 US 3992379 Trimethoprim and anaiogues Infection, general Tevenelf) 4302-95-8 t Patent API Generic Name API Chemical Name CAS No. Reference Example of Therapeutic Use Example of Indication Cytidine, 2'-deoxy-2'- (fluoromethylene)-, tezacitabine (2E)- [CAS] 130306-02-4 US 5616702 Anticancer, antimetabolite Cancer, colorectal 2-Pyridinesulfonamide, N- (6- (2- hydroxyethoxy)-5- (2-methoxyphenoxy)-2- (2- (1 H-tetrazol-5-yl)-4-pyridinyl)-4-pyrimidinyl)- tezosentan 5- (1-methylethyl)- [CAS] 180384-57-0 Cardiostimutant Oedema, general 1H-Isoindole-1, 3 (2H)-dione, 2- (2, 6-dioxa-3- thalidomide piperidinyl)- [CAS] 50-35-1 Dermatological Infection, dermatological Thenaldine 86-12-4 Thenyldiamine 91-79-2 Theobromine 83-67-0 Theofibrate 54504-70-0 1H-Purine-2, 6-dione, 3, 7-dihydro-1, 3-58-55-9 theophylline dimethyl- [CAS] 5967-84-0 Formulation, modified-release, other Asthma Thiabendazole 148-79-8 Thiacetazone 104-06-3 Carbamic acid, [4- (1-methylethyl) phenyl]-, (3aS, 8aS)-3, 3a, 8, 8a-tetrahydro-3a, 8-' dimethyl-2H-thieno [2, 3-b] indol-5-yl ester thiacymserine [CAS] 145209-51-4 Cognition enhancer Alzheimer's disease Thialbarbital 467-36-7 Thiamine 59-43-8 Thiamine 154-87-0 Thiamine 67-16-3 Thiamiprine 5581-52-2 Thiamphenicol 15318-45-3 Thiamylal 77-27-0 Thiazesim 5845-26-1 Thiazinamium 58-34-4 Thiazolinobutazone 54749-86-9 Thiazolsulfone 473-30-3 Thibenzazoline 6028-35-9 Thiethylperazine 1420-55-9) Thimerfonate 5964-24-9 Thimerosal 54-64-8 Patent API Generic Name API Chemical Name CAS No. Reference Example of Therapeutic Use Example of Indication Thiobarbital 77-32-7 Thiobutabarbital 2095-57-0 Thiocarbamizine 91-71-4 Thiocarbarsone 120-02-5 Thiocolchicine 2730-71-4 Thiocresol 26445-03-4 Thioctic Acid 62-46-4 Thioglycerol 96-27-5 Thioguanine 154-42-7 L-Thiotyrosinyl-glycinyl-glycine Thioimreg Anticancer, immunological Cancer, general Thiopental 71-73-8 Thiopropazate 84-06-0 Thioproperazine 316-81-4 Thioridazine 50-52-2 Thiothixene 5591-45-7 Thiophosphonofbrmic acid Thiovir Antiviral, anti-HIV Infection, HIV/AIDS Thiphenamil 82-99-5 Thiram Thiram 137-26-8 Thonzylamine 63-56-9 Thozalinone 655-05-0 Thromboplastin 9035-58-9 Thurfyl Nicotinate 70-19-9 thymectacin US 6245750 Anticancer, other Cancer, colorectal Thymol 89-83-8 Thymopentin 69558-55-0 Thymyl N-lsoamylcarbamate 578-20-1 Thyropropic Acid 51-26-3 Thyroxine 51-48-9 Tiadenol 6964-20-1 3-Piperidinecarboxylic acid, 1- [4, 4-bis (3- tiagabine methyl-2-thienyl)-3-butenyl]-, (R)- [CAS] 115103-54-3 WO 8700171 Antiepileptic Epilepsy, general Tiamenidine 31428-61-2 = Patent API Generic Name API Chemical Name CAS No. Reference Example of Therapeutic Use Example of Indication Heptanoic acid, 7- [ (3-chloro-6, 11-dihydro-6- methyldibenzo [c, fl [1, 2] thiazepin-11-72797-41-2 66981- tianeptine yl) amino]-, S, S-dioxide [CAS] 73-5 GB 1269551 Antidepressant Depression, general Benzamide, N- [2- (diethylamino) ethyll-2- tiapride methoxy-5- (methylsulfonyl)- [CAS] 51012-32-9 GB 1394563 Neuroleptic 2-Thiopheneacetic add, 5-benzoyl-Alpha- tiaprofenic acid methyl- [CAS] 33005-95-7 GB 1331505 Antiarthritic, other Tiaramide 32527-55-2 4-Thiazolecarboxamide, 2-ß-D-Cancer, ieukaemia, chronic tiazofurin ribofuranosyl- [CAS] 60084-10-8 EP 54432 Anticancer, antimetabolite myelogenous Tibezonium 54663-47-7 19-Norpregn-5 (10)-en-20-yn-3-one, 17- tibolone hydroxy-7-methyl-, (7Alpha, 17Alpha)- [CAS] 5630-53-5 EP 389035 Menopausal disorders Hormone replacement therapy Ticarcillin 34787-01-4 Thieno [3, 2-c] pyridine, 5-[(2- chlorophenyl) methyl]-4, 5, 6, 7-tetrahydro- 53885-35-1 ticlopidine [CAS] 55142-85-3 GB 1554424 Antithrombotic Ticrynafen 40180-04-9 4-(3-hydroxy-3-phenyi-3-thien-2-yl-propyl) 4 6252-92-2 144-12-_ tiemonium methylmorpholinium 7 Antispasmodic 2-Naphthacenecarboxamide, 4, 7- bis (dimethylamino)-9- [ [ [ (1, 1- dimethylethyl) amino] acetyl] amino]- 1, 4, 4a, 5, 5a, 6, 11, 12a-octahydro-3, 10, 12, 12a tetrahydroxy-1, 11-dioxo-, tigecycline (4S, 4aS, 5aR, 12aS)- [CAS] 220620-09-7 EP 582829 Tetracycline Infection, general Tigemonam 102507-71-1 Tigloidine'495-83-0 Tilidine 20380-58-9 Tilisolol 85136-71-6 Benzenesulfonamide, 4- (4-cyclohexyl-2- tilmacoxib methyl-5-oxazolyl)-2-fluoro- [CAS] 180200-68-4 WO 9619463 Alimentary/Metabolic, other Polyp Phosphonic acid, [ [ (4- tiludronic acid chlorophenyi) thio] methylene] bis- [CAS] 89987-06-4 EP 100718 Osteoporosis treatment Paget's disease Timentin 86482-18-0 Cntibiotic, other infection, generaí Patent API Generic Name API Chemical Name CAS No. Reference Example of Therapeutic Use Example of Indication Piperidinium, 3- (di-2-thienylmethylene)-5- timepidium methoxy-1, 1-dimethyl-, [CAS] 35035-05-3 GB 1358446 Antispasmodic Timiperone 57648-21-2 (-)-1- (t-butylamino)-3- [ (4-morpholino-1, 2, 5- thiadiazol-3-yl) oxy]-2-propanolmaleate (1 : 1) 26839-75-8 Antihypertensive, adrenergic, t molol salt 26921-17-5 GB 1253709 antiglaucoma Timonaac 444-27-9 Tin Ethyl Etiopurpurin 113471-15-1 1 H-lndole, 3-[(4, 5-dihydro-1 H-imidazoi-2- finazoline YI) thio]- [CAS] 62882-99-9 US 3376311 Vasodilator, peripheral Tinidazole 19387-91-8 Tinoridine 24237-54-5 Tiocarlide 910-86-1 Tioclomarol 22619-35-8 1H-Imidazole, 1- [2- [ (2-chloro-3- thienyl) methoxy]-2- (2, 4- 61675-64-7 tioconazole dichlorophenyl) ethyl]- [CAS] 65899-73-2 US 4062966 Antifungal Infection, fungal, general tiopronin Glycine, N-(2-mercapto-1-oxopropyl)- [CAS] 1953-02-2 US 3246025 Urological Homocystinuria 3-Oxa-9-azoniatricyclo (3. 3. 1. 02, 4) nonane, 7 ((hydroxydi-2-thienylacetyí) oxy)-9, 9-dimethyi Chronic obstructive pulmonary tiotropium, [CAS] 136310-93-5 EP 418716 COPD treatment disease Tioxolone 4991-65-5 Tipepidine 5169-78-8 2 (1 H)-Quinolone, 6-(amino (4- chlorophenyl) (1-methyl-1 H-imidazol-5- yl) methyl)-4- (3-chlorophenyl)-1-methyl 192185-68-5 tipifarnib [CAS] 192185-72-1 WO 9716443 Anticancer, other Cancer, breast N- [3- [1 (R)- [4-Hydroxy-2-oxo-6 (R)- (2- phenylethyl)-6-propyl-5, 6-dihydro-2H-pyran- 3-yl] propyl] phenyl]-5- tipranavir (trifluoromethyl) pyridine-2-sulfonamide 174484-41-4 Antiviral, anti-HIV Infection, HIV/AIDS 2H-Quinclizinium, 3- (di-2- thienylmethylene) octahydro-5-methyl-, tiquizium [CAS] 71731-58-3 US 4205074 Antispasmodic Patent API Generic Name API Chemical Name CAS No. Reference Example of Therapeutic Use Example of Indication 20028-80-2 1, 2, 4-Benzotriazin-3-amine, 1, 4-dioxide- 27314-97-2 tirapazamine [CAS] 5424-06-6 DE 2204574 Radio/chemosensitizer Cancer, lung, non-small cell Tiratricol 51-24-1 Pregna-1, 4, 9 (11)-triene-3, 20-dione, 21- [4- 110101-65-0 (2, 6-di-1-pyrrolidinyi-4-pyrimidinyiE1-110101-67-2 tirilazad piperazinyl]-16-methyl-, (16AIpha)-, [CAS] 110101-66-1 WO 8701706 Neuroprotective Haemorrhage, subarachnoid L-Tyrosine, N- (butylsulfonyl)-O- [4- (4- 142373-60-2 tirofiban piperidinyl) butyl]-, [CAS] 144494-65-5 EP 478363 Antithrombotic Infarction, myocardial Benzenepropanamide, Alpha- (benzoylamino)-4- [2- (diethylamino) ethoxy]- tiropramide N, N-dipropyl-, (+\-)- [CAS] 55837-29-1 DE 2503992 Antispasmodic Muscle spasm, general Titanium Sulfate 13825-74-6 Pregn-4-ene-3, 20-dione, 21- [ (2, 2-dimethyl- 1-oxopropyl) thio]-11, 17-dihydroxy-, (11 ß)-5S560-96-8 Antiallergic, non-asthma, mucosal, tixocortol [CAS] 61951-99-3 GB 1475795 topical Rhinitis, allergic, general 2, 1, 3-Benzothiadiazol-4-amine, 5-chloro-N- tizanidine (4, 5-dihydro-1 H-imidazol-2-yl)- [CAS] 51322-75-9 GB 1429926 Muscle relaxant Spastic paralysis Glycine, L-Gamma-glutamyl-S- (phenylmethyl)-L-cysteinyl-2-phenyl-, diethyl TLK-199 ester, (2R)- [CAS] 168682-53-9 US 5679643 Immunostimulant, other Myelodysplastic syndrome Glycine, L-Gamma-glutamyl-3- [ [2- ( [bis [bis (2 chloroethyl) amino] phosphinyl] oxy) ethyl] sulfo TLK-286 nyl]-L-alanyl-2-phenyl-, (2R)- [CAS] 158382-37-7 US 5545621 Anticancer, other Cancer, ovarian TNF-ß analogue RU 2035185 Anticancer, immunological Cancer, general TNP-470 129298-91-5 Pregna-1, 4-diene-3, 20-dione, 9-fluoro- im, 17, 21-trihydroxy-16. beta.-methyl-, 17- TO-186 butyrate 21-propionate [CAS] 5534-02-1 Antipruriticlinflamm, allergic 0-3-amino-3-deoxy-Alpha-D-glucopyranosyl (1, 6)-O- (2, 6-diamino-2, 3, 6-trideoxy-Alpha-D Infection, respiratory tract, tobramycin ribo-hexopyranosyl- (1-4)-2-deoxy- [CAS] 32986-56-4 Formulation, inhalable, topical general Patent API Generic Name API Chemical Name CAS No. Reference Example of Therapeutic Use Example of Indication Propanamide, 2-amino-N- (2, 6- tocainide dimethylphenyl)- [CAS] 41708-72-9 US 4218477 Antiarrhythmic Fibrillation, ventricular Tocamphyi 5634-42-4 8-Chloroadenosine 3'5'-cyclic phosphate tocladesine 41941-56-4 Anticancer, other Cancer, colorectal Tocoretinate 40516-48-1 Todralazine 14679-73-3 Tofenacin 15301-93-6 5H-Pyrazolo [3, 4-c]-1, 2, 4-triazol [4, 3- a] pyridine, 9-cyclopentyl-7-ethyl-6, 9-dihydro- 3- (2-thienyl)- tofi m 185954-27-2 Antiasthma Asthma 5H-2, 3-Benzodiazepine, 1- (3, 4- dimethoxyphenyl)-5-ethyl-7, 8-dimethoxy-4- tofisopam methyl- [CAS] 22345-47-7 GB 1334271 Anxiolytic Anxiety, general Tolazamide 1156-19-0 Tolazoline 59-98-3 Tolbutamide 64-77-7 Methanone, (3, 4-dihydroxy-5-nitrophenyl) (4- tolcapone methylphenyl)- [CAS] 134308-13-7 EP 237929 Antiparkinsonian Parkinson's disease Carbamothioic acid, methyl (3-methylphenyl) , 0- (1, 2, 3, 4-tetrahydro-1, 4- tolciclate methanonaphthalen-6-yl) ester [CAS] 50838-36-3 GB 1364407 Antifungal Infection, dermatological Tolcyclamide 664-95-9 Benzenesulfonic acid, 4-ethenyl-, homopolymer, tolevamer 28038-50-8 Antibacterial, other Infection, Clostridium, general Benzoic acid, 2- [ (3-chloro-2- tolfenamic acid methylphenyl) amino]- [CAS] 13710-19-5 DE 1543295 Anti-inflammatory Inflammation, general Tolindate 27877-51-6 Toliprolol 2933-94-0 Tolmetin 26171-23-3 Toinaftate2398-96-1 Tolonidine 4201-22-3 Tolonium 92-31-9 ) Patent API Generic Name API Chemical Name CAS No. Reference Example of Therapeutic Use Example of Indication 2-Oxazolidinone, 5- (hydroxymethyl)-3- (3- toloxatone methylphenyl)- [CAS] 29218-27-7 GB 1250538 Antidepressant Tolperisone 728-88-1 Tolpropamine 5632-44-0 Toirestat 82964-04-3 Carbamic acid, (2-methylphenyl)-, (3aS, 8aR)-1, 2, 3, 3a, 8, 8a-hexahydro-1, 3a, 8- to trimethylpyrrolo [2, 3-b] indol-5-yl ester [CAS] 145209-30-9 Cognition enhancer Alzheimer's disease Phenol, 2- (3- (bis (1-methylethyl) amino)-1- tolterodine phenylpropyl)-4-methyl-, (R)- [CAS] 124937-51-5 EP 325571 Urological Incontinence Benzamide, N- [4- [ (7-chloro-2, 3, 4, 5- tetrahydro-5-hydroxy-1H-1-benzazepin-1- yl) carbonyl]-3-methylphenyl]-2-methyl- tolvaptan [CAS] 150683-30-0 EP 450097 Cardiovascular Heart failure Tolycaine 3686-58-6 Topiramate Beta-D-Fructopyranose, 2, 3 : 4, 5-bis-0-(1-97240-79-4 Epilepsy, generalized, tonic- methylethylidene)-, sulfamate [CAS] EP 533483 Antiepileptic clonic topoisomerase inhibitors US 5733880 Anticancer, other Cancer, general 1 H-Pyrano [3', 4' : 6, 7] indolizino [1, 2- b] quinoline-3, 14 (4H, 12H)-dione, 9- [(dimethylamino) methyl]-4-ethyl-4, 10- topotecan dihydroxy-, (S)- [CAS] 123948-87-8 EP 321122 Anticancer, other Cancer, ovarian 3-Pyridinesulfonamide, N- [ [ (1- methylethyl) amino] carbonyl]-4- [ (3- torasemide methylphenyl) amino]- [CAS] 56211-40-6 US 4018929 Antihypertensive, diuretic Hypertension, general ethyl (2R, 4S)-4- [ (3, 5-bis (trifluoromethyl) benzyl] (methoxycarbonyl) amino]-2-ethyl-6- (trifluoromethyl)-34-dihydroquinoline-1 (2HE carboxylate torcetrapib 262352-17-0 Hypolipaemic/Antiatherosclerosis Atherosclerosis ß-L-2 Deoxycytidine orcitabine Antiviral, other Infection, hepatitis-B virus Ethanamine, 2- [4- (4-chloro-1, 2-diphenyt-l- 89778-26-7 toremifene butenyl) phenoxy]-N, N-dimethyl-, (Z)- [CAS] 89778-27-8 EP 95875 Anticancer, hormonal Cancer, breast Torsemide 56211-40-6 L Patent API Generic Name API Chemical Name CAS No. Reference Example of Therapeutic Use Example of Indication Tositumomab 208921-02-2 1, 8-Naphthyridine-3-carboxylic acid, 7- (3- amino-1-pyrrolidinyl)-1-(2, 4-difluorophenyi)-100490-36-6 tosufloxacin 6-fluoro-1, 4-dihydro-4-oxo-, [CAS] 115964-29-9 US 4704459 Quinolone antibacterial Infection, urinarytract Cyclohexanol, 2-[(dimethyEamino) methyi]-1-27203-92-5 tramadol (3-methoxyphenyl)-, cis- (+/-)- [CAS] 36282-47-0 Analgesic, other Pain, general Tramazoline 1082-57-1 1H-Indole-2-carboxylicacid, 1- [2- [ (1- carboxy-3-phenylpropyl) amino]-1- oxopropyl] octahydro-, [2S-87679-71-8 87679- trandolapril [1 [R* (Ri)], 2Aipha, 3aAlpha, 7aß]] [CAS] 37-6 52-53-9 DE 3151690 Antihypertensive, renin system Hypertension, general Cyclohexanecarboxylic acid, 4- tranexamic acid (aminomethyl)-, trans- [CAS] 1197-18-8 US 3950405 Antifibrinolytic Menstrual disorder, general Benzoic acid, 2-[[3-(3, 4-dimethoxyphenyi)-1 tranilast oxo-2-propenyl] amino]- [CAS] 53902-12-8 US 3940422 Vulnerary Wound healing trans-retinoic acid Retinoic acid [CAS] 302-79-4 Anticancer, other Cancer, general Tranylcypromine 155-09-9 [1, 2, 4] Triazol [1, 5-a] pyrimidin-7-amine, N, N trapidil diethyl-5-methyl- [CAS] 15421-84-8 DD 55956 Vasodilator, coronary Trastuzumab 180288-69-1 5-Heptenoic acid, 7- (3, 5-dihydroxy-2- (3- hydroxy-4- (3- (trifluoromethyl) phenoxy)-1- butenyl) cyclopentyl)-, 1-methylethylester (1 R (lAlpha (Z), 2ß (1 E, 3Ri), 3Alpha, 5Alpha) travoprost [CAS] 157283-68-6 Formulation, mucosal, topical Glaucoma Traxanox 58712-69-9 1-Piperidineethanol, 4-hydroxy-Alpha- (4- hydroxyphenyl)-fs-methyl-4-phenyl-, 134234-12-1 traxoprodil (AiphaS, ßS)- [CAS] 188591-67-5 Analgesic, other Pain, general 1, 2, 4-Triazolo [4, 3-a] pyridin-3 (2H)-one, 2- [3- [4- (3-chlorophenyl)-1-piperazinyl] propyl]- 19794-93-5 trazodone [CAS] 25332-39-2 US 4215104 Antidepressant Tremacamra 155576-45-7 Patent API Generic Name API Chemical Name CAS No. Reference Example of Therapeutic Use Example of Indication Trenbolone 10161-33-8 Trengestone 5192-84-7 1, 2, 3, 4-Butanetetrol, 1, 4- treosulfan dimethanesulfonate, [S- (R*, R*)]- [CAS] 299-75-2 WO 8401506 Anticancer, alkylating Benzenebutanoic acid, 2, 4, 5-triethoxy- trepibutone Gamma-oxo- [CAS] 41826-92-0 GB 1387733 Antispasmodic Prosta-5, 13-dien-l-oic acid, 6, 9-epoxy- 11, 15-dihydroxy-, 35121-78-9 treprostinol [5Z, 9Alpha, 11 Alpha, 13E, 15S]- [CAS] 61849-14-7 US 6054486 Formulation, parenteral, other Hypertension, pulmonary tretinoin Retinoic acid [CAS] 302-79-4 Formulation, dermal, topical Acne 6, 7-Isoquinolinediol, 1, 2, 3, 4-tetrahydro-1- 18559-59-6 [(3, 4, 5-trimethoxyphenyi) methyl}, (S)-30418-38-3 21650- tretoquinol [CAS] 42-0 ZA 6802416 Antiasthma TRH 24305-27-9 TRI-50b TRI 50b [CAS] 226214-49-9 Antithrombotic Thrombosis, general Triacetin 102-76-1 Triamcinolone Acetonide 76-25-5 Triamcinolone Benetonide 31002-79-6 Triamcinolone Hexacetonide 5611-51-8 Pregna-1, 4-diene-3, 20-dione, 9-fluor- 11, 21-dihydroxy-16, 17- [ (I- methylethylidene) bis (oxy)]-, (1113, 16Alpha)- 76-25-5 triamcinolone [CAS] 124-94-7 Formulation, inhalable, topical Asthma Triamterene 396-01-0 triapine Triapine [CAS] 236392-56-6 US 6458816 Anticancer, antimetabolite Cancer, leukaemia, general Triaziquone 68-76-8 8-chloro-6- (2-chlorophenyl)-1-methyl-4H- triazolam [1, 2, 4]-triazolo [4, 3-a] [1, 4] benzodiazepine 28911-01-5 US 3980790 Hypnotic/Sedative Insomnia Tribenoside lo3lo-32-4 Tr-X _ 52-68-6 Trichlormethiazide 133-67-5 Trichlormethine 555-77-1 Trichloroethylene 79-01-6 Triclobisonium 79-90-3 Triclocarban 101-20-2 t Patent API Generic Name API Chemical Name CAS No. Reference Example of Therapeutic Use Example of Indication Triclofenol Piperazine 5714-82-9 Triclofos 306-52-5' Triclosan 3380-34-5 Tricromyl 85-90-5 Tridihexethyl iodide 125-99-5 1, 2-Ethanediamine, N, N2-bis (2aminoethyl)-, 38260-01-4 112- trientine [CAS] 24-3 Metabolic and enzyme disorders Wilson's disease Triethanolamine 102-71-6 Triethylenemelamine 51-18-3 Triethylenephosphoramide 545-55-1 Triethylenethiophosphoramide 52-24-4 Trifluoperazine 117-89-5 Trifluperidol 749-13-3 Triflupromazine 146-54-3 Thymidine, Alpha, Alpha, Alpha-trifluoro- trifluridine [CAS] 70-00-8 US 3201387 Antiviral, other Infection, herpes virus, general Benzoic acid, 2- (acetyloxy)-4- triflusal (trifluoromethyl)- [CAS] 322-79-2 US 4096252 Antithrombotic Thrombosis, general Trihexyphenidyl 52-49-3 Androst-2-ene-2-carbonitrile, 4, 5-epoxy- 3, 17-dihydroxy-, (4Alpha, 5Alpha, 1775)- trilostane [CAS] 13647-35-3 US 3296255 Anticancer, hormonal Cancer, breast Trimazosin 35795-16-5 Benzoic acid, 3, 4, 5-trimethoxy-, 2- (dimethylamino)-2-phenylbutyl ester, (Z)-2-34140-59-5 39133- trimebutine butenedioate (1 : 1) [CAS] 31-8 DE 2151716 Antispasmodic Trimecaine 616-68-2 Trimeprazine 84-96-8 Trimetazidine 5011-34-7 Trimethadione 127-48-0 Trimethaphan 68-91-7 Trimethobenzamide 138-56-7 Trimethoprim 738-70-5 Trimetozine 635-41-6 l Patent API Generic Name API Chemical Name CAS No. Reference Example of Therapeutic Use Example of Indication 2, 4-Quinazolinediamine, 5-methyl-6- [ [ (3, 4, 5- 52128-35-5 trimetrexate trimethoxyphenyl) amino] methyl]- [CAS] 82952-64-5 US 4391809 Antifungal Infection, Pneumocystis jiroveci 5H-Dibenz [b. f) azepine-5-propanamine, 10, 11-dihydro-N, N, ß-trimethyl-, (Z)-2-521-78-8 trimipramine butenedioate (1 : 1) [CAS] 739-71-9 Antidepressant Trimoprosüi 69900-72-7 Trioxsalen 3902-71-4 Benzamide, 3- (aminosulfonyl)-4-chloro-N- (octahydro-4, 7-methano-2H-isoindol-2-yl)-, tripamide (3aAlpha, 4Alpha, 7Alpha, 7aAlpha)- [CAS] 73803-48-2 JP 7305585 Antihypertensive, diuretic Hypertension, general Triparanol 78-41-1 Tripelennamine 91-81-6 Triprolidine 486-12-4 Luteinizing hormone-releasing factor (pig), 124508-66-3 triptorelin 6-D-tryptophan- [CAS] 57773-63-4 US 4010125 Releasing hormones Cancer, prostate Morpholine, 4- [thioxo (3, 4, 5- tritiozine trimethoxyphenyl) methyl]- [CAS] 35619-65-9 US 3862138 Antiulcer Tritoqualine 14504-73-5 Phosphonicacid, [[4- (methylthio) phenyl] thio] methylene] bis-, TRK-530 disodium salt [CAS] 151425-92-2 WO 9410181 Antiarthritic, other Arthritis, rheumatoid 2-Propenamide, N- [ (5AIpha, 6ft)-17- (cyclopropylmethyl)-4, 5-epoxy-3, 14- dihydroxymorphinan-6-yi]-3- (3-furanyl)-N- TRK-820 methyl-, monohydrochloride, (2E)- [CAS] 152658-17-8 WO 9315081 Antipruritic/inflamm, non-allergic Pruritus Troclosene 2244-21-5 3-2- (chloroethyl)-2- [bis (2- chloroethyl) amino] tetrahydro-2H-1, 3, 2- trofosfamide oxazaphosphorin 2-oxide 22089-22-1 GB 1188159 Anticancer, alkylating Troglitazone 97322-87-7 Troleandomycin 2751-9-9 Trolnitrate 588-42-1 = I Patent API Generic Name API Chemical Name CAS No. Reference Example of Therapeutic Use Example of Indication N- (1-adamantyl)-2- (2-dimethylamine tromantadine ethoxy) acetamide 53783-83-8 DE 1941218 Antiviral, other Infection, herpes simplex virus Tromethamine 77-86-1 Tropacine 6878-98-4 Tropesin 65189-78-8 Tropicamide 1508-75-4 1H-indole-3-aceticacid, 1- (4-chlorobenzoyl) 5-methoxy-2-methyi-, 2-carboxy-2- tropine phenylethyl ester, (+/-)- [CAS] 65189-78-8 Antiarthritic, other 1 H-Indole-3-carboxylic acid, 8-methyl-8-Chemotherapy-induced nausea tropisetron azabicyclo [3. 2. 1] oct-3-yl ester, endo- [CAS] 89565-68-4 GB 2125398 Antiemetic and vomiting Trospectomycin 88669-04-9 3Ai pha-Hydroxyspiro [1 AiphaH, 5AlphaH- trospium nortropane-8, 1'-pyrrolidinium] benzilate 10405-02-4 Urological Pollakisuria 1, 8-Naphthyridine-3-carboxylic acid, 7- (6- amino-3-azabicyclo [3. 1. 0] hex-3-yl)-1- (2, 4- difluorophenyi>6-fluoro-1, 4-dihydro-4-oxo-, 147059-72-1 Infection, respiratory tract, trovafloxacin (lAlpha, 5AIpha, 6Alpha)-, [CAS] 147059-75-4 US 5164402 Quinolone antibacterial general 2 (1 H)-Pyrimidinone, 4-amino-1- (2- (hydroxymethyl)-1, 3-dioxclan-4-yl)-, (2S-cis) Cancer, leukaemia, acute troxacitabine [CAS] 145918-75-8 Anticancer, other myelogenous Troxerutin 7085-55-4 Benzamide, 3, 4, 5-trimethoxy-N-3-piperidinyl 30751-05-4 99777- troxipide [CAS] 81-8 US 3647805 Antiulcer Ulcer, gastric Trypan Red 574-64-1 Tryparsamide 554-72-3 Tryptophan 73-22-3 TSH 9002-71-5 6, 14-Ethenomorphinan-7-methanol, 17- (cyclopropylmethyl)-Aipha-(1, 1- dimethylethyl)-, 5-epoxy-18, 19-dihydro-3- hydroxy-6-methoxy-Alpha-methyl-, TSN-09 [5Alpha, 7Aipha, (S)]- [CAS] 52485-79-7 Formulation, transdermal, patch Pain, cancer ! Patent API Generic Name API Chemical Name CAS No. Reference Example of Therapeutic Use Example of Indication Nonanedioic acid, bis [ (2- (ethoxycarbonyl) phenyl] ester TU-2100 US 6180669 Antacne Acne Tuaminoheptane 123-82-0 Tubercidin 69-33-0 Tubocurarine Chloride 57-94-3 Benzenemethanol, 2-chloro-Alpha- [ [ (1, 1- tulobuterol dimethylethyl) amino] methyl- [CAS] 41570-61-0 DE 2244737 Antiasthma Asthma N- (Propargyl- (3R) aminoindan-5-yl)-ethyl methyl carbamate TV-3326 Cognition enhancer Alzheimer's disease Acetic acid, [2- [2, 3, 3a, 6, 7, 7a-hexahydro-2- hydroxy-l- (3-hydroxy-4, 4-dimethyl-1, 6- nonadiynyl)-1 H-inden-5-yl] ethoxy]-, [1 S- TY-11223 [1Alpha (R*), 2a, 3aAlpha, 7aAlpha]]- [CAS] 140694-43-5 US 4837342 Antithrombotic Unspecified 6, 7, 8, 9-Tetrahydro-2-methyl-5H- cyclohepta [b] pyridine-3-carbonylguanidine maleate TY-12533 US 6258829 Antiarrhythmic Unspecified D-Glucitol, 1, 4 : 3, 6-dianhydro-, nitrate TYB-3215 [CAS] 87-33-2 Formulation, modified-release, other Angina, general Tybamate 4268-36-4 4- (1, 1, 3, 3-Tetramethylbutyl) phenol polymer tyloxapol with formaldehyde and oxirane [CAS] 25301-02-4 Formulafion, inhalable, topical Cystic fibrosis Tymazoiine 24243-97-8 Tyramine 51-67-2 Tyropanoate 7246-21-1 Ubenimex 58970-76-6 Benzoic acid, 2- [ [3- (trifluoromethyl) phenyl] amino]-, butyl ester ufenamate [CAS] 67330-25-0 BE 861852 Antipruritic/inflamm, non-allergic Undecylenic Acid 112-38-9 Unoprostone 120373-36-6 i Patent API Generic Name API Chemical Name CAS No. Reference Example of Therapeutic Use Example of Indication 4- [4-Chloro-5- (3-fluoro-4- methoxyphenyl) imidazol-1-imidazol-1- UR-8880 yi] benzenesulfonamide- [CAS] Anti-inflammatory Inflammation, general Uracil Mustard 66-75-1 1, 2, 3-Propanetricarboxylic acid, 2-hydroxy-, potassium sodium salt (5 : 6 : 6), hydrate Uralyt-U [CAS] 55049-48-4 US 4400535 Urological 2, 4 (1H, 3H)-Pyrimidinedione, 6- [ [3- [4- (2- methoxyphenyl)-1-piperazinyl] propyi] amino]- urapidii 1, 3-dimethyl- [CAS] 34661-75-1 GB 1309324 Antihypertensive, adrenergic Hypertension, general urea Urea [CAS] 57-13-6 Antipsoriasis Uredepa 302-49-8 Urethan 51-79-6 Uridine 50-Triphosphate 63-39-8 Urinastatin 80449-31-6 Formulation, other, Cirrhosis, primary 3Alpha, 7B-dihydroxy-513-cholan-24-oic acid biliary, hepatic dysfunction, biliary ursodeoxycholic acid [CAS] 128-13-2 calcalus Cirrhosis, primary biliary Ursodiol 128-13-2 Ushercell US 6063773 Formulation, mucosal, topical Contraceptive, female Uzarin 20231-81-6 L-Valine, 2-[(2-amino-1, 6-dihydro-6-oxo-9H valaciclovir purin-9-yl) methoxy] ethyl ester [CAS] 124832-26-4 EP 308065 Antiviral, other Infection, herpes simplex virus Valacyclovir 124832-26-4 Benzenesulfonamide, 4- (5-methyl-3-phenyl- vaidecoxib 4-isoxazolyi)- [CAS] 181695-72-7 US 5859257 Antiarthritic, other Arthritis, rheumatoid Valdetamide 512-48-1 Valethamate 90-22-2 L-Valine, 2- ( (2-amino-1, 6-dihydro-6-oxo-9H- purin-9-yl) methoxy)-3-hydroxypropyl ester 175865-59-5 valganciclovir [CAS] 175865-60-8 EP 694547 Antiviral, other Infection, cytomegalovirus Vainoctamide 4171-13-5 L-Valine (3R)-3- ( (2-amino-1, 6-dihydro-6- oxo-9H-purin-9-yi) methylp4-((1- valomaciclovir oxooctadecyl) oxy) butyl ester [CAS] 195156-77-5 Antiviral, other infection, herpes simplex virus Patent API Generic Name API Chemical Name CAS No. Reference Example of Therapeutic Use Example of Indication 76584-70-8 Epilepsy, generalized, tonic- valproate Pentanoic acid, 2-propyl-, [CAS] 1069-66-5 US 4988731 Antiepileptic clonic Valproic Acid 99-66-1 Valpromide 430-27-5 Pentanamide, N- (2-amino-2-oxoethyl)-2- valrocemide propyl- [CAS] 92262-58-3 US 5585358 Antiepileptic Epilepsy, general Pentanoic acid, 2- (1, 2, 3, 4, 6, 11-hexahydro- 2, 5, 12-trihydroxy-7-methoxy-6, 11-dioxo-4- ( (2, 3, 6-t (ideoxy-3- ( (trifluoroacetyl) amino)- Alpha-L-lyxo-hexopyranosyi) oxy)-2- naphthacenyl)-2-oxoethyl ester (2S-cis)- valrubicin [CAS] 56124-62-0 US 4035566 Anticancer, antibiotic Cancer, bladder L-Valine, N- (1-oxopentyl)-N- [ [2'- (1H-tetrazol valsartan 5-yl) [1, 1'-biphenyl]-4-yl] methyl]- [CAS] 137862-53-4 EP 443983 Antihypertensive, renin system Hypertension, general Valspodar 121584-18-7 Piperazine, 1- (3- (1, 4-dihydro-5-methyl (-4- oxo-7-propylimidazo (5, 1-f) (1, 2, 4)-triazin-2- Sexual dysfunction, male, vardenafil yl)-4-ethoxyphenyl) sulfonyl)-4-ethyl- [CAS] 224785-90-4 Male sexual dysfunction general Acetic acid, ( (3- (aminooxoacetyl)-2-ethyl-l- 172732-68-2 varespladib (phenylmethyl)-1 H-indol-4-yl) oxy)- [CAS] 172733-42-5 EP 675110 Septic shock treatment Sepsis Varicella Virus Vaccine 3, 5-Pyridinedicarboxylic acid, 1, 4-dihydro- 2, 6-dimethyl-4- (3-nitrophenyl)-, 2- [4- [4- (diphenylmethyl)-1-piperazinyl] phenyl] ethyl 116308-55-5 vatanidipine methyl ester, [CAS] 133743-71-2 EP 257616 Neuroprotective Hypertension, general VEA US 6007817 Radio/chemosensitizer Cancer, general Piperidinium, 1- [(2ß, 3Alpha, 5Aipha, 16ß, 17ß)-3, 17- bis (acetyloxy)-2-(1-piperidinyi) androstan-16 vecuronium yl]-1-methyl-, [CAS] 50700-72-6 US 4237126 Muscle relaxant Anaesthesia, adjunct Veinacrine 104675-29-8 Cyclohexanol, 1- [2- (dimethylamino)-1- (4- 93413-69-5 venlafaxine methoxyphenyl) ethyl]-, [CAS] 99300-78-4 GB 2227743 Antidepressant Depression, general Patent API Generic Name API Chemical Name CAS No. Reference Example of Therapeutic Use Example of Indication Veralipride 66644-81-3 Benzeneacetonitr'ile, Alpha- [3- [ [2- (3, 4- dimethoxyphenyl) ethyl] methylamino] propyi]- verapamil 3, 4-dimethoxy-Alpha- (1-methylethyl)- [CAS] 52-53-9 Formulation, modified-release, other Hypertension, general 23H, 25H-Benzo [b] porphine-9, 13- dipropanoic acid, 18-ethenyl-4, 4a-dihydro- 3, 4-bis (methoxycarbonyl)-4a, 8, 14, 19- tetramethyl-, monomethyl ester, trans- verteporfin [CAS] 129497-78-5 US 5238940 Ophthalmological Macular degeneration Piperazine, 1- (3, 4-dimethoxybenzoyl)-4- (1, 2, 3, 4-tetrahydro-2-oxo-6-quinolinyl)- vesnarinone [CAS] 81840-15-5 GB 2086896 Cardiostimulant Heart failure Vetrabutine 3735-45-3 Benzene carboximidamide, N, 3, 4, 5- VF-233 tetrahydroxy- [CAS] 95933-74-7 US 4623659 Cardiovascular Reperfusion injury VI-0134 US 6403597 Male sexual dysfunction Premature ejaculation 3H-Purin-6-amine, 9-13-D-arabinofuranosyl-24356-66-9 vidarabine [CAS] 5536-17-4 GB 1159290 Antiviral, other Infection, herpes virus, general 68506-86-5 60643- vigabatrin 5-Hexenoic acid, 4-amino- [CAS] 86-9 GB 1472525 Antiepileptic Epilepsy, partial (focal, local) 2-Benzofurancarboxamide, 5- [4- [4- (5-cyano vilazodone 1H-indol-3-yl) butyl]-1-piperazinyl]- [CAS] 163521-12-8 EP 648767 Antidepressant Depression, general Viloxazine 46817-91-8 Viminol 21363-18-8 Vinbarbital 125-44-0 Vinblastine 666-214 Eburnamenin-14 (15H)-one, 474-00-0 vinburnine Alpha, 16Alpha)-[CAS] 4880-88-0 DE 1932245 Cognition enhancer Vincamine 1617-90-9 Vinconate 70704-03-9 Vincaleukoblastine, 22-oxo-, sulfate (1 : 1) 2068-78-2 vincristine (salt) [CAS] 57-22-7 EP 207831 Formulation, parenteral, other Cancer, general Vincaleukoblastine, 3- (aminocarbonyl)-04- 53643-48-4 Cancer, leukaemia, acute vindesine deacetyl-3-de (methoxycarbonyl)- [CAS] 59917-39-4 GB 1463575 Anticancer, other lymphocytic Patent API Generic Name API Chemical Name CAS No. Reference Example of Therapeutic Use Example of Indication Aspidospermidine-3-carboxylic acid, 4- (acetyloxy)-6, 7-didehydro-15- [(2R, 4R, 6S, 8S)-4- (1, 1-difluoroethyl)- 1, 3, 4, 5, 6, 7, 8, 9-octahydro-8- (methoxycarbonyl)-2, 6-methano-2H- azecino [4, 3-b] indol-8-yl]-3-hydroxy-16- methoxy-l-methyl-, methyl ester,- vinfl unine (2 ß, 3ß, 4ß, 5Alpha, 1 2ß, 1 9Aipha)- [CAS] 162652-95-1 FR 2707988 Anticancer, other Cancer, general C'-Norvincaleukoblastine, 3', 4'-didehydro-4'- vinorelbine deoxy- [CAS] 71486-22-1 EP 10458 Anticancer, other Cancer, lung, non-small cell Eburnamenine-14-carboxyiic acid, ethyl vinpocetine ester, (3Aipha, 16Aipha)- [CAS] 42971-09-5 GB 1405127 Cognition enhancer Cognitive disorder, general Vinyl Ether 109-93-3 Vinylbital 2430-49-1 Viquidil 84-55-9 Viridin 3306-52-3 Visnadine 477-32-7 Vitamin A 68-26-8 vitamin B12 Vitamin B12 [CAS] 68-19-9 Formulation, transmucosal, nasal Anaemia, general vitamin C L-Ascorbic acid [CAS] 50-81-7 Formulation, modified-release, <=24hr Nutrition Vitamin D2 50-14-6 Vitamin D3 67-97-0 Vitamin K5 83-70-5 Vitamins, Prenatal ( (R, S)-4- (4- (Amino-imino-methyl)-phenyl)-3- ( (4-biphenylyl)-methyl)-4-methyl-2, 5- dioxoimidazolidin-1-yl)-acetyl-L-N-methyl- VLA-4 antagonists aspartyi-L-phenyigiycine EP 842943 Antiasthma Asthma 1, 2-Bis (methylsulfonyl)-1-(2-chioroethyi)-2- (methylamino) carbonylhydrazine VNP-40101M US 6040338 Anticancer, alkylating Cancer, general i Patent API Generic Name API Chemical Name CAS No. Reference Example of Therapeutic Use Example of Indication D-epi-lnositoi, 3, 4-dideoxy-4- [ [2-hydroxy-1- (hydroxymethyi) ethyl] amino]-2-C- voglibose (hydroxymethyl)- [CAS] 83480-29-9 EP 56194 Antidiabetic Diabetes, Type II 4-Pyrimidineethanol, Alpha- (2, 4- difluorophenyi)-5-fluoro-ß-methyl-Aipha-(1 H voriconazole 1, 2, 4-triazol-1-ylmethyl)-, (R- (R*, S*))- [CAS] 137234-62-9 EP 440372 Antifungal Infection, fungal, general Vorozole 129731-10-8 7- [3- [4- (2-Quinolinylmethyl)-1- piperazinyl] propoxy]-3, 4-dihydro-2H-1, 4- benzothiazine-3-one VUF-K-8788 Antiasthma Asthma Warfarin 81-81-2 Chemotherapy-induced injury, WF-10 Tetrachlorodecaoxide [CAS] 92047-76-2 Radio/chemoprotective bone marrow, general 2- (3- [4- [3- (6-oxo-6H-2, 10b-diaza- aceanthrenylen-5-ylamino) propyl]-piperazin- 1-yl] propyl)-5-nitro-2-aza-phenalene-1, 3- dione WMC-79 Anticancer, other Cancer, colorectal wound healing matrix US 5897880 Formulation, transdermal, patch Ulcer, diabetic WP-170 US 6531121 Cytokine Unspecified Pyridine, 1, 2, 3, 6-tetrahydro-1- [2- (2- naphthalenyl) ethyl]-4- [3- 90494-79-4 xaliproden (trifluoromethyl) phenyl]-, [CAS] 135354-020-8 EP 101381 Neuroprotective Amyotrophic lateral sclerosis 4-Morpholinecarboxamide, N-[2-[[2-hydroxy- 3- (4-hydroxyphenoxy) propyl] amino] ethyl]-, 73210-73-8 xamoterol [CAS] 81801-12-9 GB 2002748 Cardiostimulant Heart failure Xanomeline 131986-45-3 Xanthinol Niacinate 437-74-1 Xemilofiban 149820-74-6 Xenbucin 959-10-4 Xibenolol 81584-06-7 Phenol, 4, 5-dimethyl-2- (1, 7, 7- ixibornol ltdmethylbicyclo [2. 2. 1] hept-2-yi)-, exo- [CAS] 13741-18-9 GB 1206774 Antibacterial, other Infection, general Patent API Generic Name API Chemical Name CAS No. Reference Example of Therapeutic Use Example of Indication Glycine, N- ( (R)-cyclohexyl-2- ( (2S)-2- ( ( ( (4- (hydroxyamino) iminomethyl) phenyl) methyl) amino) carbonyl)-1-azetidinyl) 2-oxoethyl ximelagatran ethyl ester [CAS] 192939-46-1 Antithrombotic Thrombosis, venous Ximoprofen 56187-89-4 Benzamide, 5- (aminosulfonyl)-4-chloro-N- xipamide (2, 6-dimethylphenyl)-2-hydroxy- [CAS] 14293-44-8 US 3567777 Antihypertensive, diuretic Morphinan-3-ol, 17- (cyclobutylmethyl)-8- xorphanoi methyi-6-methylene-, (813)- [CAS] 77287-89-9 Analgesic, other Pain, cancer 2, 5-Piperazinedione, 3- [ [5- [ [2- (dimethylamino) ethyl] thio]-2- thienyl] methylene]-6- (phenylmethylene)-, XR-5118 monohydrochloride, (3Z, 6Z)- [CAS] 174766-49-5 WO 9532190 Anticancer, other Cancer, general N, N'- (1, 2-Ethanediyl) bis (imino-2, 1- ethanediyl) bis (9-methylphenazine-1- carboxamide) XR-5944 EP 934278 Anticancer, other Cancer, general Xylometazoline 526-36-3 Xylose 58-86-6 2-Pyrimidinamine, 4- (3, 4-dihydro-1-methyl- 2 (1 H)-isoquinolinyl)-N- (4-fluorophenyl)-5, 6- YH-1885 dimethyl-, monohydrochloride [CAS] 178307-42-1 WO 9605177 Antiulcer Ulcer, Gl, general BenzonitrDe, 4-[[(4-bromophenyi) methyi]-4H YM-511 1, 2, 4-triazol-4-ylamino]- [CAS] 148869-05-0 WO 9305027 Anticancer, hormonal Cancer, breast potassium (E)-N- [6-methoxy-5- (2- methoxyphenoxy)-2- (pyrimidin-2- yl) pyrimidin-4-yl]-2- YM-598 phenylethenesulfonamidate Anticancer, other Cancer, prostate Yohimbine 146-48-5 YT-146 Adenosine, 2- (1-octynyl)- [CAS] 90596-75-1 US 5270304 Anti-inflammatory Inflammation, general Thiazolidine, 3-((2, 3-dihydro-1H-inden-2- yl) acetyl)-4- (1-pyrrolidinylcarbonyl)-, (R)- Z-321 [CAS] 130849-58-0 EP 372484 Cognition enhancer Dementia, senile, general I Patent API Generic Name API Chemical Name CAS No. Reference Example of Therapeutic Use Example of Indication (1 H-lndene-5-acetic acid, 2 [[[(4- chlorophenyl) sulfonyl amino] methyl]-2, 3- Z-335 dihydro, monosodium salt) [CAS] 146731-14-8 JP 92506077 Antithrombotic Peripheral vascular disease Carbamic acid, [3- [ [2-methoxy-4- [ [ [ (2- methylphenyl) sulfonyl] amino] carbonyl] phen yl] methyl]-1-methyl-1 H-indol-5-yl]-, zafirlukast cyclopentyl ester [CAS] 107753-78-6 EP 199543 Antiasthma Asthma zalcitabine Cytidine, 2', 3'-dideoxy- [CAS] 7481-89-2 US 4879277 Antiviral, anti-HIV Infection, HIV/AIDS Zaldaride 109826-26-8 Acetamide, N- [3- (3-cyanopyrazolo [1, 5- zaleplon a] pyrimidin-7-yl) phenyl]-N-ethyl- [CAS] 151319-34-5 EP 776898 Hypnotic/Sedative insomnia Dibenzo [b, f ; thiepin-2-acetic acid, 10, 11- zaltoprofen dihydro-Alpha-methyl-10-oxo- [CAS] 74711-43-6 JP 55053282 Anti-inflammatory 5-Acetamido-2, 6-anhydro-3, 4, 5-trideoxy-4- guanidino-D-glycero-D-galacto-non-2- zanamivir enonic acid [CAS] 139110-80-8 WO 9116320 Antiviral, other Infection, influenza virus 1-Propanone, 3-(1-(phenyimethyl)-4- piperidinyl)-1- (2, 3, 4, 5-tetrahydro-1 H-1- zanapezil enzazepin-8-yl)- [CAS] 142852-50-4 EP 487071 Cognition enhancer Alzheimer's disease Zatebradine 85175-67-3 Platinum, amminedichloro (2-methylpyridine) ZD-0473 (SP-4-3)- [CAS] 181630-15-9 EP 727430 Anticancer, alkylating Cancer, ovarian ZD-0947 WO 9528388 Urological Overactive bladder N-acetylcolchinol-O-phosphate ZD-6126 Anticancer, other Cancer, general 1 H-Tetrazole-5-butanoic acid, Alpha- ( (4- ((1, 4-dihydro-2, 7-dimethylXoxo-6- quinazolinyl) methyl)-2-propynylamino)-2- ZD-9331 fluorobenzoyl) amino) (S)- [CAS] 153537-73-6 GB 2264946 Anticancer, antimetabolite Cancer, pancreatic 2 (1H)-Pyrimidinone, 1-ß-D-ribofuranosyi- zebularine [CAS] 3690-10-6 Anticancer, other Cancer, general 7, 8-lsoquinolinediol, 4-(3, 4- zelandopam dihydroxyphenyl)-1, 2, 3, 4-tetrahydro-, [CAS] 138086-00-7 JP 03190818 Vasodilator, renal Hypertension, general Zenarestat 112733-06-9 Ziconotide 107452-89-1 zidovudine Thymidine, 3-azido-3-deoxy- [CAS] 30516-87-1 US 4724232 Antiviral, anti-HIV Infection, HIV/AIDS Patent API Generic Name API Chemical Name CAS No. Reference Example of Therapeutic Use Example of Indication Urea, N- (1-benzo [b] thien-2-ylethyl)-N- zileuton hydroxy- [CAS] 111406-87-2 EP 279263 Antiasthma Asthma Zimeidine 56775-88-3 Infection, herpes simplex virus zinc acetate hexakis (\m-acetato)-\m4-oxotetrazinc 12129-82-7 Antiviral, other prophylaxis Hexanoic acid, 6- (acetylamino)-, zinc salt zinc acexamate (2 : 1)- [CAS] 70020-71-2 EP 369088 Antiulcer Ulcer, duodenal zinc ibuprofenate 78416-80-5 Anti-inflammatory, topical Inflammation, dermal Zinc p-Phenolsulfonate 127-82-2 Zinc Salicylate 16283-36-6 Zinostatin 9014-2-2 zinostatin stimalamer 123760-07-6 EP 136791 Anticancer, antibiotic Cancer, liver Zipeprol 34758-83-3 2H-lndol-2-one, 5-(2-(4-(1, 2-benzisothiazol 3-yl)-1-piperazinyl) ethyl)-6-chloro-1, 3- 122883-93-6 ziprasidone dihydro- [CAS] 146939-27-7 EP 281309 Neuroleptic Schizophrenia L-Proline, 1- [3- (benzoylthio)-2-methyl-1- 75176-37-3 oxopropyl]-4- (phenylthio)- 81872-10-8 zofenopril, [1 (R*), 2Aipha, 4Aipha]- [CAS] 81938-43-4 GB 2028327 Antihypertensive, renin system Hypertension, general L-Proline, 1- [3- (benzoylthio)-2-methyl-1- oxopropyl]-4- (phenylthio)- , [1 (R*), 2Alpha, 4Alpha]-+ 6-Chloro-3, 4- dihydro-2H-1, 2, 4-benzothiazide-7- zofenopril + HCTZ sulfonamide 1, 1-dioxide [CAS] Formulation, fixed-dose combinations Hypertension, general Phosphonic aCd, [1-hydroxy-2-(1 H-imidazo 118072-93-8 zoledronic acid 1-yl) ethylidene] bis- [CAS] 165800-06-6 EP 531253 Osteoporosis treatment Hypercalcaemia of malignancy 2- (p-methylsulfonylphenyl) imidazo [1, 2- zolimidine a] pyridine 222-57-7 US 3318880 Antiulcer Gastritis 2-Oxazolidinone, 4- ( (3- (2- (dimethylamino) ethyl)-1 H-indol-5-yl) methylr zolmitriptan 39264-17-8 WO 9118897 Antimigraine Migraine Imidazo [1, 2-a] pyridine-3-acetamide, N, N, 6- trimethyl-2- (4-methylphenyl)- (R- (R*, R*))-2, 3 99294-93-6 82626- zolpidem dihydroxybutanediotade (2 : 1) [CAS] 48-0 EP 50563 Hypnotic/Sedative Insomnia Zomepirac 33369-31-2 i Patent API Generic Name API Chemical Name CAS No. Reference Example of Therapeutic Use Example of Indication 1 (2H)-Quinoxalineacetic acid, 3, 4-dihydro-7- zonampanel (1 H-imidazol-1-yi)-6-nitro-2, 3-dioxo- [CAS] 210245-80-0 Neuroprotective Ischaemia, cerebral 1 H-pyrazole-4-carboxamide, N- (aminoimino methyl)-5-cyclopropyl-1- (5-quinolinyl)-, zoniporide 249296-45-5 Cardiovascular Unspecified 1, 2-Benzisoxazole-3-methanesulfonamide 68291-97-4 Epilepsy, generalized, tonic- zonisamide [CAS] 68291-98-5 GB 2025931 Antiepileptic clonic 1-Piperazinecarboxylic acid, 4-methyl-, 6- (5- chloro-2-pyridinyi)-6, 7-dihydro-7-oxo-5H- zopidone pyrrolo [3, 4-b] pyrazin-5-yi ester [CAS] 43200-80-2 GB 1358680 Hypnotic/Sedative Insomnia Zopolrestat 110703-94-1 Zorubicin 54083-22-6 1-Piperazineethanol, 4- (1, 1-difluoro- 1, 1a, 6, 10b- tetrahydrodibenzo [a, e] cyclopropa [c] cyclohe pten-6-yi)-Aipha-l (5-quinolinyloxy) methy8-Cancer, leukaemia, acute zosuquidar [6 (R)- (laAlpha, 6Alpha, 10bAlpha)]- [CAS] 167465-36-3 Radio/chemosensitizer myelogenous Ethanamine, 2- [ (8-chlorodibenzo [b, flthiepin- zotepine 10-yl) oxy]-N, N-dimethyl- [CAS] 26615-21-4 GB 1247067 Neuroleptic Schizophrenia ZP-123 WO 0162775 Antiarrhythmic Arrhythmia, general Ethanamine, 2- [4- (1, 2-diphenyl-l- Z-tamoxifen butenyi) phenoxy]-N, N-dimethyi-, (Z)- [CAS] 10540-29-1 Anticancer, hormonal Cancer, colorectal 53772-83-1 982-24-1 1-Piperazineethanol, 4- [3- (2-chloro-9H- 85721-05-7 zuclopenthixol thioxanthen-9-ylidene) propyl]-, (Z)- [CAS] 64053-00-5 EP 270282 Neuroleptic Psychosis, general t t